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Abstract 
 
Integrin targeted fluorescent peptides for in vivo imaging  
Integrins are cellular surface receptor proteins involved in numerous cellular signalling and 
adhesion processes. The αvβ3 subtype is up-regulated around sites of malignancy especially 
solid tumour masses. This is due to its expression on the endothelial and smooth muscle 
cells which are concentrated in areas of cancer, where the uncontrolled proliferation and 
longeitivity of cells characterises the malignant process. Sustaining such a process is 
achieved through the development of a labyrinth of new blood vessels to supply nutrients to, 
and remove waste from the accumulating tumour mass. This is the process of angiogenesis. 
Endothelial and smooth muscle cells bearing the αvβ3 integrin amass to form new blood 
vessels.  
Crystallographic studies have determined that the tri-amino acid sequence RGD is crucial 
for the recognition and binding of extracellular proteins in the αvβ3 integrin binding site. 
Cyclic penta-peptides bearing this RGD motif have been found to exhibit preferential in vivo 
stability properties over their linear counterparts without affecting recognition and binding. 
In this study the cyclic peptide cRGDfK was synthesised using solid phase peptide 
chemistry and the lysine (K) residue was derivatised and proved an efficient means of 
attaching a fluorophore for potential diagnostic imaging applications. 
Targeted fluorescent imaging is the backbone of this study. Novel lanthanide metal 
complexes with a variety of appended chromophores were synthesised via the Ugi four-
component condensation reaction. The plan was to discern the most effective energy 
transfer mediated long-lifetime luminescent combinations of chromophore and metal, for 
subsequent attachment to the cyclic peptide. These potential long-lifetime imaging agents 
would allow the use of time-gated technology to eliminate troublesome background 
fluorescence. This chemistry was published (see page 338). 
Near-IR emissive organic fluorophores were also appended to the cyclic peptide and 
intraveneously injected into live lung tumour bearing mice. This interesting work 
investigated the in vivo potential of these targeted probes.  
 
Galectin targeted fluorescent disaccharides for in vivo imaging 
Galectins are a family of intra and extra-cellular proteins which bind specifically to the β-
galactoside carbohydrate residues of cellular glycoproteins. Several galectins, but most 
significantly galectin-3, have been found to mediate important inter- and intra-cellular 
processes particular to cancer cells, including signalling, proliferation and also metastasis.  
Galectin-3 targeted lactosamine derivatives were synthesised with various organic 
fluorophores appended via an N-caproic spacer unit. These compounds were then tested 
against galectin expressing cell lines and the binding and subsequent emission visualised 
through fluorescence microscopy. 
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Chapter 1: An introduction to diagnostic imaging 
 
The overarching aim of this research was to develop efficient new synthetic routes 
to novel fluorescent and MRI active probes with potential future applications both 
in enhancing cancer diagnosis in whole body imaging, and as surgical tools to 
accurately highlight areas of malignancy. 
 
 
1.1 Cancer & diagnostics 
Modern diagnostic imaging technology is constantly improving with higher specification, 
more advanced and more powerful machinery becoming widespread.1 This offers 
advantages in the increased speed with which imaging and diagnosis can be achieved. 
Earlier stage diagnosis allows more rapid therapy and improved prognosis.2 The advance of 
knowledge and technology is constantly trying to keep up with and on top of disease, and 
diagnostic imaging is a fundamental tool in the battle against cancer.3  
Vast changes in the incidence of, and the mortality from cancer have occurred over the 
past century. The statistical analysis is complex as huge advances in diagnostics and 
therapeutics have transpired, but currently still approximately one third of all people in 
England will develop cancer at some point in their lifetime. Indeed, in 2006, there were 
367,000 new cases of cancer registered, and 139,000 people died from the disease. In 
England, £4.35 billion was spent by the NHS on cancer services in 2006, and research in 
the area is extensive across academia and industry.4 
Rate per 100,000 population Rate per 100,000 population
Male Female
 
 
Figure 1: Age standardised major cancers in the UK 2004-2006. Adapted from Ref. 4b. 
 
There are more than 200 types of cancer, each with different symptoms and treatment. It is 
a huge challenge, but roughly half of all people diagnosed with cancer now survive more 
than five years. More than 70% of childhood cancers are now successfully treated in 
comparison to 30% in the 1960s,5 however the most prevalent cancers (breast, lung, 
colorectal and prostate) are most often found in the over 60 age group.2 Overall incidence of 
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cancer increased by 25% in the years 1975-1995 but has since stabilised with increases in 
more avoidable cancers such as skin, womb and kidney, but significant decreases in 
stomach, cervical, bladder and lung cancer (male) cases especially (Figure 2). 
 
-50.0 -30.0 -10.0 10.0 30.0 50.0
Bladder
Stomach
Cervix
Lung
Ovary
Brain + CNS
Colorectal
Leukaemia
Pancreas
Oesophagus
Multiple Myeloma
Non-Hodgkin Lymphoma
Breast
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Oral
Liver
Uterus
Mesothelioma
Prostate
Malignant Melanoma
All malignant neoplasms ex NMSC*
 Females
Males
% change in incidence rates
*
 
 
Figure 2: A representation of the changes in cancer incidence rates 1997-2006. * The increase in prostate cancer 
incidence has been enhanced by the use of PSA testing since the early 1990s which detects malignancy at an 
earlier and/or asymptomatic stage.3 
 
The causes of cancer are diverse, but increasingly it has become apparent that lifestyle has 
a significant impact in many cases.5b Genetic inheritance factors, age, diet, sun exposure, 
smoke inhalation and bodyweight are all considered important factors contributing to an 
individual’s likelihood of developing cancer.3 As a general trend though, it is expected that 
cancer incidence will rise. This is due to a number of factors, including an ageing 
population rendering more people in the most susceptible age group.5c This ageing 
population however, is also partly due to vast improvements in general health awareness, 
earlier diagnosis of most diseases, and subsequent successful treatment prolonging 
lifetime. Therefore the overall burden upon the NHS is unlikely to change, although it will 
shift to different types of cancer.  
Advances in diagnostic technology are contributing to the rising incidence tally, however 
early diagnosis is a fundamental factor in decreasing the mortality rates of many types of 
cancer, especially those forming solid mass type tumours, as early treatment has been 
proven to vastly improve prognosis.3 
Key people involved in cancer detection, prevention and control include scientists 
investigating the mechanisms that cause cells to become malignant and the key 
components involved; those carrying out clinical trials to evaluate new treatments; the 
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clinicians actually conducting the diagnosis and therapy for individual patients; public 
health physicians implementing screening programmes and educating the public; and 
epidemiologists identifying high- and low-risk population sections and identifying 
environmental factors providing clues to carcinogenic mechanisms.1-5 
It is within the first section of these people with which we find ourselves, the scientists; and 
it is the detection, monitoring and visible highlighting of cancer which is the cornerstone of 
this work. 
The focus of this review shall centre upon diagnostic imaging and specifically the 
development of optical imaging agents, but to introduce this we must first look at one 
element of treatment in which optical imaging could have significant application: surgery. 
 
 
1.1.1 Surgery 
Whilst cancer diagnosis continues to rise, conversely, the chances of survival are improving 
as more and more therapeutics become economically viable, disease specific, and their 
treatment programmes more thorough.  
Prior to the technological and surgical revolution in the 1970s and 80s there was an even 
higher death rate from cancer. However, with the advancement of imaging technology it is 
now possible for doctors to detect cancer at an earlier stage and surgeons are now able to 
excise many cancerous growths.6 
Three-dimensional imaging techniques such as CT, PET and MRI allow members of a 
medical team to pinpoint the exact location of a tumour and determine its margins prior to 
surgery. However, to achieve successful complete surgical removal, the surgeon must 
ensure that all diseased cells are removed and that none of the diseased tissue remains or 
is damaged during surgery. This could result in the remaining cells proliferating, causing 
relapse and possible metastasis of the cancer.6b  Even with the current imaging systems, 
during surgery the tumourous growth may not be as visibly defined as the preoperative 
images; the margins may be distorted and may not be visible even to the trained human 
eye. In order to effectively eliminate a cancerous growth it is essential to have the capacity 
to precisely locate and identify the nature of the diseased cells, without damaging the 
healthy surrounding tissue (Figure 3). 
This has prompted the search for new methods which can highlight the tumour perimeters 
throughout the surgical excision process, and this is where optical imaging agents and 
bimodal probes have great potential.  
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Figure 3: Highlighting tumours. Green fluorescent protein-labelled liver tumour highlighted by two-photon 
microscopy.4 
 
This surgical application illustrates how diagnostic imaging is key to not only highlighting 
the tumour for diagnosis, but could also be highly applicable in the subsequent treatment. 
The other advantage of a probe targeted to a tumour cell-specific entity, such as the cell 
surface receptor integrin αvβ3 which is highly upregulated in many tumour sites, is that it 
offers good evidence of the biological activity and function of the malignancy. The criterion 
for an effective optical imaging agent offers several challenges to the synthetic chemist. The 
agent must be tumour specific with good binding affinity, it must be metabolically stable 
and offer great contrast against surrounding tissues whilst being non-toxic and have 
excitation and emissive properties conducive to deep tissue penetration.7  
Another option is to incorporate a secondary function into the probe which is sensitive to 
an alternative diagnostic technique. This is bimodal imaging,7b and a tumour targeted 
fluorescent probe with an intramolecular paramagnetic MRI active component, for 
instance, could offer a versatile, non-invasive option for early accurate diagnosis, surgical 
removal or highly sensitive monitoring of treatment efficacy and progress, using a single 
molecular agent. 
It is not solely the applications we are endeavouring to advance, but the chemistry and the 
methodology involved in the synthesis of specifically targeted fluorescence probes. 
To further our understanding of where there is a place for targeted optical imaging in 
medicine we must briefly introduce the techniques primarily employed at present in the 
clinical setting. 
 
1.2 An overview of present oncological diagnostic imaging techniques. 
 
1.2.1 Ultrasound 
Medical sonography (ultrasonography) has been widely used as a valuable, harmless 
diagnostic tool for over 50 years. It is a medical imaging technique most widely recognised 
in the field of obstetrics where it is the key modality for the study and monitoring of the 
unborn. It is however more widely used in the imaging of muscles, tendons, internal organs 
and for detecting abnormalities such as tumours.8  
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In medicine this technique uses pulses of high frequency cyclic sound energy to penetrate 
tissue; the reflection signature from the various media is detected and a computerised 
tomographical image built up. Ultrasound has limitations in that it cannot see through 
bone and so visualisation within the chest cavity can be somewhat restricted.8b 
Although ultrasound has been shown to enhance inflammatory response and warm tissue 
through molecular friction, it does not employ the more contentious ionising radiation 
which is the essence of techniques such as X-ray and CT. 
 
1.2.2 X-ray 
This is a standard technique traditionally employed for observing skeletal structure and 
abnormalities especially in the field of orthopaedics.9 It employs ionising X-ray radiation 
and a two-dimensional image is built up through the observed variation in the attenuation 
of the radiation according to the density of the medium in question. Hence metallic objects 
or bone show great contrast but soft tissue often requires further investigation to 
accurately offer a diagnosis.9 
 
1.2.3 Computed Tomography (CT) 
Since its emergence in the 1970s CT has become a gold standard diagnostic tool both 
alone, as a supplement to standard X-ray and ultrasonic techniques, and also in 
conjunction with other techniques such as Positron Emission Tomography (PET-CT).10 
CT employs X-ray radiation to generate a large quantity of 2D X-ray images taken around a 
single axis of rotation. These 2D slides can then be processed using powerful geometric 
computer software programmes to generate a sophisticated 3D image of the inside of a 
patient. This ‘windowing’ allows the manipulation of the large volume of data collected in 
an increasingly short scan time to visualise the numerous physiological structures and 
media according to their ability to attenuate the X-ray beam.10 
The X-ray slice is generated by rotating the X-ray source around the object with a detector 
at the other side of the rotating loop. Scans are taken at increments as the body is 
gradually passed through the loop. The scans are combined by mathematical tomography 
to construct a 3D image where the pixels or voxels are displayed according to the mean 
attenuation of the tissue on a scale called the Hounsfield scale. Windowing then creates the 
image display on a greyscale with over 1000 available shades of grey. The third dimension 
comes from the stacking of axial slices. The software can then slice through in a different, 
usually orthogonal plane (Figure 4).10b 
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Figure 4: Left) A CT scanner; Right) The authors representation of multiplanar reconstruction. 
 
Tomography is the method of representing on radiographic film a single 2D slice of the 
body through a greyscale image. By controlling the rotation of the X-ray source and 
detector during exposure, the target level of image remains sharp with clear tissue contrast 
whereas blurring occurs at all intermediate levels.10b  
Although the maiden CT scanner was designed and built between 1967 and 1972 with 
financial support from the music company EMI, it was limited to taking tomographic 
sections of the skull and brain and employed a water tank with an ergonomic head-shaped 
rubber inlet in which the patient’s head was enclosed for scanning. This somewhat 
unorthodox arrangement was designed to reduce the range of the attenuated radiation 
reaching the detectors; water attenuation is measured as zero Hounsfield Units (HU) and 
bone can reach 2000 HU, however air is -1000 HU.10c  
The radiation dose for a particular scan is dependent of many factors including the volume 
to be scanned, the size of the patient, the number of previous scans, the potential 
requirement for future scans, and the type of scan sequence required for the desired 
resolution and quality of contrast.10c However, the number of CT scans performed 
nationwide continues to escalate despite the increasing understanding of the potential 
risks associated with the ionising radiation employed (Figure 5). There are several reasons 
for this, not least due to increasing availability and its value and reliability for an 
increasing number of conditions. 
Chest X-ray               0.1 mSv / 10 mrem
Chest CT                   5.8 mSv / 580 mrem
Typical effective dose
 
 
Figure 5: A table showing the increased exposure to X-ray radiation during CT scanning.10c 
 
CT is now employed for a whole host of disease diagnostic imaging applications through 
both the discovery and location of existing disease to preventative screening for those at 
higher risk of disease but present no immediate symptoms. 
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Advantages & disadvantages of CT 
• High contrast resolution (fractures, ligament injuries and dislocations can be visible 
at 0.2mm resolution), also the power to distinguish between tissues of just 1% 
variation in density. 
• Increasing scope of investigation can eliminate the requirement for invasive 
procedures (CT angiography avoids the need for the insertion of arterial catheter 
and guidewire).10d 
• Vastly improved modern scanners only require an approximately 1 second exposure 
per slice allowing reduced exposure for scanning children without the need of 
sedation to ensure the child remains motionless. 
• New increasingly powerful software is enabling dose reduction by filtering out more 
background noise. 
• However, whilst improvements in radiation efficiency continue, this technique still 
uses moderate to high levels of ionising radiation. Some evidence exists suggesting 
a linear relationship between X-ray radiation dose and cancer risk. Although this 
risk is low with an approximate figure of 0.35% risk per scan compared with 
approximate 23% risk of dying from cancer naturally.10 
• Contrast CT scans rely on intravenous administration and the agent itself can 
cause reactions ranging from discomfort and hotness to allergies and kidney 
damage to those with pre-existing renal conditions and diabetes. 
 
Contrast agents are sometimes used to enhance the outline of tissues especially in the 
digestive system. Iodine and barium agents have long been employed to enhance contrast.  
 
1.2.4 Positron Emission Tomography (PET) 
This is a radiative nuclear medicine technique producing a 3D image of targeted specific 
functional biological processes within the body by detecting pairs of gamma rays emitted 
indirectly through the nuclear decay of a positron-emitting radiotracer. Images are 
generated according to the concentration of the radiotracer in a defined 3D space within 
the body and then reconstructed by computational processing software.11  
 
 
 
Figure 6: Transversal chest slices. Left) CT; Centre) PET; Right) PET-CT 
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Positron emission decay involves the spontaneous emission of an antiparticle of the 
electron, the positively charged positron. After a few millimetres the positron collides with 
an electron, annihilating both, and in the process producing two pairs of gamma photons 
which fly off at nearly 180˚ to one another, pass directly through the body and crash into 
the awaiting scintillator causing a flash of light which is then detected by a photomultiplier 
tube (Figure 7). This detection is dependent on the simultaneous detection (within a few 
nanoseconds) of the two opposite moving pairs of photons or the signal is ignored; each 
‘coincidence’ event is listed and tens of thousands are statistically collected. The source of 
emission is located through a cunning software system that follows the line of response 
(LOR), which is the trajectory of the two gamma pairs from each decay event. A map of 
radioactivity is then built up by calculations of the activity of the various tissues along a 
LOR in relation to the quality of simultaneous coincidence events.11  
Positron emitting 
neutron deficient 
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Stable nuclide
Detector
Detector
Positron scatters 
into surrounding 
tissue losing energy
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Figure 7: A cartoon of the principles of PET imaging.11 
 
The radionucleotides employed are short half-life isotopes such as carbon-11 (~20 minute 
half life), nitrogen-13 (~10 min), oxygen-15 (~2 min) and fluorine-18 (~110 min) which are 
incorporated into normal biologically active compounds such as D-glucose and other 
analogues of this monosaccharide, without interfering with their primary function. The 
radiotracer bearing the isotope is obviously shortlived, and as such, PET imaging requires 
careful logistical planning to ensure the intravenous delivery, site specific accumulation 
and subsequent scan is accomplished before the tracer is rendered inert. New novel 
radiotracers are continually being synthesised, however the radioactive decay time 
constraints require a cyclotron and radiochemical laboratory in close proximity to the 
patient and scanner. For these reasons fluorine-18 is the preferred isotope and in ~90% of 
cases it is delivered to the patient intraveneously as the natural glucose derivative [18]F-
fluorodeoxyglucose (FDG) (Figure 8).11b  
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Figure 8: FDG. Post intravenous administration the patient must rest for 1 hour prior to scanning to allow an 
accurate measure of cellular uptake. 
 
Of all PET scans ~90% are FDG oncological investigations and PET-CT has become a very 
effective technique especially in Hodgkins and non-Hodgkins lymphoma, lung malignancies 
and many other types of tumour, especially when looking for metastic lesions.11c  
Just as with glucose, the FDG glucose analogue is transported into cells with the help of a 
family of transport proteins (GLUT-X). Inside the cell the process of glycolysis kicks into 
action and the FDG is phosphorylated by hexokinase. Normally glucose would now 
continue in the glycolytic pathway of energy production (see page 165/6), however, the 
glucose hydroxyl displaced by 18F is required for the next step of glycolysis, and so FDG-6-
phosphate is trapped intracellularly. Due to malignant, rapidly-growing and differentiating 
tumour cells having glycolytic rates up to 200 times higher than normal cells, the extra 
demand for energy is profound. Therefore the malignant cells display an increased density 
of the glucose transporters GLUT-1 and GLUT-3,11d and also exhibit higher levels of 
hexokinase types I and II. They also often favour a more inefficient anaerobic hypoxic 
pathway adding to the already enhanced demand for glucose. These combined mechanisms 
mediate the uptake and retention of a much higher level of FDG in tumour cells in 
comparison to normal tissue. This is the key to the power of PET imaging and what causes 
the intense emission from high glucose demand tissues such as the liver (the main organ 
for carbohydrate metabolism and storage), the heart, and tumours. It must be highlighted 
that FDG is not cancer specific. Areas of high metabolism or muscular and nervous 
hyperactivity, inflammation and tissue repair in the tumour vicinity can lead to 
ambiguity.11b  
PET is versatile, it can assess response to therapy, especially in the case of many cancers, 
and the radiation dose is minimal. Limitations include cost and logistics and therefore 
fluorine-18 and rubidium-82 are the primary isotopes in use today. Technological advances 
are however increasing the emergence of on-site cyclotron and laboratory (“hot lab”) 
facilities.11 
MRI and CT detect organic anatomical changes whereas PET and SPECT (page 11), detect 
specific areas of biological activity even without noticeable anatomical discrepancy. 
Therefore PET is a more quantitative technique. 
Recent PET research shows the versatility and power of the technique especially as studies 
show that molecules which target specific biological motifs can be labelled with the 18F 
isotope (Figure 9). In this instance the cyclic peptide was labelled with either one, two, 
three or four 18F atoms by direct electrophilic fluorination with [18F]AcOF in TFA.11e The 
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aromatic ring of phenylalanine is not involved in receptor binding and thus the probe was 
effectively used to visualise αvβ3 integrin expression through the accumulation of radiative 
signal from adenocarcinoma tumours in mice.11e However, the radioactivity level was not 
high enough to distinguish the tumour from the uptake in other organs such as the liver. 
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Figure 9: 18F labelled cyclic RGD peptide targeted to the αvβ3 integrin subtype found to be upregulated in tumour 
sites.11e 
 
1.2.5 Positron Emission Tomography – Computerised Tomography (PET-CT) 
This combination of techniques has revolutionised the field of medical diagnostics. The 
machine is a single loop (or gantry) scanner which allows the acquisition of sequential PET 
and CT images in a single session with minimal inconvenience to the patient. 
CT, PET and PET-CT techniques have limitations especially in the diagnosis of malignancy 
as low levels of disease can escape detection. Additionally, most diseases require repeat 
scans to analyse response to treatment and so the risk from ionising radiation escalates 
with X-ray, CT and PET-CT imaging.10d 
 
 PET - Spatial distribution of metabolic or biochemical activity. 
CT - Allows the accurate alignment and correlation of PET image with acquired        
anatomical data. 
 
 
 
Figure 10: The accuracy offered by PET-CT in pinpointing a lung tumour. 
 
PET-CT offers a precise 2D and 3D image construction which consequently allows more 
accurate surgical planning, radiotherapy, and has even begun influencing the staging of 
chemotherapeutic protocol.11 An example is in stereotactic radiation therapy for cancer 
where marks are made on the patient’s body prior to PET-CT then the slices are transferred 
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digitally to the linear accelerator which is then programmed to bombard the target area 
precisely with high energy photons for more accurate treatment.12  
Metabolic regions are shown on a false colour coded scale of pixels (or voxels) relative to the 
intensity, and superimposed onto the greyscale CT. 
 
 
Figure 11: Left) A CT image highlighting a lump in the right lung; Right) The identical PET-CT superimposed 
image confirming malignancy. 
 
1.2.6 Single Photon Emission Computed Tomography (SPECT) 
This is another nuclear medicine tomographic technique dependent upon gamma 
radiation. SPECT is very similar to PET, however it is able to afford true three dimensional 
information presented typically as cross-sectional slices through the anatomy. 
Just as conventional X-ray imaging is a 2D representation of 3D structure, so the SPECT 
image is a 2D representation of 3D distribution of a radionucleotide through the eyes of a 
gamma camera. 
Now, SPECT is similar to PET in that the technique relies upon the in vivo administration 
of a radioactive tracer and detects gamma emission, however, the tracer used is not a 
positron emitter which upon electronic collision emits gamma photons in opposite 
directions; it directly emits gamma radiation. Therefore SPECT is far cheaper than PET for 
the simple reason that more stable, longer-lived radioisotopes are more easily obtainable.13  
The acquisition of SPECT images involves a gamma camera being repeatedly rotated 
normally a full 360° around the body with projections (2D slices) being acquired at multiple 
defined angles usually every three to six degrees. Computer software then applies a 
tomographic reconstruction algorithm to the multitude of 2D projections to yield a 3D 
dataset. Advances in this technology has seen the introduction of two or three gamma 
camera heads simultaneously acquiring two or three projections as each head requires just 
180 or 120 degree spacing about the loop. 
As SPECT affords accurate 3D localisation it can provide precise information on specific 
internal organ function, tumour growth and many other applications such as in myocardial 
perfusion imaging where ischemic heart disease is detected by measuring a radiotracer in 
the blood flow when the heart is put under stress.13b 
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SPECT radioisotopes. 
• Technetium-99m is the best known gamma emitting metastable isotope with a half 
life of approximately six hours. Generally it is attached to pharmaceuticals for 
specific functional targeting. It has a large range of diagnostic applications such as 
in combination with tin where the 99mTc binds to red blood cells and is used in the 
diagnosis of circulatory system disorders. 
99mTc-HMPAO is brain specific and is taken up by brain tissue in a manner 
proportional to blood flow to that specific locality.13c Thus cerebral blood vessels 
and metabolism can be assessed and for difficult-to-diagnose diseases such as 
Alzheimers and Dementia. SPECT using this radionucleotide has shown accuracy 
as high as 88%.  
• Iodine-123 is a popular and useful tumour scanning isotope with a halflife of 
approximately 13 hours. 
• Indium-111 (t1/2 = 67 hours) is often used in conjuction with technetium-99m for 
the specific imaging of white cells. 
 
As with PET, scanning is time consuming and the patient must lie still. Intense areas of 
activity such as the bladder where the probe is concentrated prior to excretion, can obscure 
activity in adjacent areas. Internal attenuation of the gamma radiation can lead to the 
underestimation of deep tissue activity in comparison to more superficial tissue and for 
this reason most SPECT scanners now have integrated X-ray-CT capabilities as this 
provides an attenuation map of tissues and thus allows for computational correction of the 
gamma deep tissue attenuation. 
SPECT scans are of lower resolution than PET as the PET scanner detects time coincident 
emission of the two photons giving enhanced radiation event localisation. 
 
1.2.7 Magnetic Resonance Imaging (MRI) 
In 1971 Raymond Damadian showed that the nuclear magnetic relaxation times of 
tumours differed from surrounding tissue, thus the door was opened to the development of 
this technique as a powerful imaging weapon in the armoury of the clinician.14a 
MRI is of interest to this study for the simple reason that an important contrast agent is 
based upon the paramagnetic metal gadolinium (Gd). This metal is readily available for use 
in synthesis as, for example, a chloride, citrate or trifluoromethansulfonate Gd(III) salt, and 
is reliably chelated in a variety of macrocycles which can be appended to targeting vectors. 
 
The principles of MRI 
Subatomic particles such as protons and neutrons possess the quantum mechanical 
property of spin. Certain nuclei have non-zero spin through possession of unpaired protons 
or neutrons, and therefore display a magnetic moment. The spin states of a spin ½ nucleus 
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such as a proton (1H), are referred to as either up or down.14b Upon application of a strong 
magnetic field the spins all align around the axis in the direction of the applied field 
(Figure 12). 
 
Magnetic field Bo
Bo
Net magnetisation of nuclei 
= Sum of all vectors
 
 
Figure 12: A diagram of subatomic particular spins aligning in a magnetic field B0. 
 
A radiofrequency (RF) electromagnetic pulse is then applied perpendicular to the magnetic 
field causing protons to absorb energy and enter an excited state (Figure 13). Upon 
deactivation of the pulse the protons relax back down to a ground state with the emission 
of a resonant radiofrequency pulse which is detected by the scanner. The frequency of the 
emitted signal is dependent upon the strength of magnetic field. 
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Figure 13: The effect of the radio frequency pulse. 
 
The make up of the human body is predominantly water and fat.14c Both of these 
compounds are rich in hydrogen atoms, indeed in total, the human body consists of 
approximately 63% protons. Each water molecule bearing two hydrogen nuclei, or protons, 
of point positive charge, means that in the described powerful magnetic field these protons 
will align and point in the direction of the field. The location of these water protons can 
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then be determined by application of additional magnetic fields during the scan allowing 
the build up of an image.  
An attractive property of MRI is the tremendous contrast between the various soft tissues 
of the body.14d Diseased tissues such as tumours can readily be detected due to the water 
protons within different environments relaxing to their most stable state at different rates. 
This relaxation of in vivo water protons is the backbone of MRI and can be further 
enhanced by the oral, direct injection or intravenous administration of a paramagnetic 
contrast agent. 
Contrast is observed when variations in the strength of nmr signal is recorded from 
different physiological locations. This is dependant upon the relative density of the excited 
water protons, on the different relaxation times of nuclei after a pulse sequence, and often 
other parameters depending on the specific type of scan. Contrast can be controlled and 
manipulated through the application of specific pulse sequences. For example in the brain, 
T1 weighted MRI causes the nerve connections of grey matter to show up white, grey matter 
grey and cerebrospinal fluid dark (Figure 14).14e/f 
The combination of field gradients and radio frequency excitation is then used to create an 
image on a greyscale. 
 
 
Figure 14: An mri scan revealing a site of neuroblastoma.14f 
 
1.2.8 Contrast agents 
Of particular interest to this study is the situation where it is not possible by adjusting 
scanning parameters alone, to generate enough image contrast to adequately show the area 
of interest. In this situation a contrast agent is required to enhance the definition of fine 
structure or to more accurately distinguish between areas of similar signal strength. For 
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the bowel and stomach this may just be water, however most contrast agents are employed 
to take advantage of their magnetic properties. Commonly these are gadolinium (Gd) based 
agents. Gadolinium exhibits a magnetic moment due to its unpaired electrons, is a 
paramagnetic element, and interacts with the external magnetic field. 
 
 
 
Figure 15: The structures of five approved gadolinium clinical contrast agents.14g 
 
Gadolinium in the (3+) oxidation state exhibits seven unpaired f-electrons. This causes 
appended and local water molecules to relax more rapidly enhancing the quality of the 
image. Gd enhanced tissues and fluids appear extremely bright on T1 weighted images. 
Super paramagnetic nanoparticles such as iron oxide have also recently become available 
and these appear very dark on T2* weighted images and are useful for liver imaging as 
abnormal areas such as tumours, appear light. 
 
A comparison: 
• CT offers good spatial resolution and the ability to discern between different 
structures which are of negligible distance apart. 
• MRI offers comparable resolution and is excellent at distinguishing between two 
arbitrarily similar but not identical tissue types. Optimisation of the pulse sequence 
provides image contrast based on chemical sensitivity. MRI cannot, however, be 
used in parallel with other imaging techniques such as in PET-CT. 
 
1.2.9 Bimodal imaging agents. 
An MRI scan allows members of a medical team to pinpoint the exact location of a tumour 
and determine its margins prior to surgery. To achieve the successful surgical removal, the 
surgeon must ensure that all diseased cells are removed. This often leads to a greater than 
desirable amount of healthy surrounding tissue also being removed unnecessarily, causing 
trauma.15 Even with the current imaging systems, during surgery the tumourous growth 
may not be as visibly defined as the preoperative images; the margins may be distorted and 
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may not be visible even to the trained human eye. In order to effectively surgically eliminate 
a cancerous growth it is essential to have the capacity to precisely locate and identify the 
nature of the diseased cells, without damaging the healthy surrounding tissue. 
This has prompted the search for new methods which do not rely on the limitations of the 
human eye.15b 
One method of highlighting the exact margins of a tumourous growth is through the use of 
a single molecule multimodal in vivo imaging platform.15c 
This allows the combination of techniques, such as magnetic resonance imaging (MRI), 
positron emission tomography (PET), and single photon emission computed tomography 
(SPECT) to generate sophisticated images in vivo.  
The most advantageous use of in vivo imaging is the ability to combine different imaging 
approaches to generate information with extremely high resolution whilst diseased cells are 
still functioning within the patient. It balances the positive and negative features of each 
imaging technique and with the correct combination of techniques, this platform has the 
capability to revolutionise the diagnosis, treatment and surgical management of malignant 
growths. 
However, conventional imaging modalities provide little or no information regarding the 
specific biological markers on newly formed blood vessels, tumour cells and the molecular 
changes throughout therapy. Molecular imaging takes advantage of the traditional imaging 
technology previously described, but also introduces indicative markers of tumour 
development at different stages. Molecular imaging is non-invasive. 
 
1.2.10 Roger Tsien & visualising cell biology 
Advances in molecular biology, organic synthesis and materials science have provided the 
biologist with new classes of fluorescent probes for visualising cellular processes.16a The 
impressive 2008 Nobel prize winning work of Roger Tsien has centred around the 
development and application of visible fluorescent proteins (FPs) from jellyfish and coral. 
A revolution in cellular biological imaging has been brought about by the discovery, gene 
cloning and application of the green fluorescent protein (GFP) from the jellyfish Aequorea 
Victoria.16 With an emission maxima at 508 nm, the incredible ability of GFP to generate 
highly visible and efficient internal fluorescence is both fascinating and valuable. The 
chromophore in GFP is generated by spontaneous cyclisation and oxidation of three amino 
acids buried at the heart of a beta barrel (Figure 16). Crucial to the discovery and 
application of this fluorophore is the fact that it is independent of any jellyfish-specific 
enzymes and hence the gene can be applied to other organisms.16b 
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Figure 16: A 3D structure of GFP showing the beta barrel bearing the chromophore.16c 
 
GFP is just one of a large family of different coloured marine fluorescent proteins with 
variations in structure and the environment in which they fluoresce. Laboratory 
mutagenesis has further enhanced brightness and quantum yield. There has been an 
explosion in the availability of different FPs and they promise a wide variety of imaging 
options to the biologist especially when used in multilabelling experiments where minimal 
crosstalk between discreet excitation and emission channels is achievable.16c However, 598 
nm and 655 nm are the maximum emissive wavelengths of FPs thus far and this is still 
within range of biological interference. 
A drawback in the application of FPs in live mammalian studies has been the poor tissue 
penetration of the required excitation light. Bacteria-derived near-IR fluorescent proteins 
have been engineered to emit via a spontaneously incorporated biliverin chromophore at 
708 nm. This chromophore is generated and metabolised endogeneously in adult humans 
to the extent of 300-500 mgs per day.16a 
Thus the idea of boosting and utilising pre-existing in vivo near-IR excitable and emissive 
chromophores through engineering their adhesion into the chromophore-binding domain of 
a bacterium, is a novel means of accessing near-IR luminescence from within. However, the 
localisation and specificity of near-IR autofluorescent proteins to certain cell or protein 
types is uncertain and the extent to which they can be derivatised to target and visualise 
specific biological entities remains to be seen.16d 
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1.2.11 Optical imaging 
1.2.11.1 Fluorescence Imaging 
The original development of fluorescent probes in the 1970’s concentrated on providing a 
measurement of the cellular concentration of Ca2+ ions. Calcium is critical for life and is 
fundamental to many biological processes as a messenger and regulator. A means of 
monitoring Ca2+ ions selectively in the presence of the typically far more prevalent Mg2+ 
ions represented a considerable challenge, not least because changes in Ca2+ ion 
concentration occur rapidly, and hence the probe must have selectivity, and rapid binding 
and release kinetics. 
Tsien realised that it would be preferable to have an indicator that responded to calcium 
binding by shifting wavelengths whilst maintaining strong fluorescence rather than the 
previous probes which relied upon an just an increase in fluorescence intensity upon Ca2+ 
binding.17 The probes developed are still used today (Figure 17). 
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Figure 17: Tsein’s INDO-1 calcium probe. Adapted from Refs 17a & b. 
 
The INDO-1 probe involves an eight-coordinate EGTA-like binding site attached to a 
conjugated chromophoric system. When the ligand is free of metal, the amine lone pairs are 
conjugated with the chromophoric system and act as good electron donors to stabilise the 
excited state of the chromophore, resulting in long wavelength emission. When the Ca2+ is 
bound, the nitrogen lone pairs are involved in the metal binding reducing the ligand’s 
ability to donate electrons to form a charge-transfer excited state and thus the emission 
shifts to a lower wavelength.  
Whilst fluorescent imaging techniques such as the INDO-1 calcium probe (Figure 17) are 
highly sensitive there is a problem in that biological chromophores such as tyrosine and 
tryptophan also absorb and emit light in the same region.19 This is known as 
autofluorescence and it results in background noise from the sample interfering with the 
signal from the luminescent probe. The separation of the two signals is very difficult. 
Presently the favoured strategy for avoiding this problem is to employ either a species 
whose emission is much longer lived than the typically very short lived background 
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fluorescence (~10 ns), or to employ a species whose emission is of a much longer 
wavelength out of the range of biological noise. 
 
1.2.12 Timegating 
Longer luminescent lifetime probes typically either involve a metal complex, or organic 
species whose emission is through the formally spin-disallowed route leading to long-lived 
luminescence (phosphorescence). Therefore the luminescent signal can be easily separated 
from the autofluorescence by employing a detection time-delay whereby the detector is not 
switched on until the undesirable signal from the sample has diminished. This is known as 
timegating (Figure 18).17b 
 
td
 
 
Figure 18: Timegating. A time delay (td) of typically 10-50ns is applied to eliminate undesired background noise. 
 
This hugely improves the signal to noise ratio, and has become commonplace in the 
visualisation of metal complexes in biological media, especially lanthanides complexes. 
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Chapter 2: Integrin targeted fluorescent peptides for in 
vivo imaging 
 
This chapter follows on from chapter 1 with an introduction to the lanthanides as 
potential luminescent probes for targeted imaging. The biology surrounding the 
integrin target will also be covered, as will our synthetic strategy to specifically 
target this integrin with a cyclic peptide bearing the luminescent lanthanide 
complex. 
 
2.1 Lanthanides and Luminescence. 
A previously mentioned lanthanide was gadolinium (Gd).14g Its widespread use in clinical 
MRI as a macrocycle-chelated contrast agent was discussed. The reasons for this function 
will presently be made more apparent, however, there are other properties of certain 
lanthanide metals that render them attractive for potential luminescent applications. 
 
 
 
Figure 19: The lanthanides. 
 
Until recent years the chemistry of the ‘f’ block elements of the periodic table, the 
lanthanides and actinides, was often ignored in the training and experience of the chemist. 
These rare earth metals however, are finding increasing technological, catalytic and 
biological applications. 
It was in 1794 that the Finnish chemist J. Gadolin isolated yttria from a mineral discovered 
at the village of Ytterby, near Stockholm in Sweden. Rather than consisting of the oxide of a 
single element, as Gadolin thought, it was subsequently quite remarkably shown that yttria 
contained the oxides of ten new elements: Y; Gd; Tb; Dy; Ho; Er; Tm; Yb; Lu & Th! 
A short time later Klaproth, Berzelius and Hisinger isolated another oxide, ceria, and La, 
Ce, Pr, Nd, Sm and Eu were identified therein.18 
Whilst our attentions shall be concentrated upon the lanthanides, it is worth mentioning 
that the actinides, other than the naturally occurring thorium (Th), protactinium (Pa) and 
uranium (U), are found either within nuclear explosion debris (Es and Fm), or are 
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synthesized as a result of the nuclear bombardment of a parent element such as U, Pu or 
Am. These elements are a far more recent discovery (1940 – 1971). 
To brand lanthanides as ‘rare earth metals’ is somewhat of a red-herring as they are all 
actually relatively abundant. Cerium is the 26th most abundant element on earth, 
neodymium is more prolific than gold. The least common, thulium (Tm), is still more 
abundant than iodine. 
Shortly after 1947 it was N. Bohr who ascertained that the fundamental characteristic this 
family of fourteen elements possessed is that the fourth atomic shell could contain 32 
electrons, 14 more than the third. Hence these extra electrons are placed in the new 4f 
orbital and the first ‘f‘ series was born. It is these 4f electrons that give the lanthanides 
their unique and fascinating properties.18b 
 
2.1.1 Lanthanide coordination chemistry 
Lanthanide element ions are large ‘hard’ acids and form high coordination number 
complexes, preferably with donor atoms such as N, O and F. The partially occupied 4f 
orbitals have core-like radial distribution functions, and overlap between these orbitals and 
donor ligands is typically very small, making covalent contributions to bonding negligible; 
ligand field splittings in lanthanides are of the order of a few hundred wavenumbers (cf. the 
splitting in d-block complexes, which is typically of the order of tens of thousands of 
wavenumbers). Therefore complexes are constructed largely through electrostatic 
interactions. Upon crossing the lanthanide series the ionic radii decrease through 
lanthanide contraction; this causes a concomitant increase in charge density as, in the 
usual (+3) oxidation state, the charge is spread over a smaller area. This leads to stronger 
ionic bonding and lanthanides such as ytterbium can form very stable complexes.18c 
Lanthanides typically form stable complexes through electrostatic interactions with eight or 
nine ligands. It is the preparation of these stable and soluble complexes that is the key to 
taking advantage of the luminescence properties of lanthanides.  
The different types of lanthanide-chelating ligands in use today and the reasons for our 
choice of the DO3A type macrocycle will be covered after some discussion of this 
luminescence. 
 
2.1.2 Lanthanide luminescence 
When a molecule absorbs light in the form of a photon, it can impart enough energy to 
promote an electron up to a higher orbital. The molecule is excited from a singlet ground 
state, S0, up to an excited singlet state, S1. Upon relaxation back down to the ground state 
the released energy is often dissipated into the local environment as heat. However, many 
molecules are able expel the absorbed energy as another photon; this is luminescence.18 
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Figure 20: A representation of the excitation of an electron from ground state to excited state. 
 
There are two types of luminescence; fluorescence (short-lived) and phosphorescence (long 
lived).  
Fluorescence is the rapid radiative decay of a molecular excited singlet state and the 
luminescence lifetime is typically of nanosecond duration. Phosphorescence is a forbidden 
transition and as such is slow and long-lived with a lifetime on a microsecond to hour long 
timescale.18b, 19 
Upon elevation to an excited state (Figure 21), the electron is no longer influenced by the 
spin of the other electron of opposite spin in the pair. Hence within the excited state there 
is the possibility of the two spins being opposed (singlet excited state), or parallel (triplet 
excited state) to one another.  
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Figure 21: A simplified Jablonski diagram illustrating the fates of an excited electron. IC = Internal Conversion. 
 
Singlet-triplet and triplet transitions are formally disallowed, but occur through a 
phenomenon known as spin-orbit coupling where the magnetic field generated by the 
electronic orbital angular momentum interacts with the spin of the electron. This can lead 
to the electron flipping to the opposite spin and occupying a lower energy triplet (T1) state 
through the process of inter-system crossing (ISC). It is this relaxation from the triplet 
excited state (T1) to the singlet ground state (S0) that results in phosphorescence. This is a 
forbidden transition. It is forbidden for an electron to change orbital and flip spin 
simultaneously, therefore the transition has a low probability of occurring and 
phosphorescence can take place long after the excitation pulse has been removed.18c,19 
Although lanthanides tend not to possess emissive triplet states they are still often 
described as phosphorescent due to their relatively long lived emission.  
Lanthanides each have a very distinct unique spectrum due to the relaxation from the 
singlet excited state to a number of well defined energy levels (Figures 22 & 23). Each 
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spectral peak corresponds to a specific transition and thus an emission spectrum can aid 
characterisation through confirmation of the presence of a specific lanthanide metal. 
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Figure 22: Left) An energy level diagram for terbium transitions; Right) A terbium emission spectrum from the  
author’s own work illustrating the different electronic relaxation transitions. 
 
 
Europium 
Wavelength (nm)
5D4→7F2
Wavelength (nm)0
475
500
525
550
575
600
625
650
675
700
725
E
ne
rg
y
E
x c
it
at
io
n
E
m
ission
5D0→7F4
5D0→7F0
5D0→7F2
5D0→7F1
5D0→7F3
Wavelength (nm)
E
m
ission
 
 
Figure 23: Left) An energy level diagram for europium transitions; Right) A europium emission spectrum from 
the  author’s own work illustrating the different electronic relaxation transitions. 
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Figure 24: A ytterbium spectrum by illustrating the 980 nm emission band. Adapted from Ref. 19b.  
 
The xXx notation signifies the term symbol describing the specific energy level within the 
metal. A general form of (2S+1)LJ is applied where S is the spin multiplicity, L is the total 
orbital angular momentum and J is the quantum number describing the total angular 
momentum.19 
With an extinction coefficient (є) typically of the order of 1 M-1cm-1, the ability of lanthanide 
metals to absorb energy from a photon and enter an excited state is poor. This in turn 
leads to very weak emission in comparison to organic fluorophores which possess 
extinction co-efficients of the order of 1x105 M-1cm-1. This is due to the transitions involved 
in the formation of a lanthanide excited state being f→f transitions which are Laporte 
forbidden as there is no inversion of parity. It may be argued that the d→d transitions of 
strongly absorbent and emissive transition metal complexes are also forbidden, and this is 
true, but lanthanide f-orbitals are low lying and shielded by outer 5s2 & 5p6 orbitals and as 
such are not disturbed by the surrounding ligand structure. Transition metal ‘d’ orbitals on 
the other hand are not so well shielded and subject to distortion from molecular vibrations 
which lower the symmetry and render the Laporte selection rules less applicable.19 
However, this weak absorption characteristic of the lanthanide metals can be overcome 
through a phenomenon known as energy transfer (ET). 
 
2.1.3 Energy transfer 
A weakly absorbing lanthanide ion can be excited through energy transfer from an 
appended chromophore rather than through the disallowed and hence inefficient direct 
excitation of the metal itself. This is possible when an antenna, normally aromatic, 
chromophore absorbs light in the UV region (λ = 200-400 nm) and then directs this energy 
to the metal centre in an allowed transition.19 The metal can then relax as previously 
described and relax through the emission of luminescence (Figure 25).20 
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Figure 25: Energy transfer and the Jablonski diagram; adapted to include a nearby lanthanide metal. 
 
This luminescence is known as sensitised emission and it is normally only possible if there 
is sufficient overlap between the emission spectrum of the donor and the absorption 
spectrum of the acceptor. Another possibility is superexchange where energy transfer is 
actually mediated by another atom.  
The mechanism for energy transfer is rationalised by one of two mechanisms, dependent 
upon the ligand. A conjugated system allows the overlap of π-orbitals from donor to 
acceptor and hence the free flow of electronic energy to excite the metal; this is known as 
the Dexter mechanism.20b However if the metal is complexed within a ligand where there is 
no ‘through bond’ energy pathway, it is thought that the energy can be transferred through 
space via the dipole-dipole interactions of solvent molecules. This is known as the Förster 
mechanism and the efficiency of the process is dependent upon the proximity of the 
chromophore to the metal.20c/d 
In the case of lanthanide complexation the ligands for each of the two energy transfer 
mechanisms are not always obvious as both mechanisms can be occurring simultaneously. 
Bipyridyl (bpy) and (terpy) cryptand complexes are conjugated systems, whereas the DTPA 
and DOTA azamacrocycles are not and the favoured pathway of energy transfer must be via 
the Förster mechanism (Figure 26). However, in those systems where there is no obvious 
conjugated π-system pathway for conventional Dexter energy transfer it is still not always 
straightforward Förster energy transfer as the small spectral overlap between aryl donor 
and lanthanide acceptor state prohibits this mechanism somewhat. Indeed, all four 
compounds in Figure 27 are likely to have significant Dexter superexchange 
contributions.21  
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Figure 26: Examples of effective means of constructing energy-transfer lanthanide coordination complexes.19 
 
 
 
Figure 27: Examples of tetraazamacrocyclic systems where excitation of the appended chromophore leads to 
efficient metal centred luminescence.21b 
 
2.1.4 Luminescence lifetime (τ). 
The primary motivation for taking advantage of lanthanide luminescence brings us back to 
long-lived emission which allows time-gating to eliminate background noise. This lifetime is 
especially evident in Eu and Tb which possess lifetimes (τ) of up to 5 ms.22 
The lifetime of a luminescent species is calculated by measurement of the intensity of 
luminescence at increasing time intervals after the original excitation and using 
mathematical formulae (Figure 28), to derive a calculated fit to the observed data. 
 
 
 
 
 
Figure 28: Calculation of the luminescence lifetime (τ). 
 
 
The rate constant (kobs) is derived from all the molecular processes including luminescence 
and non-radiative decay.  
 
2.1.5 Quenching 
Non-radiative relaxation can occur through the intersystem crossing (ISC) process, but is 
predominantly used to describe the transfer of vibrational energy to the molecules in the 
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surrounding environment. This can have an adverse effect upon lanthanide luminescence 
as the metal excited state has good Franck-Condon spectral overlap with the vibrational 
harmonics of nearby O-H oscillators. Therefore if there is local protic solvent, the preferred 
route of decay is through the O-H oscillations, and luminescence intensity and lifetime is 
quenched. Lanthanides with many electrostatically coordinated water molecules show very 
weak luminescence whereas just one or two appended water molecules allows strong 
luminescent emission and long lifetimes (Figure 29).19 
The lifetime of the complex is therefore influenced by the hydration state of the metal. 
Moving from H2O to D2O, the overlap is reduced due to the lower energy of the O-D 
oscillation and the consequent energy match between the lanthanide excited state and 
higher harmonics of the O-D oscillator. This reduces the quenching and enhances the 
luminescent lifetime. From the differences in luminescent lifetime from the two hydration 
states in the deuterated and non-deuterated solvent, it is possible to quantify the number 
of water molecules bound to a certain complex.22b This however is riddled with complexities 
as the N-H and C-H oscillations may or may not also be involved depending on the ligand 
and the energy of the emissive state of the lanthanide. 
 
 
Figure 29: Energy level diagram illustrating the ground and excited states of Eu, Tb and Yb with their emissive 
levels shown in purple. The green scale shows quenching. The energy levels of O-H oscillations are shown with a 
non-radiative Tb3+ decay route reducing the luminescence lifetime and extinction co-efficient of the Tb excited 
state.19 
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However, not only will these factors need to be taken into consideration, but it also brings 
us back to the gadolinium species employed as MRI contrast agents.14g MRI images are 
enhanced by sharp variations in the rate of relaxation of water protons from tissue to 
tissue. Gadolinium has seven unpaired electrons and as such is highly paramagnetic. 
Stable complexes containing gadolinium with an appended water molecule which 
exchanges rapidly cause a reduction in the relaxation times of the 1H nuclei on the nmr 
timescale and thus enhance the contrast. The key difference however is that T1 relaxation 
in MRI is very different from the non-radiative relaxation of an excited electronic state. 
 
2.1.6 Eu, Tb and Yb and their chromophores 
The study of luminescent lanthanide complexes has predominantly centred around the use 
terbium and europium as the metals. This is due to their long-lived luminescence and 
susceptibility to energy transfer from chromophores whose emission is in the ultra violet 
region.22c  
The choice of chromophore in europium and terbium complexes is limited by the large 
energy gap between the excited emissive state and the ground state. With terbium the 
energy gap is 20,300 wavenumbers and this renders energy transfer inefficient from all but 
the simplest chromophores such as benzyl and indolyl groups with their high energy triplet 
states. Larger chromophores such as naphthalene, have triplet states too close in energy to 
the terbium excited state, resulting in reversible and temperature sensitive transfer.  
Europium has a smaller energy gap of 17,500 wavenumbers which allows a greater choice 
of effective chromophores with lower energy excited states. The most effective systems 
employ chromophores with smaller energy differences between the singlet and triplet 
states. For instance, the sensitising chromophore for an efficient europium transfer needs 
to have a triplet state of at least 2000 cm-1 above the europium 5D0 (17200 cm-1) excited 
state to avoid back energy transfer from the excited lanthanide ion to the triplet state of the 
sensitiser.19   
 
 
Figure 30: The wavelengths of Eu, Tb & Yb emission maxima. 
 
It is important to remember that the wavelength of europium and terbium metal-centred 
luminescence is still in the region where biological autofluorescence from media such as 
human serum (500-600 nm) can interfere with the emission signal.22d It is the long 
luminescent lifetime that is manipulated to distinguish the metal from the background. 
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However with ytterbium it is a different story as the emission maximum is at 980 nm in the 
near-IR region of the spectrum where biological interference is minimal. 
The quest for near-IR emissive probes suitable for bio-imaging is becoming more and more 
important. It has become apparent that to be able to use long wavelength excitation is ideal 
as this avoids unnecessary excitation of luminescent biological species, and emission 
occurs at a biologically transparent wavelength.  
Lanthanide complexes that emit in the near-IR include neodymium, ytterbium and erbium. 
The emissive states of these lanthanides are much lower in energy than the analogous 
states of terbium and europium, and a range of more complex and longer wavelength 
chromophoric ligands become available.  
However there is a large disadvantage with using near-IR emissive lanthanides as 
luminescent lifetimes are shorter but most importantly quantum yields are lower compared 
to europium and terbium complexes. Near-IR lanthanide emission is also still quenched by 
the lower harmonics of the O-H oscillations. 
Luminescent lanthanide complexes are used in biological assays.19 Traditionally 
radiotracers have been employed for the detection and study of specific antibody-antigen 
interactions at trace concentration in biological samples. These have now been eclipsed by 
fluorescent assays involving lanthanides, where the metal-centred fluorescence is either 
directly excited through the inefficient disallowed pathway, or, when the assay shows 
successful antibody to analyte binding, an energy transfer excitation pathway is available 
to provide enhanced luminescence signifying a positive outcome (Scheme 1). 
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Scheme 1: Representation of a Eu based assay; the traditional DELFIA assay. Adapted from Ref. 19. 
 
It is both the near-IR ytterbium emission and the long-lived europium and terbium 
emission that is of interest in this project for use in targeted luminescent probes that are 
not only tumour specific but also avoid the problems associated with autofluorescence 
through time-gated detection. 
 
There needs to be a means of synthetically locating the chromophore at an appropriate 
distance from the lanthanide metal. The previously discussed Förster mechanism of energy 
transfer showed a relationship of r-6 where ‘r’ is the distance from chromophore to metal.20d 
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It is envisaged that a unique way of constructing the system could be through a 
multicomponent reaction where the metal is complexed as one component, the 
chromophore is second and the third would be a means of attachment to a biological entity 
for imaging purposes. This is where a multicomponent reaction comes into its own. 
 
2.2 The Ugi 4-component condensation reaction (U-4CCR) 
Ivar Ugi (1930-2005) was a German chemist with a penchant for one-pot multicomponent 
condensation reactions where more than two starting materials react to form a complex 
product with features of each of the reactants, in a single step.23a The chemistry of 
multicomponent reactions is now vast. The benefits have become more and more obvious 
with prolific yields, mild conditions and the ability to access incredibly complex structures 
in a single step, rather than through a lengthy and often inefficient stepwise synthetic 
sequence. Another attribute of multicomponent reactions is that the structure of the 
reaction product can be easily manipulated through the variation of one or more of the 
individual components.23a/b  
The Ugi 4-component condensation reaction (U-4CCR) is analogous to the Passerini 3-
component reaction. These are classic isocyanide-based multicomponent reactions where  
the isocyano functional group is unique in its ability to react with electrophiles and 
nucleophiles at the same atom, resulting in an incredible diversity of products. The 
components in the Passerini reaction are an aldehyde or ketone, an isocyanide and a 
carboxylic acid (Scheme 2).  
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Scheme 2: An example of the Passerini reaction in the synthesis of an HIV protease inhibitor.24 
 
The Ugi 4-CCR involves a fourth substituent, an amine. Mechanistically the reactions are 
quite different. There are a number plausible proposed mechanisms for the Ugi 4-CCR, all 
of which involve the pre-formation of an imine through a condensation reaction between 
the aldehyde and the amine. One proposed mechanism involves the formation of a 
heterocyclic intermediate, but the favoured route involves a Mumm rearrangement 
(intramolecular acylation) to form a product bearing features of each component (Scheme 
3 & Page 55).23b,25-27 
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Scheme 3: An example of the Ugi 4-CC reaction in the synthesis of a HCMV protease inhibitor.28 
 
A perceived synthetic drawback in this chemistry is the isocyanide component. Low 
molecular weight isocyanides are typically highly volatile and remarkably unpleasant 
compounds to handle. The stench is offensive and the scope of their reactivity renders 
many of them toxic. The first chemists who experimented with isocyanides worked 
outdoors!26,27  
Some isocyanides are now commercially available and those which are of larger molecular 
weight and are in solid form, are odourless. Indeed the isocyanide functional group, 
unusual for bearing a formally divalent carbon, has been discovered in many natural 
products.29 The divalent carbon is obvious in 13C-nmr where a distinctive peak is observed 
at ~ 100 ppm.  
Isocyanides are typically synthesised from primary amines through either dehydration of 
the corresponding formamide, or directly from the amine precursor.27,29b 
 
It was envisaged that an Ugi 4-CCR would be an effective means of constructing a 
sensitised luminescent lanthanide containing system which can be attached to a biological 
delivery motif for specific targeted imaging. The next item of importance in this discussion 
is the biological entity that is to be the vector in the system and as such must be specific to 
the types of malignancy which require highly sensitive illumination. 
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2.3 The vehicle and its tumour targets; RGD and Integrins 
An introduction to the RGD amino acid sequence and its recognition and binding to 
specific cellular surface receptor proteins must begin with an overview of some of the 
relevant biological processes involved in malignancy and an introduction to our cancer 
specific target, the αvβ3 integrin. 
 
2.3.1 Cancer and angiogenesis 
There are many postulated models attempting to explain how discrete genetic variations 
can transform a normal healthy cell into a cancerous cell. The heterogeneous nature of 
cancer renders the unveiling of a general mechanism impossible, however, there are 
similarities between the various classes of malignant cells such that it is safe to state that 
the occurrence of spontaneous genetic changes is a major factor.30 However, the purpose of 
these words is not to discuss carcinogenesis, but to delve beyond this unfortunate 
initiation, and discuss the progression of tumours and how a fundamental aspect of this, 
angiogenesis, relates to the research carried out during this PhD. 
Angiogenesis, is the growth and development of new vasculature from existing blood 
vessels. The mechanism of angiogenesis and the unravelling of the numerous parties 
involved, with an accurate understanding of their function, is seen as an important step in 
the design of new therapeutic or diagnostic agents for a whole host of oncological, cardio, 
wound healing and other medical applications.31   
Just as in normal healthy biological tissues, tumour survival and progression is completely 
dependent upon access to the cardiovascular system not only for an adequate supply of 
oxygen and metabolites, but also for an efficient means of waste disposal. Without access 
to the blood stream, most tumours would remain small and the incredible exponential 
growth and spread commonly perceived would not occur.  
 
In some cases this process of new blood vessels sprouting or branching forth from pre-
existing vessels is unable to keep up with the rate of tumour growth and the cancer cells 
furthest from the blood supply suffer from deficiencies. 
However, the dependency upon vascular access is by no means consistent and varies 
according to the type of tumour and its stage of progression. In general however, access to 
the host blood supply and the generation of a special local vasculostructure is a rate-
limiting factor in tumour propagation.30   
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Figure 31: a) A dormant avascular tumour. It remains this way until an equilibrium of proliferating and 
apoptosing cells is achieved and angiogenesis is triggered. Pericytes are smooth muscle cells that help regulate 
blood flow. In tumours the weakness and chaotic nature of the new vessels is partly due to the inefficient 
recruitment of properly organised mural cells, or pericytes; b) The onset of angiogenesis: The dilation of the blood 
vessel; c) Sprouting; d) New vasculature forms and matures recruiting perivascular cells (vessel periphery 
‘scaffolding’ cells); e) The blood vessels continue to sprout and grow for the lifetime of the tumour and are 
specifically drawn towards the pro-angiogenic factor releasing hypoxic areas to provide the essential nutrition and 
oxygen. Adapted from Ref. 30. 
 
Pathologists and oncologists have long known that cancer cells located further than 
approximately 0.2 mm from a blood vessel have a significantly diminished survival rate 
with comparison to those found closer. This is due to the optimal distance for efficient 
oxygen diffusion being exceeded, and thus cells found within 0.2 mm can guarantee a 
steady oxygen supply; whereas those outside this limit suffer from a lesser to greater 
degree of hypoxia.29 However, this is by no means universal, as human tumour oxygen 
consumption rate is variable, with some tumours, for instance prostate or germ-cell 
testicular tumours, having a high microvessel density in comparison with normal tissue, 
and others, for instance lung, mammary and colonic carcinomas having a much lower 
oxygen necessity.32  
Hypoxic cells are in danger of necrosis triggered by the p53 protein, the cellular 
housekeeper, which orchestrates its response according to the threat posed to a cell. This 
rapid death and disappearance of a cell is known as apoptosis. However, the deactivation of 
the p53 signalling system through malignancy-directed mutation explains the survival of 
hypoxic cancer cells outside the effective oxygen diffusion radius. Hypoxic cells are 
ubiquitous in human tumours.  
Chapter 2: Introduction 
 34
A deficiency of oxygen, however, is not the only quandary faced by a cell positioned at a 
greater than 0.2 mm distance from a blood vessel. Other factors fundamental to cell 
survival include the ability to acquire nutrition and discard carbon dioxide and other 
metabolic waste products through interaction with the vasculature. Capillary networking 
within normal tissue is so dense and intricate that the majority of cells are within a few 
cells diameter of a blood source. In especially active cells with high metabolism, cells 
usually have direct contact to one or more capillaries.29 The ability of tumours to initiate 
and develop a blood supply through angiogenesis is fundamental to their survival, and 
more and more their treatment with intraveneous chemotherapeutics and steroids. 
The onset of angiogenesis, or the ‘angiogenic switch’, can occur at any time during tumour 
progression depending upon the cancer type and its specific microenvironment.30 It should 
also be made clear that angiogenesis is a quite normal procedure occurring in several 
natural biological processes including within the female reproductive organs, in tissue 
undergoing physiological growth and in the healing of injuries. This normal and organised 
regeneration and development of circulatory structure known as physiological 
angiogenesis, is distinctly different in character from tumour angiogenesis where the 
architecture is rough and chaotic. This is due to an imbalance in the variety of activators 
and inhibitors which coordinate angiogenesis. 
There are numerous influential components involved in the process of angiogenesis and 
they will not all be covered in detail in this discourse, indeed the complexity of the role of 
many of the activators such as VEGFs are still not fully understood.  
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Figure 32: A cartoon illustrating factors inducing angiogenesis, activators; and those intent on disrupting this 
process, inhibitors. 
 
The ‘activators’ are primarily growth factors released by hypoxic or pathological tissues 
such as tumours, and they stimulate new blood vessel creation through the recruitment, 
proliferation and ordering of endothelial cells.33 The release of these signalling factors, such 
as the potent VEGF (Vascular Endothelial Growth Factor), is detected and the signals 
understood by a family of endothelial and blood vessel cellular surface receptors, known as 
integrins. The resulting stimulation of endothelial cells instigates migration and 
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accumulation at the site of signalling. Enzymes such as proteases are then released and 
degrade the vessel basement membrane allowing cells to escape and proliferate in the 
surrounding extravascular matrix initiating the formation of the labyrinth of endothelial 
and smooth muscle cells that is the basis of a new vessel. 
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Figure 33: A diagram illustrating the basic mechanism of angiogenesis. a) Accumulation of endothelial (red) and 
smooth muscle cells (green); b) Smooth muscle cells detach and the blood vessel dilates as the basement 
membrane and ECM is degraded; c) Endothelial cells migrate towards angiogenic stimuli from tumour cells; d) 
Endothelial cells proliferate, presumably guided by smooth muscle cells; e) Endothelial cells adhere to one 
another alongside smooth muscle cells and a new basement membrane is formed. These sprouts will then fuse 
with other sprouts to create the new circulatory systems. Adapted from Ref. 30. 
 
2.3.2 Endothelial cells 
Endothelial cells are found throughout the circulatory system but originate in the bone 
marrow as young undifferentiated cells before being released and maturing into the 
endothelial cells in the blood stream.  
Hypoxic regions of tumours also attract macrophages. This would, at first glance, appear to 
be a mechanism of cancer cell destruction as macrophages are immune cells normally 
deployed to scavenge and eliminate infection and abnormal cells. However, evidence 
suggests that some of these immune cells actually aid tumourigenesis as, being quite 
tolerant to hypoxia, they excrete VEGF the potent angiogenic factor which, in turn, reduces 
the hypoxia by attracting endothelial cells which induce capillary formation through 
interaction with smooth muscle cells as described above (Figure 33). Some tumour 
associated macrophages (TAMs) also secrete matrix metalloproteinase enzymes (MMPs). 
These enzymes enhance angiogenesis by not only liberating endothelial cells, but also 
through excavating space for tumour expansion through the disruption of existing tissue 
structure. 
The mechanism of angiogenesis can occur in three ways. Sprouting, although the most 
commonly observed mode of blood vessel generation, is not the only type of angiogenesis. 
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Bridging and intussesception are two other, quite different angiogenic pathways (Figure 
34). 
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Figure 34: The pathways to new blood vessel formation. Adapted from Ref. 31. 
 
It is upon the cellular surface of endothelial and smooth muscle cells that are found the 
targets of interest to this project. These are surface receptor proteins and those of 
particular interest are called integrins. Certain integrins have been found to be upregulated 
on endothelial cells which accumulate at the command of cells requiring a blood supply 
and hence are in great density in and around tumours. 
 
In summary, cells lacking an adequate oxygen supply release angiogenic factors which 
stimulate the ingrowth and branching of capillaries. Cells involved in angiogenesis, 
particularly endothelial cells, bear increased levels of integrins in comparison to 
surrounding cells. As endothelial cells are in a high density around sites of angiogenesis it 
makes these integrins a potential highly specific target for the binding of luminescent 
probes to highlight tumour sites with great specificity. 
 
2.3.3 Integrins 
The past few years have seen the identification of significant roles for integrins in the 
development of cancer, especially in cell proliferation, metastasis, and angiogenesis.  
Cells are dependent upon the extracellular matrix (ECM) for growth and division. The ECM 
consists of a series of glycoproteins, including collagens, laminins, proteoglycans and 
fibronectin which are oligosaccharide-appended polypeptides and are fundamental for 
intracellular communication (Figure 35). Mammalian cells possess specialised cellular 
surface receptors to detect and bind to elements of the ECM. One special family of these 
receptor proteins are the integrins. 
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Figure 35: A representation of the complexity of the extracellular matrix (ECM). An elaborate network of proteins, 
glycoproteins and proteins such as collagen are entwined and interact with one another enabling intercellular 
signalling. Most cells require attachment to the extracellular matrix to grow, survive and proliferate. 34 
 
Integrins are protein heterodimers formed by the non-covalent association of an ‘α’ and ‘β’ 
subunit. The integrin family is composed of 18α and 8β subunits that are contained in 24 
αβ heterodimeric combinations.35 Integrins act as communication linkers allowing 
information to be transported between the extracellular matrix and the nucleus of the cell, 
and intercellularly through interactions with neighbouring cells.36 
The structure of these membrane proteins lends them to involvement in adhesion and 
signalling as they possess large extracellular domains (Figure 36). 
Integrins depend upon divalent cations (Ca2+, Mg2+) to bind extracellular ligands which, 
although being structurally diverse, are all recognised due to binding to specific amino acid 
residues. Binding specificity towards a particular ligand is achieved through contact points 
upon the integrin. High affinity binding to ligands occurs in response to so called ‘inside - 
out’ cellular signals that cause extracellular integrin structural alterations, rendering the 
integrin to ligand binding compatable. As a result, the ligand binding induces further 
structural modifications which trigger ‘outside - in’ communications.37 
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Figure 36: A cartoon of a typical αβ integrin pair. 
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2.3.4 Integrin αvβ3 
The integrins, αvβ3 and α5β1 have been found to play a key roles in angiogenesis, indeed it is 
thought that of all the integrins, the inhibition of αvβ3 signalling is one of the most 
important targets for the treatment of cancer.38 Blocking of this integrin with antibodies, 
peptides, peptidomimetics and other antagonists has demonstrated efficient disruption to 
tumour growth, angiogenesis and metastasis. αvβ3 integrins are highly expressed on 
activated endothelial cells, new born blood vessels and on some tumour cells (melanoma, 
glioblastoma, ovarian and breast) making their attraction as imaging targets even more 
promising due to the dense congregation at tumour sites making them stand out against 
surrounding tissue.38,39 
The high binding affinity of this integrin for extracellular proteins in the surrounding 
matrix means that they play mediation roles in the migration and accumulation of these 
endothelial cells and regulate their growth, survival and differentiation. It is a tri-amino 
acid sequence which is the crucial to the binding of extracellular entities to αvβ3 integrin 
known as RGD. It is this RGD sequence that will be employed in this project as the site-
specific delivery motif for the luminescent lanthanide probes discussed previously. 
 
 
RGD
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Figure 37: Crystal structure illustrating the binging site of an αvβ3 integrin interacting with the RGD. Pdb code 
1L5G.40,41 
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2.3.5 RGD 
The tri-amino acid sequence arginine(R)-glycine(G)-aspartic acid(D) is shown below. In 
extracellular matrix proteins this motif represents only a fraction of the amino acid make-
up of the whole protein but it is the small section fundamental to αvβ3 binding. 
 
 
 
Figure 38: The tri-amino acid sequence RDG. 
 
Proof of αvβ3 integrin binding to RGD has been shown through analysis of the crystal 
structure of the extracellular section of αvβ3 in complex with a cyclic RGD ligand (Figure 
39).41  
However the RGD sequence is also recognised as an essential binding motif for seven of the 
24 integrin receptors. The roles of integrins are diverse and as such RGD may not be quite 
so αvβ3 integrin specific as first thought. However, it is the increased density of integrin αvβ3 
receptors in tumour sites that still renders the ongoing research of great potential. 
 
2.3.6 Previous αvβ3 integrin targeting with RGD 
Ways of synthetically mimicking the RGD motif found in extracellular proteins are 
continuing to evolve. The field has seen the rapid development of a variety of small-
molecule integrin antagonists with diverse ligand characteristics. Linear RGD peptide 
derivatives and those cyclised through disulphide bridges have been shown to exhibit low 
specificity and poor metabolic stability, being susceptible to breakdown by peptidases and 
proteases.42 Through screening for the best spatial replication of the orientation of the RGD 
unit in the integrin binding site, high selectivity and binding affinity were recorded for 
cyclic pentapeptides with a D-phenylalanine amino acid unit.38 Of particular interest is the 
cyclic peptide cRGDfV which has been further optimised through simple N-methylation to 
afford c(RGDf(NMe)V) which is the glioblastoma drug CilengitideTM presently in phase III 
clinical trials (Figure 39).39 
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Figure 39: Left) The cyclic pentapeptide derivative c(RGDf(NMe)V; (CilengitideTM).38 Centre) Highlighted cutout of 
the crystal structure showing c(RGDf(NMe)V in complex with key αvβ3 binding site residues. Right) A surface 
map illustrating the availability of the valine residue for manipulation. From PSDB (1L5G) & adapted from Ref. 41. 
 
Although efficient as an αvβ3 antagonist the structure of these cyclic valine containing 
pentapeptides greatly limits their potential for further derivatisation to include alternative 
signalling units. In our case we need a position within the cyclic peptide which does not 
interfere with the integrin binding site and is available for elaboration with a luminescent 
probe. 
The only two amino acid residues not involved in binding are D-phenylalanine and valine. 
As the D-phenylalanine residue is important for orientation and stability purposes, 
substitution of the valine residue with lysine was deemed a perfect means with which to 
allow conjugation with chelators, prosthetic groups and dyes at a greater distance from the 
active site. Reported results were very satisfactory with the lysine residue having no 
significant impact upon binding affinity.39,43  
Technitium 99m radionucleotide targeting using RGD derivatives has been investigated 
quite thoroughly for in vivo SPECT imaging potential with mixed results. 99mTc-DKCK-
cRGDfK (Figure 40), showed specific uptake in vivo, but suffered from high renal 
accumulation and low metabolic stability.44 
 
 
 
Figure 40: Technitium 99m radioactive αvβ3 integrin targeted probe 99mTc-DKCK-cRGDfK.44 
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There is ample evidence for the potential of macrocyclic chelation of other radio metals 
such as 111In (SPECT); 68Ga, 64Cu, 86Y (PET), and their subsequent conjugation to RDG 
peptides. Also reported is the effective incorporation of the excellent 18F-galactose derivative 
(figure 41).39 Other analogues of RGD rather than cyclic pentapeptides have also been 
successfully explored for αvβ3 targeting, including multimeric 18F appended species where 
improved tumour accumulation and integrin binding affinity was observed upon 
multimerisation. Increased stability was observed using D-lysine to join the cyclic peptide 
units through PEG linkers.45 
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Figure 41: [18F] Galacto-RGD. The ‘gold standard’ for clinical PET imaging of αvβ3 integrin expression. The galacto 
moiety is to increase hydrophilicity. In comparison to directly fluorinated cyclic RGD peptides and 125I 
radiolabelled analogues, this galacto derivative shows superior tumour uptake and impressive PET contrast.39 
 
The laboratory of Chen developed a series of radiolabelled cyclic peptide ligands to target 
the integrin αvβ3, to investigate its angiogenic function, and direct the development of a 
successful antiangiogenic therapy based on integrin antagonism.46 Chen also investigated 
PET diagnostic probes using radiotracers. This involved the use of both 64Cu and 125I 
radioisotopes appended to cyclic RGDyK (y = D-tyrosine).46-48 Of particular interest in the 
125I study was the fact that the introduction of a polyethylene glycol (PEG) unit onto the 
cyclic peptide prior to labelling with 125I enhanced retention in the tumour, showed lower 
kidney uptake and improved the rate of blood clearance.48 The 64Cu study was similarly 
enhanced by a long PEG spacer unit and with a half life of 12.8 hours the probe was shown 
to bind and show good tumour specificity up to four hours post injection (Figure 42).47 
     
 
Figure 42: The c(RGDyK)-PEG-DOTA64Cu probe and a PET image showing tumour-specific accumulation.49 
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2.3.7 RGD & the near-IR (NIR) 
Whilst the construction, binding affinity, metabolic stability and tumour specificity of the 
RGD section of the probe is of great importance, the primary interest and concern of this 
project is the use of RGD in optical imaging. Near-IR optical imaging is gaining increasing 
importance for powerful preclinical disease study and operative endoscopic fluorescence 
imaging. The beauty of near-IR fluorescence is that biological absorbance is minimal and 
the excitation wavelength is out of range to incur the problematic biological chromophoric 
interference. Therefore photon tissue penetration of 7-14 cm is theoretically adequate for a 
whole host of applications.50 
Several integrin-targeted NIR probes have been developed and there are a variety of 
commercially available NIR dyes. An interesting and very recent development with only one 
reported study to date is fluorescence mediated tomography (FMT). This technique holds 
great promise and involves the fluorescence emission being resolved quantitiatively, and 
processed to give an accurate three-dimensional image analogous to PET, but without the 
expensive and logistically problematic radionucleotides.51 
The cyclic(RGDfK)-Cy5.5 (Figure 43) probes were used with great success in the targeted 
imaging of mice bearing subcutaneous human xenografts, however this is regarded with a 
level of scepticism as xenografts can be imaged without looking at the bodywide expression 
of the probe due to the tumour being grown just under the skin and the scan depth being 
set to the depth of the protruding tumour. It is also well known that Cy 5.5 is expensive 
and unstable.52 However, the clear accumulation of the probe at the tumour site and the 
efficacy of the tissue penetration from the relatively low wavelength near-IR emitter Cy 5.5 
(λem. = 650 nm) bears testament to the potential of RGD probes in optical imaging.53 
 
c
 
 
Figure 43: Left) c(RGDfK)-Cy5.5. Right) An example of the xenograft tumour image generated using a 
fluorescence spectrometer.54 
 
RGD is not the only peptidic probe with selectivity towards αvβ3 integrin. Indeed other more 
complex analogues have demonstrated good binding affinity and problems associated with 
rapid wash out from the tumour have been circumvented through incorporation of a biotin-
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streptavidin construct.39 Indeed, slightly altered amino acid sequences such as in the 
sophisticated fluorescent ligand cypate-GRDSPK, have shown highly specific uptake and 
concentration within αvβ3 expressing tumours. Interestingly in this instance the binding 
was found to be mediated exclusively through interaction with the β3 subunit.55 
Although the RGD interaction with αvβ3 integrin has been quite thoroughly investigated for 
PET and SPECT imaging purposes, its potential has yet to be fully realised in fluorescence 
imaging and so remains a very active field of research to which we will add. 
 
2.4 Molecular imaging & multimodality on the nanoscale 
The development of emissive optical probes is becoming essential to the cellular and 
biochemistry fields not so much for diagnostic imaging, but more to glean information 
about the structure and biology of specific physiological functions. It has become apparent 
that the emitted photons carry information in their energy, lifetime and polarisation which 
can be processed and interpreted into valuable information about the local cellular 
environment including the concentration of anionic metabolites and cationic species such 
as Ca2+ & Zn2+, and pH information, depending on the type of probe.39 
Molecular imaging is defined as the characterisation and measurement of biological 
processes at the molecular level.56 Whereas conventional imaging techniques detect 
anatomical and functional changes, they provide little or no information on specific 
molecular biomarkers such as growth factor receptors, protein kinases and cell adhesion 
molecules which are cancer specific.56,57 Detection of these biomarkers allows earlier 
diagnosis, prompt treatment and improved prognosis. Optical imaging is a type of 
molecular imaging and multiple probes with different spectral character could be used for 
multichannel imaging. The major drawback is the poor tissue penetration of light and 
hence this technology may be limited to more shallow monitoring and diagnostics, 
endoscopy and operative visualisation. However, if the probe, for instance, has both optical 
and PET active character, then there are clear benefits in that pre surgical pinpointing can 
be achieved through the intramolecular PET active positron emitting radioisotope, and then 
during the subsequent operative excision of the tumour, the optical component can be 
employed to afford tremendous accuracy.  
Cyclic RGD peptide
Nanocrystal
Quantum Dot (QD) / FeO / Au / Silica
Polyethylene glycol (PEG)
Fluorescent &/or paramagnetic lipids
 
Figure 44: An example of a paramagnetic and fluorescent lisosome nanoparticle for target-specific imaging. 
Adapted from Refs 58 & 59. 
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Several types of nanoparticles have demonstrated multimodal diagnostic imaging potential, 
especially lipid aggregates. The main focus is on lipid-based nanoparticles with MRI and 
optical imaging capabilities. Liposomal nanoparticles (Figure 44) are flexible platforms that 
allow the incorporation of fluorescent molecules such as rhodamine and Cy5.5, and 
chelated metals such as the paramagnetic Gd3+. Reported studies have shown great 
promise and the size of the spherical nanoparticles and quantum dots (QDs) allows 
multiple sites for the three components; the RGD peptide, the fluorescent marker and the 
paramagnetic MRI contrast metal complex, thus enhancing the signal concentration.58 
 
What must be remembered is that conventional organic dyes such as rhodamine and 
fluorescein are prone to photobleaching which renders them unstable and limits their 
storage time and efficient excitation. Quantum dots are controversial due to their inherent 
toxicity and chemical instability;118 thus the benefits of photo- and chemically stable near-
IR dyes with their long wavelength excitation and emission, makes them an even more 
attractive prospect. 
 
2.6 A summary of the cancer biology discussed. 
The biology and causes of oncogenesis are bewilderingly complex, indeed if it were fully 
understood we wouldn’t be where we are today. However, a clear picture of the many 
processes and entities involved continues to emerge. The big problem with most 
therapeutics is the lack of disease-cell specificity, but the targeting and inhibition of many 
specific contributory parties continues apace. However, the purpose of this research is not 
therapeutics and inhibition, but diagnostics, and more precisely the development of 
synthetic strategies towards targeted powerful optical fluorescence imaging agents. 
The intention of the previous pages, whilst admittedly a chemist’s eye view of biology, is to 
offer the reader an understanding of some of the important mechanisms in the propagation 
and spread of tumours; and through this to home in on some of the principal entities on a 
cellular level. It is through an understanding of the mechanism of action of the integrin 
discussed that we highlighted a tumour-specific target. 
It is hoped that the attention afforded to the αvβ3 integrin was enough to convince that this 
cellular surface protein is prolific around tumours due to its enhanced expression on the 
endothelial and other cells that are fundamental to the growth and spread of tumours 
through angiogenesis.  
The RGD tripeptide sequence will be the delivery vehicle in this study and it will be 
manipulated to incorporate a lanthanide metal centred luminescence system without 
interfering with the integrin binding site. 
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2.6 The original synthetic plan 
The proposed synthesis was broken down retrosynthetically by simply deciding that the 
coupling of the fully deprotected cyclic peptide to the fluorescent probe should, if possible, 
be the final step of the synthesis (Scheme 4). This was due to totally different synthetic 
protocols being devised for the two moieties, and also due to the risk of complications in 
further synthetic steps being enhanced with the larger more functionally complex molecule. 
 
 
Scheme 4: Left) The complete luminescent lanthanide probe. Right) The key disconnection revealing the 
protected cyclic peptide cDfKRG below, and the lumophore above. 
 
2.6.1 Synthesis of the sensitised luminescent lanthanide complex 
The initial section of the synthetic strategy involved discovering the most efficient energy 
transfer combinations of lanthanide metal and intramolecular chromophore. The Ugi amine 
functionality is where, further downstream, we intend to install an attachment point to the 
peptide vector, therefore initially a bulky model amine will be employed to discern the 
optimal conditions and route to the luminescent products.  
The backbone of the luminescent system will be achieved through an Ugi 4-CCR. It is 
unknown at this stage the exact conditions which will be required as the reaction 
components are relatively bulky. The reaction however will be carried out in a polar protic 
solvent such as EtOH as this type of solvent has been found to promote these condensation 
reactions.60 The other components of the Ugi reactions are either commercially available 
(the aldehydes and model amine), or, in the case of the carboxylic acid macrocycle and 
isocyanide would be accessed through a number of steps. 
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Scheme 5: Retrosynthetic analysis of the model compounds. 
 
The carboxylic acid complex will be derived from the tetraazadodecyl macrocycle, cyclen. 
There is plenty of literature precedent for the selective functionalisation of cyclen through 
alkylations with bromoacetates under basic conditions. However there does not seem to be 
a consistent method of selectively forming the tris-functionalised product.  
Literature conditions will be attempted and streamlined to afford a reliable and high 
yielding route to a selectively tris-alkylated cyclen, using ethyl bromoacetate. The 
remaining secondary amine will then be alkylated with tert-butyl bromoacetate prior to 
selective tBu ester cleavage of the same ester to reveal the mono-carboxylic acid ready for 
the Ugi reaction (Scheme 5). 
The isocyanide species will be a simple benzyl isocyanide which will be synthesised through 
a simple condensation between ethyl formate and benzylamine to provide the formamide 
which will then be dehydrated to the isocyanide. 
After successful completion and characterisation of the Ugi 4-CCR products, there are just 
two remaining steps to complete the synthesis. Basic hydrolysis of the ethyl esters with 
sodium, potassium or lithium hydroxide followed by lanthanide complexation from the 
trifluoromethanesulfonate, citrate or chloride salt. 
These final compounds will then be tested for their potential as the energy transfer 
luminescent probe of choice. Reactions thereafter will then employ the effective sensitised 
luminescent combinations in a system where an attachment arm is incorporated into the 
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system in place of the bulky diphenyl methyl amine to allow attachment to the cyclic 
peptide vector. 
The spacer units of choice are ethylene glycols as it is thought likely that this will enhance 
the water solubility of the luminescence probe (Scheme 6). This may or may not be 
necessary however, and a simple alkyl spacer such as amino caproic acid could be swiftly 
made into a suitable Ugi amine through acid catalysed esterification of the carboxylic acid.  
The ethylene glycol amine would be created through several well-precedented functional 
group interconversion steps from the diol.  
 
Scheme 6: Retrosynthetic analysis of the final compounds. 
 
2.6.2 Solid phase peptide synthesis (SPPS) 
The cyclic peptide would be constructed on a solid support using well known and highly 
efficient Fmoc SPPS. Since Merrifield first devised solid phase chemistry,61 this technique 
has revolutionised peptide chemistry and the variety of different solid supports, protecting 
groups and coupling reagents now available is diverse and enables thorough 
experimentation and optimisation. 
Of importance to the solid-phase construction of our pentapeptide is the choice of resin. 
The lysine protecting group which must be selectively cleavable. The precedent we shall 
endeavour to follow as much as possible is a route to the same cyclic peptide using a 
palladium-cleaved allylic lysine protecting group (Alloc), and 2-chlorotrityl resin as a highly 
acid labile solid support. However, as Fmoc-Lys(IvDde) is more readily available and as 
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IvDde can be selectively cleaved using hydroxylamine, this will be employed as our lysine 
protecting group.  
Upon successful completion and characterisation of the linear penta-peptide, DfKRD, the 
protecting group strategy will then determine the extent to which derivatisation of the 
peptide through the lysine side chain can be carried out on the solid phase without 
compromising steps further on in the synthesis such as the fundamental cyclisation.  
 
 
Scheme 7: Retrosynthetic analysis of the SPPS of DfKRG. 
 
Protecting group strategy is fundamental to successful solid phase peptide synthesis.  This 
must include consideration of the reagents required for the cleavage of the linear resin-
bound peptide from the solid support. 
The plan centres around the ability to selectively cleave the lysine protecting group on or 
indeed off the resin for derivatisation with the luminescent lanthanide probe, prior to 
simultaneous concentrated acid removal of the arginine and aspartic acid protecting 
groups (Pmc or Pbf, and tBu), as the final step. This is not ideal as the luminescent section 
must be acid stable, and therefore the extent to which elaboration of the lysine free amine 
side chain is possible on the solid phase will be investigated. Should any subsequent steps 
such as the cyclisation fail, this strategy still allows the cleavage of the linear peptide from 
the resin and solution phase cyclisation prior to selective lysine deprotection and 
derivatisation. 
The cleavage of the linear peptide from the resin must be selective as the cyclisation step 
requires that all other side chains remain protected so as to not interfere with this 
potentially tricky step. Thus a 2-chlorotrityl resin will be employed as this is highly acid 
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labile and will cleave with dilute TFA (1%) affording the linear peptide with just the 
carboxylic acid on the glycine terminus, and the free amine on the aspartic acid terminus,  
without affecting the Pmc or tBu groups (Scheme 8). 
 
 
Scheme 8: The retrosynthetic routes to final labelled peptide product (top left). 
 
There are many variables and deducing the most efficient reaction route will take time. 
Obviously with a selectively cleavable lysine side chain it would seem prudent to leave the 
peptide on the resin for as long as possible and attempt to couple the fluorophore to the 
free lysine and cleave, cyclise and deprotect as the final steps (Scheme 8). This would be 
the perfect route as just one or two final HPLC purifications would be required.  
Indeed another even more efficient route to the final labelled product will be investigated 
and that is the possibility of coupling a spacer unit onto the lysine on the solid phase and 
performing the Ugi reaction, ester hydrolysis and lanthanide complexation all on the solid 
phase prior to resin cleavage, peptide cyclisation and final deprotection. Given the steric 
bulk imparted by some of the constituents this idea does seem ambitious. Solid phase Ugi 
reactions using very simple substituents have been reported,62 so the extent to which this 
could possibly aid the synthesis of the luminescent lanthanide complex will be 
investigated. 
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2.7 Results and discussion  
2.7.1 Ugi components 
As described in the introduction and synthetic plan, the emphasis in the first phase of the 
synthesis was to establish a robust and reliable pathway to model Ugi-derived fluorophores 
which at a later date through the exchange of one substituent, the Ugi amine, would 
provide a means for attachment of the fluorophores to biological delivery motifs for targeted 
imaging. Further to this, these novel model compounds would also prove which 
combinations of lanthanide and chromophore offer the most efficient energy transfer for 
enhanced lanthanide fluorescence. 
 
2.7.1.1 Macrocycle synthesis 
The opening chemistry involved the construction of the only non-commercially available 
component for our Ugi 4-component condensation reactions, the macrocyclic carboxylic 
acid 03. Beginning from cyclen, the literature precedent for this chemistry is rich in the 
use of temporary amino protecting groups or sterically hindered reagents allowing selective 
mono-alkylation before a deprotection step and final tris-alkylation gives rise to the desired 
tris-functionalised products in a four-step sequence (Scheme 9).63 
 
 
Scheme 9: An example of a lengthy route to selective functionalisation of cyclen.64 
 
This seemed quite an inefficient method for accessing these tris N-alkylated cyclens, and it 
was envisaged that through a single step with just over three equivalents of alkylating 
agent we could afford the desired product. However, the precedent for this is inconsistent 
and unreliable.65  
It was desirable to selectively install three ethyl esters before performing an alkylation of 
the final amine with tert-butyl bromoacetate, thereby allowing selective acid hydrolysis to 
afford the mono-carboxylic acid 03. The ethyl esters would then be hydrolysed under basic 
conditions after the Ugi reaction, ready for lanthanide complexation (Scheme 10). 
 
Scheme 10: The strategy for the synthesis of 03. 
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Literature protocols for this first step were attempted and found to be profoundly unreliable 
with 20-50% yields.63,66 The reported conditions obviously require a base and the protocols 
attempted combined either NaHCO3, Na2CO3 or K2CO3 with acetonitrile as the solvent of 
choice. This yielded a combination of the bis-, tris-, and tetra-alkylated products, from 
which the desired thrice substituted product was apparently isolated through an 
unreproducible recrystallisation from hot CH2Cl2. The percentage of desired tris-alkylated 
product was difficult to judge from the crude nmr spectra, and after purification by flash 
column chromatography the nmr spectra ranged from poor to incomprehensible in a range 
of solvents. A consistent feature however, was that the resolution of the 16 central cyclen 
protons was not good and a broad mound covered the area from 2-4 ppm. This is a 
common problem in cyclen derivatives and further investigation showed that increased 
temperature nmr experiments increase the resolution and peak sharpness suggesting a 
reduced rotation issue within the molecule causing the poor resolution on the nmr 
timescale.64,66 
After many fruitless attempts using different bases and purification techniques including 
chromatography (the products streak badly on silica TLC), it was the discovery of a pair of 
papers by Wong et al that began to shed some light on the matter.67,68 Through studies of 
different solvent and base combinations it became clear that the choice of solvent is of 
utmost importance in this reaction. Wong reports that the reaction was attempted in MeCN 
without base, or with one of the following bases: pyridine, K2CO3 or Et3N. The latter was 
found to be not only by far the highest yielding, but tris-selective when alkylation was 
performed using 3.5 equivalents of tert-butyl bromoacetate. Interestingly, with K2CO3 as 
base the outcome was unfortunately an almost equal mixture of bis- tris- and tetra 
alkylated products. However, weakly polar aprotic solvents such as chloroform and 
dichloromethane were found with different alkylating bromoacetates to perform 
consistently, and interestingly, to form selectively and quite specifically either the bis- or 
tris- products. 
 
Figure 45: The X-ray crystal structure of a thrice alkylated cyclen derivative showing cross-ring H-bonding.67 
 
Strongly polar aprotic solvents such as MeCN and DMF, and polar protic solvents such as 
MeOH were found to lead to substantial losses in yield and selectivity. Further to this, the 
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combination of CHCl3 and Et3N with quantities of electrophile from two to eight equivalents 
revealed that no trace of tetra-alkylated product was created even with a great excess of the 
electrophile. The reason for this was revealed upon examination of the crystal structure. 
XRD analysis showed contraction of the macrocycle from a square (3333) conformation to a 
‘squashed’ rectangular (4242) conformation as under the reaction conditions the free 2º 
amine is protonated to a hydrochloride salt and a hydrogen bond is formed to the opposite 
amine nitrogen precluding the formation of the tetra-alkylated product (Figure 45).67 
The electrophile itself was also found to be an important factor as there may be an element 
of steric crowding around the macrocycle if bulky electrophiles are used. In general, 
bromides were found to be the leaving group of choice in these alkylations. However, ethyl 
bromoacetate has not been reported in literature synthetic protocol, and this being our 
elecrophile of choice we had to rely on similar protocols for guidance.  
It was reasoned that an inorganic base would be advantageous from a practical perspective 
as Et3N leads to TLC complications (it is visible with the KMnO4 stain and streaks up the 
plate concealing other reaction constituents). Therefore as previous literature, albeit 
unreliable, employed NaHCO3, it was decided to first attempt a combination involving this 
base with CHCl3 in place of MeCN. 
This led to consistent 70-80% yields of the desired product. The product appears as a 
creamy white precipitate which is collected by filtration. We were also able to develop a 
gradient eluent system to very effectively purify the compound on a short flash silica 
column rather than relying upon the various unreliable reported recrystallisations from hot 
CH2Cl2 or 9:1 acetone/H2O.64 
The alkylation of the fourth amine was achieved quite readily following reported 
conditions.67 By switching the solvent to THF and using Et3N as base, the product 02 was 
afforded in excellent yield. The selective hydrolysis of the tert-butyl ester was performed 
readily under the standard concentrated CH2Cl2/TFA conditions, but at this stage flash 
column chromatography became impossible as the product was stuck fast on the TLC 
baseline. It was hoped that repeated co-concentrations with CH2Cl2 and triturations with 
Et2O would remove all residual TFA to provide us with an adequately pure product, 
however the TFA proved highly tenacious leaving the product as a viscous light-brown oil. 
To fully characterise the product and obtain a satisfactorily well-resolved nmr spectrum an 
HPLC method was employed using an MeCN gradient to afford the pure carboxylic acid 
product 03 as a fine white powder after lyophilisation, in excellent yield (Scheme 11). 
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Scheme 11: The successful reagents and conditions for preparation of the Ugi carboxylic acid 03. 
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2.7.1.2 Solid phase macrocycle synthesis. 
Later in the project, after the Ugi phase, when exploring the possibility of attaching a 
gadolinium species to the peptide for MRI studies, attempts were made to construct DO3A 
macrocycles using solid phase methodology as we were having problems with gadolinium 
complexation. There is precedent for solid phase organic synthesis in the construction of 
DO3A type macrocycles.69 The advantages are significant in that solid phase synthesis 
eliminates lengthy purification steps and can offer remarkable selectivity as one of the 
cyclen amines is protected through the attachment to the resin. The research group of 
Oliver has illustrated the versatility of solid phase organic synthesis by constructing 
sophisticated DOTA conjugates. 69,70 
Successful attempts were made to selectively install three different linker units on the solid 
phase using bromoacetic acid, para-bromomethyl benzoic acid and fmoc-aminocaproic acid 
(Scheme 12). The methodology was consistently rigorous and the products were 
characterised at each stage through taking a few resin beads and employing a mini-
cleavage protocol to confirm the successful transformation by mass spectrometry, and 
measure purity by HPLC. A minor problem with solid phase synthesis is that at each step it 
is difficult to measure the yield as HPLC is non-quantitative, and to get an accurate 
measure of the yield the whole product must be cleaved from the resin thus terminating 
the synthesis. However, HPLC does give a good measure of purity.  
 
Scheme 12: The solid phase attempts at cyclen functionalisation. a) Bromoacetic acid (10 eq.), DIPEA, CH2Cl2; b) 
Cyclen (5 eq.), DIPEA, CH2Cl2; c) Ethyl or tButyl bromoacetate (15 eq.), Et3N, CH2Cl2; d) KOTMS (15 eq.), CH2Cl2; e) 
Gd(OTf)3 (3 eq.), MeOH/CH2Cl2; f) p-Bromomethyl benzoic acid (10 eq.), DIPEA, CH2Cl2; g) Fmoc aminocaproic acid 
(5 eq.), DIPEA, CH2Cl2; h) 20% piperidine / DMF; i) Bromoacetyl bromide (1.2 eq.), DIPEA, DMF, -40°C; j) TFA / 
CH2Cl2. 
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Without a chromophore a molecule is often invisible to the HPLC UV detector; so a benzylic 
group (para-bromomethyl benzoic acid) was employed to compensate for this and also to 
offer a more bulky and rigid spacer unit between the macrocycle and the terminal acid 
which is appended to the resin.  
The selective functionalisation of cyclen was remarkably efficient and in future this is the 
preferred route to the tris-ethylester mono-carboxylic acid product 03. Although often a 
great excess of reagents are employed in solid phase synthesis, the more valuable, such as 
cyclen, can easily be recycled. However, the gadolinium complexation step could not be 
accomplished whilst the macrocycle was on the solid phase, neither, in the instance of the 
benzylic system where the TFA cleavage of the tert-butyl protecting group also cleaved the 
product from the resin, could the metal be complexed in solution. 
As plenty of 01, 02 & 03 had been synthesised in the earlier solution phase synthesis, it 
was decided that there was no further requirement to continue this solid phase synthesis 
as a means of introducing gadolinium to the macrocycle. We had, however, proved its 
efficacy and versatility as an alternative means of constructing mono- and tri-
functionalised DO3A derivatives. 
 
2.7.2 The Ugi 4-component condensation reactions 
As mentioned in the introduction and synthetic plan, the strategy behind using this multi-
component reaction was to bring together the functionality required for lanthanide 
complexation. An intramolecular antenna chromophore to mediate energy transfer, and a 
means of tagging the final fluorophore to the biological delivery motif were to be united in a 
single step. 
 
 
 
Figure 46: The Ugi products. 
 
This Ugi multi-component reaction is versatile and is dependent upon a reactive isocyanide 
component for the successful outcome. However, although crucial for the reaction, the 
isocyanide functionality is the only section of the final compound which is redundant when 
it comes to the excitation and fluorescence. 
The synthetic plan proposed the exploration of different combinations of chromophore and 
lanthanide metal to establish the systems where energy transfer was most efficient. 
Chapter 2: Results and Discussion 
 55
Therefore in this Ugi multicomponent condensation reaction the four different 
chromophores were introduced as the aldehyde component. The lanthanides were to be 
introduced and complexed in the macrocycle as the final step of the sequence. 
The amine is a model bulky amine, aminodiphenylmethane, and would be exchanged for a 
linker unit upon the discovery of an efficient chromophore – lanthanide combination. For 
the purpose of increasing UV visibility in the HPLC purification protocol and latterly due to 
commercial availability, benzyl isocyanide was used as the isocyanide component. This was 
initially synthesised through dehydration of the formamide. However not only was this 
process decidedly unpleasant due to the high temperature vacuum distillation and the 
inherent volatility of the compound, but the reaction was unreliable and low yielding (30-46 
%). For these reasons a commercial source was sought and it was thereafter purchased 
from Aldrich. 
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Scheme 13: A proposed mechanism of the Ugi 4-CCR reaction showing the Mumm rearrangement as the final 
step. 
 
The Ugi reactions were performed using equimolar quantities of each of the four 
components and as polar protic solvents are typically employed in Ugi reactions we chose 
EtOH. Due to probable steric demands around the heterocyclic intermediate (Scheme 13), 
an elevated temperature of 65 °C was required. The reactions were followed clearly by TLC 
where our previous eluent system of CH2Cl2/MeOH/NH3(aq) 90 : 9.95 : 0.05 was effective. 
Both UV and KMnO4 were excellent visualisation methods and over three days the four 
starting material spots conglomerated into a single more powerful spot. Another excellent 
means of assessing reaction completion was when the TLC sample no longer gave off the 
offensive isocyanide odour! 
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Purification was achieved by flash column chromatography and the resulting nmr spectra 
were again poorly resolved and gave no indication of purity. In an attempt to achieve 
improved nmr spectra, the products were further purified by reversed phase HPLC. The 
resultant nmr were clean but the resolution was still inadequate for conclusive 
characterisation.  
A variable temperature nmr experiment was attempted and although improving the 
resolution and sharpening some of the peaks especially the aromatics and backbone 
protons, the outcome was not of high enough quality for unequivocal assignment (figure 
47). Therefore with accurate mass spectra and clean HPLC traces the pure products were 
taken on to the ester hydrolysis step. 
 
 
 
Figure 47: Variable temperature (VT) nmr data obtained for pure Ugi product 05. 
 
An initially somewhat confusing crystal structure of compound 05 was obtained through 
slow solvent evaporation (Figure 48). However, the confusion was found to be simply a 
sodium ion chelated into the macrocycle which is not an uncommon occurance in 
macrocycles of this type with the sodium ion thought to originate from the solvent or XRD 
protocol. This illustrates the susceptibility of the macrocycle to metal chelation. Thus proof 
of reaction was unambiguous. 
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Figure 48: X-ray crystal structure of 05. Complexed sodium ion illustrates the chelation-prone macrocycle. 
 
2.7.2.1 Ethyl ester hydrolysis. 
This step was straightforward as the products from the Ugi reaction stage were stable, 
clean, and afforded no solubility issues. 
 
 
Scheme 14: Ethyl ester hydrolysis. 
 
The conditions of choice involved use of the inorganic base lithium hydroxide in a THF/H2O 
solvent mixture. Using a small excess of the base this step proved quantitative and fast. 
When the construction of the cyclen tris-ethyl ester mono acid was attempted on the solid 
phase by means of a 2-chlorotrityl resin it was found that a more organic soluble basic 
source was preferable and KOTMS worked perfectly in hydrolysing the ethyl esters in 
readiness for solid phase lanthanide complexation, in that instance with gadolinium. This 
complexation however either failed or we experienced the characterisation issues which 
was a regular drawback in our work with gadolinium. 
However in this instance after a short reaction time the crude product was acidified to 
protonate the amines and form the zwitterions. In some instances this caused the product 
to precipitate out of the water (the THF was removed prior to lowering the pH), alternatively 
if the zwitterions did not precipitate out, the product was then purified by HPLC where now 
streamlined methodology was shortening run-times and affording very good yields of 
products as a single well defined peak.  
Again the charcterisation of the free acids was impossible by nmr spectroscopy and it was 
left to high resolution mass spectrometry with clean HPLC traces to provide satisfactory 
evidence for the small quantities of products to be taken on to the final lanthanide 
complexation step. 
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2.7.3 Lanthanide complexation. 
 
 
Scheme 15: The heptacoordinate Ln3+ complexes 12-23. Appended water molecules have been omitted. 
 
The three lanthanide metals chosen were rationalised in the introduction. They were 
Europium (Eu), Terbium (Tb), and Ytterbium (Yb) which emit long-lived phosphorescence 
with a luminescence lifetime of millisecond magnitude allowing timegating techniques to 
eradicate the interference from sample autofluorescence. 
Lanthanide complexation is commonly carried out from the corresponding chloride, citrate  
or trifluoromethanesulfonate (triflate) salts where the metal is readily released and shows 
high affinity for robust macrocyclic chelation due to the multiple oxidation states and high 
co-ordination numbers characteristic of these extraordinary elements.  
Complexation was attempted using a slight excess of the corresponding 
trifluoromethanesufonic acid salt in anhydrous methanol: a polar protic solvent. The 
reaction could be followed by analytical HPLC using a methanolic gradient method and 
interestingly the benzyl, naphthyl and indolyl Ugi substrates showed a pair of product 
peaks both giving the correct mass. The pyrenyl derivative gave just a single product peak. 
This will be discussed in due course. 
Lanthanides are employed as nmr shift reagents. This is a phenomenon explained by the 
interaction of a paramagnetic metal atom with a magnetic field and the resultant spectrum 
is spread over several hundred ppm as opposed to the standard 12 ppm of a regular proton 
nmr. Nmr spectra were obtained but accurate assignments were impossible (Figure 49). 
 
Figure 49: An example of an nmr spectrum of the Indolyl-Tb Ugi product 19. 
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Once again HRMS and clean HPLC were our prime characterisation techniques but now 
this could be backed up by fluorescence spectra, indeed it would be this fluorescence data 
that would direct the synthesis of future systems where those which exhibit the greatest 
potential as energy transfer NIR emitting imaging probes will be taken forward. 
The other nice feature which aids accurate characterisation is the beautiful isotope 
patterns in the mass spectra for the europium and ytterbium complexes (Figure 51). 
This work was published in Chemical Communications, a copy is found at the back of this 
thesis. 
 
2.7.4 The results 
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Figure 50: Table of results.* MALDI-TOF [M+Na]+ average isotopic mass. 
 
As explained in the publication,71 and predicted in the introduction, it was only in certain 
systems that the energy transfer was actually effective in exciting the metal to enhance the 
emission in comparison to direct excitation of the metal itself. Energy transfer is only 
effective if the donor T1 state is of significantly higher energy than the lanthanide emissive 
state. Indeed it could be predicted that certain systems such as the benzyl-Yb combination 
would show zero energy transfer due to the disparity in energy levels. However for the 
completeness of the study all combinations of lanthanide and antenna chromophore were 
synthesised. 
Eu Yb
Predicted 
Yb
                  
Figure 51: Examples of mass spectra illustrating the isotope patterns of Eu (15), Yb (22) and a sofware predicted 
Yb isotope pattern showing close correlation with the Yb pattern obtained experimentally. 
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Figure 52: Fluorescence emission spectra of the Eu-benzyl (12) energy transfer system. See appendix 3 for 
fluorescence spectra. 
 
Fluorescence spectra of Eu and Tb complexes were obtained on a standard Perkin-Elmer 
LS55 fluorimeter and Yb emission spectra was obtained using a pulsed Nd:YAG laser (266 
nm).  
Due to timegating technology eliminating background fluorescence it may initially be 
considered that the wavelength of the emission is irrelevant. However, it is actually of great 
importance as in vivo a further complication is biological interference. Therefore to avoid 
this the emission needs to be of a long enough wavelength (in the near-IR region of the 
spectrum) to afford the penetration required for effective detection outside of the body.  
The fact that a large emissive band occurs at above 700 nm in the Eu systems is very 
promising as this is at the lower end of the near-IR region which we wish to expoit to 
achieve enhanced tissue penetration and avoid background fluorescence. Of the twelve Ugi 
products, seven showed positive energy transfer.  
The systems showing enhanced emission, and therefore effective energy transfer were the 
combinations shown below (Figure 53).  
 
12 13 15
16 1921
22
 
 
Figure 53: The effective chromophore – metal energy transfer combinations. 
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The rationale behind the efficacy of certain metal to chromophore combinations was 
discussed in detail and indeed predicted in the introduction (pages 26-27). The basic 
rationale being that the triplet state of the chromophore must have sufficient overlap with 
the singlet state of the metal but the relative energy levels must not be too close as this 
opens the door to back energy transfer significantly reducing the emission. This is indeed 
believed to be what happens with the Tb-naphthyl combination. This is all discussed 
further in the publication. 
 
2.7.4.1 Characterisation 
The discovery of two well separated HPLC peaks both corresponding to the correct product 
was interesting, and in each compound (except the pyrenyl compounds where probable 
steric factors prohibited the formation of isomers and the product was observed as a single 
peak), the two peaks were collected separately. The fluorescence spectra for the individual 
peaks, however, were identical and upon checking the purity of one of the collected peaks it 
was somewhat surprising to find that the single peak had re-equilibrated to a pair of peaks 
of the original ratio. The question then arose as to the rate at which re-equilibration 
occurs. If this is a very slow process, then the fluorescence spectra obtained a few days 
after purification and isolation of the separate peaks could still be the spectrum of 
predominantly one isomer. Whereas if the re-equilibration is rapid then the emission 
spectrum will be identical as it will be the equilibrated mixture of the two isomers.  
To elucidate what was occuring an elegant piece of HPLC work was put into practise. We 
developed a rapid six minute analytical HPLC method which was programmed to record a 
chromatograph of a freshly collected single peak every six minutes over 72 hours with the 
aid of an autosampler. A semi-preparative isolation of a single peak of product was 
obtained and immediately the collected peak was inserted into the autosampler and the six 
minute cycle begun. The results are shown in Figure 54. 
24 hr
8 hr
90min
1 hr
30min
6min
a b
 
 
Figure 54: HPLC monitoring of the re-equilibration of the two lanthanide containing product peaks. a) The pure 
product prior to separation; b) the collected left hand peak re-equilibrating over 24 hours.  
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It became abundantly clear from this that there was absolutely no point in separating the 
two peaks as re-equilibration in solution begins immediately as revealed in the first trace at 
six minutes where the second peak has already begun to appear. Collection of the larger, 
longer retained peak and an identical six minute run experiment carried out revealed an 
identical rate of re-equilibration.  
To explain the observed phenomenon we searched the literature and found that Parker had 
examined a similar phenomenon with a good number of quite different DOTA and DO3A 
ligands.72 In lanthanide complexes of DOTA the four ethylene diamine groups adopt gauche 
conformations giving rise to two distinct ring conformations, λλλλ and δδδδ. In DOTA itself, 
bearing great symmetry and no real steric constraints, the acetate arms can also arrange in 
two possible ways (Λ and Δ), resulting in the appearance of a total of four stereoisomers. 
These adopt either a square antiprismatic (SAP), or a twisted square antiprismatic (TSAP) 
geometry. The key point is that these isomers may interconvert in solution through ring 
inversion (λλλλ ↔ δδδδ) or arm rotation (Λ ↔ Δ). This relates to our DO3A Ugi derived 
complex because ligand structure affects the isomeric ratio and to explain the fact that only 
two diastereoisomers are observed it is rationalised that the one extensively derivatised 
nitrogen not only renders the isomers diastereomeric, but sterically restricts the available 
conformations.72 The absolute configuration of the stereogenic carbon centre will determine 
the helicity (Λ or Δ) of the complex and therefore the two diastereomers are most likely the 
ring inversion products λλλλ (SAP) and δδδδ (TSAP) (Figure 55). 
a b
 
Figure 55: The two conformational diastereoisomeric products. a) A twisted square antiprism (TSAP); b) A square 
antiprism (SAP). Adapted from Ref. 72. 
 
With respect to why it is not an equal mix of the two diastereoisomers (Figure 56), the 
literature suggests that the isomer ratio is dependent upon the lanthanide ion, the 
temperature, pressure, and the concentration of added salts. However as a general trend 
for larger lanthanides (La3+ - Nd3+), the TSAP isomer dominates, whereas for smaller 
lanthanides (Sm3+ - Er3+) the SAP conformation is favoured.72,73  
This would suggest that the larger, more abundant right hand HPLC peak is the square 
antiprismic isomer. 
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Figure 56: The HPLC ratios of peaks A:B at equilibrium for each of the final products. 
 
Crystal structures 
The final item of discussion is the crystal structural evidence obtained to unequivocally 
prove the success of the synthesis. Unfortunately crystals were quite challenging to grow 
and the only set of sufficient quality and size were the three benzyl products (Figure 57).  
 
 
Figure 57: The three benzyl crystal structures. 
 
From these crystals the two diastereoisomers are not isolated separately, the crystal 
structures are thought to be of the square antiprismic conformations. Neither were we able 
to compare the different steric impacts of the four chromophores as we were only able to 
grow crystals of the benzylic derivatives. However the three structures, although seemingly 
identical, do show some subtle variations which are of interest. This arises purely because 
the lanthanide atoms are of different diameters with the Tb3+ having a smaller ionic radius 
than Eu3+, with Yb3+ being smaller still due to lanthanide contraction. The crystal 
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structures show a decrease in the length of all ligand to metal bonds upon moving from Eu 
to Tb to Yb. These slight changes in bondlength (approx. 0.02-0.03 Ǻ) reveal an increased 
tightness in the chelation of the metal upon reduction in metal radii.  
 
2.7.5 Model study summary 
To summarise this first area of study we have finetuned a reliable and high yielding 
synthetic route to complex luminescent lanthanide systems which exhibit intramolecular 
energy transfer from an antenna chromophore leading to long-lived, long wavelength 
emission. The ideal chromophore-metal combination was discussed and it was decided to 
proceed and develop this chemistry to incorporate a spacer unit with which to attach the 
terbium to benzyl or indolyl systems. These two systems were decided upon as they 
exhibited the greatest energy transfer and hence emission intensity. 
 
2.7.6 Installation of a spacer unit 
 
 
 
Figure 58: The initial target compounds. 
 
Essentially the chemistry required to modify the Ugi product in a fashion which allows 
attachment of the luminescent system to a biological motif such as the cyclic peptides and 
carbohydrates (to be discussed forthwith), is identical to the chemistry developed in the 
synthesis of the previous model systems where the bulky diphenylmethyl amine was the 
amine substituent.  
 
2.7.6.1 The choice and synthesis of linkers 
Various trial Ugi 4-component condensation reactions were attempted with benzyl 
isocyanide, aldehyde and carboxylic acid components with a selection of spacers. It was 
decided to attempt the Ugi reaction initially with an oligoethylene glycol spacer unit to 
enhance the aqueous solubility of the probe. Thus oligoethylene glycols of two lengths were 
created through a number of functional group transformations to afford a free amine on 
one terminus and a protected acid on the other (Scheme 16).  
Chapter 2: Results and Discussion 
 65
 
 
Scheme 16: The functional group transformations involved in the synthesis of ethylene glycol spacer units. 
 
The mono-alkylation of one end of the ethylene glycol to form tert-butyl esters 35 and 36 
was expected to be a less than 50 % yielding step as it is envisaged that the reaction must 
result in the formation of disubstituted product. However this was not the case and an 
excellent yield of monoprotected glycol was obtained through the use of silver oxide. It is 
thought that the mechanism involves one end of the ethylene glycol coordinating to the 
surface of the silver atom allowing regioselective alkylation at the other terminus.74 The free 
terminal hydroxyl could then be manipulated using well known chemistry. Mesylation was 
achieved using mesylchloride with triethylamine as base to form a good leaving group 
which in the next step was substituted for an azide by simply heating the mesylate with 
sodium azide in DMF. To finally afford the free primary amine for Ugi chemistry, the azide 
was reduced to the free amine using the Staudinger reaction (triphenylphosphine in dry 
THF followed by quenching with H2O). The product was then purified by careful flash 
column chromatography using a CH2Cl2/MeOH gradient to ensure all of the tenacious 
triphenylphosphine oxide was removed prior to recovery of product with mild base added to 
the eluent to mobilise the product. Test reactions proved successful with the formation of 
91 in reasonable yield (Figure 59). 
 
 
Figure 59: A successful 4-CCR test reaction product 91. 
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Unfortunately however this proved completely unproductive as repeated attempts at the 
Ugi reaction using the components required for our energy transfer system failed. TLC 
analysis initially looked promising with the formation of the imine, but despite adjusting 
the conditions the only product consistently isolated was the Passerini reaction product 
(Scheme 17). The Passerini reaction is a three-component reaction which does not involve 
an amine component. We are still unsure as to what a plausible explanation for this failure 
may be, especially as the chemistry proved successful in the test reactions.  
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Scheme 17: The undesirable formation of the Passerini product. 
 
This was unexpected and although disappointing, it meant that our attentions turned to 
the more easily accessible aminocaproic spacers (Scheme 17). This involved the protection 
of the acid as the tert-butyl or ethyl ester and the Ugi reaction was performed using the 
terminal amine. It was envisaged that although potentially reducing the water solubility of 
the product, when appended to a cyclic peptide this factor should be rendered 
inconsequential as the whole system would have sufficient aqueous solubility. 
 
2.7.7 Solid phase Ugi reactions. 
At this stage it was worth considering the possibility of achieving the Ugi 4-CCR on the 
solid phase as this would negate the need to assemble the cyclic peptide and the 
lanthanide fluorophore separately. However, trial solid-phase Ugi reactions were not as 
Chapter 2: Results and Discussion 
 67
successful as it was hoped from the literature precedent.75 The group of Kim showed 
successful solid phase chemistry with small simple constituents to rapidly build a library of 
compounds with therapeutic potential.62 However under similar conditions with our 
relatively bulky components there was no Ugi product outcome. The fact that SPPS is 
typically performed under mild conditions and in a polar aprotic solvent could explain the 
negative outcome as in a polar protic solvent such as the EtOH or MeOH favoured in Ugi 
chemistry, the resin shrinks and solvent penetration to mediate the reaction becomes poor. 
Therefore it was decided to continue building the two sections of the probe separately as 
this would offer greater flexibility and fewer potential problems associated with the rigidity 
of the resin-bound peptide and the steric demands of both the peptide protecting groups 
and the Ugi reaction substituents impeding the synthesis.  
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Scheme 18: Selectively hydrolysable aminocaproic acid derived spacers 49 & 50. 
 
The test Ugi reaction using the amino caproic spacers (Scheme 18) proved reliable and 
reasonably high yielding suggesting that somehow the PEG was prohibiting the success of 
the previously attempted Ugi reactions with the macrocycle. The Ugi reactions were 
performed with the DO3A derivative 03 as the carboxylic acid, indole & benzyl aldehydes, 
and benzyl isocyanide as the other substituents. The reaction proceeded straightforwardly 
following the protocol of our previous Ugi reactions. The consideration now was the order in 
which to perform the complexation and deprotection as this would influence the choice of 
aminocaproic ester used in the Ugi reaction. It was thought that as the caproic arm is a 
good distance from the macrocycle then an ethyl ester could be employed to save a step as 
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this would be hydrolysed simultaneously alongside the ethyl esters on the macrocycle, 
hopefully without also co-ordinating the metal in the next step (Scheme 19).  
Thus the synthetic route using the caproic ethyl ester 50 in the Ugi reaction was attempted 
first and we were content with the positive outcome. The basic ester hydrolysis then 
afforded the tetra acid compounds 26 & 27 as expected, but complexation with the 
terbium metal failed and despite repeated attempts with alternative conditions the isolation 
of the desired product eluded us (Scheme 19). The reasons for this could be due to the 
caproic arm looping around and interfering with terbium chelation, or in some way 
influencing the geometry of the compound. Another theory is that the terbium chelates as 
expected but the free caproic acid of neighbouring compounds agglomerate onto the metal 
atom blocking our means of attachment, this however is unproven. 
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Scheme 19: The Ugi products and the route to the final compound prior to coupling to the cyclic peptide.  
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Thus the alternative route using the base stable tert-butyl ester caproic amine 49, was 
employed and all steps proceeded to our satisfaction. Ethyl esters were selectively 
hydrolysed and a terbium ion installed in the macrocycle prior to a simple and clean acid 
cleavage of the tert-butyl ester using TFA to afford the pure product.  
 
Thus the synthesis of our lanthanide based agents was complete but for the biological 
vector which, as described in the introduction, will convey the fluorophore to the specific 
biological binding site. The attachment of terbium complexes to the free lysine amine will 
proceed via a coupling reaction. However, if steric issues arise due to the bulky PyBOP 
coupling reagent prohibiting this attachment, there is still the option of simply pre-forming 
the labile succinic ester on the free caproic acid arm thus inviting nucleophilic attack from 
the lysine free amine in basic buffer conditions. 
Thus the way became clear for the synthesis of the RGD integrin-binding cyclic peptide 
vector, cDfKRG. 
 
2.7.8 Peptide synthesis 
 
Figure 60: The integrin αvβ3 binding cyclic peptide cDfKRG. 
 
As discussed in the introduction and synthetic plan, the linear DfKRG peptide was 
constructed using standard solid-phase protocol. However, the options with regard to 
protecting group chemistry for the selective deprotection of the lysine residue, the order in 
which to achieve the coupling to the fluorophore, and the stage at which to cleave the 
linear peptide from the resin and cyclise, were all variables that were addressed and shall 
be discussed in due course. 
 
The general synthetic protocol was adapted from Dumy’s solid-phase synthesis of an RGD 
containing cyclic pentapeptide.76 Further derivatisation of the peptide through simple 
aliphatic extension units was devised to compare the efficiency of different routes to the 
target. The favoured approach, in accordance with our synthetic plan, was to take the 
synthesis as far as possible on the solid-phase with the peptide still appended to the resin. 
Chapter 2: Results and Discussion 
 70
The advantages of this are clear when it comes to the overall yield and also when it comes 
to the purification of advanced intermediate products by HPLC; the fewer steps in solution-
phase the better when considering the economics of the synthesis. 
The resin chosen was the highly acid-labile 2-chlorotritylchloride (Scheme 20). The reason 
for this was that the peptide would be selectively and rapidly cleaved from the resin in the 
presence of other, less acid-labile protecting groups such as the tBu, Boc, Pmc and Pbf 
which are typically cleaved with concentrated TFA. The other reason was that our design 
never exposes the resin to acid conditions until cleavage is required.  
Fmoc-glycine-2-chlorotrityl resin was commercially available and so taking this as our C-
terminal residue and using the Fmoc solid-phase coupling protocol described in the 
experimental section, the penta-peptide was constructed (Scheme 20).  
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Scheme 20: The solid phase peptide synthesis (SPPS). 
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Our protecting group strategy dictated that as the arginine and aspartic acid residues are 
purely involved in integrin binding, they do not need to be manipulated during the 
synthesis and should be protected with groups that are cleaved under identical conditions 
in a single step. Commercially available is Fmoc-Arg(Pmc)-OH, where Pmc is an 
appropriate, strong acid labile, bulky orthogonal protecting group (Scheme 20). Likewise, 
Fmoc-Asp(tBu)-OH was readily available and this would provide a convenient, sterically less 
demanding acid-labile protecting group for the carboxylic acid side chain of aspartic acid.  
The initial plan was to employ the cheaper and more available Fmoc-Lys(IvDde)-OH as our 
regioselectively (hydroxylamine) cleaved lysine ε-NH2 protector, but, as shall be discussed 
in due course, unforeseen problems arose and this had to be revised. 
 
The linear synthesis went smoothly and progress was monitored with bead stain tests and 
mini-cleaves at each stage. A double coupling protocol was rigorously employed to ensure 
complete coupling and an HPLC trace of the final cleaved fully protected penta-peptide 
demonstrated impressive purity (Figure 61).  
 
 
 
Figure 61: An analytical HPLC trace of the crude linear peptide 55 showing the incredible cleanliness of the SPPS.  
 
We had now reached the stage where selective deprotection of the IvDde with 
hydroxylamine would afford the free lysine amine for solid phase functionalisation.77 It was 
deemed wise to perform a test reaction to check that when a bulky fluorophore is attached 
that it is still possible to efficiently cleave the peptide from the resin, cyclise and deprotect 
the Pmc and tBu groups. To this end the peptide was subject to hydroxylamine cleavage 
conditions. However, this failed repeatedly with a mini cleave just confirming the remaining 
starting material.  
The only other reported conditions for IvDde cleavage involve the use of hydrazine which 
could also result in Fmoc cleavage. However, a small quantity of peptide-bearing resin was 
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taken and hydrazine was carefully applied to the luer flask and the reaction time 
shortened. The mini-cleavage revealed the desired loss of IvDde and so we proceeded to 
couple the well known fluorescent label, fluorescein isothiocyanate (FITC) to the lysine 
amine using a double coupling protocol. 
The crude mass spectrum of the cleaved product prior to attempted cyclisation revealed a 
problem, and after deliberation and consulting the literature it was confirmed that two 
fluorescein molecules were bonded to the peptide as the hydrazine hydrate had not only 
cleaved the IvDde group, but also the terminal Fmoc.78 This means that the appended 
fluorescein in the terminal position prohibits the crucial cyclisation step to form the RGD 
unit. This drawback was confirmed when a simple solid phase coupling was attempted on 
the hydrazine washed peptide using benzoic acid/PyBop/DIPEA, and the bis-amide was 
isolated as the sole product. The IvDde group could not be cleaved selectively in the 
presence of Fmoc. 
This did not render the resin bound IvDde penta-peptide obsolete as the way forward with 
this was now to perform the terminal Fmoc cleave (IvDde is piperidine stable), cleave the C-
terminus from the resin and cyclise the peptide before performing solution phase IvDde 
cleavage with hydrazine, and coupling selectively on the lysine. 
 
However, the desirable synthetic pathway was to perform coupling of the fluorophore on 
the solid-phase to eliminate unnecessary and time-consuming purification steps and so the 
strategy needed revising. 
 
We acquired a quantity of Fmoc-Lys(Alloc)-OH and began the SPPS protocol all over again. 
Alloc is a protecting group selectively cleaved by a Pd0 source such as Pd(PPh3)4. The 
synthesis proceeded in a now well practised and understood fashion with an excellent 
purity of crude fully protected linear peptide being revealed in the final mini-cleave.  
 
Solid-phase Alloc removal is well established and a Tsuji-Trost type reaction with an 
anhydrous system of Pd(PPh3)4/PhSiH3/CH2Cl2 was employed where PhSiH3, is acting as 
an allyl scavenger. The reaction worked perfectly with no trace of Alloc in the mini-cleavage 
mass spectrum. A common problem that has been reported in this step is the formation of 
an undesirable allylamine byproduct.79 Thankfully there was no evidence of this and the 
subsequent coupling of fluorescein isothiocyanate using conditions of Py/DMF/CH2Cl2, 
proceeded as desired with mini-cleavage revealing the product. Terminal Fmoc deprotection 
with piperidine and resin cleavage with dilute TFA afforded the labelled linear peptide ready 
for cyclisation and final Pmc and tBu protecting group cleavage. However, the penultimate 
and crucial cyclisation step failed (Scheme 21).  
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Scheme 21: The fluorescein label prohibiting cyclisation. 
 
Increasing the temperature and reaction time offered no solution and even though a trace 
of product was identified it was a pitiful quantity (4 %) in comparison to the recovered 
starting material. The fluorescein was clearly prohibiting cyclisation, probably on steric 
grounds and once more the strategy required revision. 
It was then realised that for the successful attachment of bulky fluorophores we could not 
follow the route of Dumy,76 but must cleave from the resin and cyclise prior to selective 
deallyllation, fluorophore attachment and final protecting group cleavage (Scheme 22). 
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Scheme 22: The revised synthetic route to the final labelled cyclic peptide products. 
 
Resin cleavage proceeded straightforwardly with an immediate colour change as the resin 
turned dark purple in the 1 % TFA/CH2Cl2 cleavage conditions. It was found that for 
optimal yield not only was it necessary to prolong the reaction for two minutes, but also to 
repeat until the resin stayed a deep purple colour as the resin was prone to fade upon 
washing with excess solvent indicating an incomplete cleavage. This process results in the 
use of a greater quantity of TFA than is ideal, and it is thought that although the 
predominant product is still fully protected, the reduced-pressure removal of the TFA must 
be carried out at low temperature with repeated co-concentrations to prohibit the 
simultaneous deprotection of the Pmc and tBu groups as the concentration of TFA, being 
less volatile and more tenacious than CH2Cl2 will increase in the rotary evaporator. Figure 
61 shows HPLC evidence of this with a small peak showing loss of Pmc. This is 
immeasurable by mass spectrometry as in all the mass spectra obtained there is a clear 
natural fragmentation occurring within the spectrometer giving rise to [M-protecting 
group]+ peaks (Figure 62). MALDI-TOF in the preferred matrix of gentisic acid containing 
0.1 % TFA proved reliable enabling some excellent clean spectra showing the product peak 
clearly alongside the fragmentation peaks. HPLC had to be relied upon as an accurate 
measure of purity. 
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Figure 62: MALDI-TOF mass spectrum showing the fragmentation pattern of the HPLC purified cyclised Alloc 
protected peptide 56.  
 
Resin cleavage proceeded as desired and gave the linear peptide as a single peak by HPLC 
which was taken on crude to the cyclisation step. 
 
2.7.8.1 Cyclisation 
Cyclisation was a key step in this protocol as it is easy to see how polymerisation of the 
peptide may occur. However the design of the peptide favours cyclisation due to the D-
phenylalanine residue reducing the conformational flexibility thereby favouring a 
conformation in which the termini are in close proximity. Thus under dilute coupling 
conditions at ambient temperature and given a three day reaction time with simple 
monitoring by analytical HPLC, the linear peptide peak disappeared and the cyclic peptide 
was recovered in excellent yield after preparative reversed-phase HPLC. 
 
2.7.8.2 Solution-phase Alloc cleavage 
Literature solid-phase Alloc cleavage conditions proved highly unreliable in solution phase. 
Brand new Pd(PPh3)4 (this compound is particularly air sensitive), did not alter the 
outcome. The literature cleavage methods attempted each used a different scavenger or 
solvent and it became obvious that the choice of nucleophile is crucial to this deallylation  
mechanism (Scheme 23).  
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Scheme 23: The catalytic cycle for alloc deprotection, adapted from Ref. 80.  
 
There is good precedent for solid-phase deallylations with many reported solvent and 
scavenger combinations which were considered for our solution phase attempt with 
Pd(PPh3)4 including: Me3SiN3/TBAF,80 Bu3SnH/AcOH,80 THF/DMSO/HCl/NMM,81 
NMA/AcOH,80 NMP/PhSiH3,82 (NMM)/AcOH,80 and CH2Cl2/PhSiH3.79-84  
All solid-phase nucleophilic allyl scavengers, due to the solvents used in solid-phase 
chemistry, must be organic soluble and so our solution phase Alloc cleavage attempts 
initially also revolved around the PhSiH3 protocols. These all failed with no sign of product. 
It is suggested that the PhSiH3 is too harsh on the free cyclic peptide leading to breakdown 
of product. The NMM/AcOH conditions were then also attempted but with the same 
negative outcome. It was then realised through the discovery of a paper by 
Thayumanavan,85 that allyl ethers can be cleaved under the mildly basic conditions 
Pd(PPh)3/K2CO3/MeOH and it is mentioned in the same paper that allyloxycarbonyl (Alloc) 
groups are also cleaved under these conditions. 85 
Thus it was finally realised that in solution phase an organic base is not essential. 
Potassium carbonate was found to not only perform excellently but was consistent and 
high-yielding.  The reaction was followed by hourly analytical HPLC analysis and it became 
clear that after three hours the cleavage was complete and that any increase in reaction 
time led to degradation of the product as there was a slow reduction in the size of the 
product peak and the appearance of many more signals. Thus an optimal time for reaction 
was set to three hours before prompt filtration, neutralisation and preparative HPLC 
purification.  
This was a breakthrough and our strategy was back on track especially as the final 
products were now just two steps away. 
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2.7.9 Fluorophore attachment and revised choice of fluorophore 
The choice of fluorophore was now an issue for discussion as a collaboration had been 
negotiated between ourselves and the Borlak group in Hannover at the Institute for 
Toxicology and Experimental Medicine (ITEM). This had opened an unexpected door as it 
would allow us to test our labelled peptide in live tumour-bearing (transgenic) mice through 
the use of a small animal fluorescence spectrometer with long wavelength (near-IR) 
capabilities. These facilities are hard to find and in order to exploit this excellent 
opportunity we were forced to reconsider the optimal excitation and emission wavelengths 
of the fluorophores. This is of particular importance in live animal models as the excitation 
wavelength must also be in the near-IR region not only for optimal tissue penetration and 
minimal interference, but also so as to not harm the mice. 
The fundamental foreseeable problem with our lanthanide based probes for full body 
imaging application is that although the emission is of the desirable wavelength, the 
excitation is at a much lower wavelength in the UV blue region. This is due to the point of 
excitation being the local organic chromophore which then transfers energy to the metal 
centre. Excitation at this wavelength is not conducive to either good tissue penetration or 
the health of the mouse.  
Therefore it was decided that although it will be good to show project completion through 
the formation of our final products, they would not be used in the impending mice studies, 
but rather saved for cellular work. Therefore it was decided to purchase a known organic 
fluorophore in which both excitation and emission are of near-IR wavelength to test the in 
vivo targeting potential through illumination of αvβ3 integrin binding.  
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Figure 63: Final lanthanide based luminescent labelled cyclic peptide cDfK(εLn)RG, 69. 
 
The final product (Figure 63) was afforded through standard coupling conditions 
(PyBop/DIPEA/MeCN) and the Pmc and tBu protecting groups removed with TFA prior to 
isolation by HPLC.  
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2.7.9.1 Cyanine dyes – NIR797 
Cy 7.0 and Cy 5.5 are commercially available and well known cyanine bioanalytical dyes 
(Figure 64).86 This is a growing group of large organic fluorophores being developed for not 
only their photophysical properties but also for their solubility and stability characteristics. 
These dyes are an ideal alternative to visible fluorophores as they absorb and emit in the 
long wavelength nearIR region from 700-1200 nm where there is characteristically little 
biomolecular interference. They also exhibit large molar extinction coefficients, moderate to 
high fluorescence quantum yields and broad wavelength tunability.87 
 
 
 
Figure 64: GE Healthcare near-IR bioconjugates Cy 7.0 (Ex 743 nm; Em 776 nm), and Cy 5.5 (Ex 485 nm, Em 
667 nm). 
  
Cy 7.0, however, is a heptamethylene cyanine dye restricted by not only poor stability but 
also a difficult, low yielding and unreliable synthesis. It is also prone to form non-
fluorescent aggregates. Unfortunately these are common drawbacks for many of this family 
of dyes and the other similar derivatives reported. The complicated synthesis has led to 
those that are commercially available being very expensive.87-90 However, improvements in 
stability and purification technique have been afforded through the incorporation of a rigid 
cyclohexenyl ring in the polymethine chain.  
a b c d
 
Figure 65: An example of a cRGD-Cy 5.5 conjugate used in in vivo fluorescence imaging. a) Laser scanning 
confocal microscopy of rat brain tumour cells; b) Binding and endocytosis, U87MG human glioblastoma cells; c) 
Fluorescence imaging of U87MG brain tumour xenograph; d) The removed tumour (1) vs other organs. 52,88 
 
This has led to manipulation of this central unit and, through nucleophilic substitution 
reactions with nucleophiles bearing an additional functional group, to allow the covalent 
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labelling of biomolecules.89  NIR797 (Figure 66), is of the same family of cyanine dyes used 
in all manner of biological fluorescence assays and has recently become commercially 
available through Fluka, albeit in poor (~50%) purity.90  
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Figure 66: NIR797 (Fluka). 
 
This dye is water soluble and has been effectively used in DNA sequencing, genetic 
analysis, proteomics and in vivo imaging.90 The terminal isothiocyanate is not only an ideal 
electrophile for rapid nucleophilic attack by the lysine εNH2 of the peptide, but also the 
resulting thiourea group has been found to modulate and enhance fluorescence emission 
decay in fluorescein labelled molecules.91 Although expensive, NIR797 would be an 
excellent starting point for these investigations due to the excitation and emission maxima 
being in an ideal region of the spectrum in the mid-range of the near-IR (Ex. = 797; Em. = 
815 nm). This dye would also offer an excellent and powerful probe for cellular and tissue 
slice fluorescence imaging. It has an extinction coefficient of 94100 M-1cm-1 in H2O.86,87 
 
 
2.7.9.2 Introduction of a spacer unit. 
As mentioned in the introduction and synthetic plan, it was also deemed important to 
investigate the proximity of the fluorophore to the binding site through the introduction of 
differing length spacer units. This chemistry was perfected initially for incorporation into 
the Ugi reaction as the amine substituent. However, in this peptide chemistry the spacer 
must be an extension upon the lysine terminal primary amine and therefore the terminal 
group must be subject to nucleophilic attack of the amine. Therefore the ethylene glycol 
and caproic spacers (Scheme 24) were functionalised as carboxylic acids ready for 
coupling to the lysine amine prior to deprotection to reveal a distant free amine for 
fluorophore coupling.92 
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Scheme 24: The spacer units synthesised as terminal carboxylic acids for coupling to the lysine residue. 
 
Thus the cyclised, selectively Alloc-deprotected peptide was subjected to coupling 
conditions with the Boc-aminocaproic acid and ethylene glycol spacer 44 to afford an 
elongated lysine arm in preparation for more distant fluorophore coupling.  
At this point it was decided that due to the expense of NIR797 it would be wise to couple 
the NIR797 directly to the lysine residue and test this compound prior to investigating the 
efficacy of spacer units in potentially increasing binding affinity through distancing the 
steric bulk of the fluorophore from the active site. 
After HPLC purification and MALDI-TOF mass spectrometry the product 61 (Figure 67) 
was confirmed in high purity and was ready for the mice studies in Hannover with naked 
cDfKRG 59 as a control or blocker. 
 
 
 
Figure 67: The final labelled NIR797 peptide 61, and the two spacer appended peptides 65 & 66. 
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2.7.10 Synthesis of Osmium 2,2’-bipyridine dyes 
Staying with the theme of long-lived metal-centred fluorescence, it was decided through 
discussions with our collaborators that it would be prudent to also investigate osmium 
bipyridyl complexes.  
This was our first venture into organometallic chemistry. Although identical routes to our 
devised luminescent product involving other complexed transition metals such as 
ruthenium93-95 and rhenium96 were located in the literature, the search yielded limited 
results for complexation with osmium as the metal in 2,2’-bipyridyl complexes. 
The chemistry required a knowledge of the oxidation and co-ordination status of the metal 
and also an understanding of how solubility difficulties could be overcome through the 
manipulation of the counter-ions. 
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Scheme 25: The synthesis of the Osmium complex. 
 
We were able to acquire a small quantity of the carboxylic acid intermediate 4’-methyl-2,2’-
bipyridine-4-carboxylic acid in order to test the synthesis and quite rapidly access the 
product 53 (Scheme 25). This compound is prepared through selective oxidation of a 
single 4,4’-dimethyl-2,2’-bipyridine methyl group in a relatively poor 45 % yield.93  
 
2.7.10.1 Synthesis of Cl2Os(bpy)2, 51 
In this step it is interesting to note how that DMF not only serves as an ideal polar-protic 
solvent for the dissolution of OsCl3, but also reduces the Os3+ to Os2+. The order of 
synthetic protocol is also important as pre-addition of the LiCl precludes the formation of 
the undesired ‘tris’ complex (bpy)3Os. In comparison to the identical synthesis with 
ruthenium,93 a shorter reaction duration was required as osmium is able to facilitate the 
binding of the relatively bulky 2,2’-bipyridyl units more rapidly.97-99 Dissolution in acetone 
followed by 72 hours at -8 ºC caused complete precipitation of the product which was then 
simply isolated by Büchner filtration as a solid of a deep brown colour.  
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2.7.10.2 Synthesis of (4’-Me-bpy-4-COOH)Os(bpy)2, 52 
The inclusion of the third acid-functionalised bipyridine unit renders the solubility of the 
product very poor unless a change of counter ion is enacted. Acidification with 
hexafluorophosporic acid, followed by the careful addition of aqueous ammonium 
hexafluorophosphate furnishes the product with a pair of hexafluorophosphate counter 
anions and causes it to precipitate out of the reaction solution as a solid not dissimilar in 
colour to the traditional British racing green. 
 
2.7.10.3 Synthesis of succinic ester, 53 
This final step is not fundamental as standard coupling conditions could be employed 
between the carboxylic acid and peptide amine to join the two parties together. However it 
is desirable to limit any possible side reactions with other functionality as shall be 
discussed forthwith when it is discovered that the tBu and Pmc groups are redundant and, 
if left deprotected, the carboxylic acid of the aspartic acid residue would become vulnerable 
to coupling reagents. So the installation of a good leaving group to enable a simple 
nucleophilic substitution reaction under mildly basic or neutral conditions with the lysine 
free amine was desirable. 
It was chosen to attempt to install a succinic ester due to the ease and mildness of reaction 
conditions in comparison to the thionyl chloride conditions required to form an acid 
chloride. This reaction was also precedented and N-hydroxysuccinimide afforded the 
product in excellent yield via a DCC coupling. However it was not anticipated how reactive 
the succinic ester would be and this led to problems with purification and characterisation. 
Ready hydrolysis of the succinnic ester in aqueous and polar protic solvents such as MeOH 
was apparent when standard HPLC protocols using water/organic solvent gradients 
revealed a combination of ester product and the carboxylic acid starting material peaks. 
Initially this was rationalised as an incomplete reaction, but repeated HPLC runs revealed 
only an increase in carboxylic acid. MALDI-TOF and electrospray mass spectrometry on the 
crude and HPLC pure peaks revealed again predominantly the carboxylic acid, and, when 
in MeOH, the MeOH adduct. Interestingly a loss of CO2 was also always visible on the mass 
spectrum. Nmr of the filtered dry crude product did reveal the succinic ester CH2 protons, 
suggesting a successful reaction, but the standard of the nmr was not good enough for 
unequivocal proof of product through measurement of peak integration. Thus it was 
decided that the best proof of succinic ester formation was to take a small quantity of the 
crude and couple to the peptide.  
The result was very satisfying with the reaction followed clearly by analytical HPLC and the 
mass spectrum revealing the attachment of osmium complex in excellent yield with only a 
slight excess of the fluorophore added to the peptide in dry MeCN (Figure 68). 
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Figure 68: The fully deprotected Osmium-cDfKRG conjugates prepared for biological testing. 
 
The final deprotection was achieved very cleanly with TFA/CH2Cl2 and although initially it 
was feared that this might replace the PF6- counterions, we need not have worried as these 
proved robust. The tBu and Pmc protecting groups were removed cleanly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
Figure 69: The MALDI-TOF of the product 68.  
 
MW = 1624
[M+H]+
+M+2(PF ) +2Na6
-
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Interestingly, mass spectrometry became invaluable as the PF6- counter ions showed on the 
spectrum with the [M+2(PF6)-+Na]+ ion visible. This was very indicative of the product 
(Figure 69). The main point of interest now was to discover the photochemistry of the 
peptide probe. UV spectroscopy followed by fluorescence emission spectroscopy revealed 
that the optimum excitation and emission wavelengths were indeed in the desired near-IR 
region of the spectrum (Figure 70).  
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Figure 70: The fluorescence emission spectrum of Osmium conjugate 68. 
 
This was great news and we took to Hannover the cyclic peptide bearing both NIR797 and 
Osmium fluorophores for testing in transgenic mice using optical imaging technology (see 
the imminent biological results and discussion section and appendices 4 & 5).  
 
2.7.11 Streamlining the synthetic route. 
It became apparent due to the failure of the peptide cyclisation step after solid phase 
attachment of FITC, that the selective removal of the lysine protecting group was no longer 
necessarily fundamental to the successful outcome of the synthesis, indeed, it now 
appeared to be adding unnecessary steps, reducing the overall yield and efficiency of the 
protocol.  
The rationale for this is that the free arginine side chain, being a stabilised π-system is 
relatively non-nucleophilic in comparison to the lysine ε-primary amine; similarly the 
carboxylic acid of the aspartic acid is far less nucleophilic than the lysine ε-NH2. Therefore, 
as the peptide is now cyclic, there are no other functionalities to consider when appending 
a fluorophore selectively to the lysine side chain. This means that the acid cleavage of tBu 
and Pmc can be accomplished prior to a final labelling step. Indeed, taking this into 
account, the peptide could now be built with an acid labile protecting group also on the 
lysine amine. This would eradicate the tricky palladium-catalysed selective deallylation 
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step as the linear peptide could be Fmoc deprotected, cleaved from the resin, cyclised, and 
totally deprotected before a final fluorophore attachment step (Scheme 26). This was an 
excellent realisation and offered a far more rapid and higher yielding route to the products 
with two fewer HPLC purifications.  
 
 
 
 
Scheme 26: Possible streamlining of the peptide synthesis and fluorophoric labelling. 
 
As a quantity of resin bound Lys(IvDde) and Lys(Alloc) penta peptides had been synthesised 
by SPPS we elected to make use of these and promptly cleaved, cyclised and performed the 
deprotections affording a good quantity of naked cDfKRG peptide for appending the desired 
fluorophores. 
However this strategy does not take into account the insertion of spacer units which have 
required coupling conditions which could lead to derivatisation of the aspartic acid and 
arginine side chains. It would be wise to investigate the selective elongation of the lysine 
arm with the spacers whilst the peptide is still on the solid phase and deduce whether they 
offer an improvement before redesigning the whole strategy.  
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2.8 Summary & conclusions 
 
Although time-consuming, the selective manipulation of tetraazadodecane (cyclen) side-
chains to efficiently afford the Ugi carboxylic acid 03 was ultimately very satisfactory. The 
ensuing Ugi 4-component condensation reactions were again a great success although 
relatively laborious in their purification. Lanthanide complexation afforded a small library 
of potential energy transfer mediated long-lifetime fluorophores. These were downselected 
according to the efficacy of the energy transfer mechanism. This work was published.  
The next step was to incorporate into the fluorophores a means of attachment onto the 
integrin αvβ3 specific cyclic peptide vector cDfKRG, via the lysine εNH2. This was attempted 
unsuccessfully using varying length ethylene glycols as the Ugi amine component which 
had been selectively derivatised at one end and protected at the other. However, success 
came in the form of an aminocaproic spacer.  
The solid phase synthesis of the linear penta peptides was remarkably clean and efficient 
with the coupling reagent combination of PyBop / DIPEA in anhydrous DMF proving 
reliable and fast. The failure of the selective cleavage of the IvDde lysine protecting group 
directed a change of tactics with the Pd0 cleaved Alloc protecting group then being 
employed to good effect. It was then discovered that the attachment of a fluorescein tag to 
the exposed lysine εNH2 whilst the peptide was still resin bound, prohibited the subsequent 
fundamental cyclisation step, and therefore the strategy was again amended.  
Cyclisation of the peptide, lysine deprotection and fluorophore coupling, followed by a final 
deprotection step to remove all other amino acid protecting groups afforded an effective 
route to the final luminescent labelled, integrin targeted cyclic peptides. A more 
streamlined route was also realised and future work will now be both simple and reliable. 
In addition, the system was further derivatised to distance the bulky fluorophores further 
from the peptide to reduce the possibility of binding site interference. 
Due to the weak emission from lanthanide metal-centred luminescence in comparison to 
some commercially available fluorophores such as fluorescein and the near-infrared 
emitter NIR797, it was initially decided to test the specificity of the cyclic RGD peptides to 
their integrin targets using these dyes, prior to incorporating the originally developed Ugi 
derived lanthanide fluorphores. The other drawback was that timegated technology was 
rendered unavailable to us to capture the long lived luminescence from the lanthanide 
probes. 
A door opened to us to test the cyclic peptide probes in lung and liver tumour-bearing mice 
and we took advantage of this offer to image tumour accumulation and specificity of the 
near-IR emissive systems in vivo. This work was perhaps premature but did produce some 
results of great promise. The tissue penetration of the emission was excellent although the 
anatomy of the mouse and the limitations of the imager complicated things. At the 
completion of this thesis, the cyclic peptide probes were being tested against tumour cells. 
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2.9 In vivo studies: small animal testing 
(COST0602 collaboration. Host: Prof. J. Borlak; ITEM Fraunhofer, Hannover, Germany) 
Jan & April 2009 
 
2.9.1 Optical in vivo imaging  
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Figure 71: Cyclic DfKRG peptides with NIR797 and Osmium complex fluorophores attached either through the 
lysine side chain or via a caproic spacer. 
 
2.9.2 The probes 
Four compounds (Figure 71) were taken to Germany for whole body fluorescence imaging 
in mice. The purpose of the journey was to ascertain what potential the near-IR wavelength 
emission from these targeted imaging agents possessed for in vivo application.  
There were several interesting and important questions that required addressing in this 
study that would impact upon the development of further synthetic protocol and ultimately 
the direction of the project: 
• Is NIR797 a viable in vivo fluorophore? 
• Is there any sign of instability and in vivo breakdown? 
• Does the proximity of the fluorophore to the peptide vector influence the binding 
and specificity of the agent (spacer efficacy)? 
• Is the Osmium complex a viable in vivo fluorophore? 
• Is the peptide vector specific enough for unambiguous in vivo tumour recognition? 
• Is the tissue penetration sufficient for potential human local in vivo imaging e.g 
endoscopic investigation? 
• Are there any obvious toxicological issues? 
 
2.9.3 The experimental protocol 
c-Myc and c-raf type transgenic mice of various ages expressing tumour burdens 
specifically of the lung or liver were subjected to Isoba isofluran/O2 inhalation anaesthesia 
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prior to 100 μL intravenous injections of fluorescent agent or control peptide at 0.5 mg/mL 
concentration via the dilated tail vein. Whole body fluorescence emission images were 
recorded at 5, 30, 60, 120 and 240 minutes post injection.  
Mice used in organ imaging experiments were anaesthetised and injected as described 
above, and a whole body scan taken at five minutes. The mouse was then sacrificed at 30 
minutes post injection and the organs excised and imaged. Lungs were imaged both flaccid, 
and perfused with preserving formaldehyde solution. As there was no diminishing or 
interference of fluorescence due to the perfusion it was decided to always attempt perfusion 
as this allowed more accurate tumour site identification as illustrated in Figure 72 where 
the enhancement of emission specificity in the right hand lobes of the perfused lung is 
revealed. 
 
a b
 
 
Figure 72: Excised transgenic lung. a) non-perfused; b) perfused. Red indicates areas of highest concentration of 
fluorescent signal. Three lobes in the perfused lung are clearly visible indicating potentially greater accumulation 
of fluorescent agent in the lobes of the right hand lobes of the organ than in the left lobe, whereas the non-
perfused lung image offers less local information. 
 
Lung tumour transgenic mouse models were predominantly utilised throughout this study 
due to this being the primary interest and expertise of the host’s organisation. These solid 
tumours exhibit high level expression of the αvβ3 integrin due to accumulation of 
endothelial and smooth muscle cells triggered by the the pre-explained process of 
angiogenesis. An advanced liver cancer c-myc mouse model was also employed as a 
comparison and as a measure of the versatility of this science. 
The transgenic mice models are briefly explained below. The mice were all bred in-house at 
ITEM Hannover and were of varying ages depending on the aggression, and thereafter 
progression of tumourigenesis, which is directly related to the lifetime of the mice.  
 
2.9.4 Transgenic mice 
The creation of transgenicity involves the integration of genes into a germline and their 
subsequent successful expression in a host. This provides an opportunity to study the 
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function of a certain gene in the initiation and propagation of disease.100 Transgenic mice 
are useful as they can be employed to mirror human disease. They are generated by 
microinjection of mutated linear DNA into the male pronuclei of fertilised eggs from hybrid 
female mice. Viable eggs are then transferred into the oviduct of pseudopregnant surrogate 
recipient mice. The newborn transgenic founder mice are grown and confirmed by tail 
biopsy DNA dot blot assays, before being mated for propagation of transgenics.100-103 
 
2.9.4.1 SP-C raf 
This was the predominant transgenic line used in these studies. SP-C is a lung-specific 
Surfactant Protein ‘C’ promoter that contributes to the reduction of surface tension in the 
lung and the facilitation of gas exchange, it is one of a family of four known surfactant 
proteins. The expression of SP-C is restricted to AT-II cells whereas the other three are 
secreted by other cells too, therefore the promoter regions of this surfactant protein gene 
are appropriate candidates for the construction of lung specific mutations.101 
 
 
 
 
 
 
Figure 73: Cartoon showing the construction of an example linear DNA strand delivered to the germline for the 
initiation of oncogenesis. Notl and Ndel are restriction endonucleases. 
 
The SP-C promoter is used to generate transgenic mouse lines specifically overexpressing 
the oncogene c-Raf. The Raf protein bears a terminal NH2 regulatory domain which 
mediates the interaction with Ras and a COOH terminal kinase domain. c-Raf expression is 
a critical parameter in tumour development. Overexpression of c-Raf kinase sensitises cells 
for Ras transformation where the kinase becomes activated and triggers a phosphorylation 
signalling cascade that leads to continual activation and proliferation of cells - cancer.100 
 
2.9.4.2 AAT-myc 
This gene construct is genetically predisposed to the formation of hepatocellular carcinoma 
(HCC). This liver specificity is directed by α1 alpha antitrypsin (AAT) promoter.102 
Interestingly this construct has been shown to cooperate with a second transgene, ALB-
DS4, to vastly accelerate HCC formation.103 
c-Myc is a member of a group of regulatory proteins involved in controlling cell cycle entry, 
progression and differentiation. This oncogene is again frequently overexpressed in human 
adenocarcenomas, suggesting a direct involvement in carcinogenesis. Mice of this line are 
useful authentic models to study the disease.  
c-Raf SP-C promoter 
Ndel EcoRI EcoRI Notl 
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2.9.4.3 SPC-myc 
This transgenic mouse line again exhibits lung carcinomas as directed by the SP-C 
promoter, but the oncogene is the c-myc protein. In this instance the mice were a black 
furred strain and the fur had to be removed to prevent interference with the long 
wavelength excitation and emission. 
 
2.9.4.4 raf-cox 
This transgenic mouse line was only used in one instance during this study and it was 
within a different white-haired mouse species.  
 
2.9.5 Fluorescence imaging 
A GE Healthcare eXplore Optix MX small animal fluorescence spectrometer was employed 
for the in vivo imaging of the anaesthetised mice. In this study the machine was set up to 
utilise three lasers with specific discrete excitation wavelengths of 635, 670 and 785 nm. 
Pulse durations were set to 100 ps and the maximum optical power was 800 μW. The 
detection system operated by means of a time-correlated single photon counting system 
with a photomultiplier tube detecting emission within a spectral range of 450 – 900 nm. 
eXplore Optix with automated data 2D image processing and display image analysis 
software was the operating system. 
 
Emission 
filter
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Illumination 
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Figure 74: A highly simplified cartoon illustrating the important components of the imaging machine (right). 
 
Put simply the machine functions by illuminating the subject with a short subnanosecond 
laser pulse and then a fast detector measures the distribution of the photons emitted as a 
function of time relative to the specific location of excitation. This is known as time-domain 
(TD) imaging.104 It is important to consider that the laser light pulse propagating through 
different tissue types is broadened and attenuated due to background scattering and 
absorption, then having reached an embedded fluorophore, the resulting fluorescence is 
similarly affected by these factors although this is minimised through the use of near-IR 
fluorophores.  
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The ambiguity and complexity of live mammalian and specifically lung imaging became all 
too apparent in this study. Some of the problems encountered are well known.105-108 A 
mammalian body is deemed a ‘dirty’ system where metabolic and excretory pathways and 
the complexities of the immune system, especially when hyperactive, combine to make the 
physiology and genetics of the mice from subtly dissimilar, to completely different from one 
another. This in some ways makes mouse testing a thorough and quite pseudohuman 
experiment, however for these initial studies, as will be discussed forthwith, the 
interpretation of images and development of a practical understanding of optimal machine 
settings were challenging. The results are interpreted somewhat tentatively and for a more 
conclusive study a greater sample would be required. The following results were obtained 
in less than a week of testing. 
 
2.9.6 Results and discussion 
2.9.6.1 Visibility and stability: NIR797 
The NIR797 cyanine dye proved a very promising in vivo fluorophore. The excellent 
detectable emission intensity combined with great versatility in simple synthetic coupling 
protocol to primary amines, renders this a very useful organic fluorophore. NIR797 is also 
ideal when considering the capabilities of the optical spectrometer settings and available 
laser excitation wavelengths, 785 nm excitation proved perfect for the purposes of this 
work. 
5 min 30 min 120 min 240 min
 
 
Figure 75: Early images of a cPep-NIR797 (61) injected raf-cox transgenic mouse showing what appears to be 
rapid accumulation in the renal region. The tumour-bearing lungs are higher up, above the forelegs, and show low 
level (purple) fluorescence. The fluorescence intensifies in what appears to be the liver over the first 30 minutes 
and then reduces as the metabolic excretion pathways eliminate the probe through the digestive tract. 
 
The stability of cPep-NIR797 was immediately thrown into question (Figure 75). The first 
few images showed what was thought to be either preferential strong binding to the liver 
reticular endothelial system or efficient macrophage scavenging and metabolising of either 
the whole or broken down probe. The stability was tested by injection of cPep-NIR797, a 30 
minute incubation period, mouse sacrifice and liver excision. The liver was then frozen, 
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ground and extracted with Et2O and MeOH in an attempt to retrieve any unbound probe. 
MALDI-TOF mass spectrometry revealed a trace of whole compound at the correct mass 
suggesting the compound is stable. 
 
2.9.6.2 Tumour specificity and masking 
Generally speaking the whole body fluorescent images although showing excellent 
fluorescence intensity (with NIR797 fluorophore), showed far higher signal intensity from 
the liver region than from the tumour site to which the cyclic peptide probes are targeted. 
This issue of abdominal signal masking the tumour uptake has been reported previously 
with some RGD αvβ3-targeted probes such as the 99mTc conjugate applied in SPECT 
imaging,109 and in the RGD-Cy5.5 conjugate, which also showed only moderate integrin 
binding affinity as a monomer, but showed great improvement as a multimeric peptide 
conjugate probe.110 
This will be discussed further in due course with relation to our results. The lack of 
immediate tumour visualisation when our NIR797-cyclic peptide conjugates were injected 
into mice could initially be viewed with a measure of disappointment. However, the 
evaluation and interpretation of the results has led to some important discoveries with 
regards to the penetrative requirements of the fluorescence excitation and emission and the 
capabilities of the machinery employed with relation to the anatomy and physiology of the 
transgenic mice.  
The weak to seemingly non-existent fluorescence observed from the chest cavity where the 
lung tumours are located is likely to be due to the net amount of time that the lung is 
within range of the excitation laser and emission detector with relation to the abdominal 
region. Indeed, Figure 76 casts some light upon the situation as the excised perfused lung 
shows strong emission, whereas the whole body image, pre-sacrifice, shows negligible 
fluorescence from the chest region and the signal is concentrated in the abdominal region. 
This clearly suggests that the lung is completely out of range of the detection. 
 
a b c
 
 
Figure 76: SP-C raf transgenic mouse with cPep-NIR injection: a) Blind; b) 30 minute post injection scan; c) The 
excised lung from the same mouse. The arrow highlights the chest cavity - the lung location in the live mouse. 
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This phenomenon could be explicable by considering the relative tissue penetrations of the 
excitation and emission. The excitation laser penetration and the subsequent maximum 
depth from which the near-IR emission penetrates back out through tissue and bone and is 
detected from the lung may well be intermittent as the lung is likely to be going in and out 
of range with each respiratory cycle, albeit a relatively rapid cycle of ~0.4 seconds.114 
Therefore it would seem plausible that the lung may or may not be within range of the laser 
excitation at any given time relative to the immediate position of the expanding and 
contracting organ. Alternatively, the laser excitation penetration could be sufficiently deep 
enough to excite the lung but the emission is experiencing quenching as a result of the 
depth of the lung, the tissue penetration of the emission and the inaccessibility of the rear 
right hand lobes and the left lobe where the tumour may be located relative to the detector 
as this is a two dimensional technique. 
It is therefore important to consider the anatomy of the mouse and consider the optimum 
and maximum depth of tissue penetration for efficient specific fluorescence relative to the 
depth of the tumour bearing lungs.  
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Figure 77: Adapted cartoons of a 4-D digital mouse phantom. Left) A representation of the direction of movement 
of organs during lung expansion, with an approximate depth of scan (5mm) used in our fluorescence imaging 
studies. Right) Anatomical images showing the position of the lungs to the rear and right of the thoracic cage. The 
dotted line indicates the relative positions of the diaphragm. Adapted from Ref. 111. 
 
The lungs in a regular healthy mouse (Figure 77), are clearly predominantly to the rear 
and right hand side of the chest cavity even when fully inflated (typical volume change of 
~0.15 mL).111 It is envisaged through study of this universal model that only the middle 
lobe of the right lung may be within range (the machine was set at approximately 5 mm 
excitation depth with 100 μW power). It is also interesting to see the sheer bulk and 
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accessibility of the liver in relation to any other organ 
and hence any binding within, or excretion through this 
organ should be highly visible.  
Given that the time between excitation pulse and 
detectable emission, the impulse response, is of 400 
picosecond duration, it is therefore impossible that 
between excitation and emission the lung has 
contracted to a location too deep within the chest cavity 
for the emission to be detectable. It is therefore a fair 
approximation that the tumour bearing lung is either 
out of excitable range, or if excited, is partially or totally 
out of detectable emission range for potentially over half 
of the total scan time and even then perhaps only the right hand lobes are within range. 
The left lobe is deeper and more encompassed by the heart than the right lobes.  
Research accomplished using an identical spectrometer investigated to some extent the 
effect of depth. Figure 79 offers a simplistic idea of the difficulties associated with scan 
depth and penetration. The cartoon shows that if the probe is evenly spread throughout the 
sample and the laser fired to different depths, clearly the strongest signal is obtained at the 
shallowest depth. This is expected but serves to give a measure of maximum penetration. 
Future work would need to consider this as we have proved the power of our NIR797 probe. 
 
11 mm5mm 8 mm0 mm  
 
Figure 79: Cartoon illustrating penetrative issues associated with in vivo fluorescence imaging.113 
 
Respiratory gating is a cunning technique employed in most micro-CT and MRI small 
animal scanning protocol. It very simply involves gating out the periods in the respiratory 
cycle when the lung perfusion is minimal and hence the signal is achieved at specific 
periods when the lungs are at maximum expansion. Figure 80 below shows a graphical 
representation of respiratory gating and a comparison of micro-CT images between a non-
gated (a) and gated (b) mouse lung slice. Unfortunately the spectrometer we employed in 
these experiments did not have respiratory gating capabilities.  
Figure 78: Diagram of the deflated 
lobes of mouse lungs.112 
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Figure 80: Left) Respiratory gating: graph depicting the breathing cycle of a mouse and the triggering of the 
micro-CT acquisition when fully inspired. The micro-CT acquires signals for 100 msec and the average breath 
cycle time is 600 ms. Right) The resulting micro-CT images a) normal breathing (no gating); b) respiratory gated. 
Adapted from Ref. 114. 
 
It is important however to consider that the lungs of a transgenic mouse, depending on the 
extent of tumour progression, are generally of far greater size and mass than the lungs of a 
healthy mouse. Figure 81 shows this enlargement due to tumour burden. In the diseased 
lung (b), the tumours are white specks. Therefore it is plausible that this engorgement 
could work in our favour and that the depth issue may not be quite as pronounced as the 
images would suggest.  
 
a b
 
 
Figure 81: MRI size comparison between (a) healthy and (b) diseased lungs.115 
 
However MRI and micro-CT images (Figure 82) of mouse lung adenomas still confirm the 
suspicions that the tumours are predominantly beyond the optimal depth of scan. These 
images show the dramatic contrast in lung depth depending on the level of the slice 
through the rib cage. The left hand image shows the lower lung and the large liver is clearly 
visible whereas the right hand image shows the lung filling the chest cavity but for the 
heart shielding the left hand lobe. The lower slice (left) highlights that even when the lung 
is perfused and bloated with tumour burden it is still completely out of scan range whereas 
the higher slice (right) shows clearly that one or more right hand lobes are within range. 
However promising this may appear it must be considered that the vast majority of the 
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lung is still out of range and hence the probability of visualising a tumour is slim unless 
deeper laser excitation and tissue penetration can be achieved to build up a three 
dimensional image. 
 
       
H
 
 
Figure 82: Left) Respiratory gated micro-CT image showing a lower chest slice with the lungs highlighted in green 
and tumours in blue. L = liver, S = spine. Adapted from Ref. 168. Right) Respiratory gated mid-lung slice. H = 
heart. Adapted from Ref. 169. Dotted lines in both images represent an approximate 5mm scan depth.  
 
The results show that the stationary and accessible abdominal region reveals consistently 
far stronger fluorescence intensity than the chest. This has the effect of masking any lung 
fluorescence as shown in Figure 83, where an upper-limit has been set on the abdominal 
fluorescence intensity allowing any emission from the chest to become easier to see. 
 
a b  
 
Figure 83: Transgenic mouse 30 minutes post injection of cPep-NIR797. a) No upper limit; b) The same mouse 
with an upper limit set at 130 counts with arrows highlighting perceived lung fluorescence. 
 
All this discussion of the lungs being out of range and the implication that this may have 
been an inappropriate tumour model in which to test the synthesised fluorescent probes, 
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may at first seem all quite speculative. A measure of proof however, lies in the images of 
the lung whilst still functioning inside the mouse compared with the same lung excised. 
Figures 76 & 84 reveal that the counts observed for the excised lung are comparable with 
those observed from the abdominal region in the full body image prior to sacrifice. 
 
a b
 
 
Figure 84: a) SP-C raf transgenic mouse injected with cPep-NIR797 (61), 30 minute scan; b) Excised lung from 
the self-same mouse. 
 
The AAT-myc transgenic mouse liver tumour model serves to reinforce this proposition that 
there are problems associated with lung depth. It also offers a beam of hope for this 
technology.  
Figure 85 reveals the whole body image of the advanced distended liver tumour. The 
intensity of the fluorescence from the tumour mass is clearly visible suggesting that not 
only is this a good mouse model to be studying with good binding and high levels of αvβ3 
integrin but that the masking of tumour fluorescence by the strong abdominal signals an 
be overcome with careful imaging of the area of interest.  
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Figure 85: AAT-myc liver tumour mouse with cPep-NIR797 (61) injection. 30 minute images. a) No lower limit; b) 
Lower limit applied. Arrows highlight tumour site. 
 
Many questions arise as to the nature and kinetics of the metabolism and waste 
management pathways and processes of transgenic mice in comparison to healthy mice. 
Figure 86 shows a more body-wide spread of fluorescence 
emission throughout a healthy non-transgenic mouse. In a 
transgenic mouse the expulsion process seems much more 
efficient and the rapid accumulation and concentration of 
signal in the abdominal region suggests a hyperactive 
foreign body recognition and eviction mechanism is in place. 
This seems plausible as the mouse would be expected to 
mount a huge immune response to the malignancy.127 These 
studies are therefore in accord with this evidence that there 
is an enhancement of immune system kinetics and 
metabolic pathways. Another possible contributing factor in 
lung tumour mice is that the swollen lung can impart 
restrictive pressure upon the heart; subsequently the heart 
beats faster to allow the normal respiratory reoxygenation 
mechanism to cope. This also enhances the rate of other 
systems within the body including metabolism and the dispersion of fighting antibodies 
and scavenging macrophages.128 
 
2.9.6.3 3-Dimensional reconstructions 
Surgery is the cure or partial cure for many types of solid tumours. 3D imaging techniques 
offer far more accurate diagnostic options and the most recent optical spectrometers have 
3D capabilities. Perhaps a more novel approach that has recently been shown to hold 
Figure 86: Healthy mouse 
cPep-NIR injection. 
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potential is a dual modal imaging agent which combines an MRI active component for non-
invasive 3D diagnosis, with a fluorescent component for accurate surgical excision. 
Another option could involve a combination of a PET-CT active isotope such as fluorine-18 
with an optical fluorophore could be employed for similar purposes. SPECT is also available 
to be combined with the above advanced diagnostic imaging tools. It is envisaged that 
through a combinational approach more sophisticated and accurate imaging could be 
achieved. These techniques were discussed in greater depth in the introduction. 
2D image 3D reconstruction
 
 
Figure 87: The potential of 3D optical imaging.113 
 
2.9.6.4 Blocking studies 
Ideally these studies would have been carried out using the same mouse with sufficient 
time between experiments for all traces of probe to have been excreted and the mouse to 
have recovered from the procedure. However due to time constraints the experiment was 
performed using different mice of the same transgenic class. The mouse was injected with 
non-labelled masking peptide and after an interval, during which the peptide is designed to 
block the integrin binding sites, the luminescent peptide was injected. 
The blocking studies accomplished appear to have been successful due to the magnitude of 
the fluorescence intensity of blocked mice being far lower than that of a mouse not pre-
injected with non-labelled cyclic blocking peptide, especially the 30 minute example 
(Figure 88). The incubation period is obviously variable and in this study a very swift five 
minute blocking period was initially attempted as firstly, the fluorescence is clearly visible 
after this time in previous experiments and secondly, it can be rationalised that even after 
five minutes there should be competition for binding sites and therefore there should be 
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reduced tumour-specific fluorescence. Literature blocking studies on different transgenic 
mouse strains have allowed one hour before introducing a probe to the system.118 
 
No block 30 min block5 min block
 
 
Figure 88: Three mice involved in blocking studies. All scans at 30 minutes post injection of cPep-NIR797. 
 
It is abundantly clear that the efficacy of the standard blocking peptide is greatly enhanced 
when a longer time delay is applied. This confirms that the targeted cyclic peptide vector is 
an effective fluorophore delivery vehicle, but also suggests that the binding is strong and 
the kinetics of a desirable timescale. 
Another possible factor of importance is dose. An overdose could easily lead to lower 
tumour specificity and a more body-wide distribution and therefore a greater accumulation 
throughout the excretion system. A much lower dose is likely to result in much greater 
economy of agent and therefore enhancement of specificity. 
However, in this blocking study this is of less relevance as each mouse was given an 
identical dose. It could be argued that the intensity is also dependent on the extent of 
tumour development as each mouse will be different as described previously.  
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2.9.7 Appendix of all mouse images 
 
1: AAT myc liver transgenic mouse with cPep-NIR797 (61) injection 
5 min 30 min 120 min 240 min 24 hr
 
 
This is a very interesting and useful range of images from a specificity and kinetics 
perspective. Optimal tumour image was again 30 minutes post injection and it would 
appear that most of the fluorophore had been excreted within 24 hours. Compare with the 
image set below, where using the software a lower limit has been applied to the emission 
counts in an attempt to show the specificity of our luminescent probe to the tumour. 
 
5 min 30 min 120 min 240 min 24 hr
 
 
Compare and contrast these images with the non tumour-bearing AAT myc mouse below 
where a bodywide spread of imaging agent is shown with far less localisation. 
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5 min 30 min 120 min 240 min 24 hr
 
 
2: SP-C raf transgenic mouse blocking study: cPep std (59) injection, 30 minute wait, cPep-
NIR797 30 minute scan, sacrifice, excise and image organs. 
Blind 30 min Lung Organs Gastronomy
 
 
Again, these are two identical sets of images but the lower range has an upper limit of 2150 
counts applied revealing the accumulation of fluorescent probe in the perfused lung. The 
same lung has been arrowed on the organs plate (the liver was dissected to carefully 
eliminate the gall bladder which in previous excisions had dominated the signal). However, 
part of the liver still dominates the signal intensity and this is clear as the upper limit cuts 
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it out to reveal lung florescence in the lower series. The kidneys also give strong signal and 
in the gastric plates there is fluorophoric presence in the stomach and small intestine. 
Importantly the black areas on the organs plates correspond to areas untouched by the 
laser either from being too shallow or too deep. This confirms to some extent the 
hypothesis that the depth of scan is absolutely key to accurate representation of the probe 
concentration in the tissues being imaged and that to build an accurate ‘3-D’ picture 
perhaps the depth of scan needs to be adjusted several times as in fluorescence 
tomography.  
 
3: SP-C raf transgenic mouse with NIR797 (61) injection. 
5 min 30 min 120 min 240 min 24 hr
5 min 30 min 120 min 240 min 24 hr
 
 
These image series of a lung tumour-bearing transgenic mouse are very telling not least 
because even with an upper limit there is no visible fluorescence from the lung region. 
Admittedly the front paws of the mouse have moved and are no longer held back but even 
so, the images, below, of the excised lungs show very strong fluorescence from the 
perfused and non-perfused excised organ adding evidence to the pre-discussed issues 
relating to the lung being out of range.  
Also most apparent from this image is the importance of thorough hair removal as the dark 
pigmentation completely blocks the signal. Perhaps the position of the mouse also needs 
more consideration. 
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3b: Transgenic mouse with cPep-NIR (61) injection. Organs excised after 30 minutes. Lung 
images shown. Left) No upper limit set; right) upper limit set to reveal strong lung 
fluorescence in both perfused and non-perfused lungs. 
 
30 min PerfusedNon-perfused 30 minPerfused Non-perfused
 
 
Organs 
The significance of the excised organs images below is twofold; firstly the liver on the 
organs plate is completely black suggesting, initially, that it is not the liver emitting 
strongly in the abdominal region. The actual reason for the blackness of the liver is again 
due to depth of scan being set too low and the liver fluorescence being invisible. This is 
rationalised by the fact that the gall bladder fluoresces strongly as does the upper 
gastrointestinal tract on the gastric plate. Secondly, the masking effect of small regions of 
localised concentrated fluorescence easily leads to misinterpretation of images where it may 
seem there is no tumour specificity at first glance. This again calls for a 3D technique or 
the ability of the machinery to measure relative fluorescence counts at varying depths.  
 
Organs: SP-C raf transgenic mouse with cPep-NIR797 (61) injection & sacrificed at 30 
mins. 
Non-perfused30 min Perfused Organs Gastronomy
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4: AAT myc Ntr transgenic mouse with cPep-NIR (61) injection. 
5 min 30 min 120 min 240 min 24 hr
 
 
This is an example of a non tumour-bearing transgenic mouse where employing an upper 
limit reveals enhanced fluorescence from the chest cavity. Interestingly, due to a consistent 
administered dose, it is also obvious when compared with mouse ‘1’ that the relative 
intensity has reduced suggesting less localisation and more of an even spread throughout 
the body, most of which is out of range.  
Below is the same mouse with the upper limit of 2200 counts applied. It is uncertain as to 
what exactly is highlighted in the chest region (arrowed). Due to the aforementioned spread 
throughout the whole mouse it is envisaged that perhaps this is the heart rather than the 
lungs. This is in accord with the fact that tumour bearing lungs are enlarged and thus are 
perceived as being more visible, or within range, whereas healthy lungs are far smaller and 
predominantly located to the rear of the ribcage out of range. Therefore this is testament to 
the fact that this is likely a non tumour-bearing, or lowly expressing transgenic mouse.  
 
4b: AAT myc Ntr transgenic mouse with cPep-NIR (61) injection with upper limit applied.   
5 min 30 min 120 min 240 min 24 hr
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5: SP-C raf transgenic mouse cPep-Cap-NIR797 (67). l) No upper limit; r) Upper limit set. 
30 minBlind 30 minLung LungBlind
 
 
Firstly these images confirm that there is negligible difference in specificity when a caproic 
spacer is applied between the cyclic peptide vector and the fluorescent chromophore. 
Secondly, as previously discussed, excision of the lung reveals a far higher concentration of 
probe than the full body images would suggest. 
 
 
6: Raf cox transgenic mouse 10.6, cPep-NIR797 (61). 
5 min 30 min 120 min 240 min 24 hr
 
 
It is reasonable to assume that this mouse has none or relatively young tumours as 
excretion occurred completely within 24 hours. Emission intensity is reduced in 
comparison to tumour-bearing mice suggesting more even distribution throughout the 
vasculature with less localisation.  
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7: raf cox transgenic 10.4, cPep-NIR 797 (61). 
5 min 30 min 120 min 240 min
 
5 min 30 min 120 min 240 min
 
 
 
8: SP-C myc transgenic mouse cPep-NIR797 (61). 
5 min 30 min 120 min 240 min 24 hr
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8b: SP-C myc transgenic mouse cPep-NIR797 (61), with upper limit. 
5 min 30 min 120 min 240 min 24 hr
 
 
9: SP-C raf transgenic cPep-NIR797 (61). Above-no upper limit; below-upper limit set. 
5 min 30 min 120 min 240 min 24 hr
 
5 min 30 min 120 min 240 min 24 hr
 
These images show very rapid metabolism and movement through the digestive tract but 
very little thoracic localisation. The heart is perhaps visible in the lower 30 minute image. 
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Osmium complex 68 
This metal based system is reliant upon intramolecular energy transfer as explained in the 
introduction. It proved inefficient as an in vivo imaging agent. The compound showed no 
detectable emission even when a maximum laser power was applied with alternative laser 
excitation wavelengths (see appendix 4). There was no suggestion of compound breakdown 
or issues with toxicology.  
 
10: SP-C raf transgenic mouse injected with cPep-Cap-Os (68). 
5 min 30 min 120 min 240 min 24 hr
 
 
These images illustrate the inefficacy of the Osmium metal complex as a fluorescence 
imaging agent in vivo. Although the absorption and emission spectra of this probe were 
very promising due to excitation and emission showing in the near-IR region, this study 
confirms the realisation that the energy transfer mechanism of fluorescence renders the 
quantum yield and extinction co-efficient too low for observable in vivo imaging. This scan 
is identical to a pre-injection blind. Note the magnitute of the count scale. 
The cPep-Cap-Os systems remain very promising for cellular imaging studies and possible 
mass spectrometric imaging using laser ablation inductively coupled plasma exchange (LA-
ICP-MS) technology. 
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11: Different transgenic mice types at 24 hr post injection of cPep-NIR797. 
C-Raf cox SP-C myc AAT myc SP-C raf AAT myc
 
 
This is a very interesting comparison between different transgenic mouse types at 24 hours 
post injection showing clearly that AAT myc transgenic mice retain the fluorescent probe in 
vivo for a longer duration. The SP-C promoter lung cancer mouse models obviously have an 
enhanced metabolism, or, the binding in AAT myc transgenic mouse models is far stronger 
suggesting a greater prolificacy of the αvβ3 integrin. 
 
Summary and conclusion 
In summary the technique seems very dependent on the depth of the 2D plane of excitation 
and as such is unreliable for specific tumour imaging as other organs of the mouse also 
show uptake. This raises a questionmark over the tumour specificity of the cyclic peptide 
vector or the required dose (it is deemed that an overdose was applied in these studies), 
and the optimum time delay after injection before commencement of imaging. To answer 
the specificity question, unambiguous blocking study results need to be obtained on a 
greater sample quantity of mice. Optimal dose studies need to also be accomplished as, 
although 50 and 100 μL injections were compared from a fluorescence intensity 
perspective, the relative specificity was not studied. However, on a much more positive 
note, the system is obviously highly fluorescent in the near-IR region, and tissue 
penetration is more than sufficient for cellular, tissue slice and oncological biopsy studies. 
Different types of tumour (as was shown nicely by the liver tumour mouse), hold promise, 
especially if they are more accessible than the lungs. There are also questions over the 
accessibility of lung carcinoma integrins as there is very little extracellular matrix in lung 
tumours. The system does however hold great potential for 3-dimensional technology. Both 
the NIR797 label and the Osmium complex were non-toxic to the mice and easy to handle, 
store and were relatively stable. The lethargic solubility of the NIR797 cyclic peptides in 
saline is perhaps something that will be addressed through the incorporation of a PEG 
spacer unit.   
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In conclusion this has been a very interesting and worthwhile experience. In hindsight 
perhaps more shrewd design of the mouse experiments taking into consideration the 
anatomy of the mouse and perhaps altering its subsequent imaging position could have 
been applied. However, the results were very useful in determining the direction that the 
project should now take and being the first in vivo studies accomplished in the group it will 
serve as a good lesson to those continuing the research. It was a case of taking advantage 
of a great offer even though it wasn’t perhaps what the compounds had been designed for. 
  
I thank Prof. Borlak for the kind use of his facilities, mice and manpower. I thank Dr. 
Roman Halter for the days he spent anaesthetising, injecting and dissecting mice with me, 
and of course our excellent assistant Claudia. 
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Chapter 2: Experimental 
This section incorporates all experimental data gathered for compounds successfully 
synthesised during this PhD. The compounds are presented in numerical order as referred 
to when discussed previously in the prose of the synthetic plan and results & discussion 
sections. The compounds have been split into six general categories as shown below.  
This experimental section is followed by the appendices wherein lies a record of some of the 
most important or most significant data for unambiguous proof of characterisation, and to 
display data too prolific for the results and discussion section.  
 
• Ugi experimental 
• Linkers experimental 
• Osmium experimental 
• Peptide experimental 
• Miscellaneous experimental 
 
 
2.10 General information 
 
2.10.1 Chromatography 
Thin layer chromatography (TLC) was performed of pre-coated glass-backed silica gel 
plates: (silica gel 60, F254 s, 0.25mm thickness, supplied by Merck). Reversed phase TLC 
was performed using identical glass plates with RP-C18 F254 s silica coating. Visualisation 
was achieved using a variety of methods including UV light (254 / 365 nm lamp), basic 
KmnO4 solution, acidic α-naphthol and acidic p-anisaldehyde.  
 
Flash column chromatography was carried out using laboratory grade solvents on silica gel 
40-63μ 60A, supplied by Fluorochem, UK. The eluent solvents and TLC visualisation 
technique are specified for each compound. Columns were run either under gravity, or with 
gentle pressure applied using hand bellows. 
 
High performance liquid chromatography (HPLC) was performed on Dionex summit HPLC 
systems with Chromeleon 6.11 software. Analytical separation and purifications were 
acquired with the aid of a Summit p580 quaternary low pressure gradient pump with built 
in vacuum degasser. Similarly, for semi-preparative and preparative HPLC a high pressure 
gradient pump was employed and the identical multi-channel detector with a preparative 
flow cell. Helium degassed HPLC grade solvents were used throughout.  
Phenomenex luna 10u C18 (2) 100A 10 micron columns were used of the following 
dimensions: Analytical 250 x 4.6 mm; Semi-preparative 250 x 10 mm with phenomenex 10 
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x 10 mm security guard cartridge system; Preparative 250 x 21.2 mm with phenomenex 
21.2 x 60 mm security guard cartridge system. 
A variety HPLC methods and solvent programmes (see below) were employed to maximise 
separation and streamline purification. The method used is specified for each compound 
and, where necessary, in the appendices.  
 
2.10.2 HPLC methodology 
Method Solvent A Solvent B Run time 
A H2O + 0.05 % TFA MeCN + 0.05 % TFA 0 – 100 % B over 40 minutes followed by 
20 minute 100 % B wash 
B H2O + 0.05 % TFA MeCN + 0.05 % TFA 0 – 100 % B over 50 minutes followed by 
20 minute 100 % B wash 
C H2O + 0.05 % TFA MeCN + 0.05 % TFA 0 – 100 % B over 60 minutes followed by 
20 minute 100 % B wash 
D H2O + 0.05 % TFA MeOH + 0.05 % TFA 0 – 100 % B over 40 minutes followed by 
20 minute 100 % B wash 
E H2O + 0.05 % TFA MeOH + 0.05 % TFA 0 – 100 % B over 50 minutes followed by 
20 minute 100 % B wash 
F H2O + 0.05 % TFA MeOH + 0.05 % TFA 0 – 100 % B over 60 minutes followed by 
20 minute 100 % B wash 
 
2.10.3 NMR spectroscopy 
1H nmr spectra were recorded on Bruker AV300 and AVIII300 spectrometers. 13C nmr 
spectra were recorded on Bruker AC300, AV400 and AVIII400 machines sing a pendant 
pulse sequence. Variable temperature (VT) 1H nmr spectra were recorded on a Bruker 
AC500 spectrometer. COSY-90, HSQC and HMBC spectra were recorded on the 
aforementioned AVIII400 and AC500 machines.  
Coupling constants (J) are given in hertz (Hz) and the multiplicities of spectral signals 
recorded as follows: ‘s’ singlet; ‘d’ doublet; ‘dd’ doublet of doublets; ‘ddd’ doublet of double 
doublets; ‘t’ triplet; ‘q’ quartet; ‘m’ multiplet; ‘br’ broad; ‘stack’ overlapping peaks arising 
from different protons. Chemical shifts (δ) are expressed in parts per million (ppm) 
downfield from trimethyl silane (TMS). Individual spectra are referenced relative to the 
residual solvent signal according to the values reported by Gottlieb.244 
Off-line processing was accomplished using TOPSPIN, WINNMR and MestreC software. 
 
2.10.4 Mass spectrometry 
Positive and negative ion electrospray (ES+ & ES-) were measured on a Micromass LCT 
spectrometer using a methanol mobile phase. High resolution mass spectra (HRMS) were 
achieved using an appropriate lockmass. 
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Matrix assisted laser desorption ionisation time of flight (MALDI-TOF) mass spectra were 
recorded on a Bruker Biflex IV instrument and the matrix employed was gentisic acid with 
0.1 % TFA unless otherwise stated. 
Electron impact (EI) mass spectra were recorded on a VG Prospec spectrometer with a DS-
90 data system. High resolution EI spectra were measured using perfluorokerosene (PFK) 
as an internal calibrant. 
 
2.10.5 Infrared spectroscopy 
A Perkin Elmer Paragon 1600 FTIR spectrophotometers was employed. Wavenumbers (v) 
are reported in cm-1 and the conditions are specified in the script. 
 
2.10.6 Melting points 
Melting points were determined in open ended glass capilliaries using Stuart scientific 
SMP1 apparatus and reported in degrees centigrade (˚C). 
 
2.10.7 XRD 
Single crystal X-ray diffraction data was recorded on a Rigaka R-axis 11c diffractometer 
equipped with a molybdenum rotating anode source and an image plate detector system. 
Alternatively a Bruker smart 6000 diffractometer with CCD detector and a sealed Cu tube 
source was employed. 
 
2.10.8 Ultraviolet spectroscopy 
Absorption spectra were recorded on a Shimadzu UV-3101PC UV-vis-NIR spectrometer 
using matched pairs of 1 cm path length quartz cuvettes. 
 
2.10.9 Fluorescence spectroscopy 
Yb - The sample was dissolved in the stated solvent and excited using the fourth harmonic 
from a pulsed Nd:YAG laser (266 nm) operating at 10 Hz. Light emitted at 90º to the 
excitation beam was focused onto the Spex TRIAX320 monochromator slits from which the 
appropriate wavelength was selected. The growth and decay of luminescence at selected 
wavelengths was detected using a germanium photodiode (Edinburgh instruments, EI-P) 
and recorded using a digital oscilloscope (Tektronix TDS220) for computational analysis. 
 
Tb/Eu/Fluorescein – The samples were dissolved in the stated solvent and excited at 
selected wavelengths using a Perkin Elmer LS55 fluorometer or a PTI L-210M fluorescence 
system with a 75W xenon arc lamp as illumination source. Detection was achieved with a 
Shimadzu R298 PMT in a PTI model 814 analogue/photon counting multiplier. The 
emission monochromator was equipped with interchangeable 500 nm and 750 nm blazed 
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gratings. PTI Felix fluorescence analysis software for Windows produced the spectra. 
Excitation and emission spectra were recorded in solution with the stated solvent at 
ambient temperature. A 1 x 1 cm path length quartz cuvette with four transparent polished 
faces was used as the detection system was at 90º to the excitation source. Appropriate 
long-pass filters were used in each experiment. 
 
2.10.10 Optical rotation spectroscopy 
This data was obtained with the compound dissolved in either CDCl3 or CD3OD as stated, 
and inserted into an Optimal Activity PolAAr 2001 automatic polarimeter. [α]D values are 
reported in units of 10-1degcm2g-1. 
 
2.10.11 Reactions 
Solution phase reactions were carried out, whenever appropriate, in flame or oven-dried 
(150 ˚C) glassware using laboratory grade solvents. Anhydrous solvents and reagents were 
either purchased or rigorously dried in the correct manner and stored under argon over 3Ǻ 
molecular sieves.  
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2.11 Ugi experimental 
 
Preparation of 1,4,7-tris-(ethoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecane (01). 
 
N
NH
N
N
O
OEt
OEtO
O
EtO
C20H38N4O6
Mol. Wt.: 430.54  
 
Ethyl bromoacetate (6.08 mL, 54.9 mmol), dissolved in dry CHCl3 (20 mL), was added 
dropwise to a mixture of 1,4,7,10-tetraazacyclododecane (cyclen) (2.70 g, 15.7 mmol) and 
sodium hydrogen carbonate (13.17 g, 157 mmol) in dry CHCl3 (40 mL). The resulting 
mixture was stirred vigorously at room temperature for 72 hours.  
The thick white precipitate was removed by gravity filtration, washed with chloroform (3 x 
10 mL) and the solvent evaporated under reduced pressure to leave the product as a 
viscous pale brown oil. 
Purification by gradient flash column chromatography (silica, CH2Cl2 to CH2Cl2 / MeOH / 
NH3(aq) 9 / 1 / 0.05, Rf = 0.59 in CH2Cl2 / MeOH / NH3(aq) system) yielded the pure product 
as a pale brown oil (4.77 g, 71%); νmax (CHCl3) / cm-1 1735 (C=O); δH (300 MHz, CDCl3) 0.96 
(9H, t, J 7.1, 3 x OCH2CH3), 2.59, 2.62, 2.71, 2.81 (16H, 4 x s, 8 x CH2 from cyclen), 3.11 
(2H, s, NCH2COOEt), 3.22 (4H, s, 2 x NCH2COOEt), 3.86 (6H, q, J 7.1, 3 x OCH2CH3), 9.55 
(1H, s, NH); δC (300 MHz CDCl3) 12.1 (OCH2CH3), 45.2, 46.1, 47.1, 49.2 (4 x cyclen CH2 
envir.), 55.0 (NCH2COOEt), 58.5 (OCH2CH3), 168.2, 169.1 (2 x C=O envir.); m/z (TOF ES+) 
453.2689 ([M+Na]+, 100 %, C20H38N4O6Na requires 453.2686).  
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Preparation of 1,4,7-tris-(ethoxycarbonylmethyl)-10-(tert-
butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane (02). 
 
 
N
N
N
N
O
OEt
OEtO
O
EtO
OtBuO
C26H48N4O8
Mol. Wt.: 544.68  
 
 
Tris-ethyl ester (01) (4.77 g, 11.1 mmol) was combined with dry Et3N (7.79 mL, 55.4 mmol) 
in dry THF (20 mL). Tert-butyl bromoacetate (2.13 mL, 14.4 mmol) in dry THF (20 mL) was 
then added dropwise and the resulting mixture stirred at room temperature under N2 for 
72 hr.  
The thick white precipitate was then removed by gravity filtration and washed with THF (3 
x 10 mL). The solvent was then evaporated under reduced pressure and the flask subjected 
to high vacuum drying for 24hr to leave the product as a viscous pale brown oil (5.42 g, 
89%);  νmax (CHCl3) 1736 (C=O); δH (300MHz, CDCl3) 1.20 (9H, t, J 7.1, OCH2CH3), 1.39 (9H, 
s, (CH3)3C), 2.77 (16H, s, 8 x CH2 from cyclen), 3.22 (2H, s, NCH2COOR), 3.34 (6H, s, 
NCH2COOR), 4.08 (6H, q, J 7.1, OCH2CH3); δC (300 MHz CDCl3) 12.7 ((CH3)3C), 26.5 
(OCH2CH3), 53.6, 53.9, 54.4 (cyclen CH2 envir.), 59.9 (OCH2CH3), 80.8 ((CH3)3C), 171.7, 
172.2 (2 x C=O); m/z (ES) 545 ([M+H]+ 100%), 567 ([M+Na]+ 11%). m/z (TOF ES+) 567.3370 
([M+Na]+, 100 %, C26H48N4O8Na requires 567.3381). 
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Preparation of 1,4,7-(tris-ethoxycarbonylmethyl)-1,4,7,10-
tetraazacyclododecyl ethanoic acid (03). 
 
 
N
N
N
N
O
OEt
OEtO
O
EtO
OHO
C22H40N4O8
Mol. Wt.: 488.57  
 
 
To the tri-ethyl ester-mono tert-butyl ester derivative (02) (0.20 g, 0.37 mmol) was added 
TFA (3 mL) and CH2Cl2 (3 mL) at 0 °C. The mixture was then allowed to warm to ambient 
temperature and stirred for 16 hours. The solvent and excess TFA were then removed 
under reduced pressure and the viscous light brown oil dissolved and re-evaporated in 
CH2Cl2 (3 x 10 mL) in an attempt to remove all excess TFA. The crude product was then 
purified by preparative HPLC (Method E, tr = 35.06 min) and lyophilised to afford the 
product as a fine white powder (0.17 g, 95%); νmax (CHCl3) 1746 (C=O), 3380 (COOH); δH 
(300MHz, CD3OD) 1.25-1.34 (9H, m, 3 x OCH2CH3), 3.13 (8H, br s, 4 x cyclen CH2), 3.46 
(8H,  br s, 4 x cyclen CH2), 3.74 (6H, br s, 3 x NCH2COOEt), 3.89 (2H, s, NCH2COOH), 4.19 
(6H, q, J 7.2, OCH2CH3), 4.25-4.32 (3H, q, J 7.2, OCH2CH3), 4.91 (1H, br s, COOH); δC (300 
MHz CD3OD) 11.9 (OCH2CH3), 48.2 (NCH2COOEt), 51.1, 51.4, 53.2, 53.6 (4 x cyclen CH2 
envir.), 54.6 (NCH2COOH), 59.4, 59.6 (2 x OCH2CH3 envir.), 167.9, 170.1 (2 x C=O envir.); 
m/z (TOF ES+) 489.2924 ([M+H]+, 100 %, C22H41N4O8 requires 489.2918). 
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Preparation of Ugi 4-CCR bis-amide products: benzyl (04), naphthyl (05), 
pyrenyl (06) & indolyl (07). 
 
 
 
1,4,7-tris-(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecyl ethanoic acid (03) (0.14 g, 
0.29 mmol) was dissolved in dry EtOH (5 mL) under nitrogen). Benzaldehyde (0.029 mL, 
0.29 mmol), aminodiphenylmethane (0.049 mL, 0.29 mmol) and benzyl isocyanide (0.035 
mL, 0.29 mmol) were then added simultaneously, and the mixture stirred vigorously at 65 
°C for 72 hours. The solvent was then removed under reduced pressure and the crude 
product purified using gradient flash column chromatography (Silica, CH2Cl2 to CH2Cl2, 
MeOH, NH3(aq) 9 : 1 : 0.05, Rf = 0.43). The product was then further purified by preparative 
HPLC (Method B), and lyophilised to afford the product as a fine white powder. 
 
04$ (0.17 g, 68 %) Rf = 0.43; m.p. = 60-62 ˚C ; νmax (CHCl3)/cm-1 1681, 1730, 1741 (3 x 
C=O), 3249, 3300 (NH); m/z (TOF ES+) 899.5683 ([M+Na]+, 100 %, C50H64N6O8Na requires 
899.4695). Analytical HPLC tr = 23.7 minutes. 
05*$ (0.22 g, 70 %) Rf = 0.40; m.p. = 66-68 ˚C ; νmax (CHCl3)/cm-1 1683, 1736 (2 x C=O), 
3246, 3296 (NH); m/z (TOF ES+) 927.5020 ([M+H]+, 100 %, C54H67N6O8 requires 927.5001). 
Analytical HPLC tr = 22.3 minutes. 
06$ (0.11 g, 36 %) Rf = 0.39; m.p. = 165-167 ˚C ; νmax (CHCl3)/cm-1 1676, 1740 (2 x C=O), 
3258, 3310 (NH); m/z (TOF ES+) 1023.4996 ([M+Na]+, 100 %, C60H68N6O8Na requires 
1023.5010). Analytical HPLC tr = 24.6 minutes. 
07 (0.25 g, 86 %) Rf = 0.48; m.p. = 160-162 ˚C ; νmax (CHCl3)/cm-1 1664, 1678, 1738, 1745 
(4 x C=O), 3258, 3310 (NH); m/z (TOF ES+) 938.4792 ([M+Na]+, 100 %, C52H65N7O8Na 
requires 938.4769). Analytical HPLC tr = 26.2 minutes. 
 
*See appendix 1 for XRD crystal structure proof of successful synthesis. 
$Due to the conformational flexibility in the molecule the NMR spectra were too complex to 
assign. However see appendix 2 for VT nmr studies. 
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Preparation of hydrolysed Ugi 4-CCR bis-amide products: benzyl (08), 
naphthyl (09), pyrenyl (10) & indolyl (11). 
 
 
 
The Ugi products 04, 05, 06 & 07 (0.1 g) were dissolved in a 1:1 (v/v) mix of THF / H2O (8 
mL). LiOH (3.5 eq.) in H2O (2 mL) was then added and the reaction mixture stirred for 24 
hours at ambient temperature. Excess THF was then removed under reduced pressure and 
the mixture neutralised with 1M HCl. The product was purified using preparative HPLC 
(method D), and lyophilised to afford the product as a fine white powder. 
 
08 (0.077 g, 85 %); νmax (nujol)/cm-1 1658, 1727 (2 x C=O); m/z (TOF ES+) 815.6831 
([M+Na]+, 100 %, C44H52N6O8Na requires 815.6822); m/z (TOF ES-) 791.3 (M-H), 100 %. 
Analytical HPLC tr = 23.3 minutes. 
09 (0.080 g, 88 %); νmax (nujol)/cm-1 1650, 1726 (2 x C=O); m/z (TOF ES+) 865.3901 
([M+Na]+, 100 %, C48H54N6O8Na requires 865.3910).  Analytical HPLC tr = 32.8 minutes. 
10 (0.079 g, 86 %); νmax (nujol)/cm-1 1654, 1730 (2 x C=O); m/z (TOF ES+) 939.4057 
([M+Na]+, 100 %, C54H56N6O8Na requires 939.4048). Analytical HPLC tr = 26.4 minutes. 
11 (0.075 g, 83 %); νmax (nujol)/cm-1 1660, 1728 (2 x C=O); m/z (TOF ES+) 854.3853 
([M+Na]+, 100 %, C46H53N7O8Na requires 854.3867). Analytical HPLC tr = 23.9 minutes. 
 
Due to the conformational flexibility in the molecule, NMR spectra were too complex to 
assign.  
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Preparation of Europium complexed Ugi 4-CCR products: benzyl (12), 
naphthyl (13), pyrenyl (14) & indolyl (15). 
 
 
 
The carboxylic acids 08, 09, 10 & 11 (0.005 g) were dissolved in anhydrous MeOH (5 mL), 
and Eu(OTf)3 (1.1 eq.) was added. The mixture was then stirred at 40 ºC under argon for 3 
days. The MeOH was then removed under reduced pressure and the product purified using 
HPLC (method D) to afford the products as fine white powders. 
 
12* (0.005 g, 86 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1595 br (COO-), 1658, 1679 (2 x 
C=O); m/z (TOF ES+) 965.2722 ([M+Na]+, 100 %, C44H49N6O8EuNa requires 965.2733). 
Analytical HPLC tr = 37.5 & 40.7 minutes. 
13 (0.005 g, 84 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1599 br (COO-), 1659, 1670 (2 x 
C=O); m/z (TOF ES+) 1015.2879 ([M+Na]+, 100 %, C48H51N6O8EuNa requires 1015.2865). 
Analytical HPLC tr = 35.0 & 37.8 minutes. 
14 (0.005, 90 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1588 br (COO-), 1670, 1682 (2 x 
C=O); m/z (TOF ES+) 1067.3216 ([M+H]+, 100 %, C54H54N6O8Eu requires 1067.3239). 
Analytical HPLC tr = 43.1 minutes. 
15 (0.006 g, 96 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1600 br (COO-), 1655, 1678 (2 x 
C=O); m/z (TOF ES+) 1002.2817 ([M+Na]+, 100 %, C46H50N7O8Na151Eu requires 1002.2802). 
Analytical HPLC tr = 38.0 & 41.0 minutes. 
 
Due to the conformational flexibility of the molecule and the shift effect of the lanthanide 
ion, the NMR spectra were too complex to assign. See appendix 5 for HPLC and m/z data. 
 
*See appendix 1 for crystal structure. 
Experimental – Ugi chemistry 
 122
Preparation of terbium complexed Ugi 4-CCR products: benzyl (16), 
naphthyl (17), pyrenyl (18) & indolyl (19). 
 
 
 
The carboxylic acids 08, 09, 10 & 11 (0.005 g) were dissolved in anhydrous MeOH and 
Tb(OTf)3 (1.1 eq.) was added. The mixture was stirred at 40 ºC under Ar(g) for 72 hours. The 
MeOH was then removed under reduced pressure and the product purified using HPLC 
method B.  
 
16* (0.006 g, 92 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1592 br (COO-), 1674, 1698 (C=O); 
m/z (TOF ES+) 971.2763 ([M+Na]+, 100 %, C44H49N6O8TbNa requires 971.2735). Analytical 
HPLC tr = 37.2 & 40.5 minutes.* 
17 (0.005 g, 88 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1588 br (COO-), 1669, 1694 (C=O); 
m/z (TOF ES+) 1021.2920 ([M+Na]+, 100 %, C48H51N6O8TbNa requires 1021.2952). 
Analytical HPLC tr = 38.7 & 41.6 minutes. 
18 (0.004 g, 73 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1598 br (COO-), 1689, 1712 (C=O); 
m/z (TOF ES+) 1095.4239 ([M+Na]+, 100 %, C54H53N6O8TbNa requires 1095.4221). 
Analytical HPLC tr = 41.7 minutes.  
19 (0.005 g, 91 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1595 br (COO-), 1666 br (C=O); m/z 
(TOF ES+) 1010.2872 ([M+Na]+, 100 %, C46H50N7O8TbNa requires 1010.2843). Analytical 
HPLC tr = 38.2 & 41.1 minutes. 
 
Due to the conformational flexibility of the molecule and the shift effect of the lanthanide 
ion, the NMR spectra were too complex to assign. See appendix 5 for HPLC and m/z data. 
 
*See appendix 1 for crystal structure.
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Preparation of ytterbium complexed Ugi 4-CCR products: benzyl (20), 
naphthyl (21), pyrenyl (22) & indolyl (23). 
  
O
N
R
N
H
N
N
N
N
O
O
O
O
O
O
O
R1 =
R2 =
R3 =
R4 =
N
H
Benzyl
2-Naphthyl
1-Pyrenyl
3-Indolyl
Yb
C44H49N6O8Yb
Mol. Wt.: 962.94
C48H51N6O8Yb
Mol. Wt.: 1012.99
C54H53N6O8Yb
Mol. Wt.: 1087.07
C46H50N7O8Yb
Mol. Wt.: 1001.97
 
 
The carboxylic acids 08, 09, 10 & 11 (0.005 g) were dissolved in anhydrous MeOH (5 mL), 
and Yb(OTf)3 (1.1 eq.) added. The mixture was stirred at 40 ºC under N2(g) for 72 hours. The 
MeOH was then removed under reduced pressure and the crude product purified using 
HPLC method B to afford pure product as a fine white powder. 
 
20* (0.005 g, 83 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-11597 br (COO-), 1674, 1712 (C=O); 
m/z (TOF ES+) 986.2898 ([M+Na]+, 100 %, C44H49N6O8YbNa requires 986.2921). Analytical 
HPLC tr = 36.6 & 40.3 minutes.* 
21 (0.005 g, 84 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1595 br (COO-), 1670, 1699 (C=O); 
m/z (TOF ES+) 1036.3044 ([M+Na]+, 100 %, C48H51N6O8YbNa requires 1036.3055). 
Analytical HPLC tr = 35.5 & 39.6 minutes. 
22 (0.006 g, 92 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1587 br (COO-), 1673 br, 1728 
(C=O); m/z (TOF ES+) 1110.311 ([M+Na]+, 100 %, C54H53N6O8YbNa requires 1110.3243). 
Analytical HPLC tr = 43.3 minutes.  
Product discoloured rapidly. 
23 (0.005 g, 78 %); m.p. = >300 ˚C ; νmax (CHCl3)/cm-1 1598 br (COO-), 1671 br, 1723 
(C=O); m/z (TOF ES+) 1025.3007 ([M+Na]+, 100 %, C46H50N7O8174YbNa requires 
1025.3014). Analytical HPLC tr = 38.1 & 40.8 minutes. 
 
Due to the conformational flexibility of the molecule and the shift effect of the lanthanide 
ion, the NMR spectra were too complex to assign. See appendix 5 for HPLC and m/z data. 
*See appendix 1 for crystal structure. 
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Preparation of ethyl ester caproic linker Ugi 4-CCR products: benzyl (24) & 
indolyl (25). 
 
 
 
Aminocaproic ethyl ester hydrochloride 50 (0.092 g, 0.55 mmol) was combined with 
anhydrous Et3N (0.076 mL, 0.55 mmol) and stirred in anhydrous EtOH (10 mL) for 5 
minutes at ambient temperature under argon. Aldehyde (0.08 g, 0.55 mmol) was then 
applied and the mixture stirred for a further 30 minutes. 1,4,7-tris-(ethoxycarbonylmethyl)-
1,4,7,10-tetraazacyclododecyl ethanoic acid 03 (0.55 mmol) and benzyl isocyanide (0.55 
mmol) were then added simultaneously and the cocktail stirred at 65°C for 3 days under 
argon. The solvent was then removed under reduced pressure and the crude product 
purified using gradient flash column chromatography (Silica, CH2Cl2 100 % to CH2Cl2, 
MeOH, NH2(aq) 9.3 : 0.65 : 0.05). The product was then further purified by preparative HPLC 
(Method C) and lyophilised to afford the product as a fine white powder. 
 
24 (0.27 g, 59 %); Rf = 0.42; νmax (CHCl3)/cm-1 1572, 1673, 1742 (C=O), 3249, 3300 (NH); 
m/z (TOF ES+) 875.1 ([M+Na]+, 100 %); HRMS 875.4895 ([M+Na]+, 100%, C45H68N6O10Na 
requires 875.4887). Analytical HPLC tr = 18.6 minutes. 
 
25 (0.26 g, 53 %); Rf = 0.62; νmax (CHCl3)/cm-1 1565, 1654, 1739 (C=O), 3246, 3296 (NH); 
m/z (TOF ES+) 893.6 ([M+H]+, 100 %), 915.5 ([M+Na]+, 25 %); HRMS 892.5184 ([M+H]+, 
100%, C47H70N7O10 requires 892.5197). Analytical HPLC tr = 19.7 minutes. 
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Preparation of hydolysed ethyl ester caproic linker Ugi 4-CCR products: 
indolyl (26). 
O
N
N
H
N
N
N
N
O
OH
O
HO
O
HO
O
O
OH
C37H52N6O10
Mol. Wt.: 740.84  
 
The Ugi product 24 (0.20 g, 0.24 mmol) was dissolved in a 1:1 mix of THF / H2O. LiOH (3.5 
eq.) in H2O (2 mL) was then added and the reaction mixture stirred for 24 hours at ambient 
temperature. The excess THF was then removed under reduced pressure and the mixture 
neutralised with 1M HCl. The product was purified using preparative HPLC (method B), 
and lyophilised to afford the product as a fine white powder (0.15 g, 88 %). HPLC tr = 13.6; 
m/z (TOF ES-) 739.62 ([M-H]-, 100 %). 
 
 
Preparation of alternative protecting group strategy Ugi products. Tris-ethyl 
ester, caproic tert-butyl ester, benzyl (27) and 3-indolyl (28) Ugi reaction 
products. 
 
 
Amino caproic tert-butyl ester 49 (1.03 mmol) was combined with aldehyde (1.03 mmol) in 
anhydrous EtOH (5 mL) and stirred for 10 minutes under argon at ambient temperature. 
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1,4,7-tris-(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecyl ethanoic acid 03 (1.03 
mmol) and benzyl isocyanide (1.03 mmol) were then added simultaneously and the cocktail 
stirred at reflux for 3 days under argon. The solvent was then removed under reduced 
pressure and the crude product purified using gradient flash column chromatography 
(CH2Cl2 to CH2Cl2 / MeOH / NH2(aq), 9 : 0.95 : 0.05). The product was then further purified 
by preparative HPLC (Method X) and lyophilised to afford the product as a fine white 
powder. 
27 (68 %); Rf = 0.42; m/z (TOF ES+) 881.5388 ([M+H]+, 100 %, C47H73N6O10 requires 
881.5392); 903.5208 ([M+Na]+, 100%, C47H72N6O10Na requires 903.5203). Analytical HPLC 
tr = 26.9 minutes. 
28 (67 %); Rf = 0.45; m/z (TOF ES+) 942.5317 ([M+Na]+, 100 %, C49H73N7O10Na requires 
942.5303). Analytical HPLC tr = 31.9 minutes. 
 
 
Preparation of ethyl ester hydrolysis products: benzyl (29), indolyl (30). 
 
 
 
The Ugi products 27 & 28 were dissolved in a 1:1 (v/v) mix of THF / H2O (8 mL). LiOH (3.5 
eq.) in H2O (2 mL) was then added and the reaction mixture stirred for 24 hours at ambient 
temperature. The excess THF was then removed under reduced pressure and the mixture 
neutralised with 1M HCl. The product was purified using preparative HPLC (method D), 
and lyophilised to afford the product as a fine white powder. 
29 (0.03 g, 90 %); m/z (TOF ES+) 798.0 ([M+H]+, 10%) 400.1 ([M/2+2H]+, 100 %); 
Analytical HPLC tr = 30.3 minutes. 
30 (0.05 g, 88 %); m.p. = 66-68 ˚C; m/z (MALDI-TOF) 836.4 ([M+H]+, 100 %), 858.4 
([M+Na]+, 60 %). Analytical HPLC tr = 34.3 minutes. 
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Preparation of terbium complexation Ugi products: benzyl (31), indolyl (32). 
 
 
 
The carboxylic acids 29 & 30 were dissolved in anhydrous MeOH and Tb(OTf)3 (1.1 eq.) 
added. The mixture was stirred at 40 ºC under argon for 3 days. The crude mixture was 
then concentrated under reduced pressure and the product purified using HPLC method E.  
 
31 (0.01 g, 48 %); m/z (TOF ES+) 953.5 ([M+H]+, 40 %), 449.2 ([M/2+2H]+, 100 %). 
Analytical HPLC tr = 32.3 minutes. 
32 (0.014 g, 57 %); m/z (MALDI-TOF) 992.4 ([M+H]+, 90 %), 936.1 ([M-tBu)+, 100 %). 
Analytical HPLC tr = 35.7 minutes. 
 
 
Preparation of terbium complexed caproic linker Ugi 4-CCR products: 
benzyl (33), indolyl (34). 
  
 
Preparation of 33 
The terbium complexed Ugi product 31 (0.016 g, 0.016 mmol) was taken up in CH2Cl2 (1 
mL) and with stirring at ambient temperature a concoction consisting of TFA / TIPS / H2O 
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(98 : 1 : 1 repectively) (1 mL) applied. The mixture was stirred for 2 hours and concentrated 
under reduced pressure repeatedly using co-concentration with CH2Cl2 (5 x 5 mL) and 
trituration with Et2O to ensure complete removal of all waste products and the recovery of 
the product as a white powder. 
33 (0.013 g, 88 %); m/z (TOF ES+) 897.2842 ([M+H]+, 100%, C37H50N6O10Tb requires 
897.2813). Analytical HPLC tr = 23.7 minutes. 
 
Preparation of 34 
The tetra ethyl ester 25 (0.02 g, 0.022 mmol) was dissolved in a 1:1 mix of THF / H2O. 
LiOH (3.5 eq.) in H2O (2 mL) was then added and the reaction mixture stirred for 24 hours 
at ambient temperature. The excess THF was then removed under reduced pressure and 
the mixture neutralised with 1M HCl. The crude product was lyophilised and taken on 
without further purification. 
The crude tetra acid (0.015 g, 0.0025 mmol) was then dissolved in anhydrous MeOH (5 
mL), and Tb(OTf)3 (0.09 g, 0.15 mmol) added. The mixture was stirred at 40 ºC under argon 
for 72 hours. The solvent was then removed under reduced pressure and the crude product 
purified using HPLC (method D) and lyophilised to afford the product as a fine white 
powder.  
34 (0.02 g, 18 %); νmax m/z (TOF ES+) 958.0 ([M+Na]+, 100 %), 980 ([M-H+2Na]+, 5 %); m/z 
(TOF ES-) 934.1 ([M-H]+, 100 %), 956.2 ([M-H+Na]+, 15 %). Analytical HPLC tr = 31.2 
minutes. 
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2.12 Linkers experimental 
 
PEG 
 
Preparation of tert-butoxycarbonylmethyl (ethylene glycol): tetra (35), hexa 
(36). 
 
 
 
 
 
 
 
 
 
Hexa (ethylene glycol) (1.00 mL, 1.13 g, 4.00 mmol) was combined with tert-
butylbromoacetate (0.65 mL, 4.39 mmol), silver (I) oxide (1.39 g, 6.0 mmol) and potassium 
iodide (0.13 g, 0.80 mmol) in dry CH2Cl2 at 0ºC under argon. The mixture was allowed to 
warm to ambient temperature and stirred for 8 hours. The silver was removed by filtering 
the crude cocktail through celite and the solvent then removed under reduced pressure. 
Purification was achieved by flash column chromatography (9.5 CH2Cl2 : 0.5 MeOH) to 
afford the pure product as a colourless oil.  
 
35 (0.94 g, 76 %). Rf = 0.43; νmax (Neat)/cm-1 3329 (OH), 2883 (CH), 1742 (C=O), 1101 
(COC); δH (300 MHz; CDCl3) 3.98 (2H, s, CH2C=O), 3.55-3.69 (16H, stack, 8xOCH2), 2.71 
(1H, br s, OH), 1.42 (9H, s, C(CH3)3); δC (75 MHz) 169.6 (C=O), 81.4 (C(CH3)3), 72.4 (OCH2), 
70.6 (OCH2), 70.5 (OCH2), 70.2 (OCH2), 68.9 (OCH2), 61.6 (OCH2), 28.0 (C(CH3)3); m/z (TOF 
ES+) 331.1733 ([M+Na]+, 100%, C14H28O7Na requires 331.1729). 
 
36 (1.27 g, 80 %). Rf = 0.41; νmax (Neat)/cm-1 3332 (OH), 2880 (CH), 1740 (C=O), 1100 
(COC); δH (300 MHz; CDCl3) 3.97 (2H, s, OCH2C=O), 3.55-3.68 (24H, stack, 12xOCH2), 3.02 
(1H, br s, OH), 1.42 (9H, s, C(CH3)3); δC (75 MHz) 169.5 (C=O), 81.3 (C(CH3)3), 72.3 (OCH2), 
70.4 (OCH2), 70.2 (OCH2), 69.9 (OCH2), 68.8 (OCH2), 61.5 (OCH2), 27.8 (C(CH3)3); m/z (TOF 
ES+) 419.2257 ([M+Na]+, 100%, C18H36O9Na requires 419.2254). 
Please see Ref 159. 
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Preparation of O-tert-butoxycarbonylmethyl-6-mesyl-(ethylene glycol): tetra 
(37), hexa (38). 
 
 
 
 
 
 
 
Ester 36 (1.00 g, 2.52 mmol) was dissolved in dry CH2Cl2 (50 mL) and cooled to 0 ºC under 
argon. Mesyl chloride (0.20 mL, 0.29 g, 2.52 mmol) and triethylamine (0.42 mL, 0.31 g, 
3.03 mmol) were then added and the mixture stirred for a further hour at 0ºC prior to 
allowing the return to ambient temperature and stirring overnight. The crude cocktail was 
then washed with 2% citric acid soln. (2 x 30 mL), sat. NaHCO3 (2 x 30 mL), H2O (2 x 30 
mL) and brine (30 mL) and dried with anhydrous MgSO4 prior to removing the solvent 
under reduced pressure. Purification by flash column chromatography (9.5 CH2Cl2 : 0.5 
MeOH) yielded the pure product as a colourless oil. 
 
37 (1.18 g, 94 %). Rf = 0.47; νmax (Neat)/cm-1 2867 (CH), 1747 (C=O), 1349 (S=O), 1100 
(OCO); δH (300 MHz; CDCl3) 4.33 (2H, m, CH2OSO2), 3.96 (2H, s, OCH2C=O), 3.71 (2H, m, 
CH2CH2OSO2), 3.58-3.68 (12H, stack, OCH2), 3.03 (3H, s, SO2CH3), 1.42 (9H, s, C(CH3)3); 
δC (100 MHz) 169.8 (C=O), 81.1 (C(CH3)3), 70.3 (OCH2), 70.2 (OCH2), 70.1 (OCH2), 69.8 
(OCH2), 69.3 (OCH2), 68.9 (OCH2), 37.4 (SO2CH3), 27.5 (C(CH3)3); m/z (TOF ES+) 409.2401 
([M+Na]+, 100%, C15H30O9SNa requires 409.2394). 
 
38 (0.97 g, 81 %). Rf = 0.50; νmax (Neat)/cm-1 2865 (CH), 1745 (C=O), 1348 (S=O), 1102 
(OCO); δH (300 MHz; CDCl3) 4.28 (2H, m, CH2SO2), 3.91 (2H, s, OCH2C=O), 3.67 (2H, m, 
CH2CH2SO2), 3.50-3.60 (20H, stack, OCH2), 2.99 (3H, s, SO2CH3), 1.37 (9H, s, C(CH3)3); δC 
(100 MHz) 169.5 (C=O), 81.3 (C(CH3)3), 70.5 (OCH2), 70.4 (OCH2), 70.3 (OCH2), 70.2 (OCH2), 
69.2 (OCH2), 68.8 (OCH2), 37.5 (SO2CH3), 27.9 (C(CH3)3); m/z (TOF ES+) 497.2033 
([M+Na]+, 100%, C19H38O11SNa requires 497.2018). 
Please see Ref 159. 
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Preparation of O-tert-butoxycarbonylmethyl-6-azido-(ethylene glycol): tetra 
(39), hexa (40). 
 
 
 
 
 
 
 
 
Mesylate 38 (0.80 g, 1.69 mmol) was combined with sodium azide (0.16 g, 2.53 mmol) in 
dry DMF (40 mL). The mixture was heated at reflux for 8 hours under argon and cooled to 
ambient temperature. EtOAc (100 mL) was added and the crude cocktail extracted with 
H2O (5 x 100 mL), dried over anhydrous MgSO4, and finally the solvent removed under 
reduced pressure to afford the product as a colourless oil. Analysis revealed the product to 
be of high enough pueity to proceed without further purification. 
 
39 (0.52 g, 75 %); Rf = 0.45 (9.5 CH2Cl2 : 0.5 MeOH). νmax (Neat)/cm-1 2102 (N3), 1739 
(C=O), 1112 (COC); δH (300 MHz; CDCl3) 3.88 (2H, s, CH2C=O), 3.56-3.49 (14H, stack, 7 x 
OCH2), 3.21 (2H, t, J 5.2, CH2N3), 1.33 (9H, s, C(CH3)3); δC (75 MHz) 168.2 (C=O), 79.7 
(C(CH3)3), 69.4 (OCH2), 69.3 (OCH2), 68.7 (OCH2), 67.6 (OCH2), 49.3 (CH2N3), 26.8 (C(CH3)3); 
m/z (TOF ES+) 356.1798 ([M+Na]+, 100%, C14H27N3O6Na requires 356.1785. 
 
40 (0.54 g, 77 %), Rf = 0.43 (9.5 CH2Cl2 : 0.5 MeOH). νmax (Neat)/cm-1 2104 (N3), 1740 
(C=O), 1110 (COC); δH (300 MHz; CDCl3) 3.91 (2H, s, CH2C=O), 3.50-3.60 (22H, stack, 
OCH2), 3.28 (2H, t, J 4.9, CH2N3), 1.37 (9H, s, C(CH3)3); δC (100 MHz) 169.4 (C=O), 81.2 
(C(CH3)3), 70.5 (OCH2), 70.4 (OCH2), 69.8 (OCH2), 68.8 (OCH2), 50.5 (CH2N3), 27.9 (C(CH3)3); 
m/z (TOF ES+) 444.2322 ([M+Na]+, 100%, C18H35N3O8Na requires 444.2321). 
 
Please see Ref 159. 
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Preparation of O-tert-butoxycarbonylmethyl-6-amino-(ethylene glycol): tetra 
(41), hexa (42). 
 
 
 
 
 
 
 
 
Azide 39 (2.29 g, 5.23 mmol) was dissolved in dry THF (20 mL) under argon at 0 ºC. PPh3 
(1.57 g, 5.98 mmol) was then added and after 30 minutes the ice bath was removed and 
the mixture stirred overnight at ambient temperature. H2O (3 ml) was then added with 
stirring for 10 minutes prior to the solvent being removed under reduced pressure and the 
crude product purified by flash column chromatography (9.5 CH2Cl2 : 0.5 MeOH to elute 
OPPh3, 9.2 CH2Cl2 : 0.75 MeOH : 0.05 NH3(aq)  to elute product Rf = 0.20) to reveal the 
product as a colourless viscous oil.  
 
41 (1.35 g, 84 %); νmax (Neat)/cm-1 3368 (NH), 1739 (C=O), 1097 (OCO); δH (300 MHz; 
CDCl3) 3.96 (2H, s, CH2C=O), 3.65-3.55 (12H, stack, 6xOCH2), 3.47 (2H, t, J 5.2, CH2NH2),  
2.82 (2H, t, J 4.9, OCH2), 2.30 (2H, br s, NH2), 1.41 (9H, s, C(CH3)3); δC (100MHz) 169.6 
(C=O), 81.5 (C(CH3)3), 72.7 (OCH2), 70.5 (OCH2), 70.4 (OCH2), 70.1 (OCH2), 68.9 (OCH2), 
41.5 (CH2NH2), 28.0 (C(CH3)3); m/z (TOF ES+) 308.2073 ([M+H]+, 100%, C14H30NO6 requires 
308.2061). 
 
42 (1.80 g, 87 %); νmax (Neat)/cm-1 3370 (NH), 1741 (C=O), 1100 (OCO); δH (300 MHz; 
CDCl3) 3.69 (2H, s, CH2C=O), 3.66-3.40 (22H, stack, OCH2), 3.46 (2H, t, J 5.2, CH2NH2),  
2.81 (2H, t, J 4.9, NH2), 1.41 (9H, s, C(CH3)3); δC (100MHz) 169.5 (C=O), 81.5 (C(CH3)3), 73.0 
(OCH2), 70.6 (OCH2), 70.4 (OCH2), 70.1 (OCH2), 68.9 (OCH2), 41.6 (CH2NH2), 28.3 (C(CH3)3); 
m/z (TOF ES+) 396.2597 ([M+H]+, 100%, C18H38NO8 requires 396.2583). 
 
Please see Ref 159. 
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Preparation of amino hexa (ethylene glycol) acetic acid 43. 
 
 
 
 
tert-Butyl ester hydrolysis was achieved by taking 1-amino-6-tert-butoxycarbonylmethyl-
hexa ethylene glycol 42 (2.00 g, 5.06 mmol) up in a cocktail of CH2Cl2 and TFA (1 : 1, v / v, 
20 mL) and stirred at ambient temperature for 2 hours. The reation was monitored by TLC 
(Rf = 0.1, 9.0 CH2Cl2 : 1.0 MeOH). Excess solvent and TFA was removed through cycles 
involving repeated dissolution in CH2Cl2 and removal under reduced pressure to afford the 
product as a very pale brown oil (1.70 g, 99 %); νmax (Neat)/cm-1 3000 (br COOH); δH (300 
MHz; CDCl3) 12.73 (1H, br s, COOH), 7.21 (2H, br s, NH2), 4.16 (2H, s, CH2C=O), 3.61-3.83 
(22H, stack, OCH2), 3.10 (2H, m, CH2NH2); δC (100MHz) 173.8 (C=O), 69.9 (OCH2), 69.6 
(OCH2), 69.1 (OCH2), 67.9 (OCH2), 66.8 (OCH2), 40.2 (CH2NH2); m/z (TOF ES+) 340.1971 
([M+H]+, 100%, C14H30NO8 requires 340.1958). 
 
 
Preparation of N-tert-butoxycarbonyl-amino-hexa(ethylene glycol) acetic acid 
44. 
 
 
 
 
 
Amino acid 43 (1.20 g, 3.54 mmol) was dissolved in anhydrous CH2Cl2 (10 mL). Anhydrous 
DIPEA (1.23 mL, 7.07 mmol) was added and the mixture stirred at ambient temperature 
under argon. Di-tert-butyldicarbonate (0.93 g, 4.24 mmol) in anhydrous CH2Cl2 (10 mL) 
was then added dropwise over 40 minutes and the cocktail stirred for a further 2 hours 
with monitoring by TLC. The crude product was concentrated thoroughly (repeated co-
concentration cycles with toluene) under reduced pressure and purified by gradient flash 
column chromatography to afford the pure product as a colourless oil (1.41 g, 91 %); νmax 
(Neat)/cm-1 2894 (br COOH), 1718 (C=O); δH (300 MHz; CDCl3) 10.59 (1H, br s, COOH), 
5.25 (1H, br s, NH), 3.87 (2H, s, CH2C=O), 3.50-3.61 (22H, stack, OCH2), 3.43 (2H, app t, J 
5.1, CH2NH), 1.33 (9H, s, C(CH3)3); δC (100MHz) 174.8 (COOH), 155.9 (C=ONH2), 78.8 
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(C(CH3)3), 70.3 (OCH2), 70.2 (OCH2), 69.9 (OCH2), 69.8 (OCH2), 41.3 (CH2NH), 28.2 
(C(CH3)3); m/z (TOF ES+) 462.2315 ([M+Na]+, 100%, C19H37NO10Na requires 462.2297). 
Please see Ref 159. 
 
Preparation of N-tert-butoxycarbonyl-3,6-dioxaoctane-1,8diamine, 45 
 
 
 
 
Di-tert-butyl-dicarbonate (1.49 g, 6.85 mmol) was dissolved in CH2Cl2 (25 mL) and added 
dropwise to a mixture of tris-ethyleneglycol diamine (2.0 mL, 0.014 mol) and DIPEA (2.38 
mL, 0.014 mol) at ambient temperature over 40 minutes. The cocktail was then stirred for 
a further 2 hours and monitored by TLC. Upon completion the mixture was evaporated 
thoroughly under reduced pressure and the crude residue purified by flash column 
chromatography Rf=0.33 (CH2Cl2 / MeOH / NH3(aq), 9.0 : 9.95 : 0.05) to afford the product 
as a viscous colourless oil (2.01 g, 50%). νmax (Neat)/cm-1 3368, 3384 (NH), 1725 (C=O); δH 
(300 MHz; CDCl3) 5.20 (1H, br s, NH), 3.55 (4H, s, 2xOCH2), 3.43-3.49 (4H, stack, 
2xOCH2), 3.24 (2H, mound, CH2NH), 2.81 (2H, t, J 5.2, CH2NH2), 1.52 (2H, br s, NH2), 1.37 
(9H, s, (C(CH3)3); δC (100MHz) 155.9 (C=O), 79.0 (C(CH3)3), 73.2 (OCH2), 70.1 (2xOCH2), 41.6 
(CH2NH2), 40.2 (CH2NH), 28.3 (C(CH3)3); m/z (TOF ES+) 271.1634 ([M+Na]+, 100%, 
C11H24N2O4Na requires 271.1623).                
 
 
Caproic 
Preparation of mono-tert-butoxycarbonyl hexa ethylene diamine 46. 
 
 
  
 
Di-tert-butyldicarbonate (0.94 g, 4.30 mmol), was taken up in chloroform (10 mL) and 
added dropwise to a solution of hexamethylenediamine (2.50 g, 21.5 mmol) also in 
chloroform (90 mL) over 2 hours at 0˚C under argon. The reaction mixture was then 
allowed to warm to ambient temperature and stirred overnight. The precipitate was 
removed through filtration and the crude cocktail concentrated under reduced pressure. 
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The resulting heavy oil was taken up in EtOAc (100 mL) and extracted with H2O (3 x 100 
mL) and brine (3 x 50 mL) alternately before drying over MgSO4. Removal of the solvent 
under reduced pressure afforded the product as a colourless oil (2.28 g, 49 %). νmax 
(Neat)/cm-1 3279, 3301 (NH), 1721 (C=O); δH (300 MHz; CDCl3) 4.83 (1H, br s, NH), 2.98 
(2H, m, H2NCH2), 2.56 (2H, t, J 6.9, CH2NH), 2.29 (2H, br s, NH2), 1.38-1.18 (17H, stack, 
4xCH2 & C(CH3)3); δC (100MHz) 155.7 (C=O), 78.2 (C(CH3)3), 41.4 (H2NCH2), 40.0 (CH2NH), 
32.8 (CH2), 29.6 (CH2), 28.0 (C(CH3)3), 26.1 (2xCH2); m/z (TOF ES+) 217.1916 ([M+H]+, 
100%, C11H25N2O2 requires 217.1918). 
 
 
Preparation of N-benzoyl amino caproic acid 47. 
 
 
O N
H
O
OH
O
C14H19NO4
Mol. Wt.: 265.3  
 
 
Benzylchloroformate (8.71 mL, mmol) was taken up in 1M NaOH (31 mL) and added 
dropwise to a mixture of 6-aminocaproic acid (8.00 g, 0.06 mol) in a further equivalent of 
1M NaOH (31 mL) over 30 minutes at 0˚C. The cocktail was then allowed to warm to 
ambient temperature and stirred overnight. The aqueous solution was washed with Et2O (2 
x 50 mL) prior to acidification to pH = 1 with concentrated HCl. Again the aqueous solution 
was extracted with Et2O (3 x 100 mL) and the organic phases combined, washed with brine 
(50 mL) and dried over MgSO4 to afford the pure product as a fine white solid (14.18 g, 88 
%). νmax (Neat)/cm-1 2853 (br COOH), 1694 (C=O); δH (300 MHz; CDCl3) 10.96 (1H, br s, 
COOH), 7.26-7.35 (5H, stack, CHarom), 5.09 (2H, s, PhCH2O), 4.98 (1H, mound, NH), 3.18 
(2H, m, NHCH2), 2.34 (CH2COOH), 1.66 (2H, m, CH2), 1.51 (2H, m, CH2), 1.35 (2H, m, CH2); 
δC (100MHz) 179.0 (COOH), 156.2 (C=ONH), 136.4 (Cqarom), 128.4 (Carom), 128.0 (Carom), 
66.6 (PhCH2O), 40.7 (NHCH2), 33.8 (CH2COOH), 29.5 (CH2), 26.0 (CH2), 24.2 (CH2); m/z 
(TOF ES+) 288.1212 ([M+Na]+, 100%, C14H19NO4Na requires 288.1205). 
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Preparation of benzyl 5-(tert-butoxycarbonyl)pentylcarbamate 48. 
 
 
 
 
 
Under dry conditions N-benzoyl aminocaproic acid 47 (5.0 g, 0.019 mol) was combined 
with pyridine (3.05 mL, 0.038 mol) and tBuOH (9.012 mL, 0.095 mol) in anhydrous CH2Cl2 
(50 mL) at 0˚C under argon. POCl3 (1.76 mL, 0.038 mol) was then added dropwise and the 
mixture stirred overnight at ambient temperature. The crude mixture was washed with H2O 
(2 x 30 mL), 5% NaHCO3 (2 x 30 mL), H2O (2 x 30 mL) and brine (20 mL) prior to drying 
with MgSO4 and concentration under reduced pressure. The crude product was purified by 
careful gradient flash column chromatography Rf = 0.37 (100 % CH2Cl2 to 9.5 CH2Cl2 : 0.5 
MeOH) and the product recovered as a fine white solid (4.60 g, 75 %). νmax (Neat)/cm-1 
1747, 1688 (C=O); δH (300 MHz; CDCl3) 7.34-7.28 (5H, stack, CH arom), 5.06 (2H, s, 
PhCH2O), 4.81 (1H, br s, NH), 3.16 (2H, dd, J 6.7, 13.2, NHCH2), 2.18 (2H, t, J 7.4, 
CH2C=O), 1.61-1.15 (15H, br stack, C(CH3)3 & 3xCH2); δC (100MHz) 173.0 (CH2C=O), 156.3 
(C=ONH), 136.6 (Cqarom), 128.5 (Carom), 128.0 (Carom), 80.1 (C(CH3)3), 66.5 (PhCH2O), 
40.8 (NHCH2), 35.3 (CH2C=O), 29.6 (CH2), 28.1 (C(CH3)3), 26.1 (CH2), 24.6 (CH2); m/z (TOF 
ES+) 344.1838 ([M+Na]+, 100%, C18H27NO4Na requires 344.1846). 
 
 
Preparation of tert-butyl 6-aminohexanoate 49. 
 
 
H2N
O
O
C10H21NO2
Mol. Wt.: 187.28  
 
 
Under scrupulously dry conditions benzyl ester (1.05 g, 3.27 mmol) was taken up in 
anhydrous MeOH and stirred under argon with Pd/C (0.16 g, 15 % w/w of 10 %) at 
ambient temperature. The flask was well vented under high vacuum before allowing H2(g) 
into the flask with further venting 3 times to ensure complete evacuation of argon. The 
mixture was then stirred under balloon pressure of for H2(g) for 4 hours. The reaction was 
monitored by TLC, Rf = 0.03 (9.5 CH2Cl2 / 0.5 MeOH). Upon completion the mixture was 
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filtered through a pad of Celite and concentrated under reduced pressure to afford the pure 
product as a colourless oil (0.61 g, 99 %). νmax (Neat)/cm-1 3322, 3329 (NH), 1737 (C=O); δH 
(300 MHz; CDCl3) 3.26 (2H, br s, NH2), 2.64 (2H, t, J 7.1, CH2NH2), 2.14 (2H, t, J 7.4, 
CH2C=O), 1.57-1.22 (15H, br stack, C(CH3)3 & 3xCH2); δC (100MHz) 173.0 (C=O), 80.0 
(C(CH3)3), 41.3 (CH2NH2), 35.4 (CH2C=O), 32.2 (CH2), 30.1 (C(CH3)3), 26.2 (CH2), 24.7 (CH2); 
m/z (TOF ES+) 210.1470 ([M+Na]+, 100%, C10H21NO2Na requires 210.1478). 
 
 
Preparation of N-ethoxycarbonyl amino caproic acid 50. 
 
 
 
H2N
O
O
C8H17NO2
Mol. Wt.: 159.23  
 
 
 
Thionyl chloride (5.56 mL, 76.2 mmol) was added dropwise to freshly distilled anhydrous 
EtOH (10 mL) at 0˚C under argon over 20 minutes. Aminocaproic acid (5.0 g, 38.1 mmol) in 
anhydrous EtOH (10 mL) was then added over 5 minutes and the mixture heated at reflux 
for 1 hour. Upon cooling to ambient temperature the solvent was removed under reduced 
pressure and the residue redissolved in ice water. Saturated NaHCO3 solution was added 
until the pH=10 and extracted with CHCl3 (10 x 50 mL). The combined organic phases were 
then extracted with brine (50 mL) and dried over MgSO4. Concentration under reduced 
pressure afforded the product as colourless oil which became a crystalline solid overnight ( 
5.58 g, 92 %). νmax (Neat)/cm-1 3338, 3346 (NH), 1742 (C=O); δH (300 MHz; CDCl3) 7.96 (2H, 
br s, NH2), 3.98 (2H, q, J 7.1, OCH2CH3), 2.89 (2H, mound, H2NCH2), 2.19 (2H, t, J 7.2, 
CH2C=O), 1.68 (2H, mound, CH2), 1.50 (2H, m, CH2), 1.30 (2H, mound, CH2), 1.12 (3H, t, J 
6.3, OCH2CH3); δC (100MHz) 173.5 (C=O), 60.2 (OCH2CH3), 39.6 (H2NCH2), 33.7 (CH2C=O), 
26.8 (CH2), 25.7 (CH2), 24.0 (CH2), 13.9 (OCH2CH3); m/z (EI) 159.1259 ([M+Na]+, 100%, 
C8H17NO2 requires 159.1262). 
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2.13 Osmium experimental 
 
Preparation of cis-dichloro-bis(2,2’-bipyridine)osmium(II) 51. 
 
 
 
 
 
 
 
Lithium chloride (0.34 g, 8.09 mmol) and 2,2’-bipyridine (0.22 g, 1.42 mmol) were 
combined in degassed DMF (20 mL). Osmium trichloride (0.20 g, 0.67 mmol) was added 
and the mixture stirred under reflux for 2.5 hours. Upon cooling to ambient temperature 
Et3N (0.50 mL) was added and the cocktail heated at reflux for a further hour and again 
allowed to cool. The crude solution was then poured into cold acetone (80 mL) and cooled 
at -5 ˚C for 2 days. The precipitated product was recovered by Büchner filtration and 
washed thoroughly with H2O (100 mL) and dried scrupulously under high vacuum to reveal 
the product as a deep red-brown solid which was stored in the dark in a dessicator over 
silica gel (0.33 g, 85 %). m.p. = 186-188 ˚C; m/z (MALDI-TOF) 537.5 ([M-Cl+H]+, 30 %), 
573.0 ([M+H]+, 80%), 656.1 (M + gentisic acid matrix (MW = 153) – Cl + H]+, 30 %), 691.0 
([M+matrix+H]+, 100 %). 
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Preparation of bis (2,2’-bipyridine)(4’-methyl-2,2’-bipyridine-4-carboxylic 
acid)-osmium(II) bis(hexafluorophophate) 52. 
 
 
 
 
 
 
Os(bpy)2Cl2 51 (0.064 g, 0.112 mmol) and 4’-methyl-2,2’-bipyridine-4-carboxylic acid 
(0.022 g, 0.102 mmol) were suspended in 70 % EtOH (10 mL) and heated at reflux for 8 
hours. The EtOH was then removed under reduced pressure and the flask left to stand 
overnight. The precipitate was removed by filtration and washed with H2O (50 mL). The 
filtrate was then acidified to pH=1 with HPF6 and sat. NH4PF6(aq) added dropwise until no 
further precipitation occurs. The precipitate was recovered by Büchner filtration and 
washed thoroughly with Et2O (50 mL) and dried scrupulously under high vacuum to reveal 
the product as a deep green solid. Purification was achieved by HPLC (method C) tr = 13.6 
minutes (analytically); tr = 19.7 minutes (semi-preparatively), to afford the pure product 
which was stored in the dark in a dessicator over silica gel (0.055 g, 68 %). νmax (Neat)/cm-1 
3200-2600 (COOH); m.p. = 144-146 ˚C; δH (300 MHz; d3-MeCN) 2.59 (3H, s, CH3), 7.13 (1H, 
app dd, J 1.0, 5.8, arom CH), 7.21-7.29 (4H, stack, arom CH), 7.40 (1H, app d, J5.8, arom 
CH), 7.55-7.58 (4H, stack, arom CH), 7.62 (1H, app dd, J 1.5, 5.8, arom CH), 7.72 (1H, d, J 
5.8, arom CH), 7.77-7.84 (4H, stack, arom CH), 8.41-8.45 (4H, stack, arom CH), 8.50 (1H, 
app s, arom CH), 8.88 (1H, app s, arom CH); m/z (MALDI-TOF) 673.7 ([M-COO+H]+, 75 %), 
701.8  ([M-Me+H]+, 20 %), 717.7 ([M+H]+, 100 %), 739.2 ([M+Na]+, 50 %). 
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Preparation of bis (2,2’-bipyridine)(4’-methyl-2,2’-bipyridine-4-carbonyloxy)-
2,5-pyrrolidinedione)-osmium(II) bis(hexafluorophophate) 53. 
 
 
 
 
 
 
 
DCC (0.022 g, 0.105 mmol) was added to a stirring solution of carboxylic acid 52 (0.05 g, 
0.070 mmol) and N-hydroxysuccinimide (0.009 g, 0.073 mmol) in anhydrous MeCN (2.5 
mL) at ambient temperature under argon. This concoction was stirred for 8 hours during 
which a colour change to rusty-brown was observed. Filtration through a fine-porosity 
glass frit and removal of the solvent under reduced pressure was then accomplished prior 
to the crude mixture being taken up in 2-propanol (20 mL) and stored at -8 ˚C for 2 days. 
The precipitated product was recovered by filtration and thorough washing with Et2O (30 
mL) followed by prolonged drying under high vacuum. The product was identified by 
analytical HPLC (method ) at Rt = 14.6 minutes but not further purified due to the 
product’s susceptibility to hydrolysis. The product was afforded as a deep green/brown 
solid (0.05 g, 88 %). νmax (Neat)/cm-1 1739 (C=O); m.p. = 150-152 ˚C. Due to the rapid 
hydrolysis of the ester in the mass spectrometry methodology we were unable to see the 
product, only the precursor 52. As described in the results and discussion, the product 53 
was taken on without further action. 
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2.14 Peptide experimental 
 
2.14.1 General solid phase reagents and equipment 
Protected resin-bound glycine and all subsequent Fmoc protected amino acids were bought 
in fresh from Novabiochem or AGTC Bioproducts Ltd. Coupling reagent PyBop was also 
purchased from Novabiochem; anhydrous Hunig’s base (DIPEA), piperidine and anhydrous 
TFA were sourced from Sigma-Aldrich; bead stain test reagent, picrylsulphonic acid 
(TNBSA), was supplied by Fluka as a 1% solution in DMF. 
Dry solvents for coupling, capping, and washing protocols were all freshly distilled over 
appropriate drying agents and stored over molecular sieves, or purchased as dry, prior to 
the commencement of synthesis. 
All solid-phase chemistry was carried out in plastic Luer vessels with replacable filters and 
agitation was achieved using a IKA-Vibrax-VXR machine. HPLC purification was performed 
using the methods listed in section 3.1.3. The ideal UV absorbance wavelength was found 
to be 254 nm and the most effective MALDI-TOF matrix was Gentisic Acid with 0.1 % TFA. 
 
2.14.2 General solid phase synthetic protocol 
Prior to initiation of the synthetic procedure the dry resin was always swollen by soaking in 
dry DMF for 10 minutes. Peptide synthesis was performed on a 0.33 mmol scale. 
 
Fmoc removal 
A 20% solution of piperidine in DMF (10 mL) was prepared and the deprotection enacted by 
shaking the resin-bound Fmoc protected peptide in 5 mL of this solution for 12 minutes. 
Following removal of solvent under reduced pressure and a rinse with fresh DMF (2 x 5 
mL), the process was repeated a second time. Removal of the solvent under reduced 
pressure after the second shake was followed by a full washing protocol and a bead stain 
test. 
 
Washing protocol 
MeOH (2 x 5 mL) 1 minute shakes (capping is also effected in this washing step through 
the shrinking of the resin). 
DMF (6 x 5 mL) 1 minute shakes. 
CH2Cl2 (2 x 5mL) 1 minute shakes (only necessary prior to resin cleavage) 
 
Bead stain test 
A few resin beads were removed from the luer flask and placed in a small vial with DMF (2 
drops), DIPEA (2 drops) and TNBSA (1 drop). A positive test was confirmed when upon 
gentle agitation for 1 – 2 minutes the beads turned an orange/red colour. Any uncoloured 
beads indicated an incomplete reaction and a further cleavage step was carried out. 
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Coupling protocol 
When necessary a double coupling procedure was performed as follows: the protected 
peptide next in the amino acid sequence (2 eq) was pre-activated in a dry round-bottomed 
flask with PyBop (2 eq) & DIPEA (5 eq) in DMF (5 mL), and stirred under argon for 10 
minutes. This mixture was then directly transferred into the Luer vessel containing the free 
amine of the swollen resin-bound peptide and shaken for 2 hours. The resin was then 
rinsed with DMF (2 x 5 mL, 1 min. shakes) and the coupling procedure repeated again. A 
washing protocol was then effected. 
 
 
2-Chlorotrityl resin cleavage 
A solution of 1% TFAin dry CH2Cl2 (15 mL) was prepared. A quantity (3 mL) of this solution 
was then added to the resin-bound peptide and a 1 minute shake repeated 3 - 5 times to 
effect full cleavage of the peptide from the acid labile 2-chlorotrityl resin. The naked resin 
was then washed thoroughly with CH2Cl2 and the washings all collected and combined 
with the TFA cleavage washings. The solvent and TFA were removed under reduced 
pressure and tenacious excess TFA then subject to thorough trituration with Et2O to reveal 
the crude fully protected linear peptide. 
 
 
Mini cleave protocol 
The resin-bound peptide was suspended in CH2Cl2 and a few beads removed via a glass 
pipette. This was then transferred to a clean Luer vessel and the 2-chlorotrityl resin 
cleavage protocol performed. The crude peptide was then subject to HPLC and mass 
spectrometric analysis. 
 
 
 
Individual protocols referred to in the following experimental pages are highlighted by italics. 
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2.14.3 Peptide synthesis 
Solid phase preparation of fully protected linear peptide DfKRG.  
Alloc 54, IvDde 55. 
 
Fmoc-Asp(tBu)-DPhe-Lys(Alloc)-Arg(pmc)-Gly               Fmoc-Asp(tBu)-DPhe-Lys(IvDde)-Arg(pmc)-Gly    
 
C73H97N9O15S
Exact Mass: 1371.68
Mol. Wt.: 1372.67
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Both fully protected linear penta-peptides were constructed by hand using standard Fmoc 
solid phase peptide synthesis protocol. Scrupulous sequential deprotection, washing and 
coupling steps were observed.  
Fmoc-Gly-2-Cltrl resin (0.50g, 0.33 mmol) was pre-swollen by soaking in DMF for 10 
minutes prior to being subject to Fmoc removal and washing protocols. A bead stain test 
revealed the primary amine and a pre-described double coupling protocol effected using: 
Fmoc-Arg(pmc)-OH (0.44 g, 0.66 mmol), PyBop (0.34 g, 0.66 mmol) and DIPEA (0.29 mL, 
1.65 mmol) in DMF (5 mL).  
Washing, Fmoc removal and bead stain test protocols were then performed prior to the next 
protected amino acid being installed by an identical double coupling protocol using: Fmoc-
Lys(IvDde)-OH (0.38 g, 0.66 mmol) or Fmoc-Lys(Alloc)-OH (0.30 g, 0.66 mmol), PyBop (0.34 
g, 0.66 mmol) and DIPEA (0.29 mL, 1.65 mmol) in DMF (5 mL).  
Washing, Fmoc removal and bead stain test protocols were then performed prior to the next 
protected amino acid being installed by an identical double coupling protocol using: Fmoc-
DPhe-OH (0.26 g, 0.66 mmol), PyBop (0.34 g, 0.66 mmol) and DIPEA (0.29 mL, 1.65 mmol) 
in DMF (5 mL).  
Washing, Fmoc removal and bead stain test protocols were then performed prior to the next 
protected amino acid being installed by an identical double coupling protocol using: Fmoc-
Asp(tBu)-OH (0.27 g, 0.66 mmol), PyBop (0.34 g, 0.66 mmol) and DIPEA (0.29 mL, 1.65 
mmol) in DMF (5 mL). A final double washing protocol then completed the solid phase 
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synthesis leaving the crude fully protected penta-peptide on the resin stored at -8 ºC under 
argon. 
A mini cleave protocol was then carried out to confirm the success of the synthesis and to 
observe the purity of the product and identify any impurities:  
54 Alloc peptide: Analytical HPLC (method A, tr = 30.5 minutes); m/z (MALDI-TOF) 
1272.9 (10 %, [M + Na]+), 1250.9 (100 %, [M + H]+), 1194.8 (5 %, [M - tBu + H]+), 984.9 (70 
%, [M - Pmc + H]+). 
55 IvDde peptide: Analytical HPLC (method A, tr = 28.6 minutes); m/z (MALDI-TOF) 
1372.5 [10 %, M + H]+), 1150.6 (100 %, [M – Fmoc + H]+), 1104.4 (80 %, [M - Pmc + H]+), 
866 (30 %, [M - Fmoc - Pmc + H]+). 
 
See appendix 5 for HPLC & m/z data  
 
 
Preparation of cyclic fully protected peptides. Alloc 56, IvDde 57. 
 
Cyc Asp(tBu)-DPhe-Lys(Alloc)-Arg(pmc)-Gly      Cyc Asp(tBu)-DPhe-Lys(IvDde)-Arg(pmc)-Gly 
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C49H71N9O12S
Exact Mass: 1009.49
Mol. Wt.: 1010.21
C58H85N9O12S
Exact Mass: 1131.6
Mol. Wt.: 1132.41  
 
Cyclisation protocol 
Resin bound fully protected linear peptide was subject to Fmoc removal and resin cleavage 
protocol (see general protocol section 3.4.2) followed by thorough trituration with Et2O and 
dried overnight under high vacuum. The free peptide was then made up as a 0.5 mM 
solution in dry CH2Cl2. PyBop (1.2 eq) and DIPEA (3.0 eq) were added and the mixture 
stirred at ambient temperature for 5 hours with monitoring by analytical HPLC method D 
(230 nm). The crude mixture was then concentrated under reduced pressure and purified 
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by preparative HPLC. Lyophilisation revealed the pure cyclic peptide as a fine white 
powder. 
56 Alloc peptide: Analytical HPLC (method A, tr = 30.5 minutes); m/z (MALDI-TOF) 
1010.9 (100 %,  [M + H]+), 954.8 (10 %, [M - tBu + H]+), 744.1 (70 %, [M - Pmc + H]+). 
57 IvDde peptide: Preparative HPLC (method D, tr = 44.6 minutes); m/z (MALDI-TOF) 
1133 [M + H]+, 1077 [M - tBu + H]+, 867 [M - Pmc + H]+. 
 
See appendix 5 for HPLC and m/z data 
 
 
Deprotection to afford free lysine εNH2 58. 
 
Cyc Asp(tBu)-DPhe-Lys-Arg(pmc)-Gly 
 
 
 
 
 
A. Alloc deprotection 
Fully protected cyclised peptide 56 (0.015 g, 1.49 x 10-5 mol) was taken up in dry MeOH (5 
mL) and stirred under argon at ambient temperature prior to addition of Pd(PPh3)4 (1.00 
mol %). After 5 minutes stirring at ambient temperature, K2CO3 (0.0124 g, 8.91 x 10-5 mol) 
was added and the mixture stirred for a further 3 hours. The solvent was removed under 
reduced pressure and the crude mixture purified by semi-preparative HPLC (method A, tr = 
20.1 minutes) and lyophilised to give pure deprotected cyclic peptide 58 as a fine white 
powder (0.0125 g, 91 %). m/z (MALDI-TOF) 926 [M + H]+, 870 [M - tBu + H]+, 660 [M - Pmc 
+ H]+. 
 
B. IvDde deprotection 
Fully protected cyclised peptide 57 (0.020 g, 1.77 x 10-5 mol) was dissolved in a solution of 
2 % hydrazine hydrate in MeCN (2 mL). The mixture was stirred for 3 hours at ambient 
temperature, the solvent removed under reduced pressure and the crude product promptly 
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purified by semi-preparative HPLC (method E, tr = 33.6 minutes). Lyophilisation yielded the 
pure deprotected product as a fine white powder (0.015 g, 92 %). m/z (MALDI-TOF) 926 [M 
+ H]+, 870 [M - tBu + H]+, 660 [M - Pmc + H]+. 
 
See appendix 5 for HPLC & m/z data 
 
Preparation of fully deprotected cyclic peptide (blocking peptide) 59. 
 
Cyc Asp-DPhe-Lys-Arg-Gly 
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C27H41N9O7
Exact Mass: 603.31
Mol. Wt.: 603.67  
 
 
Alloc or IvDde deprotected cyclic peptide 58 (0.02 g, 2.16 x 10-5 mol) was dissolved in 
anhydrous CH2Cl2 (2 mL) and anhydrous TFA (2 mL) added. The mixture was then stirred 
at ambient temperature under Ar(g) for 4 hours and concentrated under reduced pressure. 
For free cyclic peptide to be then coupled to a fluorophore via the lysine εNH2 the crude 
product was then repeatedly co-concentrated with CH2Cl2 and triturated with Et2O before 
being taken on without further purification. Free cyclic peptide for blocking studies was 
purified by semi-preparative HPLC (method C, tr = 23.08 minutes) and lyophilised to afford 
the pure product as a fine white powder (0.012 g, 95 %). m/z (MALDI-TOF) 604.2 [M + H]+, 
626.2 [M + Na]+. 
 
See appendix 5 for HPLC and m/z data 
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Preparation of fluorescein labelled cyclic peptide 60. 
 
Cyc Asp(tBu)-DPhe-Lys(fluorescein)-Arg(pmc)-Gly 
 
O
N
H
OH
N
O
HN
N
H
H2N NH
OH
N
HN
O
HO
O
HN
HN
S
OO OH
HOOC
C48H53N10O12S
Exact Mass: 993.36
Mol. Wt.: 994.06
 
 
Pmc and tBu protected cyclic peptide 58 (0.002 g, 1.08 x 10-5 mol) was dissolved in a 
solution of DMF / CH2Cl2 / Py (5 : 7 : 12 (v/v), 5 mL) and fluorescein isothiocyanate (0.002 
g, 4.98 x 10-6) added. The reaction was then monitored by analytical HPLC (method A, tr = 
25.1 minutes) M/z MALDI-TOF showed 994 [M + H]+, 1260 [M + Pmc + H]+, 1282 [M + Pmc 
+ Na]+ and was complete after stirring for 72 hours at ambient temperature in the dark. 
The crude product was concentrated under reduced pressure and immediately taken up in 
a 1:1 (v/v) mix of CH2Cl2 and TFA and stirred for a further 4 hours at ambient 
temperature. Again the crude mixture was analysed by analytical HPLC (method A), 
purified by semi-preparative HPLC (method B, tr = 31.9 minutes), and lyophilised to afford 
the pure product as an orange coloured powder (0.009 g, 56 %). m/z (MALDI-TOF) 994 ([M 
+ H]+, 100 %). 
 
See appendix 4 for HPLC and m/z data 
See appendix 5 for HPLC and m/z data 
 
Experimental – Peptide chemistry 
 148
Preparation of NIR797 labelled cyclic peptide 61. 
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C72H91N12NaO13S4
Exact Mass: 1482.56
Mol. Wt.: 1483.82
 
From 58 
Pmc and tBu protected cyclic peptide 58 (0.001 g, 1.08 x 10-6 mol) was dissolved in pH 9.2 
phosphate buffer solution (3 mL) and NIR797 isothiocyanate (0.0019 g, 2.16 x 10-5 mol) 
added. The reaction was then stirred for 72 hours at ambient temperature in the dark with 
monitoring by analytical HPLC (method B). The crude product was concentrated under 
reduced pressure, immediately taken up in a 1:1 (v/v) mix of CH2Cl2 and TFA and stirred 
for a further 4 hours at ambient temperature. The crude mixture was then concentrated 
and purified by semi-preparative HPLC (method C, tr = 34.4 minutes), and lyophilised to 
afford the pure product as a deep green powder (0.001 g, 62 %).  
From 59 
Fully deprotected cyclic peptide 59 (0.001 g, 1.66 x 10-6 mol) was dissolved in pH 9.2 
phosphate buffer solution (3 mL) and NIR797 isothiocyanate (0.003 g, 3.32 x 10-6 mol) 
added. The reaction was then stirred for 72 hours at ambient temperature in the dark. The 
crude product was then concentrated under reduced pressure, purified using semi-
preparative HPLC (method C, tr = 34.4 minutes) and lyophilised to afford the product as a 
deep green solid (0.0015 g, 63 %). m/z (MALDI-TOF) 1461 ([M – Na + H]+, 100 %). 
 
See appendix 4 for fluorescence data 
See appendix 5 for HPLC & m/z data 
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Preparation of Os(bpy)2(4-methylbpy) labelled cyclic peptide 62. 
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Exact Mass: 1303.48
Mol. Wt.: 1302.47
2+
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Pmc & tBu protected cyclic peptide 58 (0.002 g, 2.16 x 10-6 mol) was dissolved in 
anhydrous MeCN (5 mL) and osmium bipyridyl succinic ester derivative MXXM (0.0018 g, 
2.16 x 10-6) added. The mixture was heated in the dark at 70 ºC under Ar(g) for 48 hours. 
The product was revealed by analytical HPLC (method E, tr = 30.3 minutes). The crude 
mixture concentrated under reduced pressure, purified using semi-preparative HPLC 
(method E, tr = 39.3 minutes) and lyophilised to afford the product as a deep brown solid 
(0.002 g, 57 %). M/z MALDI-TOF 1624 [M + Pmc + tBu + H]+, 1938 [M + Pmc + tBu + 2PF62- 
+ Na + 2H]+.  
This intermediate product was then treated with a mixture of TFA in CH2Cl2 (1 : 1 (v/v), 4 
mL) and stirred for 4 hours at ambient temperature. The crude mixture was then 
concentrated under reduced pressure with repeated co-concentrations with CH2Cl2 to 
remove all TFA and finally triturated with Et2O to afford the product as a deep brown solid 
(0.0015 g, 96 %). m/z (MALDI-TOF) 1303 ([M + H]+, 100 %) , 1617 ([M + 2PF62- + Na + 2H]+, 
60 %).  
 
See appendix 4 for fluorescence data 
See appendix 5 for HPLC & m/z data 
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Preparation of spacer appended cyclic peptides 63 & 64. 
 
 
 
 
 
 
 
 
Pmc & tBu protected cyclic peptide 58 (0.02 g, 2.16 x 10-5) was dissolved in anhydrous 
MeCN (5 mL). Boc-aminocaproic acid (0.0075 g, 3.24 x 10-5) or N-Boc-amino hexa(ethylene 
glycol) acetic acid 44 (0.014 g, 3.24 x 10-5) was combined with PyBop (0.022 g, 4.39 x 10-5) 
and DIPEA (0.011 g, 6.48 x 10-5) in anhydrous MeCN (5 mL) and stirred at ambient 
temperature under Ar(g) in a separate vessel for 10 minutes prior to addition to the peptide 
and stirring under Ar(g) for 72 hours. The product was identified by analytical HPLC 
(method A, tr = 39.3 minutes (caproic)), (method E, tr = 38.2 minutes (PEG)), concentrated 
under reduced pressure and purified by semi-preparative HPLC. 
63 (0.017 g, 68 %) Semi-preparative HPLC (method A, tr = 33.8 minutes); m/z (MALDI-
TOF) 1161 [M + Na]+, 1139 [M + H]+, 1039 [M – Boc + H]+, 873 [M – Pmc + H]+. 
64 (0.016 g, 54 %)  Semi-preparative HPLC (method E, tr = 32.5 minutes); m/z (MALDI-
TOF) 1347 [M + H]+, 1291 [M – tBu + H]+, 1247 [M – Boc + H]+, 1191 [M – Boc – tBu + H]+, 
1081 [M – Pmc + H]+.  
 
See appendix 5 for HPLC & m/z data 
 
 
 
Cyc Asp(tBu)-DPhe-Lys(Butoxycarbonylamino 
hexaethylene glycol)-Arg(pmc)-Gly 
Cyc Asp(tBu)-DPhe-Lys(Butoxycarbonyl 
aminocaproic acid)-Arg(pmc)-Gly 
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Deprotection of Boc, tBu & Pmc to afford free extended cyclic peptides 65 & 
66. 
 
 
 
Cyclic peptides 63 (0.005 g, 4.39 x 10-6 mol) & 64 (0.005 g, 3.71 x 10-6 mol) were dissolved 
in anhydrous CH2Cl2 (2 mL) and TFA (2 mL) added. The mixture was then stirred at 
ambient temperature under Ar(g) for 4 hours before being concentrated under reduced 
pressure and repeatedly co-concentrated with CH2Cl2. The crude mixture was then 
triturated with Et2O and dried to afford the products as either a fine white solid (65), or a 
colourless oil (66). 
65 (0.003 g, 93 %), m/z (MALDI-TOF) 717.1 ([M + H]+, 100 %) 
66 (0.003 g, 95 %), m/z (MALDI-TOF) 926.4 ([M + H]+, 100 %) 
 
See appendix 5 for m/z data 
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Preparation of NIR797 appended cyclic peptide 67. 
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Exact Mass: 1595.64
Mol. Wt.: 1596.97
 
 
Extended cyclic peptide 65 (0.001 g, 1.40 x 10-6 mol) was dissolved in pH 9.2 phosphate 
buffer solution (5 mL) and NIR797 (0.0025 g, 2.79 x 10-6 mol) added. The mixture was then 
stirred at ambient temperature for 72 hours in the dark and monitored by analytical HPLC 
(method B, tr product = 26.9 minutes). The crude product was concentrated under reduced 
pressure, purified by semi-preparative HPLC (method B, tr = 27.9 minutes) and lyophilised 
to afford the product as a deep green solid (0.0015 g, 66 %). M/z (MALDI-TOF) 1631 [M + 
K]+, 1596 [M + H]+, 1574 [M – Na + H]+.  
 
See appendix 4 for fluorescence data 
See appendix 5 for HPLC and m/z data 
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Preparation of osmium complex appended cyclic peptide 68. 
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Exact Mass: 1416.56
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Caproic extended cyclic peptide 65 (0.002 g, 2.79 x 10-6 mol) was dissolved in anhydrous 
DMF (5 mL) and osmium succinic ester complex 53 (0.0027 g, 3.35 x 10-6 mol) added. The 
mixture was then stirred at ambient temperature under Ar(g) in the dark for 72 hours. 
Analytical HPLC revealed the product (method A, tr = 15.2 minutes). The crude product was 
concentrated under reduced pressure, purified by semi-preparative HPLC (method A, tr = 
21.4 minutes) and lyophilised to afford the product as a deep brown solid (0.0018 g, 46 %). 
M/z (MALDI-TOF) 1417 [M + H]+, 1439 [M + Na]+, 1708 [M + 2PF62- + 2H]+.  
 
See appendix 4 for fluorescence data 
See appendix 5 for HPLC & m/z data 
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Preparation of Ugi complex appended cyclic peptide 69. 
 
O
N
H
OH
N
O
HN
N
H
H2N N
OH
N
HN
O
O
O
HN O
N
N
N
N
O
O
O O
O
O
O
N
NH
O
Tb
S
O
O
O
C82H115N15O19STb
Exact Mass: 1804.75
Mol. Wt.: 1805.87
 
 
Protected cyclic peptide 58 (0.001 g, 1.08 x 10-6 mol) was dissolved in anhydrous DMF (2 
mL). PyBop (0.0007 g, 1.30 x 10-6 mol), DIPEA (0.0004 mL, 2.16 x 10-6 mL) were prestirred 
for 10 minutes with Ugi terbium derivative 34 (0.001 g, 1.08 x 10-6 mol) in anhydrous DMF 
(2 mL) before addition to the peptide. The mixture was then stirred for 72 hours at ambient 
temperature and monitored by analytical HPLC (method A). Upon completion the crude 
product was purified by semi-preparative HPLC (method B, tr = 37.2 minutes) and 
lyophilised to afford the product as a fine white powder (0.0008 g, 37 %). m/z (MALDI-TOF) 
1805.0 ([M+H]+, 100 %). 
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2.15 Miscellaneous experimental 
 
PEG Ugi test reaction: preparation of 92. 
  
 
 
  
 
 
 
O-tert-butoxycarbonylmethyl-6-amino-(ethylene glycol) 42 (0.20 g, 0.51 mmol) was 
combined with benzaldehyde (0.05 mL, 0.51 mmol) and stirred for 10 minuted in 
anhydrous MeOH (8 mL) under argon at ambient temperature. Benzoic acid (0.06 g, 0.51 
mmol) and benzyl isocyanide (0.06 mL, 0.51 mmol) were the added and the reaction stirred 
for a further 48 hours. Upon reaction completion the crude product was concentrated 
under reduced pressure and purified by flash column chromatography (CH2Cl2 / MeOH / 
NH3(aq) 85 : 14.9 : 0.1, Rf = 0.53) to afford the product as a colourless glassy solid. (0.34 g, 
93 %). δH (300 MHz; CDCl3) 7.60-7.22 (15H, stack, CH arom), 4.60 (1H, br s, NH), 4.02 (2H, 
s, CH2C=O), 3.72-3.44 (26H, stack, OCH2, PhCH2), 1.48 (9H, s, C(CH3)3); δC (75 MHz) 169.4 
(C=O), 169.1 (C=O), 168.2 (C=O), 138.4 (Cq arom), 135.7 (Cq arom), 135.4 (Cq arom), 132.6 
(C arom), 129.6 (C arom), 128.9 (C arom), 128.7 (C arom), 128.6 (C arom), 128.5 (C arom), 
128.3 (C arom), 128.0 (C arom), 127.6 (C arom), 127.2 (C arom), 127.1 (C arom), 127.0 (C 
arom), 126.9 (C arom), 81.2 (C(CH3)3), 70.4 (OCH2), 70.3 (OCH2), 70.2 (OCH2), 69.9 (OCH2), 
69.8 (OCH2), 68.7 (PhCH2), 43.2 (NCH2CH2O), 28.3 (C(CH3)3); m/z (TOF ES+) 745.3676 
([M+Na]+, 100%, C40H54N2O10Na requires 745.3670). 
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Preparation of N-tert-butoxycarbonyl-N’biotinyl-3,6-dioxaoctane-1,8diamine 
93. 
 
 
 
 
 
Biotin (0.50 g, 2.04 mmol), HBTU (0.67 g, 1.77 mmol) and DIPEA (0.38 mL, 2.18 mmol) 
were combined in anhydrous DMF (50 mL) and sonicated under argon at ambient 
temperature for 15 minutes. N-Boc-3,6-dioxaoctane-1,8-diamine 45 (0.34 g, 1.36 mmol) in 
DMF (10 mL) was then added dropwise over 20 minutes and the mixture stirred for a 
further hour at ambient temperature under argon. The crude cocktail was then 
concentrated under reduced pressure and purified either by gradient flash column 
chromatography Rf = 0.36 (CH2Cl2 to CH2Cl2 / MeOH / NH3(aq), 8.8 : 0.9 : 0.3), or 
preparative HPLC (method C) tr = 31.9 minutes. The pure product was recovered as a fine 
white powder (0.57 g, 98 %). νmax (Neat)/cm-1 ;δH (500 MHz; CDCl3) 6.79 (1H, br s, NH-18), 
6.72 (1H, br s, NH-10), 6.13 (1H, br s, NH-20), 5.12 (1H, br s, NH-3), 4.49 (1H, dd, J 4.9, 
7.5, H-21), 4.30 (1H, dd, J 4.6, 7.5, H-17), 3.58 (4H, app s, 2 x H-6, 2 x H-7), 3.53 (4H, 
stack, 2 x H-5, 2 x H-8), 3.41 (2H, mound, 2 x H-9), 3.28 (2H, mound, 2 x H-4), 3.12 (1H, 
dd, J 7.2, 11.8, H-16), 2.87 (1H, dd, J 4.9, 12.8, H-22), 2.72 (1H, d, J 12.8, H-22), 2.21 
(2H, t, J 7.4, 2 x H-12), 1.65 (4H, br stack, 2 x H-13, 2 x H-15), 1.41 (11H, app s, (CH3)3, 2 
x H14); δC (125 MHz) 173.5 (C-11), 164.4 (C-19), 156.0 (C-2), 79.3 (C-1), 70.0 (C-5, C-6 & 
C-7), 69.8 (C-8), 61.9 (C-17), 60.3 (C-21), 55.5 (C-16), 40.4 (C-22), 40.3 (C-4), 39.1 (C-9), 
35.8 (C-12), 28.3 (C(CH3)3), 28.1 (C-14), 27.9 (C-15), 25.5 (C-13); m/z (TOF ES+) 497.2410 
([M+Na]+, 100%, C21H38N4O6Na requires 497.2420). 
 
This compound was unequivocally assigned using COSY-90, HSQC & HMBC 2D nmr 
experiments. See appendix 6. 
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Preparation of N-biotinyl-3,6-dioxaoctane-1,8diamine 94. 
 
 
 
Boc protected compound 92 (0.074 g, 0.156 mmol) was dissolved in a mixture of TFA (2 
mL) and anisole (0.02 mL). The mixture was then stirred at ambient temperature for 1 
hour. By-products and TFA were removed under reduced pressure with repeated re-
evaporation using CH2Cl2 (3 x 10 mL) and toluene (3 x 10 mL). Trituration with Et2O 
afforded the pure product as a fine white powder (0.058 g, 99%). δH (300 MHz; d4MeOH) 
4.52 (1H, dd, J 4.6, 7.9, H-21), 4.32 (1H, dd, J 4.4, 7.9, H-17), 3.70 (2H, app t, J 5.2, 2xH-
8 or 2xH-5), 3.65 (4H, app s, 2xH-6 & 2xH-7), 3.55 (2H, app t, J 5.2, 2xH-8 or 2xH-5), 3.37 
(2H, app t, J 5.9, 2xH-9), 3.21 (1H, m, H-16), 3.13 (2H, mound, 2xH-4), 2.93 (1H, dd, J 4.9, 
12.8, H-22), 2.71 (1H, d, J 12.8, H-22), 2.22 (2H, t, J 7.3, 2xH-12), 1.65 (4H, stack, 2xH-15 
& 2xH-13), 1.44 (2H, m, 2xH-14); δC (300MHz) 176.3 (C-11), 166.1 (C-19), 72.1 (C-6 or C-
7), 71.9 (C-6 or C-7), 71.4 (C-5), 68.6 (C-8), 64.1 (C-17), 62.3 (C-21), 57.7 (C-16), 41.7 (C-
22), 41.3 (C-4), 40.8 (C-9), 37.4 (C-12), 30.4 (C-14), 30.2 (C-15), 27.5 (C-13); m/z (TOF ES+) 
375.2066 ([M+H]+, 100%, C16H31N4O4S requires 375.2072). 
See appendix 6 for nmr data 
 
Preparation of N-tert-butoxycarbonyl-N’biotinyl-3,6-octane-1,8diamine 95. 
 
 
 
Biotin (0.39 g, 1.60 mmol), HBTU (0.53 g, 1.39 mmol) and DIPEA (0.30 mL, 1.70 mmol) 
were combined in anhydrous DMF (50 mL) and sonicated under argon at ambient 
temperature for 15 minutes. N-Boc-1,8-diamine 46 (0.23 g, 1.06 mmol) in DMF (10 mL) 
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was then added dropwise over 20 minutes and the mixture stirred for a further hour at 
ambient temperature under argon. The crude cocktail was then concentrated under 
reduced pressure and purified by gradient flash column chromatography Rf = 0.36 (CH2Cl2 
to CH2Cl2 / MeOH / NH3(aq), 8.8 : 0.9 : 0.3) to afford the product as a fine white powder 
(0.36 g, 76 %). δH (300 MHz d4-MeOH) 4.49 (1H, dd, J 4.2, 7.9, H-21), 4.30 (1H, dd, J 4.4, 
7.9, H-17), 3.22-3.14 (4H, stack, 2xH-4, 2xH-9), 3.02 (1H, app t, 6.9, H-16), 2.93 (1H, dd, J 
4.9, 12.7, H-22), 2.70 (1H, d, J 12.7, H-22), 2.20 (2H, t, J 7.3, 2xH-12), 1.76-1.46 (25H, br 
stack, 8xCH2 & C(CH3)3); δC (750 MHz, d6-DMSO) 170.9 (C-11), 162.6 (C-19), 155.5 (C-2), 
77.2 (C-1), 60.1 (C-17), 58.2 (C-21), 54.5 (C-16), 38.3 (CH2), 38.1 (CH2), 35.2 (CH2), 29.4 
(CH2), 29.1 (CH2), 28.2 (C(CH3)3), 28.0 (CH2), 26.1 (CH2), 26.0 (CH2), 25.3 (CH2); m/z (TOF 
ES+) 465.2511 ([M+Na]+, 100%, C21H38N4O4SNa requires 465.2501). 
 
 
Preparation of N’biotinyl-3,6-octane-1,8diamine, 96. 
 
 
 
 
 
Boc protected compound 95 (0.078 g, 0.176 mmol) was dissolved in a mixture of TFA (2 
mL) and anisole (0.02 mL). The mixture was then stirred at ambient temperature for 1 
hour. By-products and TFA were removed under reduced pressure with repeated re-
evaporation using CH2Cl2 (3 x 10 mL) and toluene (3 x 10 mL). Trituration with Et2O 
afforded the pure product as a fine white powder (0.060 g, 99%) δH (300 MHz d4-MeOH) 
4.49 (1H, dd, J 4.4, 7.9, H-21), 4.30 (1H, dd, J 4.4, 7.9, H-17), 3.20-3.14 (4H, stack, 2 x H-
4, 2 x H-9), 3.02 (4H, stack, H-16, H-22, 2 x CH2),  2.69 (1H, d, J 12.7, H-22), 2.19 (2H, t, J 
7.3, 2 x H-12), 1.74-1.36 (16H, br stack, 8 x CH2); δC (75 MHz, d6-DMSO) 173.4 (C-11), 
162.9 (C-19), 155.8 (C-2), 77.6 (C-1), 60.8 (C-17), 58.7 (C-21), 55.0 (C-16), 38.9 (CH2), 38.8 
(CH2), 35.7 (CH2), 30.1 (CH2), 29.5 (CH2), 28.4 (CH2), 26.7 (CH2), 25.9 (CH2), 25.4 (CH2); m/z 
(TOF ES+) 343.2168 ([M+H]+, 100%, C16H31N4O2S requires 343.2174). 
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Preparation of benzyl formamide, 97 
 
 
 
Ethyl formate (17.77 mL, 0.22 mol) was added dropwise to benzylamine (27.30 mL, 0.25 
mol) and stirred gently until the exothermic reaction ceased. The solution was then heated 
under reflux for 2 hours and the crude product distilled through a 25 cm Vigreux column. 
The pure product was a colourless viscous oil (27.9 g, 94 %); ν max (CHCl3) 1688 (C=O), 
3270, 3298 (NH); δH (300MHz, CDCl3) 4.42 (2H, d, J 5.88, CH2), 6.32 (1H, s, NH), 7.24-7.32 
(5H, stack, Arom CH), 8.18 (1H, s, COH); δC (75 MHz, CDCl3) 40.7 (CH2), 126.8, 127.2, 
128.3 (3 x Arom CH), 138.9 (Arom Cq), 160.9 (C=O); m/z (EI) 135 ([M]+, 100 %), 106 ([M-
COH]+, 28 %), 91 ([M-NHCOH]+). 
 
Preparation of benzyl isocyanide, 98 
 
N
C
C8H7N
Exact Mass: 117.06
Mol. Wt.: 117.15  
 
Benzyl formamide 97 (20.0 g, 0.15  mol) was mixed with pyridine (75.20 mL, 0.92 mol) in 
petroleum ether (100 mL) and stirred at 0ºC in a three-necked round bottomed flask. POCl3 
(8.28 mL, 0.09 mol) was then added dropwise over 40 minutes and the resulting mixture 
stirred under reflux for 10 minutes. The cooled mixture was cooled and quenched with ice 
water until all solid material had dissolved. The solution was then extracted with pet. ether 
(3 x 60 mL) and the combined organic layers extracted with water (3 x 100 mL) before being 
dried over MgSO4 and evaporated under reduced pressure. The crude product was then 
distilled under vacuum using a rotating glass oven (165 ºC, 45 mbar) to yield the product 
as a pale brown pungent smelling oil (4.5 mL, 41 %); ν max (CHCl3) 2132 (N≡C); δH (300 MHz, 
CDCl3) 4.64 (2H, s, CH2), 7.34-7.44 (5H, stack, Arom CH); δC (75 MHz, CDCl3) 44.5 (CH2), 
127.3, 127.4, 128.0 (3 x Arom CH), 131.3 (Arom Cq), 148.9 (N≡C); m/z (EI) 117 ([M]+, 100 
%), 90 ([M-NΞC]+, 72 %). 
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The following compounds were designed as inert smelling alternatives to 
benzyl isocyanide. The additional aromaticity was intended to provide added 
UV visibility and the potential for energy transfer in an alternative position 
to the aldehyde component in the Ugi 4-CCRs. This would then open up the 
possibility of using the Passerini reaction as the aldehyde could now be the 
linker position and the amine would have no function. 
However, attempts at using these tosmic derivatives in multicomponent 
reactions failed.  
 
Preparation of benzyl tosylmethylisocyanide, 99 
 
 
 
Tosylmethylisocyanide (TosMIC) (0.50 g, 2.56 mmol), tetrabutylammoniumiodide (TBAI) 
(0.19 g, 0.50 mmol) in CH2Cl2 (5 mL), and NaOH (1.50 g, 30 % in 5 mL H2O) were 
combined, stirred vigorously for 5 minutes, and cooled to 0ºC. Benzylbromide (0.31 mL, 
2.56 mmol) was then added dropwise and the reaction stirred for 90 minutes at ambient 
temperature. 
H2O (25 mL) was added and the reaction mixture extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were dried over MgSO4 and the solvent removed under reduced 
pressure. The crude product was purified using flash column chromatography (Silica, 
Hexane / EtOAc 2 : 8, Rf = 0.48), to afford the pure product as a fine white crystalline solid 
(0.50 g, 98 %). Mp = 80-82 ºC; ν max (CHCl3) 2138 (N≡C); δH (300 MHz, CDCl3) 2.46 (3H, s, 
CH3), 2.99 (1H, X of ABX, dd, J 12.0, 2.2, CH), 3.59 (1H, A of ABX, dd, J 12.0, 2.9, CH2), 
4.71 (1H, B of ABX, dd, J 8.5, 2.9, CH2), 7.27-7.34 (5H, stack, 5 x benzyl CH), 7.42 (2H, d, 
J 8.1, tosyl CH), 7.91 (2H, d, J 8.1, tosyl CH); δC (75 MHz CDCl3) 21.7 (CH3), 34.5 (CH2), 
73.9 (CH), 129.9, 130.9, 131.2, 131.9, 132.1 (5 x Arom CH), 132.9, 135.1, 148.7 (3 x Arom 
Cq), 167.5 (N≡C); m/z (ES+) 308 ([M+Na]+, 100 %), 326 ([M+K]+, 15 %), HRMS (ES+) Found: 
308.0721, required for C16H15NO2NaS: 308.0706. 
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Preparation of Di-benzyl tosylmethylisocyanide, 100 
 
 
S
O O
N
C
C23H21NO2S
Exact Mass: 375.13
Mol. Wt.: 375.48
 
 
 
Tosylmethylisocyanide (TosMIC) (0.50 g, 2.56 mmol), tetrabutylammoniumiodide (TBAI) 
(0.19 g, 0.50 mmol) in CH2Cl2 (5 mL), and NaOH (1.50 g, 30 % in 5 mL H2O) were 
combined, stirred vigorously for 5 minutes, and cooled to 0 ºC. Benzylbromide (0.61 mL, 
5.20 mmol) was then added dropwise and the reaction stirred for 24 hours at ambient 
temperature. 
H2O (25 mL) was then added and the reaction mixture extracted with CH2Cl2 (3 x 15 mL). 
The combined organic layers were dried over MgSO4 and the solvent removed under 
reduced pressure. The crude product was purified using flash column chromatography 
(Hexane / EtOAc 1 : 8, Rf = 0.20) to afford the pure product as a fine white crystalline solid 
(0.80 g, 85 %). Mp = 88-91 ºC; ν max (CHCl3) 2136 (N≡C); δH (300 MHz, CDCl3) 2.47 (3H, s, 
CH3), 3.29 (4H, d of ABq, J 14.2, 27.0, 2 x CH2), 7.14-7.29 (10H, stack, benzyl arom CH), 
7.36 (2H, d, J 8.1, tosyl CH), 7.85 (2H, d, J 8.1, tosyl CH); δC (300 MHz CDCl3) 21.8 (CH3), 
39.7 (2 x CH2), 81.8 (Cq), 127.9, 128.4, 129.8, 130.9, 131.2 (5 x Arom CH), 130.5, 132.5, 
146.3 (3 x Arom Cq), 166.8 (N≡C); m/z (ES) 398 ([M+Na]+, 100%); HRMS (ES+) Found: 
398.1191, required for C23H21NO2NaS: 398.1195. 
 
Preparation of 2-naphthyl tosylmethylisocyanide, 101 
 
 
 
Tosylmethylisocyanide (TosMIC) (0.50 g, 2.56 mmol), Tetrabutylammoniumiodide (TBAI) 
(0.185 g, 0.50 mmol) in CH2Cl2 (5 mL), and NaOH (1.50 g, 30 % in 5 mL H2O) were 
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combined, and the mixture stirred vigorously. 2-Naphthylmethylbromide (0.57 g, 2.56 
mmol) was then added dropwise and the reaction stirred for 90 minutes at ambient 
temperature. 
H2O (25 mL) was then added and the reaction mixture extracted with CH2Cl2 (3 x 15 mL). 
The combined organic layers were dried over MgSO4 and the solvent removed under 
reduced pressure. The crude product was purified using flash column chromatography 
(Hexane / EtOAc 2 : 7, Rf = 0.36) to give the pure product as a fine white crystalline solid 
(0.53 g, 63 %). Mp = 102-104 ºC; νmax (CHCl3) 2125 (N≡C); δH (300 MHz, CDCl3) 2.43 (3H, s, 
CH3), 3.16 (1H, X of ABX, dd, J 11.0, 2.2, CH), 3.76 (1H, A of ABX, dd, J 11.0, 2.9, CH2), 
4.82 (1H, B of ABX, dd, J 8.5, 2.9, CH2), 7.32-7.95 (11H, stack, Arom CH); δC (75 MHz 
CDCl3) 21.0 (CH3), 34.1 (CH2), 73.2 (CH), 125.6, 125.8, 125.9, 127.0, 127.8, 128.1, 129.4, 
129.5 (8 x Arom CH), 129.9, 130.3, 132.0, 132.7, 146.0 (5 x Arom Cq), 165.0 (N≡C); m/z 
(ES) 358 ([M+Na]+, 100 %), HRMS (ES+) Found: 358.0878, required for C20H17NO2NaS: 
358.0872. 
 
Preparation of Di-2-Naphtylmethyl tosylmethylisocyanide, 102 
 
S
O O
N
C
C31H25NO2S
Exact Mass: 475.16
Mol. Wt.: 475.6  
 
Tosylmethylisocyanide (TosMIC) (0.24 g, 1.25 mmol), tetrabutylammoniumiodide (TBAI) 
(0.092 g, 0.25 mmol) in CH2Cl2 (5 mL), and NaOH (1.50 g, 30 % in 5 mL H2O) were 
combined, stirred vigorously, and cooled to 0 ºC. 2-(bromomethyl) napthalene (1.13 g, 5.20 
mmol) was then added dropwise and the reaction stirred for 24 hours at ambient 
temperature. 
H2O (25 mL) was then added and the reaction mixture extracted with CH2Cl2 (3 x 15 mL). 
The combined organic layers were dried over MgSO4 and the solvent removed under 
reduced pressure. The crude product was then recrystallised from CH2Cl2 / MeOH (1 : 1), 
to give the pure product as a fine white crystalline solid (0.86 g, 72 %). Mp = 151-153 ºC; 
νmax (CHCl3) 2122 (N≡C); δH (300 MHz, CDCl3) 2.36 (CH3), 3.42 (2H, d of ABq, A of AB, J 
14.1, CH2), 3.56 (2H, d of ABq, B of AB, J 14.1, CH2), 7.19-7.79 (18H, stack, Arom CH); δC 
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(75 MHz, CDCl3) 21.8 (CH3), 40.1 (2 x CH2), 81.9 (C), 127.7, 127.9, 128.1, 128.5, 130.3, 
131.3 (8 x Arom CH), 129.7, 130.7, 132.9, 133.2, 146.3 (4 x Arom Cq), 167.3 (N≡C); m/z 
(ES) 498 ([M+Na]+, 100 %), 514 ([M+K]+, 8 %); HRMS (ES+) Found: 498.1504, required for 
C31H25NO2NaS: 498.1501. 
 
Preparation of 9-anthracenyltosylmethylisocyanide, 103 
 
 
 
Tosylmethylisocyanide (TosMIC) (0.50 g, 2.56 mmol), Tetrabutylammoniumiodide (TBAI) 
(0.185 g, 0.50 mmol) in CH2Cl2 (5 mL), and NaOH (1.50 g, 30% in 5 mL H2O) were 
combined, and the mixture stirred vigorously. 9- bromomethyl-anthracene (0.69 g, 2.56 
mmol) was then added slowly over 10 minutes, and the reaction stirred for 90 minutes at 
ambient temperature. 
H2O (25 mL) was then added and the reaction mixture extracted with CH2Cl2 (3 x 15 mL). 
The combined organic layers were dried over MgSO4 and the solvent removed under 
reduced pressure. The crude product was purified using flash column chromatography 
(Hexane / EtOAc 2 : 7, Rf = 0.36) to give the pure product as a fine yellow crystalline solid 
(0.53 g, 63 %); Mp = 163-165 ºC; νmax (CHCl3) 2130 (N≡C); δH (300 MHz, CDCl3) 2.49 (CH3), 
4.35 (1H, X of ABX, dd, J 12.0, 3.5, CH), 4.54 (1H, A of ABX, dd, J 12.0, 2.7, CH2), 4.95, B 
of ABX, dd, J 8.4, 2.7, CH2), 7.44-8.44 (13H, stack, Arom CH); δC (75 MHz CDCl3) 21.9 
(CH3), 26.3 (CH2), 72.8 (CH), 123.3, 125.4, 127.1, 128.6, 129.7, 130.4 (6 x Arom CH), 
124.5, 130.6, 131.2, 131.6, 147.0 (5 x Arom Cq), 167.0 (N≡C); m/z (ES) 408 ([M-CH3]+, 100 
%), 440 ([M+Na]+, 10 %). 
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Chapter 3: Galectin targeted fluorescent disaccharides 
for in vivo imaging 
 
Cyclic peptide becomes disaccharide – change of target and delivery vehicle 
 
3.1 Introduction to carbohydrates 
Carbohydrates, sugars and saccharides, are all generic terms for the same type of chemical 
compound. Mono- and disaccharides are commonly referred to as sugars whereas longer 
more complex chains of these sugars are termed either poly- or oligosaccharides. All these 
come under the more general term of carbohydrate, which is the family of compounds 
possessing the empirical formula Cn(H2O)n.119  
Glucose is the most well known sugar and indeed the most abundant organic molecule on 
the face of the planet. It is the monosaccharide unit most well known and researched for 
being a source of energy. It is also, however, the primary building block for some of 
Nature’s most structurally important compounds such as cellulose and starch (Figure 89).  
O
HO
OH
OH
O
O
HO
OH
OH
O
HO
HO
OH
OH
OH
O
O
HO
OH
OH
O
O
HO
OH
OH
O
O
HO
OH
OH
O
O
HO
OH
OH
O
O
HO
OH
O
OH
O
O
HO
OH
OH
O
O
O
HO
OOH
HOO
O
HO
OH
HO O
O
HO
OOH
HOO
HO
OH
HO O
O
HO
OOH
HOO
HO
OH
HO O
O
HO
OOH
HOO
HO
OH
HO
O
HO
HO
OH
OH
OH
Starch
Cellulose
-D-glucose
-D-glucose
 
 
Figure 89: D-glucose in cellulose and starch showing the contrasting structures resulting from the two anomeric 
glycosidic bonds. 
 
Being from several hundred to over ten thousand D-glucose repeat units in length, the 
strands are held together as layered fibres through van der Waals forces and hydrogen 
bonding. This creates a substance of great versatility and strength. Cotton is 90% cellulose 
and timber around 50%, this explains the status of cellulose as the most abundant 
substance on earth.119b 
Cellulose and starch differ in their glycosidic bond geometry. Cellulose consisting of repeat 
β(1→4) linkages and starch α(1→4). The starch alpha bond is easily hydrolysed unlike the 
cellulose beta bond which explains the dramatically different properties of the two 
compounds. 
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Starch and cellulose are synthesised in plants through the process of photosynthesis where 
CO2 is converted into glucose. Enzymes such as transferases and synthases then stimulate 
the build up of the polysaccharides which are subsequently broken down as required, to 
release energy through the citric acid cycle. 
The best known properties and applications of sugars are in the food that we eat and the 
nourishment they provide. Sucrose, fructose and lactose are some well known sugars 
commonly found in the diet, and just like complex carbohydrates such as starch, are 
broken down through hydrolysis, by hydrolases, prior to metabolism. However, being in the 
simple sugar form they are a much more rapid source of energy.  
 
3.1.1 Metabolism 
The most important and rapidly available source of energy in biological systems is 
adenosine triphosphate (ATP).  
 
 
 
Scheme 27: Adenosine triphosphate (ATP) hydrolysed to adenosine diphosphate (ADP) releasing energy. 
 
ATP is hydrolysed to ADP releasing 30.6 kJmol-1 of energy.119 This energy is stored in the 
phosphodiester bond and is vital for the function of all processes in the aqueous 
physiological environment. However ATP needs to be regenerated and it is the oxidation of 
glucose that is the major contributor to this regeneration. 
The citric acid cycle is a series of enzyme catalysed chemical transformations of great 
significance in all aerobic living cells. It is part of the metabolic process which converts 
carbohydrates, proteins and fats into water, carbon dioxide and usable energy. 
The first metabolic process prior to the citric acid cycle is glycolysis where glucose it is split 
into two molecules of pyruvate through a ten step enzyme-catalysed reaction sequence. 
This involves several key steps including a rearrangement to form a five membered 
furanose and a retroaldol cleavage (Scheme 28). 
 
 
Scheme 28: An abbreviated mechanism of glycolysis leading to two molecules of pyruvic acid. 
 
Before entering the citric acid cycle the pyruvate must be converted into an activated acetic 
acid thioester known as acetyl-SCoA. This basically imparts a good leaving group ready for 
initiation into the famous cycle (Scheme 29).120 
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Scheme 29: The author’s diagram of the Citric Acid Cycle. 
 
The key to the citric acid cycle is the conversion of acetyl-SCoA into the reducing 
compounds NADH (the reduced form of nicotinamide adenine dinucleotide) and FADH2 (the 
reduced form of flavin adenine dinucleotide). These are then oxidatively phosphorylated 
and the ten NADH and two FADH2 nucleotides from one glucose molecule are converted 
into 32 molecules of ATP. 
 
3.1.2 Carbohydrates and cancer 
Thus far we have delved into a few the well known biological properties and processes 
involving carbohydrates. It is, however, some of the less well known properties of 
carbohydrates that are of more relevance and interest to this study. Over the past 25 years 
science has begun to reveal the involvement of carbohydrates, especially small sugar 
residues, in a vast array of other fundamental and precise biological processes both inside 
and outside of cells. It is becoming clearer and clearer that a variety of carbohydrates are 
key code molecules in biological communication events influencing the control of 
proceedings as diverse as conception, inflammation, infection and the growth and spread of 
cancer. 120b 
It is the latter function of carbohydrates within the field of oncology that will become the 
cornerstone of this discussion.  
 
Most proteins synthesised in mammalian cells have carbohydrates attached to them. 
Carbohydrates are covalently bonded to these glycoproteins through either an ‘N’ linkage, 
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via asparagine, or through an ‘O’ linkage, via the amino acids serine or threonine. In fact 
carbohydrates effectively ‘coat’ the majority of cellular surface proteins, so that all 
interactions between a cell and its local environment are in some way affected by 
carbohydrates. These appended sugars can have a variety of influences upon the properties 
of the glycoproteins, including increasing or decreasing solubility and promoting resilience 
to attack and break down by peptidases and proteases.120b 
A nice example of the carbohydrate residues on glycoproteins imparting extraordinary 
function to the molecule is in a class of biological antifreeze glycoproteins (AFGPs) isolated 
from the Arctic and Antarctic deep sea Teleost fish (Figure 90). These compounds allow the 
host to survive in water temperatures as low as -2 ˚C through the inhibition of ice crystal 
growth.120c 
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Figure 90: An example of a glycoprotein, an AFGP (antifreeze glycoprotein).120c 
 
A vast array of branched sugars are also found appended to glycoproteins. These manifest 
the diverse range of variations not only in the sugar build-up of the oligosaccharides, but 
also in the position of glycosylation on the protein and the abundance of these sites. An 
example of an oligosaccharide on an ‘N’ linked glycoprotein in shown in Figure 91. 
Although this is not a true representation of conformation, it shows the branched ‘claw-
like’ nature of the carbohydrate arm which is a perfect site for sugar specific proteins such 
as lectins to dock, bind and begin influencing signalling and cellular behaviour.121 
 
 
Figure 91: A branched glycoprotein oligosaccharide.121 
 
Lectins bind to glycosylated structures with exquisite specificity even for complex, highly 
branched oligosaccharides, despite their typically very shallow binding sites, also known as 
carbohydrate recognition domains (CRDs). 
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3.1.3 Lectins 
Mammalian lectins are a class of intra- and extracellular proteins that have a binding 
affinity for specific carbohydrates. They bind to a soluble carbohydrate residue or to a 
carbohydrate moiety on a glycoprotein or lipid. An undesirable function of these proteins is 
that viruses such as human influenza strains attach themselves to the cells of a host 
organism by binding to lectins during infection.122a Results have suggested that a lectin 
cross-linkage between the virus and the cellular surface is the most plausible mechanism 
for propagation of infection.122b 
There are four types of lectins: C-type, P-type, pentraxins and galectins, each defined by 
the class of carbohydrates to which they bind, their structure, and their mode of 
action.122c/d 
 
3.1.3.1 Galectins 
To date there are over 15 known galectins and it is upon this group of lectins that our 
attention shall focus. Galectins are specifically β-galactoside binding lectins sharing 
significant amino acid sequence similarities in the CRD (Figure 92). They are divided into 
numerical categories with galectin-1 to galectin-4 being the best characterised and 
understood four galectins. 
More and more of the mysteries of the galectin family are being unravelled. This is a family 
of proteins that grows larger as more are discovered, and yet their activity and far-reaching 
influence is still far from completely understood. Recent literature describes the galectin 
family as having a “diverse and bewildering, yet intriguing, array of activities both inside 
and outside of cells”.123 However, galectins are not only involved in extracellular biology 
through their binding to surface glycoproteins and the extracellular matrix (ECM), they 
have also been detected in subcellular locations such as the nucleus. Evidence suggests 
galectins play roles in a whole host of biological events including oncogenesis and the 
adhesion and proliferation of cells. 
β-Galactosides are carbohydrate residues commonly located appended to cellular surface 
glycoproteins or within larger appended oligosaccharides which are involved trans-
membrane cellular signalling processes. 
 
 
 
Figure 92: Lactose (β-D-galactopyranosyl-(1→4) β-D-glucopyranose), a β-galactoside, is a disaccharide common 
in dairy products. A molecule of D-galactose is bonded to a molecule of D-glucose through a β-(1’→4) glycosidic 
linkage. 
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For galectin recognition and binding the β-galactoside must possess the monosaccharide β-
galactose moiety. Galectin binding specificity towards the β-galactose alone is low and does 
not effect good binding. Normally this monosaccharide unit is found incorporated into an 
oligosaccharide where the adjacent one or two monosaccharide building blocks also 
influence binding affinity and specificity. This is what differentiates between the different 
members of the galectin family as they each target and bind specific cellular surface 
protein oligosaccharide residues. This is what also makes them open to novel therapeutic 
targeting and the diagnostic imaging applications addressed in this study.  
Lactose (Figure 92), is the best known example of a β-galactoside and indeed it binds to 
galectins, albeit with a low binding constant. This will be further investigated in the 
forthcoming discussion regarding the carbohydrate recognition domain (CRD) (page 174). 
 
The galectins known thus far have either one or two characteristic CRDs within a single 
polypeptide chain. Galectins-1 and -2 are homodimers composed of two approximately 135 
amino-acid carbohydrate-binding sub-units which fold up as a globular domain.124,125 
Galectin-3 possesses a unique structure in that it contains a single CRD followed by a 
flexible proline- and glycine- rich repeat unit of approximately 100 amino-acid residues, 
before terminating with an N-terminal domain of approximately 30 amino-acids. Galectin-4 
is another dimer with a longer linking peptide between the two CRDs of approximately 30 
amino-acid residues. Figure 93 shows a simplified representation of these first four 
galectins and illustrates how they are structurally quite different despite possessing the 
required affinity for β-galactosides and CRD similarities. 
 
Galectin-3
Galectins 1,2,5,7,10,11,13,14 & 15
Galectin 3
Galectins 4,6,8,9 & 12
Galectin-1 dimer
 
 
Figure 93: A cartoon illustrating the basic structure of galectins. For the tandem repeat unit (Gal-4 etc), it is 
important to recognise that the two CRDs are as different from each other as they are from their fellow 
galectins.125 
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3.1.4 Galectin-3 
The emphasis of our discourse will now focus on galectin-3 for this is the target of the 
disaccharide probes designed and synthesised in this project. 
Apart from the prediscussed structural differences and physiological localisation, it must 
be rationalised as to why this specific galectin is a good target for site-specific imaging. 
 
Galectins are expressed in distinct but overlapping localities within mammalian tissues. 
For example, galectin-1 is abundant in skeletal, smooth and cardiac muscle, neurons, 
thymus, kidneys and placenta. In contrast, galectin-3 is most abundant in active 
macrophages, basophils, mast cells and some epithelial cells and sensory neurons. In 
many tissue types galectin-3 synthesis and propagation is only instigated under certain 
physiological conditions. It is the roles of Galectin-3, and its abundance in and around 
tumour cells, where it mediates many processes including intracellular signalling and 
intercellular adhesion, that makes it stand out as a potential vector for the site-specific 
delivery of diagnostic imaging agents. 
Extracellularly, galectins can bind either di-valently or multivalently to the β-galactoside 
residues.  The creation of these multivalent aggregates suggests that the mode of action of 
these proteins is to cross-link carbohydrate-containing chains on cellular surfaces and/or 
within the ECM. As in many other receptor-ligand systems, this can trigger a cascade of 
signalling across the cell membrane. This mechanism allows the modulation of processes 
including mitosis, apoptosis and cell-cycle progression.126 The di- and multivalent binding 
properties of galectins also allows the aggregation of cells through intercellular bridging 
(Figures 94 & 95) as previously mentioned in the mechanism of some viruses (page 168).  
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Single CRD galectins (dimer)
Galectin 3 (oligomers)
Double CRD galectins
Galactose bearing oligosaccharides 
on glycoproteins
 
 
Figure 94: The author’s diagram of the various processes involving galectins at the cell surface. 
 
Galectin-3 forms oligomers when binding to multivalent carbohydrates and thereby is able 
to form an ordered array of agglomerated glycoconjugates as illustrated in Figure 95. 
Divalent carbohydrate
 
Figure 95: Galectin-3 oligomers forming a lattice. Note the free Gal-3 binding sites for targeting. 
 
Some galectins are distributed in a wide variety of tissues whereas others are more specific. 
Distribution is modulated during the differentiation of individual cells and during the 
development and growth of organisms and tissues. As mentioned previously, this 
distribution varies according to physiological and pathological environmental conditions. Of 
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most relevance is the discovery that the expression of galectins is altered in and around 
tumour cells in comparison to their healthy counterparts. Galectins are often over-
expressed in cancer cells especially in those cell types that normally show negligible 
galectin presence.126-129 This is not ubiquitous, as some normal cells which naturally show 
good levels of galectins show a decrease in galectin expression upon the onset of 
malignancy. However, in many situations the increased expression of galectins correlates 
very clearly with an increase in the aggressiveness of tumours and the development of a 
metastatic phenotype.130 This indicates that galectins may well coordinate cancer 
propagation. Studies have shown a weakly metastatic sarcoma cell line becoming highly 
metastatic through an over expression of galectin-3.127 Further to this an intracellular 
migration of galectin-3 from the nucleus into the cytosol occurs during the transition from 
normal to healthy cells.121  
There is unambiguous evidence that galectin-1 and galectin-3 expression is necessary for 
the initiation of the transformation of a benign or young tumour into an aggressively 
metastatic phenotype.130,131 Inhibition studies of galectin-3 in breast and thyroid carcinoma 
cells revealed a reduction in the characteristic transformed phenotype, indicating a definite 
link. In an alternative study, introduction of galectin-3 into a healthy thyroid cell line 
induced the phenotype transformation and cells became cancerous.132  
The mechanisms of galectin-3 involvement in cell transformation and oncogenesisis are not 
yet fully understood, but binding studies have revealed galectin-3 binding to the Ras 
oncogene which was discussed in the biological testing section of chapter 2 as the gene 
used to initiate some transgenic mice lines (Page 88).100-103  
T-cells and macrophages are part of the immune response to cells identified as 
immunologically foreign. Once activated, T-cells divide rapidly and secrete cytokines which 
regulate and assist the immune response. Cytotoxic T-cells destroy tumour cells, however, 
the expression of cell-surface glycoproteins bearing the β-galactoside moiety allows the 
binding of galectins, and Galectin-3 can form multivalent complexes with T-cell receptors, 
restricting signal transduction, activation and motility, thereby downregulating the 
immune response to the cancer, promoting tumour cell survival and proliferation. Galectin-
3 can also induce T-cell apoptosis.127 
We are building up a picture of the diverse and widespread roles of galectins, especially 
galectin-3, in tumour development and progression. However it is the upregulation of 
galectin-3 in tumour sites that is of most interest and relevance to this study. The known 
reasons behind this tumour-specific accumulation of galectin-3 will be briefly discussed in 
order to justify its position as the site specific entity to which the probes will be targeted. 
In chapter 2 the processes of angiogenesis and metastasis were introduced with respect to  
the upregulation of αvβ3 integrin bearing cells such as endothelial cells. Here we will see 
some overlap. 
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3.1.4.1 Galectin-3 in adhesion, angiogenesis and metastasis. 
The spread of a cancer from a single primary site to other metastatic sites is a complex 
multi-step process involving cell-to-cell and cell-to-ECM adhesion and aggregation. 
Although the galectin family as a whole seems to play important specific roles, it is the fact 
that galectin-3 has been found clustered at sites of homotypic tumour cell-cell contact and 
also in heterotypic adhesion between carcinoma and endothelial cell monolayers that 
implicates its involvement in tumour cell clustering and then the break away and 
establishment of a tumour at an alternative site (Figure 96).133 
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Figure 96: A simplified illustration of tumour metastasis highlighting some of the key roles of galectin-3. Adapted 
from Ref.127. 
 
It is thought that galectin-3 encourages angiogenesis by promoting endothelial cell 
migration. Proof of this is reported where an increase in capillary density surrounding 
tumours, in comparison to controls, was observed in breast-tumour-bearing mice.120  
This attempted explanation of the role of galectin-3 in metastasis is hugely simplified and it 
must be remembered that a vast number of simultaneous complex processes involving 
galectins, integrins, glycoproteins, endothelial cells, the ECM, the immune system and 
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many other biological entities such as growth factors, are each working together and 
against each other in complex mechanisms which are not yet fully understood. However, 
the important fact that galectin-3 is central and prolific in tumours is the prime reason 
that this protein will be our target in novel tumour imaging agents. 
Having justified our target we must look more closely at the galectin-3 CRD and explore the 
binding-site with emphasis on the ensuing design of galectin-3-specific probes. 
 
3.1.5 The carbohydrate recognition domain (CRD) 
Whilst the diverse structure of the various members of the galectin family will influence 
their biological functions and physiological locations, it is first important to discuss the 
carbohydrate recognition domain in detail, as this will influence the design of β-galactoside 
probes for the imaging purposes of this study. 
CRD binding is largely due to hydrogen bonding between the galectin backbone and side- 
chain carbonyl groups, and the hydroxyls of the sugar ligands. Hydrophobic interactions 
between hydrophobic galectin side-chains and hydrophobic areas on the glycoprotein 
carbohydrate residues also serve to increase binding affinity.  
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Figure 97: A schematic showing an example of the interactions binding lactose within the galectin-3 CRD.127 
 
Known galectin carbohydrate ligands such as lactose and N-acetyllactosamine have been 
found to exhibit low inhibitory potency with IC50 = 0.2-1.0 mM. For effective galectin-3 
inhibition concentrations over 10mM are required.134  
The two specific monosaccharide building blocks of a β-galactoside have been found to 
profoundly influence the binding efficacy in the CRD. Indeed, albeit relatively shallow, 
galectins have a binding site able to accommodate species as large as tetrasaccharides.  
The D-galactose monosaccharide is fundamental for all galectin binding but will still bind 
to the CRD without the anomeric-linked D-glucose. However, binding is enhanced by the 
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presence of D-glucose, suggesting that a combination of D-galactose with one, two or three 
extra monosaccharides would afford better alignment and orientation in the binding 
pocket.135 
Crystal structure studies have shed light upon this binding pocket and Figure 98 
illustrates the D-galactose bound deeper within the CRD whereas the D-glucosamine is 
partially protruding. 
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Figure 98: Left) N-acetyllactossamine, Kd = 69000 nM. Right) The protein crystal structure of gelectin-3 bound N-
acetyllactosamine.133 Pdb code 1L5G. 
 
Galectin-3 crystal structure and modelling studies, combined with binding specificity 
measurements, have enhanced the understanding of this CRD to such a degree that 
careful scrutiny of the binding pocket has highlighted an area where there is an extended 
empty groove into the protein. Therefore an investigation was set up to establish the 
potential of this space for enhancing the binding of a β-galactoside through additional 
favourable interactions deeper within the CRD.111 Diverse structural extensions of the D-
galactose C-3’ functional group nearest to the space in the binding site found vastly 
enhanced binding affinity and kinetics was possible. Derivatisation of this single position 
on the D-galactose moiety with aromatic groups improved the binding affinity by two orders 
of magnitude.133-135  
Figure 99 shows images of the fine structure surrounding the CRD with N-
acetyllactosamine in the binding site. The space for potential derivatisation is clear in the 
region of the C-3’ hydroxyl. 
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Figure 99: Computer models of N-acetyllactosamine within the galectin-3 CRD. The green rings show the space 
between residues Asn160, Arg144 and His158 for extension of the disaccharide. Adapted from refs. 111 & 114. 
 
Nilsson et al133 showed that the C-3’ hydroxyl can be replaced with an azide which, upon 
reduction to the amine was successfully functionalised to form many different 3’-amino-N-
acetyllatosamine derivatives. This required a complete overhaul of the synthetic protocol as 
will be discussed in due course and rendered the total synthesis longer through the 
necessity of starting from the unnatural monosaccharide L-gulose. It became abundantly 
clear through competitive binding studies of these amide derivatives against LacNAc that 
binding was enhanced by as much as threefold. Inhibitory activity was most significantly 
enhanced in aromatic amide derivatives (Figure 100).133,134 
 
 
Figure 100: 3’-Amino-N-acetyllatosamine (LacNAc) derivatives found to exhibit enhanced binding to galectin-3. 
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This phenomenon was rationalised through electronic mapping and crystal structure 
studies revealing what is thought to be a key interaction between the Arg-144 residue and 
an aromatic ring. This enhances binding considerably, especially with 2-naphthamido 
derivatives, and the proposed mechanism involves the positively charged π-system of the 
guadinium ion (arginine side-chain) interacting through π-π stacking interactions with the 
naphthyl π system.136,137 
 
 
 
Figure 101: Left) Electron density map showing the blue protein surface as positive, and red as negative. Right) 
This clearer model shows the orientation of binding. Note the aromatic extension at C-3’ (arrowed) bound deeper 
within the pocket and interacting with Arg-144.133 
 
Although the binding efficiency is of great importance in this study and will be included in 
the synthetic strategy, it must be remembered that the emphasis of this study is not the 
inhibition of galectin-3 (which would be applicable to therapeutic type studies), but to 
develop galectin-3-targeted fluorescent probes to aid diagnostics.  
To label the galectin-3 targeted disaccharide we must consider the availability of 
attachment sites that do not interfere with the binding pocket, and this means looking at 
the end of the galactoside which is protruding from the CRD. 
Conveniently there are two possible sites available to append a fluorophore, and now our 
investigation must touch upon the literature precedent for derivatising the disaccharide in 
these positions. 
 
   
 
Figure 102: The two exposed positions for potential attachment of the fluorescent probe. 
 
Chapter 3: Introduction 
 178
Literature precedent for the tagging or labelling of galactosides with organic fluorophores is 
quite scant. There has been work carried out to derivatise the glucosamine anomeric 
hydroxyl in many ways, especially in lipid chemistry where lipids have been attached to the 
anomeric position of saccharides as a hydrophobic tag predominantly for solubility and 
purification reasons.136b-e 
However, surprisingly, there is little evidence of using the C-2 amino group as a point of 
attachment even though selective acetylation and other protecting group chemistry has 
been employed suggesting that this is a viable position for the incorporation of a 
fluorophore, via a spacer unit, to reduce the risk of interference with the binding site. The 
available literature in this area though, is of great interest to this study. There is precedent 
for attaching bulky groups to the amine, and again this research was carried out by the 
Swedish group of Nilsson, with the purpose of enhancing the inhibition of galectin-
3.133,134,137-139 The purpose of the study was to discover whether a second arginine residue 
(Arg-186) was within range of an aromatic moiety appended to the amine in the C-2 
position of the disaccharide. As previously discussed an aromatic motif interacts almost as 
effectively with a guadinium positive charge, as a standard ionic interaction. Nilsson 
synthesised bis-amides such as the thiogalactoside below (Figure 103), and revealed 
enhanced inhibition. This β(1’→1) thiogalactoside is of quite different conformation in 
comparison to the β(1’→4) linkage of N-acetyllactosamine as the amine is actually in the C-
3 rather than the C-2 postion. Hence it is difficult to draw comparisons in the context of 
the availability of the amine for derivatisation with a species not involved with binding such 
as a fluorophore. 
 
 
 
Figure 103: Left) A high affinity 3,3’-bisamido-thiogalactoside derivative with Kd = 50 nM (cf. C-3 NAc Kd = 1100 
nm). Right) An energy minimised molecular model of the active site showing the two arginine residues interacting 
favourably with aromatic groups.137 
 
The rationale behind the construction of a thio glycosidic 1’→1 linkage was to effect a more 
streamlined synthesis by effectively coupling together the two identical monosaccharides 
into a symmetrical species. This was a very efficient synthetic protocol, and as the 
thioglycoside had been shown previously to bind to β-galactosides comparably if not 
slightly better than LacNAc, it was a good strategy. To further selectively investigate the 
binding at Arg-186 a study discovered that a simple C-2 lactose phenyl ester bound with 
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considerably greater galectin CRD affinity than lactose, without any further functionality 
deeper in the pocket interacting with Arg-144.137 
This must be taken into consideration in our synthetic planning but bears good omens as 
this work has revealed that a bulky group on the glucosamine moiety does not interfere 
with binding; on the contrary, in the case of an appended aromatic unit, binding is 
enhanced. The implication here is that there is room enough for a spacer unit to emerge 
from the binding pocket to an appended chromaphore. Indeed, it even opens the door to 
investigating an aromatic linker or the possibility of superior binding with the fluorophore 
at the free hydroxyl position. 
We must now introduce the more hands-on side of working with carbohydrates and devise 
and rationalise a synthetic approach to building a galectin-3 targeted probe. 
 
3.1.6 Carbohydrate chemistry 
Thus far we have discussed the role of carbohydrates and how they are involved in 
widespread biological processes. We have explored the function and availability of the 
carbohydrate residues in glycoproteins and how they are used as binding sites for 
carbohydrate specific proteins such as lectins. This brought us on to why galectin-3 is a 
good target due to its up-regulation and involvement in tumour sites; and the great 
specificity of this protein towards unique carbohydrate residues. Finally we must consider 
the design and synthesis of galectin-3 specific probes and to begin with we must touch 
upon the chemistry of carbohydrates. 
The Fischer convention is commonly used to represent structures with several stereogenic 
centres such as sugars or furanoses and pyranoses. A Fischer projection simply gives a 
representation of D and L enantiomers according to whether the OH-4 is to the left or right 
of the central column.119,120 
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Scheme 30: The epimers D-glucose and D-galactose and their Fischer and chair conformations. 
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The abundance of open chain saccharide in solution, or in solid form, is negligible and the 
position of the equilibrium lies almost exclusively on the side of the cyclised structure 
(Scheme 30). However, due to the prolificacy of hydroxyls, there is of course the possibility 
of different sized lactol rings. 
The position of equilibrium is rationalised by considering that intramolecular cyclisation is 
thermodynamically and kinetically favoured over intermolecular cyclisation due to entropic 
factors. With regards to ring size it is important to remember that five and six membered 
rings are thermodynamically more stable than more strained 
four and seven membered rings. The six membered ring is 
most stable as it adopts an essentially strain free chair 
conformation when all the components are equatorial, this is 
the lowest energy conformation and in water D-glucose 
consists of 38 % α-anomer and 62 % β-anomer.119 However, 
with an electronegative substituent at the anomeric position (C-1), such as an iodide, the 
stability is reversed and the axial α-anomer becomes more stable due to the anomeric effect 
(Figure 104). 
Despite the α-position being sterically more hindered, it is the thermodynamically favoured 
anomer when the substituent is electronegative. The explanation comes down to electronic 
reasoning and the fact than an oxygen lone pair and the C-X bond are adopting an 
antiperplanar conformation allowing the delocalisation of electron density into the 
antibonding σ* orbital of the C-X bond, thus having a stabilising effect.119,120 This has many 
implications which shall be discussed further in relation to the synthetic protocol employed 
in this study. 
The presence of an oxygen substituent alpha to the anomeric centre means that any 
carbocation formed there is stabilised. Fischer glycosylation is the derivatisation of the 
anomeric centre to form an acetal (Scheme 31). Selective glycosylation is fundamental to 
sugar chemistry and synthetic design must always consider the anomeric selectivity and 
the use of the phenomenon that is neighbouring group participation (NGP). 
 
 
Scheme 31: Fischer glycosylation: the formation of a methyl glycoside. 
Figure 104: The anomeric effect 
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A source of Bronstead acid such as SOCl2 (thionyl chloride) with MeOH is used to drive the 
equilibrium through to completion. The result in this instance is the preferential formation 
of the α-product, as rationalised previously through the anomeric effect.  
However, through shrewd protecting group chemistry at the C-2 hydroxyl, the 
stereochemical outcome of the reaction can be controlled at the anomeric centre to yield 
exclusively the β-anomer, (Scheme 32).  
 
 
Scheme 32: Neighbouring group participation (NGP) controlling the anomeric centre. 
 
This will be of importance in our synthetic strategy both in the construction of the 
monosaccharide building blocks 70 and 77, and then in the crucial glycosylation step to 
form the β-galactoside 78 (Figure 105). 
 
 
 
Figure 105: The three compounds where NGP will be fundamental in the synthesis. 
 
3.1.7 The design of Galectin-3 specific carbohydrates 
To exploit the unique galectin-3 binding pocket, and effectively mimic the binding of 
galectin-3 specific carbohydrates, it is important to consider the options available to 
synthetically rise to the challenge.  
Literature work has concentrated on the binding affinity of various disaccharides. This 
research has not involved fluorescent labelling of the galectin-3 specific probes but has 
involved more of an investigative approach to explore the binding site and how to derivatise 
the disaccharides to optimise binding, solubility, stability and pharmacokinetics. Figure 
106 below, shows three of many reported disaccharides that have been tested against a 
galectin-3 rich cell line. 
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Figure 106: Three disaccharides investigated for galectin-3 inhibition.138 
 
The ultimate intended application of these disaccharide systems has been with the 
intention of developing galectin-3 inhibitors for therapeutic application.  
In the body enzymes are used to catalyse one-step glycosylations of exquisite specificity 
and complexity without the need for a protecting group strategy or even the isolation of 
glycosyl donor and acceptor. The conditions are mild and the yield quantitative.  
It is estimated that for each glycosylation performed by synthetic chemists, an additional 
six associated protection and deprotection steps are required. 
Enzymes that perform glycosylations are known as glycosyltransferases and the glycosyl 
donor leaving groups are either mono- or di-phosphates. The specific enzyme for the 
formation of our disaccharide β-galactoside is β-(1,4) galactosyltransferase. Three perfectly 
shaped binding sites ensure that the enzyme only catalyses the reaction between the 
correct substituents for the formation of a specific stereoselective and regioselective bond 
(Figure 107). The leaving group is also very important as it is often involved in the binding 
and hence the selectivity of the correct enzyme. 
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Figure 107: A simple illustration of enzymes regio- and stereoselectively controlling reactions. 
 
In metabolism it is the reverse reaction, glycosyl hydrolysis, which breaks down 
carbohydrate glycosidic bonds. This process is catalysed by glycosylhydrolases, or 
glycosidases. 
Ideally enzyme catalysed reactions would be employed in the laboratory as much as 
possible to increase the efficiency of synthesis. However, although there are numerous 
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reported examples in the literature of enzymes being employed for elegant organic synthetic 
protocol, there are problems with the isolation and stability of many enzymes. 
It was however within our overall strategy to employ more rigorous synthetic methodology 
in the laboratory to develop an economical and reproducible route to construct galectin-3 
specific fluorescent probes. 
 
3.1.8 The proposed fluorophores 
As explained in the results and discussion of chapter 2 (page 77), it was decided to initially 
move away from sensitised lanthanide chromophoric systems and attempt first to label the 
disaccharides with either commercially available or easily synthesised organic fluorophores 
(Figure 108). The reason for this was to enable the development of an efficient reaction 
pathway and then test the efficacy of the binding prior to adjusting the strategy to 
incorporate novel lanthanide systems as the fluorescent label.  
 
 
Figure 108: a) Fluorescein-the gold standard; b/c) near-IR emitting fluorophores used for peptide αvβ3 integrin 
targeted imaging (chapter 1), and d) an MRI sensitive gadolinium contrast probe. 
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3.2 Synthetic plan  
The overall plan was to report an efficient and improved synthesis of β(1’→4) galactoside 
probes targeted to the galectin-3 protein. Cellular testing would then reveal the efficacy of 
CRD binding and subsequent visualisation through a fluorophore attached at the amine C-
2 position of glucosamine through a 6-aminocaproic acid spacer unit.  
 
 
Scheme 33: Initial retrosynthetic analysis of NIR797 fluorescent labelled β-lactosamine. 
 
The proven galectin-3 binding β(1’-4)-galactoside, N-acetyllactosamine, would be a good 
model disaccharide to synthesise and test the availability and potential of the amine for the 
purpose of fluorophoric tagging. The retrosynthetic analysis (Scheme 33) shows the 
proposed breakdown of the synthesis into the simple and readily available mono-
saccharide starting materials D-galactose and D-glucosamine hydrochloride. 
The forward synthesis of the glycoside donor 70 was deemed to be relatively 
straightforward with well precedented per-acetylation with Ac2O/py followed by 
manipulation at the anomeric position.140,141 This should proceed by first forming an α-
iodide with I2/Et3SiH, followed by displacement with thiourea to form a β-thioglycoside and 
final methylation with MeI/Et3N to give the product. This chemistry is well precedented and 
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so it was envisaged that as the glycosyl acceptor could be more challenging to synthesise 
with a tricky monoacetylation at the primary C-6 hydroxyl, it was wise that this should be 
conquered first. 
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Scheme 34: The anticipated forward synthesis of the glycosyl donor 70, and acceptor 77. 
 
Synthesis of the acceptor 77, should proceed from D-glucosamine hydrochloride, which, 
upon freeing up the amine with an equivalent of base, would be ready for amine protection. 
It is wise to use a protecting group that is durable to mildly basic and strongly acidic 
conditions in this synthesis and the tetrachlorophthalic anhydride (TCP) amine protecting 
group fully meets these criteria.142,143 This step requires Ac2O to perform the role of 
completing the TCP protection by closing the anhydride, however it is reportedly feasible 
with an excess of Ac2O and pyridine to peracetylate the hydroxyls in the same step.143 The 
anomeric position would then be manipulated to selectively install a β-methyl ether under 
the control of the participating TCP neighbouring group as previously discussed. 
Deacetylation with NaOMe then sets the molecule up for monoacetylation at the primary C-
6.134 Precedent for this key step involves taking advantage of the slight increase in 
nucleophilicity of the primary alcohol, and greater steric accessibility over its tertiary 
counterparts OH-3 & OH-4. A protocol involving acetyl chloride and the mild base 2,4,6-
trimethylpyridine (sym collidine) with careful control of the temperature at -42°C should 
afford glycosyl acceptor 77. 
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Scheme 35: The proposed continued forward synthesis: a) Glycosylation; b) TCP cleavage; c) Spacer attachment; 
d/e) Deprotection; f) Fluorophoric tagging. 
 
The β(1’→4) glycosylation step is also a key step in the synthesis as there is the possibility 
of the formation of regioisomers at the C-3 and C-4 free secondary alcohols of the glycosyl 
acceptor 77. This step is precendented and was found, under certain conditions, to be 1’-4 
selective, probably due to OH-3 being more hindered and slightly less nucleophilic due to 
electron withdrawal from the NTCP group.134,144 The conditions which will be attempted in 
our protocol to mediate the glycosylation is a NIS/TfOH combination.  
Following disaccharide formation and characterisation to confirm the regioselectivity, TCP 
cleavage will be accomplished to afford the free amine for derivatisation. Precedent for this 
deprotection has often involved quite harsh conditions such as reduction using NaBH4.104 
The preferred conditions must be mild so as to not hydrolyse the glycosidic linkage. 
Reported testing of various amine and solvent combinations revealed that ethylene diamine 
in a combination of MeCN/THF/EtOH was most effective for similar disaccharides.103,120 
However, the solvents are dependant on substrate solubility and EtOH alone may serve our 
purpose.120 Interestingly most reported TCP deprotection chemistry protocols involve 
trapping the resulting free amine by immediate acetylation with Ac2O in the same pot, this 
would afford us LacNAc. This suggests that either the free amine is unstable or, more 
likely, that purification is hugely simplified with an acetamide as opposed to a reactive free 
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amine. Indeed for galectin-3 binding site competition and blocking studies some LacNAc 
will be required so a portion will be acetylated to give 82. 
The final steps of the sequence involve completely unprecedented chemistry and so the 
coupling reaction with Boc-amino caproic acid using the favoured coupling reagents for our 
peptide chemistry (PyBop/DIPEA) will be attempted to install the spacer unit. Deacteylation 
with NaOMe/MeOH and Boc cleavage with TFA should be straightforward. The final step is 
coupling to the fluorophores which will bear good terminal electrophilic functional groups 
such as isothiocyanates or succinic esters, as detailed above, for simple nucleophilic 
substitution reactions.  
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3.3 Sugars results and discussion 
 
3.3.1 Synthesis of monosaccharide building blocks 
 
 
 
Figure 109: Left) D-galactose derived glycosyl donor 70. Right) D-glucosamine derived glycosyl acceptor 77. 
 
It was envisaged that the construction of the two monosaccharide building blocks (Figure 
109) would proceed relatively straightforwardly as there is literature precedent for many of 
the synthetic steps. As explained in the synthetic plan, methyl glycoside 77 requiring the 
greater number of synthetic steps, including a potentially tricky C-6 mono-acetylation, was 
attempted first.  
 
3.3.1.1 Synthesis of glycosyl acceptor 77 
 
 
 
Scheme 36: The original strategy for the synthesis of glycosyl acceptor 77. 
 
The tetrachlorophthalic (TCP) protecting group was chosen for many reasons. It is tolerant 
to strongly acidic and mildly basic conditions, and offers keen involvement in neighbouring 
group participation (NGP) affording great β-selectivity. This is also reputedly due in part to 
the closest chlorine atom sterically hindering the α-position.143 The electron withdrawing 
character induced by the four chlorine atoms also serves to increase the glycosyl donor 
properties relative to the phthaloyl protecting group.  
Repeated attempts at the first step, tandem TCP protection of the amine with 
tetrachlorophthalic anhydride followed by per-acetylation with acetic anhydride/pyridine in 
the same pot, failed to produce a satisfactory yield of product. The attempted protocols 
followed those of Schmidt143 and Kochetkov,145 using NaOMe and NaHCO3 as the bases 
respectively to first free up the amine from the D-glucosamine hydrochloride salt prior to 
the protective sequence with tetrachlorophthalic anhydride, Ac2O and pyridine. Excess 
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acetic anhydride is applied to not only acetylate the hydoxyls, but also to ring-close the 
intermediate to the phthalimide (Scheme 37). 
 
 
 
Scheme 37: A mechanism for TCP protection illustrating the role of acetic anhydride. 
 
Both methods were attempted. The first involved D-glucosamine hydrochloride being taken 
up in aqueous NaHCO3 and a slight excess of TCP anhydride applied to the mixture. After 
stirring for 30 minutes the solution was acidified and the precipitate dried over P2O5. This 
effectively isolates the crude TCP appended glucosamine as a carboxylic acid (Scheme 38). 
The dried intermediate product is then treated with Ac2O and pyridine to afford the 
product. However this reaction failed and although the nmr clearly revealed the pyridinium 
acetic acid salt there was no sign of product.  
 
 
 
Scheme 38: The first attempted reported method.145  
 
The second method employed an equivalent of NaOMe as base in dry MeOH with TCP 
anhydride, followed by further portions of NaOMe portionwise over 3-4 hours. This 
reputedly forms the N-acetyl intermediate prior to addition of Ac2O/py to formulate the 
peracetylated N-TCP product.143 Not only did the methodology sound dubious due to the 
continuous addition of excess NaOMe, but the reaction was irreproducible in our hands 
and failed to formulate the desired products even when attempted with alternative bases, 
such as NaHCO3 from the first method (NaOMe is moisture sensitive). 
It was decided to create glycosyl acceptor 77 through an alternative, albeit longer route, 
which whilst completing an efficient high yielding synthesis, allowed a good induction into 
the world of sugar chemistry.  
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Interestingly it would appear that other groups have experienced similar problems with the 
tandem TCP protection/acetylation step and opted for an alternative route too.144,146  
The alternative route we decided to follow involved temporary protection of the amine as an 
imine 71, prior to per-acetylation 72. Acid deprotection of the amine and reprotection with 
TCP anhydride then afforded 74 in excellent overall yield (Scheme 39). 
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Scheme 39: The alternative route to formation of peracetylated TCP protected glucosamine 74. 
 
This route was accomplished without difficulty and proved scalable and reliable. The imine 
was formed through condensation of the amine with p-anisaldehyde under basic 
conditions. The reaction was very clean, the product precipitated out of the aqueous 
solution and was filtered and washed to afford crude 71 which was sufficiently pure to be 
taken on directly.  Per-acetylation was performed under the standard Ac2O/py conditions, 
except a sub-stoichiometric quantity of DMAP was also applied to act as a nucleophilic 
catalyst in the reaction. The reaction was simple to follow, with the much less polar 
product being purified on a straightforward silica flash column. Yield was again excellent. 
At this point it is worth noting a disparity in our proton nmr spectral assignments in 
comparison to those in the literature for the imine 71.144 COSY and HSQC 2D experiments 
were thus performed and confirmed our nmr assignments were correct. It was assumed 
when assigning the spectrum that the less well resolved broader looking peaks of lower 
shift than the OMe at ~3.8 ppm were hydroxyls (Figure 110), and indeed this is what the 
literature suggested. However, peracetylated glucosamine derivative 72 showed a 
significant migration of peaks leaving just the H-2 doublet of doublets below the OMe and a 
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D2O shake confirmed the disappearance of the hydroxyls. 2D-nmr spectroscopy put this 
matter of accurate assignment to rest revealing that upon acetylation the shift of the 
internal protons (H-1 to H-6) is increased considerably, proving the literature assignments 
wrong.  
 
 
Figure 110: The 1H nmr spectra for compounds 71 and 72. 
 
Returning to the synthesis, the amine was then rapidly and very cleanly deprotected with 
5M HCl in refluxing acetone to reveal the hydrochloride salt which was again immediately 
taken on crude as the nmr was excellent. Amine protection with TCP anhydride, Ac2O and 
pyridine in toluene proceeded smoothly and flash column chromatography revealed the 
product as a fine white powder. The aromatic quaternary TCP carbons gave a weak 13C-
nmr signal which was initially confusing but this was found to be a consistent feature. The 
mass spectrum revealed the characteristic isotopic signals for a tetrachloro- compound. 
 
Synthesis of compound 75 
 
 
 
Scheme 40: Transformation at the anomeric centre. 
 
The next step involved the transformation of the anomeric centre into a stable methyl 
glycoside, making this position unreactive to further chemistry; the anomeric substitution 
H-2a
H2a
H-2a
MXXM
MXXM71 
72 
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has no involvement in galectin binding. The literature is rich in examples of anomeric 
manipulation with all manner of substituents including the formation of a β-methoxide, 
but not with TCP as the adjacent participating protecting group. However it was envisaged 
that following a protocol that has installed allyl or aryl glycosides in this position using a 
simple Lewis-acid-catalysed transformation with the corresponding alcohol would afford us 
the product. 
The preliminary strategy involved a slight adaptation of the method of the work of 
Ellervik144 who glycosylated with p-methoxyphenol (Scheme 41) using borontrifluoro 
diethyletherate (BF3OEt2), as catalyst. 
 
 
Scheme 41: Ellervik’s glycosylation.144 
 
Unfortunately this chemistry was not reproducible for us with methanol as the nucleophile, 
with no sign of product formation and recovered starting material. It was then decided to 
attempt the protocol followed by Schmidt.143 This sequence was more complex and involved 
the regioselective C-1 deacetylation with hydrazinium acetate in DMF, prior to installing a 
trichloroacetimidate in a purely β-selective fashion through reaction with CCl3CN in the 
presence of DBU. Tin triflate was then added as a Lewis acid to afford the glycosyl donor 
primed for nucleophilic attack by an alcohol. In this instance the chemistry is employed to 
actually construct β(1’→4) disaccharides (Scheme 42), but there are other examples of β-
selective glycosylations under these conditions.  
 
 
 
Scheme 42: Schmidt’s glycosylation.143 
 
Again this reaction failed repeatedly with methanol in place of the reported glycosyl donor. 
However, the crude nmr of the trichloroacetimidate intermediate did show successful 
completion of the first step so the reaction failed at the final hurdle. It was therefore time to 
attempt a final strategy to install the methyl glycoside and a paper by Debenham142 
Chapter 3: Results & Discussion 
 193
revealed a possible alternative route via the bromide, similar to the well known Koenigs-
Knorr strategy (Scheme 43). 
 
 
Scheme 43: Debenham’s glycosylation.142 
 
The bromide was formed readily and isolated but taken on crude after a thorough work up. 
Due to the unavailability of silver zeolite, it was decided to substitute this promoter with a 
stoichiometric amount of silver tetrafluoroborate (AgBF4). On a very small scale, using an 
old batch of AgBF4, this worked perfectly with an excess of MeOH in CH2Cl2 yielding the 
product in good yield (86 %). The synthesis was then continued and global deacetylation 
performed by applying a small quantity of sodium metal (ca. 10 mg) to the dilute substrate 
in dry MeOH, affording fresh NaOMe in situ. Completion of hydrolysis was confirmed by 
TLC and the pH adjusted to ~5 with Dowex 50W-X8 H+ ion exchange resin to bind all 
sodium ions and protonate the hydroxyls prior to  isolation of the product from the filtrate.  
However, upon scale-up of the glycosylation with a fresh batch of AgBF4, an unexpected 
and fortuitous discovery was made. The reaction had previously been followed successfully 
by TLC but to our consternation there was no appearance of product spot and our sugar- 
specific α-naphthol TLC stain just revealed a product on the baseline. Change of eluent to a 
far more polar 10 % MeOH/CH2Cl2 mixture mobilised the product from the baseline and 
flash column chromatography isolated a pure product which analysis revealed, to our 
surprise, the fully deacteylated methyl glycoside 76. We had effectively performed two steps 
in one (Scheme 44). 
 
 
 
Scheme 44: The serendipitous transformation eliminating the NaOMe/MeOH hydrolysis step. 
 
This useful discovery proved to be reproducible and reliable when repeated, and the most 
likely explanation is that a small quantity of HF is formed during the reaction hydrolysing 
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the acetates. This is plausible, and to reason as to why the first small scale attempt 
behaved as we anticipated and stopped at the peracetylated methyl glycoside 75, it is 
suggested that the old AgBF4 had degraded over time to AgO, Ag2O, Ag2CO3 and/or BF3, 
hence no HF had formed. Usefully this also proved how robust the TCP and OMe groups 
are to strong acid conditions. Characterisation of the intermediate bromide revealed a 
characteristic Br and Cl4 isotope pattern in the mass spectrum indicative of the product. 
The product confirmed the loss of bromide and the appearance of the distinctive OMe 
singlet in the 1H nmr at ~3.3 ppm with an integration of three, and of course the complete 
disappearance of signals from the acetates. 
 
Synthesis of compound 77 
 
 
 
Scheme 45: Selective acetylation at the primary hydroxyl. 
 
The final step is the tricky C-6 monoacetylation. Sorme,134 offered an elegant route in 
which the more accessible and more reactive primary alcohol was selectively acetylated 
with a single equivalent of acetyl chloride with sym-collidine (2,4,6-trimethylpyridine) as 
base. The key to this transformation was the use of freshly distilled acetyl chloride under 
stringently dry conditions. It was also found that even a very slight excess of AcCl led to the 
acetylation of either the C-3 or C-4 hydroxyl giving the undesirable bis-acetylated product. 
The reaction proceeded as planned, with TLC clearly showing the formation of the product 
with a slightly higher Rf than the diasappearing starting material. Following flash column 
chromatography, the 1H nmr revealed a singlet at ~2.1 ppm with integration of three 
proving that monoacetylation had occurred and 2D-nmr confirmed it was at C-6. Thus the 
synthesis of the gycosyl acceptor was complete. 
 
3.3.1.2 Synthesis of glycosyl donor 70 
 
 
Scheme 46: The proposed synthetic pathway to thio-glycoside 70.140 
 
Anomeric thio groups can act as temporary protecting groups. They have traditionally been 
installed through treatment of the peracetylated sugar with the corresponding thiol under 
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Lewis-acid conditions.140,146 However these protocols use harsh and sensitive reagents and 
afford modest yields of thio glycoside after lengthy experimentation. Iadonisi140 and Field147 
have employed an alternative, much milder and more rapid strategy to access the desired 
anomeric thioalkyl derivatives. This proceeded via the creation of an α-glycosyl iodide 
intermediate followed by displacement of the iodide with thiourea to generate an 
isothiouronium species which was then readily alkylated with the required alkyl halide. 
An identical protocol was attempted and it proved remarkably efficient. Peracetylated D-
galactose (the literature precedent uses D-glucose) was treated with a slight excess of both 
I2 and triethylsilane. Upon heating to reflux rapid conversion to the iodide was obvious 
through consumption of the starting material and the appearance of a less polar product. 
Basic work-up produced the crude iodide which was shown by nmr to include Si-
containing impurities.  
These impurities, however, are deemed not to interfere with further synthetic steps,140 and 
the iodide, being susceptible to hydrolysis, was dried and the crude product taken on. This 
was then up in dry acetonitrile before a slight excess of thiourea was added. Again, upon 
heating at reflux the iodide disappeared and a polar product appeared on the baseline. 
Without further ado the reaction was cooled and at room temperature an excess of both 
methyl iodide and triethylamine were added sequentially. After stirring for 15 minutes the 
reaction was complete.  
 
Flash column chromatography afforded the pure desired gycosyl donor in excellent yield 
and the synthesis proved to be reliable upon scale-up. As expected in the 1H-nmr the SMe 
protons (~2.1 ppm) were further upfield than the OMe protons (~3.2 ppm) of the glycosyl 
acceptor 77, and appear in the same ‘bunch’ as the OAc CH3 protons so 5 singlets each of 
integration equal to three protons, were present from 2.00-2.25 ppm in CDCl3.  
 
So the two monosaccharide building blocks were accessed in excellent overall yield and 
improvements made in both reliability and yield when compared to the monosaccharide 
units reported in literature routes towards N-acetyllactosamine.123 
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3.3.2 Glycosylation: formation of the β(1’→4) glycosidic linkage to construct 
the disaccharide 78 
 
 
Scheme 47: Synthesis of fully protected lactosamine derivative 78. 
 
The key to this reaction was to perform the glycosylation in a β(1’→4) regioselective 
manner. Nilsson,134,138 tested several catalytic systems to promote the reaction including 
MeSBr/AgOTf and Br2/AgOTf. However the greatest yield and complete regioselectivity was 
achieved with an N-iodosuccinimide / triflic acid (NIS/TfOH) combination in a 1.5 : 0.15 
equivalent  molar ratio respectively. Thus we attempted this system and the reaction 
worked in our favour with the product being isolated as a fine white solid after purification 
by flash column chromatography.  
 
 
Scheme 48: Proposed mechanism for the β(1’→4) selective glycosylation reaction mediated by NIS/TfOH. 
 
To fully assign the complicated but very well resolved and remarkably clean nmr spectra, it 
was necessary to perform COSY-90 and HSQC experiments. These afforded complete 
assignment of the 1H and 13C resonances but still shed no light upon the C-3/C-4 
regioselectivity. To confirm the β(1’→4) product we obtained an HMBC spectrum which 
revealed the long range 3J proton to carbon coupling; C-1’ to H-4 and H-1’ to C-4 (Figure 
111). 
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Figure 111: The 2D nmr confirmation of β(1’→4) regioisomer by HMBC. 
 
Nilsson,134 verified the regio product through acetylating the C-3 hydroxyl and 
subsequently performing a further reaction and purification. The result was a downfield 
shift of 1.1ppm for the doublet of doublets signal of H-3 in the proton nmr. However, as 
shall be explained more in due course, this was unnecessary as firstly the unambiguous 
couplings in the HMBC spectrum (Figure 111), but also as in the formation of standard N-
acetyllactosamine for blocking and competition studies, we over-acetylated and the HMBC 
showed C-3 coupling to an acetyl group and an acetyl coupling to C-3 as well as the 
downfield shift described by Nilsson.  
First though we must touch upon the TCP deprotection step which will afford the free 
amine ready for manipulation of this point which is not involved in binding in the galectin-
3 carbohydrate recognition domain. 
 
3.3.3 TCP deprotection 
 
TCP deprotection is well precedented and a particularly useful study was accomplished by 
Fraser-Reid.143 The N-tetrachlorophthaloyl group is particularly sensitive to strongly basic 
conditions and most deprotections reported are not purified and characterised as the free 
amine, but rather Ac2O/py applied in the same pot to form the acetamide. Fraser-Reid 
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experimented with different deprotection conditions.143 Amines such as hydrazine, ethylene 
diamine and methyl hydrazine and solvent combinations involving THF, MeCN, DMF, 
isopropanol and EtOH at various temperatures were investigated and an optimum TCP 
cleavage system was developed which was employed successfully by ourselves (Scheme 
49). 
 
 
Scheme 49: Strongly basic TCP deprotection. 
 
The reaction was simple to follow by TLC with the free amine predictably dropping close to 
the baseline. Upon repetition of this deprotection it was found that when purifying, for 
solubility reasons and optimum yield from the flash column, the crude mixture should not 
be concentrated under reduced pressure to dryness but rather should be concentrated to 
sensible volume for direct application to the column. This may seem counter intuitive but 
the residual ethylene diamine seems to reduce streaking, and by reducing the acidity of the 
silica renders the product more mobile and it is recovered much more quickly and in good 
yield. 
The free amine was then divided; a portion was acetylated to afford the acetamide which 
after treatment with NaOMe/MeOH afforded the N-acetyllactosamine standard (Scheme 
50), and a portion was coupled to a protected spacer unit for the attachment of the 
fluorophore. 
 
Synthesis of N-acetyllactosamine derivative 82 
 
 
Scheme 50: Synthesis of β-1-methoxy-N-acetyllactosamine 82. 
 
This acetylation step is well documented as the final part of TCP deprotection protocol to 
immediatedly acetylate the amine as previously mentioned. However as we had isolated the 
free amine it was equally simple to proceed with an acetylation under standard conditions, 
and also gave confirmation of our nmr assignments. As the final step would involve 
hydrolsis of all the O-acetyls it was envisaged that an excess of Ac2O would simply 
78 79 
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acetylate the amine and OH-3 (Scheme 51), and then the acetates could all be promptly 
hydrolysed to afford the blocking disaccharide 82. However, it was also important to be 
able to control the synthesis and selectively acetylate the more nucleophilic amine to form 
81, in case tagging at OH-3 were required at a later stage. 
 
 
Scheme 51: The routes to the final product 82. 
 
The mono- and di- acetylations worked very effectively with the per-acetylated product 80 
being isolated in improved yield. A new quite unusual chromatography eluent mixture of 
40% acetone / 60% toluene was employed with very satisfactory results in comparison to 
the MeOH / DCM gradient eluent system used previously.  
Long range nmr studies of the acetylation performed with excess Ac2O 80, proved the 
β(1’→4) regioisomeric product. HMBC analysis showed C-3 coupling to acetate protons, the 
reverse of this, and the acetate carbonyls to H-3 (Figure 112). 
13C=O
environments
H-3
 
Figure 112: Detail of the compound 80 HMBC spectrum offering proof of acetylation in the 3-position. 
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3.3.4 Introduction of a spacer unit 
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Figure 113: Top) The coupling of Boc-aminocaproic acid to the free amine of 79. Bottom) The 1H nmr of the 
product. 
 
The purpose of the installation of a spacer unit was to distance the bulky fluorophore from 
the fundamental binding interactions that occur between the disaccharide, especially D-
galctose, and the galectin-3 CRD. To this end the simple tert-butoxycarbonyl (BOC) 
protection of amino caproic acid was accomplished (details in the ‘linkers’ section page 
129), and a well established coupling protocol applied using the reagents successfully 
employed in peptide experiments. These conditions are mild and high yielding. In hindsight 
the application of a stronger base such as NaOH could have saved us a step but would 
have brought with it the purification and characterisation problems which will be 
discussed forthwith. 
The reaction was performed using a slight excess of Pybop and base, pre-mixed with a 1.5 
equivalent excess of the carboxylic acid in dry acetonitrile prior to addition of the free 
amine.  
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The reaction was simple to follow by TLC with the clear appearance of a much more mobile 
product spot in comparison to the free amine on the baseline. After stirring at 40°C 
overnight and purification by careful flash column chromatography (by-products are of 
similar Rf), the product was afforded in an excellent 95 % yield. It was satisfying to note 
that the hydrophobic chain did not seem to reduce solubility, indeed the nmrs were 
achieved in CDCl3 and, albeit now more complicated due to the methylene units, were fully 
assigned by COSY, HSQC and HMBC experiments. 
 
2.3.5 Deprotection – synthesis of 86 
 
 
 
Scheme 52: The final deprotection steps. 
 
The successful synthesis of disaccharide with Boc protected caproic linker 83 leads us to 
the final steps of the synthesis. At this stage however, the reaction route required some 
thought and investigation due to there being no similar procedures available in the 
literature and unforeseen purification issues.  
Scheme 53 sheds a clearer light upon the situation. The options were either to deacetylate 
(NaOMe/MeOH), perform Boc cleavage (TFA) and then couple to the fluorophore in a simple 
final step, or, firstly cleave the Boc to uncover the free amine for fluorophore coupling and 
then hydrolyse the acetates as a final step.  
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Scheme 53: The plausible routes from 83 to final labelled products 
 
The favoured synthetic route was to create the fully deprotected product 86 prior to 
coupling to the fluorophore through nucleophilic attack of the primary amine as the final 
step. This was considered ideal as the complexity of the compound brought about by the 
incorporation of a bulky fluorophore means there is more potential for breakdown or 
undesirable side reactions in subsequent steps. 
However, as the deacetylation step with NaOMe/MeOH rendered the disaccharide water 
soluble, the work-up and purification protocol became complicated. It was therefore 
decided to first perform Boc cleavage with TFA which is a very simple and quantitative 
reaction as the by-products are volatile and the product is recovered pure without further 
purification and taken on to the coupling step. The free amine intermediate could then be 
deacetylated or coupled with the fluorophore and deacetylated as the final step, contrary to 
our synthetic design.  
The deacetylation products stick to silica, and although many eluents were attempted such 
as CH2Cl2 / MeOH/ NH3(aq), 79.95 : 20 : 0.05, there was no product progression from the 
TLC baseline. HPLC purification was attempted as reversed phase C18 silica TLC with 
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MeCN/H2O as eluent revealed good product mobility. However the product is not UV active 
so normal HPLC protocol became impossible with the available equipment. Pulsed 
Amperometric Detection (PAD),123 and Electronic Light Scattering (ELS),122 detection 
capabilities were available on an analytical scale, but there was no option for scale up. 
After reaction completion which was observed clearly by the plummeting of Rf on the TLC, 
neutralisation was then accomplished with ion exchange resin and the product recovered 
from the filtrate. 
However, having proved both routes possible, it was decided to pursue our policy employed 
throughout the peptide synthetic protocol which was to make the fluorophore labelling the 
final step of the synthetic sequence, thereby eliminating potential problems associated with 
the fluorophores and final deprotection reagents. New purification methodology was 
discovered and again using Dowex-50WX8 H+ resin as a scavenger,151-154 we were able to 
afford clean deacetylated product without further purification. 
This product was then subject to TFA cleavage to afford the pure fully deprotected product 
as the TFA salt in excellent yield after repeated co-concentrations and triturations with 
Et2O to remove all excess TFA and other ether-soluble impurities. 
 
Coupling was then performed on the crude using the pre-decided fluorophores (fluorescein, 
osmium complex & NIR797). As predicted, the fluorophores not only rendered the product 
visible by HPLC but also afforded excellent baseline separation for scale-up to semi-
preparative quantities. The products seemed to stick to the reversed phase HPLC column 
when a methanolic solvent gradient was employed, but a mildly acidic acetonitrile (MeCN + 
0.05 % TFA) gradient afforded the product in good yield. 
Characterisation was no longer available by nmr as firstly the quantities of final product 
were approximately one milligram, and secondly, the added complexity incurred by the 
sophisticated fluorophore renders accurate assignment difficult. High resolution mass 
spectrometry, fluorescence spectroscopy and a clean HPLC trace were therefore the 
analytical techniques used to prove the identity and purity of the final products. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results & Discussion 
 204
3.3.6 Coupling of Fluorescein & NIR797 
• Fluorescein 
This reaction was performed in a tried and tested solvent mixture of pyridine, DMF and 
CH2Cl2. The reaction was rapid and readily followed by analytical HPLC. The product was 
isolated in good yield and taken on to the cellular testing phase as an excellent standard 
with which to draw comparisons in further studies. 
 
 
 
Scheme 54: The final products: 1-methoxy-N-caproic-fluorescein-lactosamine (87), and 1-methoxy-N-caproic-
NIR797-lactosamine (88). See appendix 4 for fluorescence spectra & appendix 5 for HPLC & m/z data. 
 
• NIR797 
This reaction was performed in basic phosphate buffer conditions (pH = 9.2) to free up the 
amine from the trifluoroacetic acid salt and the appearance of the product peak was clear 
in the HPLC at 31 minutes (Figure 115).  
 
Thus the synthetic phase was complete and the compounds ready for biological testing. 
Examples of a MALDI-TOF mass spectrum and HPLC trace of final product are shown in 
figures 114 and 115 overpage. The next step was to test the binding and fluorescence of 
these compounds in cells. The choice of cells was obviously important as the positive cell 
lines must express galectin-3 and the controls either must not, or the levels of gelectin-3 
expression must be known. This work was carried out in the twilight of the research phase 
of this PhD and as such the results must be regarded as preliminary and at the time of 
writing are by no means conclusive.   
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[M+Na]+
MW=1347
 
Figure 114: MALDI-TOF mass spectrum of the final product 88. 
 
 
 
Figure 115: Analytical HPLC of the final product 88. 
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3.4 Cellular studies 
This work was accomplished in collaboration with Dr. Carmel McConville of the institute 
for cancer studies at the University of Birmingham and Queen Elizabeth Hospital 
Birmingham. 
These studies are by no means conclusive and the work is continuing with both the 
fluorescent labelled cyclic peptides targeted towards αvβ3 integrins (chapter 2), and the 
labelled β-galactosides targeted to galectin-3.   
Pure galectin-3 targeted compound 88 from HPLC purification was dissolved in phosphate 
buffer solution (PBS) and used in varying concentrations to stain cell lines either 
expressing or not expressing galectin-3 both inter- and extra-cellularly. The cell lines used 
initially were designed to develop reliable protocol with relation to both the growth and 
staining of the cells, and the microscope settings. The literature precedent for targeting 
galectin-3 predominantly involves the use of the U87-MG gliobastoma cell line,52,54,56,156 
which has a proven high galectin-3 expression. However this cell line is relatively slow 
growing and due to the time constraints and the ready availability of SHEP1 cells grown 
from an actual neuroblastoma biopsy sample, which also express galectin-3, it was decided 
to proceed with staining. 
Cell lines:  
SHEP1 neuroblastoma (positive Galectin-3 expressing cancer cell line); an 'S-type' 
(substrate adherent, Schwannian) cell line. 
SH-SY5Y glioblastoma negative control (non/low galectin-3 expressing cancer cell line); an 
'N-type' (neuronal) cell line.   
Both are derived from the same patient and probably represent alternative pathways of 
differentiation from a neural crest derived precursor. 
 
General synthetic protocol: 
DCFl staining of SHEP1 and SH-SY5Y neuroblastoma cell lines. 
 
1. Innoculate 6.0 x 105 U87-MG, 7.5 x 105 SHEP cells or 106 SY5Y cells into 6 cm cell 
culture grade petri dishes and culture for 24 hours at 37ºC/5%CO2. (Culture 
medium is DMEM/F12 (Invitrogen) supplemented with non-essential amino acids 
(Invitrogen), 2 mM Glutamine and 15 % fetal bovine serum). 
2. Remove medium and wash with 4 mL PBS. 
3. Fix with 3 mL cold methanol for 10 min (pre-chill methanol at -20 ºC for at least one 
hour), (methanol will both fix and permeabilize the cells). 
4. Rinse with 4 mL PBS, 3 x 5 min, OR, 4a. Rinse 3 x 5' with PBS/0.5 % bovine serum 
albumin (BSA) (Sigma aldrich A2153). 
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5. Stain with 10 mM DCFl or cRGDfK in PBS (in the dark, room temp) for 30-40 min, 
OR, 5a. Stain with 10mM DCFl or cRGDfK in PBS/0.5% BSA (in the dark, room 
temp) for 30-40 min. 
6. Wash with PBS with gentle agitation, 3 x 15 min. 
7. Mount in Vectashield (Vector Labs) containing 0.5 ug/ml DAPI (DAPI: 4',6-diamidino-
2-phenylindole is a fluorescent stain that binds strongly to DNA) 
8. View using a Nikon Eclipse E600 fluorescence microscope (ExEm filters 480/535 for 
fluorescein, 400/450 for DAPI), using x20 or x40 objective. 
 
Results & discussion  
Cell line: SHEP-1 
Probe: Disaccharide-Caproic-Fluorescein, DCFl, compound 87. 
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Figure 116: SHEP-1 cells stained with fluorescein labelled disaccharide 87. Dividing cells show higher levels of 
fluorescence and appear a more intense green. The outlines of the nuclei are clearly visible and the less intense 
areas of emission are the cytoplasm. Top right) DNA binding of the DAPI blue stain showing clearly the location of 
the nuclei. The two stains are non competitive and fluoresce at different wavelengths and hence can be used 
simultaneously. 
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The images obtained were immediately aesthetically pleasing and definitely show a level of 
cellular binding. The cellular nuclei are well defined (Figure 116), with enhanced emission 
from the surface creating an outline. Interestingly, there is also emission from within the 
nucleus and the surrounding cytoplasm confirming the presence of galectins inside the 
cell. There is no fluorescence from the cellular surface or indeed from the extracellular 
matrix (ECM), as the cell membranes are not defined. This is somewhat disappointing as 
literature suggests that the majority of galectin-3 should be located extra-cellularly. 
However, although definitely expressing galectin-3, there is no report of the SHEP-1 cell 
line having ever been used for galectin-3 targeting studies and so comparisons cannot be 
drawn.  
 
 
 
Figure 117: SHEP-1 neuroblastoma cells stained with probe 87. Again cells of a brighter green are in the process 
of dividing. A greater degree of cytoplasm staining is shown on this slide. 
 
It was found that the cells must be fixed and that permeabilising the cell membrane, in this 
case with methanol, allows the fluorescent probe to infiltrate the cytoplasm and bind to the 
glycoproteins therein expressing the β-galactoside moiety. This may also explain the reason 
why the cell membrane is not obvious in these images. 
As a control it was again the ready availability and ease of cultivation that dictated our 
choice of cell line. SH-SY5Y was the negative control as it is reported to express very low 
levels of galectin-3 and should offer a good contrast in fluorescence intensity when 
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compared to the positive SHEP-1 cells under identical experimental conditions. It should 
also offer a measure of the binding specificity of the probe towards exclusively galectin-3. 
However, somewhat disconcertingly the SH-SY5Y cell line showed almost equivalent uptake 
and fluorescence intensity (Figure 118).  
 
 
 
Figure 118: SH-SY5Y cells stained with 87. DAPI nucleus staining confirmed the outlines of the cell nuclei. 
  
The reason for this effect is likely to be the fact that both cell lines express galectin-1 in 
equal measure. The binding sites of galectin-1 and galectin-3 are very similar and hence it 
is plausible that the probes could also be binding to galectin-1.157 Therefore any galectin-3 
specific binding is being eclipsed by strong galectin-1 based emission.  
Therefore our attempts to use the non-galectin-3 expressing cell line SH-SY5Y as a control 
could have been thwarted by the fact that the disaccharide vector of our targeted 
fluorescent probes were also binding to galectin-1.  
Thus this study requires a cell line which expresses galectin-3 in the absence of galectin-1 
as the positive; and a cell line expressing neither as the negative control. 
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The U87-MG cell line was acquired and the labelled disaccharides and cyclic peptides 
(U87-MG also expresses the αvβ3 integrin on the cell surface), are to be tested against these 
cells when they mature. This could also afford a great comparative study between cyclic 
peptide and β-galactoside targeting; chapters two and three of this thesis. 
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3.5 Summary & conclusions 
 
The synthesis of the fluorescent labelled, fully deprotected, galectin-3 targeted probes 
involved a challenging 13 step reaction sequence.  
The target was retrosynthetically broken down into two monosaccharides which would be 
coupled together in a regioselective β(1’→4) glycosylation reaction to form the required 
galectin-3 targeted β-galactoside. The challenge was then to develop an effective means of 
extending a spacer from the sugar to a distant fluorophore without interfering with the 
galectin carbohydrate recognition domain. 
The synthesis of the D-glucosamine derived glycosyl acceptor started off on the wrong foot 
with the failure of the tandem acetylation and TCP protection step. This was rectified 
through employing an alternative route utilising a temporary amine protection with p-
anisaldehyde to afford the imine followed by acetylation, hydrolysis and subsequent TCP 
protection. Although a lengthier reactive sequence this proved a very efficient alternative 
route with all yields higher than 93 %.  
Our synthetic design centred around derivatisation of the acceptor C-2 amino position. It is 
clear from the crystal structures of reported N-acetyllactosamine derivatives that it is only 
this amine and the anomeric C-1 position that protrude from the binding site. Therefore 
the anomeric position was sealed off in the next step to prevent any further involvement in 
the synthesis. This involved the formation of a β-methyl glycoside which again proved 
tricky. The silver tetrafluoroborate system which was eventually implemented and 
optimised proved excellent. It proved not only high yielding, but also simultaneously 
hydrolysed the acetals which was anticipated to be a further step; two steps were thus 
achieved in one. Selective acetylation of the C-6 position then went smoothly with careful 
temperature control to afford the glycosyl acceptor in good yield. 
The thio-glycosidic donor was synthesised straightforwardly from D-galactose following 
some elegant reported chemistry. The subsequent regioselective formation of the β(1’→4) 
galactoside was accomplished with great efficacy. The reaction sequence was then subject 
to some scrutiny as it became clear that after TCP cleavage, deacetylation at any stage 
renders the compound difficult to purify. Hence the amino caproic or ethylene glycol spacer 
was coupled to the amine, the terminus deprotected and the fluorophore coupled, prior to a 
final deacetylation to afford the products. 
Initial cellular binding and microscopy studies with the fluorescein labelled β-galactoside 
revealed a promising uptake and emission from a SHEP-1 neuroblastoma cell line. However 
the negative control cell line also showed considerable fluorescence. As both cell lines 
express galectin-1 and literature suggests that our β-galactoside may well bind to both 
galectin-3 and galectin-1 this may well explain the observations. Therefore studies are 
continuing with a U87-MG glioblastoma cell line known to express exclusively galectin-3 
and it is hoped that uptake and binding affinity can be measured accurately in due course. 
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3.6 Sugars experimental 
 
Preparation of thioglycoside 70. 
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Exact Mass: 378.1
Mol. Wt.: 378.39
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D-galactose pentaacetate (1.00 g, 2.56 mmol) was taken up in dry CH2Cl2 (20 mL). Iodine 
(0.91 g, 3.59 mmol) and triethylsilane (0.58 mL, 0.42 g, 3.59 mmol) were added slowly 
(exothermic), and the mixture heated at reflux for five minutes. TLC analysis (hexane / 
EtOAc, 6 : 4) revealed the complete consumption of starting material and the reaction was 
allowed to cool to rt. The crude mixture was then diluted with CH2Cl2 (40 mL) and 
extracted with an aqueous mix of Na2CO3 and Na2S2O3 (3 x 100 mL) and water (2 x 50 mL). 
The crude iodide was then dried over MgSO4 and concentrated under reduced pressure. Rf 
= 0.60 (hexane / EtOAc, 6 : 4). 
Dry crude iodide was then taken up in MeCN (10 mL), treated with thiourea (0.29 g, 3.84 
mmol) and heated at 60 ºC for 30 minutes until TLC analysis (hexane / EtOAc, 6 : 4) 
revealed a new baseline product and the disappearance of the iodide. The reaction was 
allowed to cool to rt and methyl iodide (0.31 mL, 0.71g, 5.12 mmol) and triethylamine (1.43 
mL, 1.04 g, 0.01mol) were added sequentially. The mixture was then stirred at ambient 
temperature for 10 minutes until TLC analysis (hexane / EtOAc, 6 : 4) proved reaction 
completion. The crude product was concentrated under reduced pressure and purified by 
flash column chromatography (hexane / EtOAc, 3 : 7) to afford the product as a fine white 
solid (1.00 g, 98 %). Rf = 0.41; [α]22D = +2.8 (c 1.0 CHCl3), lit.147 +3.0 (c 1.0 CHCl3) m.p =  
110-112 ºC, lit.147 112-113 ºC; νmax (Neat)/ cm-1 1701, 1733 (C=O); δH (300 MHz; CDCl3); 
5.42 (1H, dd, J 3.3, 6.7, H-4’) 5.25 (1H, app t, J 9.9, H-2’), 5.04 (1H, dd, J 3.3, 9.9, H-3’), 
4.38 (1H, d, J 9.9, H-1’), 4.07-4.16 (2H, stack, 2 x H-6’), 3.95 (1H, app t, J 6.7 H-5’), 2.18 
(3H, s, SCH3), 2.14(3H, s, OCOCH3), 2.06(3H, s, OCOCH3), 2.03(3H, s, OCOCH3), 1.97(3H, 
s, OCOCH3); δC (75 MHz; CDCl3); 9.87, 19.13, 19.20, 19.32, 60.05, 65.11, 65.96, 70.42, 
72.97, 81.86, 168.16, 168.55, 168.73, 168.90; m/z (TOF ES+) 401.0882 ([M+Na]+, 100% 
C15H22O9SNa requires 401.0873).  
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Preparation of imine 71.  
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D-Glucosamine hydrochloride (20.0 g, 0.093 mol) was dissolved in 1M aqueous sodium 
hydroxide (96 mL). p-Anisaldehyde (12.65 mL, 0.11 mmol) was then added dropwise to the 
mixture with vigorous stirring, forming a cloudy solution. After 15 minutes of stirring at 
ambient temperature, a thick white precipitate formed. Stirring was continued in an ice 
bath for one hour to ensure complete precipitation. The solid was then collected by 
Büchner filtration and washed with H2O (2 x 100 mL) and a 1:1 mixture of MeOH and Et2O 
(2 x 100 mL). The filter cake was dried further under high vacuum overnight, affording the 
product as a fine white solid. Analysis revealed the product to be sufficiently pure to be 
taken on without further purification (18.00 g, 66 %). [α]22D = +24.3 (c 0.5 D2O); m.p = 158-
160 ˚C (lit.146 = 148-150 ˚C); νmax (Neat)/cm-1 3486, 3322 (br-OH), 2972-2897 (CH), 1638 
(C=N), 1604 (Ar C=C); δH (400 MHz; d6DMSO) 2.79 (1H, t, J 8.5, H-2), 3.10-3.18 (1H, m, H-
4), 3.21-3.38 (1H, m, H-5), 3.41-3.46 (1H, m, H-3), 3.48-3.52 (1H, m, H-6), 3.71-3.79 (1H, 
m, H-6), 3.86 (3H, s, OCH3), 4.57 (1H, t, J 5.7, OH-6), 4.69 (1H, t, J 7.2, H-1), 4.84 (1H, d, 
J 5.6, OH-3), 4.95 (1H, d, J 5.1, OH-4), 6.54 (1H, d, J 6.7, OH-1), 6.99 (2H, d, J 8.7, H 
aromatic), 7.69 (2H, d, J 8.7, H aromatic), 8.11 (1H, s, OCH3); δC (75 MHz; DMSO-d6) 54.91 
(OCH3), 60.92 (C-6). 70.01 (C-4), 74.24 (C-3), 76.49 (C-5), 77.83 (C-2), 95.27 (C-1), 113.54 
(aromatic CH), 128.75 (aromatic Cq), 129.26 (aromatic CH), 160.69 (aromatic COMe), 
160.87(HC=N); m/z (TOF ES+) 320.1112 ([M+Na]+, 100%, C14H19NO6Na requires 320.1110).  
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Per-Acetylation to afford tetra acetate 72. 
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Compound 71 (18.00 g, 0.06 mol) was combined with acetic anhydride (54.27 mL, 0.57 
mol), pyridine (97.9 mL, 1.21 mol) and DMAP (1.8 g) and stirred at 0 ºC. The solid slowly 
went into solution and the reaction mixture was stirred at ambient temperature overnight. 
The solution was then poured onto 300 mL of ice resulting in the formation of a thick white 
crystalline precipitate. These crystals were isolated by Büchner filtration, washed with 
water (2 x 50 mL) and ether (2 x 50 mL) and dried under vacuum to afford the product as a 
fine white solid which analysis revealed to be sufficiently pure to be taken on without 
further purification (19.54 g, 70 %). [α]22D = +19.4; m.p = 180-183 ˚C, (lit.146, 168-172 ˚C); 
νmax (Neat)/cm-1 2977-2868 (C-H), 1749 (C=O), 1737 (C=O), 1637 (C=N), 1605 (Ar C=C); δH 
(300 MHz; CDCl3); 1.84 (3H, s, COCH3) 1.98 (3H, s, OCOCH3), 1.99 (3H, s, OCOCH3), 2.06 
(3H, s, OCOCH3), 3.41 (1H, t, J 8.5, H-2), 3.80 (3H, s, OCH3), 3.91 (1H, ddd J 2.0, 4.6, 9.5, 
H-5), 4.08 (1H, s, J 2.0, 12.4, H-6), 4.34 (1H, dd, J 4.6, 12.4, H-6 ), 5.10 (1H, app t, J 9.5, 
H-4 ), 5.39 (1H, app t, J 9.5, H-3), 5.90 (1H, d, J 8.5, H-1), 6.87 (2H, d, J 8.7, H aromatic), 
7.61 (2H, d, J 8.7, H aromatic), 8.12 (1H, s, CH=N); δC (100 MHz; CDCl3); 23.23 (CH3), 
23.40 (CH3), 23.48 (CH3), 58.12 (OCH3), 64.56 (C-6), 70.79 (C-4), 75.50 (C-2/5), 75.68 (C-
2/5), 75.99 (C-3), 95.90 (C-1), 116.79 (aromatic CH), 131.05 (aromatic Cq), 132.97 
(aromatic CH), 162.2 (aromatic COMe), 166.97 (C-7), 168.7(C=O), 169.5 (C=O), 169.8 (C=O), 
170.6 (C=O); m/z (TOF ES+) 488.1527 ([M+Na]+, 100%, C22H27NO10Na requires 488.1533). 
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Preparation of per-acetylated D-glucosamine hydrochloride salt 73. 
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Exact Mass: 347.12
Mol. Wt.: 347.32  
 
Imine 72 (10.00 g, 0.021 mol) was dissolved in acetone (50 mL) and heated to reflux. To 
this solution was added 5M HCl (5 mL) dropwise and after five minutes a white thick 
precipitate formed. The system was then cooled to room temperature and the precipitate 
collected through Büchner filtration. The filter cake washed thoroughly with acetone (2 x 
20 mL), and ether (2 x 50 mL) and the product dried further under high vacuum overnight 
to afford the product as a fine white solid. Analysis revealed the product to be sufficiently 
pure to be taken on without further purification (7.45 g, 98 %). [α]22D = +33.2 (c 1.0 CHCl3); 
m.p = >250 ˚C (decomposed at 215-218 ˚C), (lit.146, >200 ˚C); νmax (Neat)/cm-1 2830 (br N-H), 
1757 (C=O), 1746 (C=O); δH (300MHz; DMSO-d6); 1.97 (3H, s, OCOCH3), 2.00 (3H, s, 
OCOCH3), 2.03 (3H, s, OCOCH3), 2.17 (3H, s, OCOCH3), 3.57 (1H, dd, J 8.8, 10.2, H-2), 
3.96-4.09 (2H, stack, H-5 & H-6), 4.19 (1H, dd, J 4.3, 12.5, H-6), 4.93 (1H, app t, J 9.5, H-
4), 5.34 (1H, dd, J 9.5, 10.2, H-3), 5.89 (1H, d, J 8.8, H-1), 8.70 (3H, br s, NH3); δC (75 
MHz; DMSO-d6); 20.94 (CH3), 21.07 (CH3), 21.48 (CH3), 21.57 (CH3), 52.77 (C-4), 61.86 (C-
6), 68.41 (C-3), 70.92 (C-5). 72.19 (C-2), 90.66 (C-1), 169.22 (C=O), 169.90 (C=O), 170.33 
(C=O), 170.56 (C=O); m/z (TOF ES+) 370.1110 ([M + Na]+, 100%, C14H21NO9Na requires 
370.1114). 
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TCP protection to afford tetraacetate 74. 
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Tetraacetate 73 (10.00 g, 0.026 mol) was dissolved in pyridine (50 mL). Tetrachlorophthalic 
anhydride (8.86 g, 0.030 mol) was then added and the mixture stirred at ambient 
temperature for 10 hours, cooled to 0 ˚C and Ac2O (2.95 mL, 0.030 mol) added. The 
mixture was then allowed to warm to rt and stirred for a further hour. Concentration under 
reduced pressure was then performed with repeated co-concentrations with toluene. The 
crude product was purified by gradient flash column chromatography (hexane to EtOAc / 
hexane, 1 : 1) to afford the product as a fine white solid (7.20 g, 78 %). [α]23D = +58.3 (c 1.1 
CHCl3), lit.145 +69.7 (c 0.9 CHCl3); m.p = 165-167 ˚C, (lit.145, 169-171˚C); νmax (Neat)/cm-1 
2971 (C-H), 1749 (C=O), 1721 (C=O); δH (300 MHz; CDCl3) 1.88 (3H, s, OCOCH3), 2.00 (3H, 
s, OCOCH3), 2.01 (3H, s, OCOCH3), 2.09 (3H, s, OCOCH3), 3.95 (1H, ddd, J 4.4, 9.0, 10.1, 
H-5), 4.11 (1H, dd, J 9.0, 12.5, H-2), 4.35 (1H, dd, J 4.4, 12.5, H-6), 4.25 (1H, dd, J 9.0, 
10.1, H-6), 5.21 (1H, dd, J 9.0, 10.1, H-4), 5.77 (1H, dd, J 9.0, 10.1, H-3), 6.44 (1H, d, J 
9.0, H-1); δC (75 MHz; CDCl3); 22.25 (CH3), 22.37 (CH3), 22.53 (CH3), 22.63 (CH3), 56.13 (C-
2), 63.22 (C-6), 69.72 (C-3), 72.51 (C-4), 74.44 (C-5), 91.44 (C-1), 128.63 (Cq),131.40 (Cq), 
141.53 (phthalimide C=O) 170.42 (C=O), 171.14 (C=O), 172.29 (C=O), 172.40 (C=O), one Cq 
not visible; m/z (TOF ES+) 635.9610 ([M+Na]+, 100%, C22H19NO1135Cl4Na requires 
635.9614).  
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Preparation of methyl glycoside 75.  
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Tetraacetate 74 (0.20 g, 0.33 mmol) was combined with HBr in acetic acid (0.53 mL, 32 wt. 
%), and Ac2O (0.08 mL, 0.88 mmol) and stirred in darkness at ambient temperature 
overnight. The reaction mixture was then diluted with CHCl3 (10 mL) and poured onto ice 
(15 mL). Subsequent to the ice melting, the layers were separated and the organic portion 
washed with H2O (2 x 15 mL) and NaHCO3(sat.) (2 x 10 mL), dried over MgSO4 and 
concentrated under reduced pressure to afford the intermediate as a syrup. To this crude 
glycosyl bromide was promptly added anhydrous MeOH (0.2 mL, 4.93 mmol) and silver 
tetrafluoroborate (0.06 g, 0.32 mmol) in anhydrous CH2Cl2 (10 mL). The reaction was 
stirred in darkness for 36 hours at reflux and was then allowed to cool before filtration 
through a pad of Celite. Concentration of the filtrate under reduced pressure and 
purification by gradient flash column chromatography (CH2Cl2 to CH2Cl2 / MeOH, 9 : 1), 
afforded the product as a fine white solid (0.18 g, 92 %). Rf = 0.48 (CH2Cl2 / MeOH, 9 : 1);  
[α]22D = +32.2 (c 1.10 CHCl3); m.p = 159-161 ˚C; νmax (Neat)/ cm-1 1748 (C=O), 1721 (C=O); 
δH (300MHz; CDCl3) 1.87 (3H, s, OCOCH3), 2.01 (3H, s, OCOCH3), 2.09 (3H, s, OCOCH3), 
3.43 (3H, s, OCH3), 3.79-3.84 (1H, m, H-2), 4.05-4.35 (3H, stack, H-5, 2 x H-6), 5.17 (1H, 
app t, J 9.7, H-4), 5.24 (1H, d, J 3.0, H-1), 5.68 (1H, app t, J 9.7, H-3); δC (75 MHz; CDCl3) 
20.5 (CH3), 20.6 (CH3), 20.7 (CH3), 21.0 (CH3), 55.3 (C-2), 57.0 (OCH3), 61.9 (C-6), 68.7 (C-
3), 70.9 (C-4), 71.9 (C-5),  98.6 (C-1), 127.0 (Cq), 130.0 (Cq), 140.5 (phthalimide C=O), 169.3 
(C=O), 170.5 (C=O), 170.6 (C=O), one Cq was not visible; m/z (TOF ES+) 609.9645 ([M+Na]+, 
100%, C21H19NO1035Cl337Cl requires 609.9631).  
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Deacetylation to afford triol 76.  
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C15H13Cl4NO7
Exact Mass (4 x 35Cl): 458.94
Mol. Wt.: 461.08  
 
 
Triacetate 75 (0.15 g 0.25 mmol) was dissolved in anhydrous MeOH (10 mL) with stirring 
at ambient temperature under argon. Sodium metal (0.01 g) was then added and the 
reaction stirred for a further 15 minutes. Thin layer chromatography (hexane / EtOAc, 6.5 
: 3.5) indicated reaction completion with a single strong baseline spot and the 
disappearance of the starting material. DOWEX-50WX8-200 ion exchange resin (pre-
washed with 5M HCl then MeOH) was then added to the reaction mixture with stirring 
until the pH = 5. The crude mixture was filtered and concentrated under reduced pressure 
to afford the product as a fine white solid which analysis revealed to be sufficiently pure to 
be taken on without further purification (0.11 g, 99 %). [α]22D = +7.7 (c 1.0 CHCl3), lit.147 
+3.0 (c 1.0 CHCl3); m.p = 159-161 ˚C, no lit. m.p found; νmax (Neat)/ cm-1 3363 (OH), 1750 
(C=O); δH (300 MHz; CDCl3); 5.05 (1H, d, J 8.4, H-1), 4.20 (1H, dd, J 8.4, 11.3, H-6), 3.85-
4.00 (2H, stack, H-6, H-3), 3.75 (1H, dd, J 5.10, 11.3, H-4), 3.38-3.45 (5H, stack, OCH3, H-
2, H-5); δC (75 MHz; CDCl3) 56.0, 57.9, 60.7, 70.3, 70.4, 77.3, 98.3, 127.3, 127.6, 128.2, 
148.7; m/z (TOF ES+) 481.9344 ([M+Na]+, 100%, C15H13NO735Cl4Na requires 481.9359).  
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Mono-acetylation to afford compound 77. 
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C17H15Cl4NO8
Exact Mass (4 x 35Cl): 500.96
Mol. Wt.: 503.11  
 
Triol 76 (0.20 g, 0.43 mmol) was taken up in dry CH2Cl2 (10 mL) and cooled to -42 ºC by 
means of a CO2(s) / MeCN bath whilst stirring under argon. Sym-collidine (2, 4, 6-
trimethylpyridine) (0.29 mL, 2.17 mmol) was then added to the reaction vessel followed by 
dropwise addition of acetyl chloride (0.034 mL, 0.48 mmol) over 10 minutes. The mixture 
was stirred at -42 ºC for 3 hours and monitored by TLC. Further acetyl chloride (8.48 μL, 
0.12 mmol) and sym collidine (0.13 mL, 0.95 mmol) were then added and the mixture 
allowed to warm to -20 ºC over one hour. The reaction was then quenched with MeOH (10 
mL) and diluted with CH2Cl2 (20 mL) prior to washing with 0.5 M HCl (2 x 30 mL) and 
saturated NaHCO3 (2 x 30 mL). The combined organic phases were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by gradient flash 
column chromatography (CH2Cl2 to CH2Cl2 / MeOH, 9 : 1), to afford the product as a fine 
white solid (3.97 g, 88 %). Rf = 0.66 (CH2Cl2 / MeOH, 9 : 1); [α]22D = -16.7 (c 1.0 CHCl3), 
lit.144 -18.4 (c 1.0 CHCl3); m.p = 135-137 ˚C, no lit. m.p found; νmax (Neat)/cm-1 3407 (OH), 
1781 (C=O), 1718 (C=O); δH (300 MHz; CDCl3) 5.01 (1H, d, J 8.5, H-1), 4.35 (1H, dd, J 2.4, 
12.0, H-6), 4.27 (1H, dd, J 5.2, 12.0, H-6), 4.14 (1H, dd, J8.5, 12.0, H-3) 3.88 (1H, dd, J 
8.5, 10.5, H-4), 3.60 (1H, ddd, J 2.4, 5.2, 10.5, H-5), 3.35-3.45 (4H, stack, OCH3 & H-2), 
2.06 (3H, s, OCOCH3); δC (75 MHz; CDCl3) 19.7, 55.8, 57.0, 62.7, 70.2, 70.8, 73.6, 98.4, 
117.0, 127.3, 139.2, 170.5; m/z (TOF ES+) 525.9 (1 x 37Cl, 3 x 35Cl isotope, [M+Na]+, 
100%). 523.9449 ([M+Na]+, 100%, C17H15NO835Cl4Na requires 523.9453). 
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Glycosylation to afford disaccharide: 1-Methoxy-O-(2’,3’,4’,6’-tetra-O-acetyl-
β-D-galactopyranosyl)-(1’->4)-2-tetrachlorophthalimido-6-O-acetyl-3-deoxy-
β-D-glucopyranoside 78.  
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Exact Mass (4 x 35Cl): 831.05
Mol. Wt.: 833.4
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Diol 77 (0.20 g, 0.40 mmol) and thioglycoside 70 (0.17 g, 0.44 mmol) were combined in dry 
CH2Cl2 (15 mL) with pre-activated 3 Ǻ molecular sieves (1.0 g). This mixture was stirred at 
ambient temperature under argon for 30 minutes before cooling to -42 ºC. Catalytic triflic 
acid (5.27 μL, 0.06 mmol) and N-iodosuccinimide (0.13 g, 0.59 mmol) were then added to 
the reaction vessel and after 2 hours at -42 ºC the crude cocktail was allowed to warm to 
room temperature, filtered, diluted with CH2Cl2 (35 mL) and washed with 10 % aqueous 
Na2S2O3 (2 x 25 mL). Subsequent drying with MgSO4 and removal of the solvent under 
reduced pressure revealed the crude product as a pale brown oil. Purification by flash 
column chromatography yielded pure product as a fine white powder (0.24 g, 72 %). Rf = 
0.50 (hexane / EtOAc, 3 : 2); [α]22D = +9.1 (c 1.0 CHCl3), lit.144 +7.6 (c 1.0 CHCl3); mp = 204-
206 ˚C; δH (300 MHz; CDCl3) 5.32 (1H, d, J 3.3, H-4’), 5.18 (1H, dd, J 8.3, 10.3, H-2’), 5.07 
(1H, d, J 8.3, H-1), 4.97 (1H, dd, J 3.3, 10.3, H-3’), 4.54 (1H, d, J 8.3, H-1’), 4.34-4.26 (3H, 
stack, H-3, 2 x H-6’), 4.10-3.98 (4H, stack, H-4, 2 x H-6, H-5’), 3.68 (1H, dd, J 3.3, 9.7, H-
5), 3.54 (1H, app t, J 8.3, H-2), 3.38 (3H, s, OCH3), 2.09 (3H, s, OCOCH3), 2.08 (3H, s, 
OCOCH3), 2.04 (6H, s, 2 x OCOCH3), 1.92 (3H, s, OCOCH3); δC (75MHz; CDCl3); 20.3  
(OCOCH3), 20.4 (OCOCH3), 20.5 (OCOCH3), 20.8 (OCOCH3), 21.0 (OCOCH3), 56.3 (C-4 or C-
5’), 56.8 (OCH3), 61.6 (C-6), 62.6 (C-6’), 66.8 (C-4’), 67.2 (C-2’), 67.8 (C-3), 68.7 (C-3’), 69.5 
(C-4 or C-5’), 70.6 (C-5), 83.2 (C-2), 98.8 (C-1), 101.9 (C-1’), 127.3 (Cq), 169.4 (C=O), 169.7 
(C=O), 169.9 (C=O), 170.4 (C=O), 170.6 (C=O), two Cq signals were not visible; m/z (TOF 
ES+) 854.0407 ([M+Na]+, 100% C31H33NO17Na 35Cl4 requires 854.0400).  
 
See appendix 6 for COSY 90 and HSQC 2D-nmr experiments confirming the assignments. 
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TCP cleavage to afford acetylated lactosamine: 1-Methoxy-O-(2’,3’,4’,6’-tetra-
O-acetyl-β-D-galactopyranosyl)-(1’->4)-2-amino-6-O-acetyl-3-deoxy-β-D-
glucopyranoside, 79. 
 
 
 
 
Disaccharide 78 (0.20 g, 0.24 mmol) was combined with ethylenediamine (0.032 mL, 0.48 
mmol) in the three solvent blend MeCN / THF / EtOH (2 : 1 : 1, 12 mL) and stirred at 60 ºC 
for 12 hours. The reaction was monitored by thin layer chromatography (CH2Cl2 / MeOH, 
9.7 : 0.3). Upon disappearance of the TCP protected starting material 77 (Rf = 0.6), the 
solvents were removed under reduced pressure and the crude concoction purified by flash 
column chromatography (9.7 CH2Cl2 : 0.3 MeOH). To afford the product as a pale yellow 
film (0.125 g, 92 %). Rf = 0.10; [α]22D = +14.2 (c 1.0 CHCl3); H (500 MHz, CDCl3) 5.33 (1H, 
d, J 3.3, H-4’), 5.17 (1H, dd, J 8.0, 10.4, H-2’) 4.93 (1H, dd, J 3.3, 10.4, H-3’) 4.48 (1H, d, J 
8.0, H-1’), 4.25 (1H, dd, J 1.7, 12.8, H-6’), 3.95-4.15 (6H, stack, H-1, H-5, 2 x H-6 & 2 x H-
6’), 3.46-3.56 (5H, stack, OCH3, H-3, H-5’), 3.41 (1H, dd, J 8.3, 9.4, H-4), 2.71 (1H, dd, J 
8.3, 9.4, H-2), 2.4 (2H, br, NH2), 2.10 (3H, s, OCOCH3), 2.03 (3H, s, OCOCH3), 2.02 (3H, s, 
OCOCH3), 2.00 (3H, s, OCOCH3), 1.91 (3H, s, OCOCH3); C (75 MHz, CDCl3) 170.7 (C=O), 
170.4 (C=O), 170.0 (C=O), 169.9 (C=O), 169.5 (C=O), 104.1 (C-1), 102.0 (C-1’), 82.6 (C-4), 
74.3 (C-5’), 71.9 (C-3), 71.4 (C-5), 70.9 (C-3’), 68.8, 66.9 (C-4’), 62.9 (C-6’), 61.8 (C-6), 57.3 
(OCH3), 56.6 (C-2), 20.8 (OCOCH3), 20.6 (OCOCH3), 20.4 (OCOCH3), only three seen; m/z 
(TOF ES+) 588.1927 ([M+Na]+, 100% C23H35NO15Na requires 588.1904).  
 
See appendix 6 for COSY 90, HSQC and HMBC 2D-nmr experiments confirmind the 
assignments.  
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Preparation of per-acetylated N-acetyllactosamine: 1-Methoxy-O-(2’,3’,4’,6’-
tetra-O-acetyl-β-D-galactopyranosyl)-(1’->4)-2-acetamido-3,6-di-O-acetyl-2-
deoxy-β-D-glucopyranoside 80. 
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Exact Mass: 649.22
Mol. Wt.: 649.60  
 
 
Disaccharride 79 (0.05 g, 0.088 mmol) was dissolved in anhydrous pyridine (20 mL) at 
ambient temperature under argon. Acetic anhydride (0.017 mL, 0.18 mmol) was then 
added and the cocktail stirred overnight. Thin layer chromatography revealed the 
appearance of product at Rf = 0.63 (toluene / acetone, 3 : 7). Excess solvent was removed 
under reduced pressure and the crude product purified by flash column chromatography 
using the aforementioned eluent. The product was recovered as a fine white powder (0.049 
g, 92 %). [α]22D = +18.2 (c 1.2 CHCl3); m.p = 134-137 ºC; H (400 MHz, CDCl3) 6.04 (1H, d, J 
9.4, NH), 5.29 (1H, d, J 3.3, H-4’), 4.99-5.03 (2H, stack, H-2’ & H-3), 4.92 (1H, dd, J 10.4, 
3.3, H-3’), 4.41-4.47 (2H, stack, H-6 & H-1’ (d, J 7.7)), 4.33 (1H, d, J 7.7, H-1), 4.04 (4H, 
stack, 2 x H-6’, H-6 & H-2), 3.84 (1H, app t, J 3.3, H-5’), 3.73 (1H, app t, J 8.6, H-4), 3.57 
(1H, m, H-5), 3.38 (3H, s, OCH3), 2.08 (3H, s, OCOCH3), 2.05 (3H, s, OCOCH3), 2.01 (3H, s, 
OCOCH3), 1.99 (6H, s, 2 x OCOCH3), 1.90 (6H, s, 2 x OCOCH3); C (100 MHz, CDCl3) 170.6 
(C=O), 170.4 (C=O), 170.3 (C=O), 170.3 (C=O), 170.1 (C=O), 170.0 (C=O), 169.3 (C=O), 
101.6 (C-1), 101.1 (C-1’), 75.9 (C-4), 72.7 (C-5 or C-3), 72.6 (C-5 or C-3), 70.8 (C-5’ or C-3’), 
70.7 (C-5’ or C-3’), 69.1 (C-2’), 66.6 (C-4’), 62.3 (C-6), 60.8 (C-6’), 56.3 (OCH3), 53.0 (C-2), 
23.1 (OCOCH3), 20.8 (2 x OCOCH3),  20.5 (2 x OCOCH3),  20.4 (2 x OCOCH3); m/z (TOF 
ES+) 672.2116 ([M+Na]+, 100% C27H39NO17Na requires 672.2114).  
 
See appendix 6 for COSY 90, HSQC and HMBC nmr experiments confirming the 
assignments. 
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Preparation of O-(2’,3’,4’,6’-tetra-O-acetyl-β-D-galactopyranosyl)-(1’->4)-2-
acetamido-6-O-acetyl-3-deoxy-β-D-glucopyranoside 81. 
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Exact Mass: 607.21
Mol. Wt.: 607.56
OO
 
 
 
Disaccharride 79 (0.04 g, 0.071 mmol) was dissolved in pyridine (15 mL) and stirred at 
ambient temperature. Acetic anhydride (0.067 mL, 0.071 mmol) was then added and the 
cocktail stirred for 12 hours. Upon reaction completion (according to thin layer 
chromatography) the crude mixture was concentrated under reduced pressure and the 
crude product purified by flash column chromatography (toluene / acetone, 4 : 6) to afford 
the product as a fine white powder (0.032 g, 81 %). Rf = 0.40; [α]22D = +12.6 (c 1.1 CHCl3); 
m.p = 154-156 ºC; νmax (Neat)/ cm-1 1739, 1667 (C=O); H (400 MHz, CDCl3) 5.63 (1H, d, J 
8.0, NH), 5.39 (1H, d, J 3.3, H-4’), 5.22 (2H, dd, J 8.0, 10.4, H-2’), 5.00 (1H, dd, J 3.3, 
10.4, H-3’), 4.67 (1H, d, J 8.0, H-1), 4.57 (1H, d, J 8.0, H-1’), 4.33 (2H, stack, H-6, H-6’), 
4.35-3.98 (5H, stack, H-6, H-6’, H-3, H-5’ & OH), 3.61 (1H, stack, H-5), 3.51-3.42 (5H, 
stack, H-4, H-2), 3.45 (3H, s, OCH3), 2.16 (3H, s, OCOCH3), 2.10 (3H, s, OCOCH3), 2.07 
(3H, s, OCOCH3), 2.06 (3H, s, OCOCH3), 2.01 (3H, s, NHCOCH3), 1.97 (3H, s, OCOCH3); C 
(100 MHz, CDCl3) 170.7 (C=O), 170.5 (C=O), 170.1 (C=O), 170.0 (C=O), 169.6 (C=O), 164.5 
(C=O), 101.8 (C-1’), 101.0 (C-1), 82.7 (C-4), 71.8 (C-5’ & C-3), 71.3 (C-5), 70.8 (C-3’), 68.8 
(C-2’), 66.8 (C-4’), 62.8 (C-6), 61.6 (C-6’), 56.8 (C-2 or OCH3), 56.6 (C-2 or OCH3), 23.7 
(NHCOCH3), 20.9 (OCOCH3), 20.6 (2 x OCOCH3),  20.5 (2 x OCOCH3); m/z (TOF ES+) 630.2 
([M+Na]+, 100 %), HRMS 630.2010 ([M+Na]+, 100% C25H37NO16Na requires 630.2027). 
  
See appendix 6 for COSY 90 and HSQC 2D-nmr experiments confirming the assignments. 
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Deacetylation to afford blocking sugar 1-methoxy-N-acetyl-lactosamine 82. 
 
 
 
 
Per-acetylated disaccharide 80 (or 81) (0.04 g, 0.062 mmol) was dissolved in anhydrous 
MeOH (10 mL) with stirring at ambient temperature under argon. Sodium metal (0.005 g) 
was then added and the reaction stirred for a further 15 minutes. Thin layer 
chromatography (toluene / acetone, 3 : 7) indicated reaction completion with a single 
strong baseline spot and the disappearance of the starting material. DOWEX-50WX8-200 
ion exchange resin (pre-washed with 5M HCl then MeOH) was then added to the reaction 
mixture with stirring until the pH = 5. The crude mixture was filtered and concentrated 
under reduced pressure to afford the product as a fine white solid which analysis revealed 
to be sufficiently pure to be taken on without further purification (0.023 g, 96 %). [α]22D = -
20.2 (c 0.5 H2O); m.p = 220-223 ˚C, (lit.158, 216-218 ˚C); H (300 MHz, D2O) 2.05 (3H, s, 
CH3CO), 3.45 (3H, s, OCH3), 3.48 (1H, m, H-5’), 3.58 (1H, m, H-5), 3.61-3.75 (3H, m, H-4, 
H-3 & H-2’), 3.70 (2H, m, H-6 & H-6’), 3.78 (1H, s, H-3’), 3.83 (2H, dd, J 12.2, 5.9, H-6 & 
H-6’), 3.93 (1H, d, J 1.9, H-4’), 4.37 (1H, d, J 5.9, H-1), 4.61 (1H, s, H-1’); C (75 MHz, D2O) 
21.4 (COCH3), 53.8 (C-2), 55.9 (OCH3), 59.3 (C-6’), 60.1 (C-6), 67.6 (C-2’), 68.0 (C-3’), 69.8 
(C-4’), 72.0 (C-3), 73.9 (C-5’), 75.4 (C-5), 78.9 (C-4), 100.1 (C-1’), 101.3 (C-1); m/z (TOF 
ES+) 420.1482 ([M+Na]+, 100% C15H27NO11Na requires 420.1477).  
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Coupling of Boc-aminocaproic acid to form disaccharide 83. 
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tert-Butoxycarbonyl aminocaproic acid (0.12 g, 0.52 mmol) was dissolved in anhydrous 
MeCN (10 mL) and stirred under argon at ambient temperature. PyBOP (0.26 g, 0.52 mmol) 
and DIPEA (0.18 mL, 1.04 mmol) were added and the reaction stirred for 30 minutes. This 
mixture was then added to TCP cleaved disaccharide 79 (0.15 g, 0.25 mmol) in anhydrous 
MeCN (5 mL). The mixture was then stirred at reflux for 24 hours and TLC clearly showed 
the appearance of product Rf = 0.62 (toluene / acetone, 2 : 3). Concentration under 
reduced pressure with repeated co-concentration with toluene afforded the crude product 
as a brown oil which was purified by flash column chromatography afford the pure product 
as a transparent glassy solid. (0.16 g, 82 %). [α]22D = +10.3 (c 1.1 CHCl3); νmax (Neat)/ cm-1 ; 
H (400 MHz, CDCl3) 5.98 (1H, br s, NH), 5.38 (1H, d, J 3.3, H-4’), 5.21 (1H, dd, J 8.1, 10.4, 
H-2’), 5.01 (1H, dd, J 10.4, 3.3, H-3’), 4.67 (1H, d, J 8.1, H-1), 4.58 (1H, d, J 8.1, H-1’), 
4.33 (1H, dd, J 1.6, 10.0, H-6), 4.16 - 3.98 (5H, stack, 2 x H-6’, H-5’, H-3, H-6), 3.60 (1H, 
dd, J 3.3, 10.0, H-5), 3.50 (4H, stack, H-2 & OCH3), 3.10 (3H, stack, H-4 & alkyl CH2), 2.33 
(1H, app t, J 7.4, alkyl CH2), 2.21 (1H, app t, J 7.4, NH), 2.16 (3H, s, OCOCH3), 2.10 (3H, s, 
OCOCH3), 2.07 (3H, s, OCOCH3), 2.05 (3H, s, OCOCH3), 1.98 (3H, s, OCOCH3), 1.63 (3H, 
stack, alkyl CH2’s), 1.48 (2H, m, alkyl CH2), 1.43 (9H, s, (CH3)3), 1.36 (2H, m, alkyl CH2); C 
(75 MHz, CDCl3) 177.1 (C=O), 173.9 (C=O), 170.7 (C=O), 170.5 (C=O), 170.1 (C=O), 169.9 
(C=O), 169.5 (C=O), 101.8 (C-1’), 101.0 (C-1), 82.7 (Cq(CH3)3)), 71.8 (C-5), 71.3 (C-3 & C-5’), 
70.9 (C-3’), 68.8 (C-2’), 66.8 (C-4’), 62.8 (C-6), 61.5 (C-6’), 56.8 (OCH3), 56.5 (C-2), 40.3 (C-
4), 36.5 (CH2-alkyl), 33.7 (CH2-alkyl), 29.6 (CH2-alkyl), 28.4 (C(CH3)3)), 26.1 (CH2-alkyl), 
25.2 (CH2-alkyl), 20.8 (OCOCH3), 20.6 (OCOCH3), 20.5 (2 x OCOCH3), 20.4 (OCOCH3); m/z 
(TOF ES+) 801.3263 ([M+Na]+, 100% C34H54N2O18Na requires 801.3269).  
 
See appendix 6 for COSY 90, HSQC and HMBC nmr experiments confirming the 
assignments. 
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Preparation of N-Boc-Caproic-lactosamine blocking sugar 84. 
 
 
 
 
Pentaacetate 83 (0.001 g, 0.0013 mmol) was dissolved in anhydrous MeOH (10 mL) with 
stirring at ambient temperature under argon. Sodium metal (0.005 g) was then added and 
the reaction stirred for 15 minutes. DOWEX-50WX8-200 ion exchange resin (pre-washed 
with 5M HCl then MeOH) was then added to the reaction mixture with stirring until the pH 
= 5. The crude mixture was filtered and concentrated under reduced pressure to afford the 
product as a fine white solid which analysis revealed to be sufficiently pure to be taken on 
without further purification (0.0007 g, 96 %).  
m/z (TOF ES+) 591.2 ([M+Na]+, 100 %), HRMS 591.2741 ([M+Na]+, 100% C24H44N2O13Na 
requires 591.2767). 
 
Preparation of free amine 85. 
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Boc protected disaccharide 83 (0.03 g, 0.04 mmol) was dissolved in CH2Cl2 (5 mL) and TFA 
(2 mL) was added dropwise with stirring at ambient temperature. The Boc deprotection was 
followed by thin layer chromatography and the reaction was complete after 2 hours with a 
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single spot on the baseline (toluene / acetone, 4 : 6). Excess solvent and TFA was removed 
through cycles involving repeated dissolution in CH2Cl2 and removal under reduced 
pressure. The crude product was a light brown oil, pure product was recovered as a fine 
white solid by thorough trituration with Et2O (0.026 g, 99 %). νmax (Neat)/ cm-1 3364, 3387 
(NH2), 1724, 1737 (C=O); H (500 MHz, CDCl3) 7.88 (2H, br s, NH2), 6.01 (1H, br s, NH), 
5.39 (1H, app s, H-10), 5.18 (1H, app t, J 9.0, H-8), 5.02 (1H, app d, J 10.2, H-9), 4.62 (1H, 
d, J 7.6, H-1), 4.38 (1H, d, J 6.4, H-7), 4.32 (1H, d, J 10.7, H-6), 4.18 (1H, stack, H-12), 
4.08 (4H, stack, H-3, H-6, H-11 & H-12), 3.74 (1H, stack, H-5), 3.54 (1H, stack, H-2), 3.42 
(3H, s, OCH3), 2.96 (3H, app br s, H-4, CH2NH2), 2.32-2.18 (3H, stack, alkyl CH2), 2.14  
(3H, s, OCOCH3),  2.09 (3H, s, OCOCH3), 2.06 (3H, s, OCOCH3), 2.01 (3H, s, OCOCH3), 
1.97 (3H, s, OCOCH3), 1.71-1.54 (6H, mound, alkyl CH2’s), 1.38 (2H, app br s, alkyl CH2); 
C (100 MHz, CDCl3) 176.8 (C=O), 174.9 (C=O), 170.9 (C=O), 170.2 (C=O), 170.0 (C=O), 
169.8 (C=O), 169.5 (C=O), 101.8 (C-1’), 101.7 (C-1), 72.0 (C-5), 71.3 (C-3 & C-5’), 70.9 (C-
3’), 68.8 (C-2’), 67.0 (C-4’), 62.8 (C-6), 61.3 (C-6’), 56.8 (OCH3), 55.3 (C-2), 51.6 (C-4), 39.7 
(CH2-alkyl), 33.5 (CH2-alkyl), 26.4 (CH2-alkyl), 24.6 (CH2-alkyl), 23.8 (CH2-alkyl), 20.7 (2 x 
OCOCH3), 20.6 (2 x OCOCH3), 20.5 (OCOCH3); m/z (TOF ES+) 679.2 ([M+H]+, 100 %), 701.2 
([M+Na]+, 75 %); HRMS 679.2926 ([M+H]+, 100% C29H47N2O16 requires 679.2916).  
   
 
Deacetylation to afford fully deprotected extended disaccharide 86. 
 
 
 
 
Acetylated disaccharide 85 (0.003 g, 4.42 x 10-6 mol) was dissolved in anhydrous MeOH 
(10 mL) with stirring at ambient temperature under argon. Sodium metal (0.005 g) was 
then added and the reaction stirred for a further 15 minutes. Thin layer chromatography 
(toluene / acetone, 3 : 7) indicated reaction completion with a single strong baseline spot 
and the disappearance of the starting material. DOWEX-50WX8-200 ion exchange resin 
(pre-washed with 5M HCl then MeOH) was then applied to the reaction mixture until the 
pH = 5. The crude mixture was filtered and concentrated under reduced pressure to afford 
the product as a fine white solid which analysis revealed to be sufficiently pure to be taken 
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on without further purification (0.002 g, 96 %). m/z (TOF ES+) 469.1 ([M+H]+, 100%), 491.1 
([M+Na]+, 50 %); HRMS 491.2217 C19H36N2O11Na requires 491.2228).  
 
Coupling of FITC and deacetylation to afford labelled disaccharide 87. 
 
 
 
Acetylated disaccharide 85 (0.005 g, 7.37 x 10-6 mol) was dissolved in a combination of 
anhydrous DMF, CH2Cl2, and py (10 mL, 5 : 7 : 2) and FITC (0.0043 g, 1.11 x 10-5 mol) 
added. The reaction mixture was then stirred at ambient temperature under argon for 48 
hours. The crude mixture was filtered and concentrated under reduced pressure prior to 
semi-preparative HPLC purification (method B, tr = 29.1 minutes) and lyophilised to afford 
the product as a fine orange solid (0.007 g, 87 %). m/z MALDI-TOF 1068.0 ([M+H]+, 100 %), 
1090.1 ([M+Na]+, 10 %) 
Fluorescein labelled acetylated disaccharide (0.006 g, 5.62 x 10-6 mol) was dissolved in 
anhydrous MeOH (10 mL) with stirring at ambient temperature under argon. Sodium metal 
(0.002 g) was then added and the reaction stirred for 15 minutes. DOWEX-50WX8-200 ion 
exchange resin (pre-washed with 5M HCl then MeOH) was then applied to the reaction 
mixture until the pH = 5. Filtration and concentration under high vacuum afforded the 
pure product as a fine orange powder (0.0046 g, 96 %). Analytical HPLC tr = 23.2 minutes; 
m/z MALDI-TOF 858.1 ([M+H]+, 100 %), 880.1 ([M+Na]+, 30 %) 
 
 
See appendix 4 for Fluorescence spectra. 
See appendix 5 for HPLC and m/z data. 
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 Preparation of NIR797 labelled disaccharide 88. 
 
 
 
Fully acetylated N-caproic disaccharide 85 (0.003 g, 4.42 x 10-6 mol) was dissolved in a 
mixture of MeCN (5 mL) and acetone (0.5 mL) and stirred at ambient temperature. NIR797 
isothiocyanate (0.006 g, 6.40 x 10-6 mol) in pH = 9.2 phosphate buffer (4.5 mL) was then 
added and the mixture stirred at ambient temperature for 72 hours. Analytical HPLC 
(method A, tr = 22.4 minutes) revealed the product which was then purified by semi-
preparative HPLC (method A, tr = 28.7 minutes) and lyophilised to afford the product as a 
deep green powder (0.006 g,  89 %). m/z MALDI-TOF 1580.4 ([M+Na]+, 100 %). 
NIR797 labelled acetylated disaccharide (0.005 g, 3.16 x 10-6 mol) was dissolved in 
anhydrous MeOH (10 mL) with stirring at ambient temperature under argon. Sodium metal 
(0.002 g) was then added and the reaction stirred for 15 minutes. DOWEX-50WX8-200 ion 
exchange resin (pre-washed with 5M HCl then MeOH) was then applied to the reaction 
mixture until the pH = 5. The crude product was concentrated under reduced pressure and 
purified by semi-preparative HPLC (method A, tr = 23.7 minutes) to afford the product as a 
deep green solid (0.003 g, 68 %). m/z MALDI-TOF 1370.5 ([M+Na]+, 100 %). 
 
See appendix 4 for Fluorescence spectra. 
See appendix 5 for HPLC and m/z data. 
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Preparation of osmium complex labelled disaccharide 89. 
 
 
 
Fully acetylated N-caproic disaccharide 85 (0.002 g, 2.95 x 10-6 mol) was dissolved in 
anhydrous DMF (8mL) and Osmium succinic ester 53 (0.0036 g, 4.42 x 10-6 mol) added to 
the mixture which was then stirred in the dark at ambient temperature under argon for 10 
minutes. Anhydrous pyridine (1 mL) was then added and the cocktail stirred for a further 
48 hours. Analytical HPLC revealed the product (method A, tr = 17.1 minutes). The crude 
mixture was concentrated under reduced pressure prior to purification by semi-preparative 
HPLC (method B, tr = 17.07 minutes), and lyophilisation to afford the product as a brown 
solid (0.003 g, 79 %). m/z MALDI-TOF 1378.5 ([M+H]+, 100 %), 1693.5 [M+ 2PF6 + Na]+.  
 
See appendix 4 for Fluorescence spectra. 
See appendix 5 for HPLC and m/z data. 
 
Preparation of hexa-PEG extended disaccharide derivative 90. 
 
 
 
Butoxycarbonyl hexaPEG carboxylic acid 44 (0.035 g, 7.96 x 10-5 mol) was dissolved in 
anhydrous CH2Cl2 (5 mL) and stirred under argon at ambient temperature. PyBOP (0.055 g, 
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1.061 x 10-4 mol) and DIPEA (0.046 mL, 2.65 x 10-4 mol) were added and the cocktail 
stirred for 30 minutes. This mixture was then added to disaccharide 79 (0.03 g, 5.31 x 10-5 
mol) which had been pre-dissolved in anhydrous CH2Cl2 (5 mL). The reaction was then 
stirred at ambient temperature for 48 hours with TLC monitoring Rf = 0.33 (CH2Cl2 / 
MeOH, 9.7 : 0.3). The crude product was then concentrated under reduced pressure and 
purified by very slow gradient flash column chromatography (CH2Cl2 to CH2Cl2 / MeOH, 9.7 
: 0.3) for afford the product as a pale brown oil (0.03 g, 58 %). m/z MALDI-TOF 1009.3 
[M+Na]+, 909 [M – Boc + Na]+. 
Nmr spectra were not sufficiently well resolved for accurate assignment. 
 
 
Boc cleavage to afford free amine 91. 
 
 
 
PEG appended disaccharide 90 (0.02 g, 2.03 x 10-5 mol) was dissolved in CH2Cl2 (5 mL) 
and TFA (5 mL) was added dropwise with stirring at ambient temperature. The Boc 
deprotection was followed by thin layer chromatography and the reaction was complete 
after 2 hours with a single spot on the baseline (CH2Cl2 / MeOH, 9.7 : 0.3). Excess solvent 
and TFA was removed under reduced pressure with repeated co-concentrations with 
CH2Cl2. Trituration with Et2O revealed the product was a light brown oil, and the product 
was taken on without further purification (0.017 g, 97 %). m/z (TOF ES+) 887.1 ([M+H]+, 
100 %), HRMS 887.3872 ([M+H]+, 100% C37H63N2O22 requires 887.3868). 
Nmr spectra were not sufficiently well resolved for accurate assignment. 
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Table 1.  Crystal data and structure refinement for m150m 
. 
Identification code  m150m 
Empirical formula  C54 H74 N6 Na O12 
Formula weight  1022.18 
Temperature  296(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.8283(17) Å = 90°. 
 b = 21.445(3) Å = 93.842(6)°. 
 c = 21.426(3) Å  = 90°. 
Volume 5881.3(13) Å3 
Z 4 
Density (calculated) 1.154 Mg/m3 
Absorption coefficient 0.730 mm-1 
F(000) 2188 
Crystal size 0.30 x 0.20 x 0.20 mm3 
Theta range for data collection 3.90 to 56.45°. 
Index ranges -12<=h<=13, -22<=k<=22, -23<=l<=22 
Reflections collected 36735 
Independent reflections 7471 [R(int) = 0.0790] 
Completeness to theta = 56.45° 96.2 %  
Max. and min. transmission 0.8678 and 0.8108 
Refinement method Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.148 
Final R indices [I>2sigma(I)] R1 = 0.1185, wR2 = 0.3078 
R indices (all data) R1 = 0.1967, wR2 = 0.3668 
Extinction coefficient 0.0011(2) 
Largest diff. peak and hole 0.732 and -0.326 e.Å-3 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for m150mm.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 8631(7) 2770(4) 8274(3) 106(2) 
C(2) 9676(7) 2404(4) 8381(3) 110(3) 
C(3) 10965(7) 3217(4) 8399(4) 118(3) 
C(4) 11590(8) 3632(5) 7992(4) 137(3) 
C(5) 10278(8) 4395(4) 7630(4) 121(3) 
C(6) 9418(7) 4553(3) 7136(4) 115(3) 
C(7) 7957(6) 3943(4) 7467(4) 106(2) 
C(8) 7505(6) 3290(4) 7486(3) 101(2) 
C(9) 11289(7) 2199(4) 7959(4) 127(3) 
C(10) 10986(8) 1805(4) 7399(5) 130(3) 
C(11) 11490(12) 926(7) 6802(7) 281(11) 
C(12) 12120(30) 1164(19) 6279(9) 600(30) 
C(13) 11637(8) 4057(5) 6943(5) 148(3) 
C(14) 11923(10) 3515(6) 6566(6) 178(6) 
C(15) 12702(14) 3190(17) 5590(15) 560(30) 
C(16) 11722(18) 2888(12) 5310(14) 500(20) 
C(17) 8204(7) 4088(4) 6372(4) 112(3) 
C(18) 8984(10) 3977(4) 5879(4) 112(3) 
C(19) 9311(12) 4149(6) 4817(5) 204(6) 
C(20) 8860(15) 4511(6) 4290(5) 262(8) 
C(21) 7839(5) 2200(3) 7387(3) 87(2) 
C(22) 7827(5) 2148(3) 6683(3) 77(2) 
C(23) 7080(3) 1673(1) 5713(1) 77(2) 
C(24) 7897(3) 1337(1) 5377(1) 80(2) 
C(25) 7575(3) 942(1) 4886(1) 104(2) 
C(26) 8311(3) 617(1) 4568(1) 133(3) 
C(27) 9369(3) 686(1) 4739(1) 126(3) 
C(28) 9691(3) 1081(1) 5229(1) 131(3) 
C(29) 8956(3) 1406(1) 5548(1) 104(2) 
C(30) 6791(6) 2322(3) 5447(4) 89(2) 
C(31) 7284(7) 2583(4) 4966(4) 111(3) 
C(32) 7018(12) 3168(5) 4722(5) 147(4) 
C(33) 6233(14) 3487(6) 4963(7) 169(6) 
C(34) 5708(10) 3240(6) 5433(8) 171(5) 
C(35) 5975(7) 2641(4) 5680(5) 137(3) 
C(36) 6813(2) 1175(1) 6758(1) 80(2) 
C(37) 6192(2) 227(1) 6111(1) 88(2) 
C(38) 6991(2) 530(1) 6460(1) 76(2) 
C(39) 7985(2) 270(1) 6520(1) 89(2) 
C(40) 8180(2) -294(1) 6230(1) 96(2) 
C(41) 7381(2) -598(1) 5881(1) 83(2) 
C(42) 6387(2) -337(1) 5821(1) 79(2) 
C(43) 5588(2) -641(1) 5471(1) 113(2) 
C(44) 5783(2) -1205(1) 5181(1) 137(3) 
C(45) 6777(2) -1465(1) 5241(1) 133(3) 
C(46) 7576(2) -1162(1) 5591(1) 116(3) 
C(47) 5667(7) 1322(3) 6856(4) 92(2) 
C(48) 4386(3) 1460(3) 7658(3) 166(5) 
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C(49) 4400(3) 2149(3) 7866(3) 139(4) 
C(50) 4473(3) 2303(3) 8498(3) 187(5) 
C(51) 4518(3) 2926(3) 8679(3) 215(8) 
C(52) 4491(3) 3393(3) 8229(3) 210(8) 
C(53) 4418(3) 3239(3) 7598(3) 175(4) 
C(54) 4373(3) 2617(3) 7416(3) 161(4) 
N(1) 8275(4) 2795(2) 7608(2) 79(1) 
N(2) 10503(5) 2673(3) 8060(3) 98(2) 
N(3) 10964(6) 3875(3) 7449(3) 111(2) 
N(4) 8717(5) 4012(2) 6993(3) 93(2) 
N(5) 7265(4) 1683(2) 6396(2) 70(1) 
N(6) 5438(5) 1277(3) 7466(3) 111(2) 
O(1) 11658(6) 1333(3) 7377(4) 187(3) 
O(2) 10266(5) 1880(3) 7032(3) 145(2) 
O(3) 12503(9) 3646(6) 6108(6) 270(5) 
O(4) 11637(7) 2984(5) 6649(4) 178(3) 
O(5) 8660(6) 4263(3) 5344(3) 150(2) 
O(6) 9758(5) 3663(3) 5950(3) 124(2) 
O(7) 8303(3) 2532(2) 6379(2) 82(1) 
O(8) 5040(4) 1468(3) 6439(3) 121(2) 
Na(1) 9767(2) 3011(1) 6942(1) 85(1) 
O(9) 7407(18) 904(8) 8473(8) 128(5) 
O(10) 6705(15) 1060(7) 8547(7) 195(6) 
O(11) 7941(16) 739(7) 8223(8) 176(5) 
O(12) 8680(20) 776(11) 8031(11) 208(9) 
O(13) 8812(17) 979(12) 9298(10) 230(8) 
O(14) 8578(13) 342(9) 9272(8) 194(6) 
O(15) 7574(14) 675(8) 9610(8) 209(6) 
O(16) 8364(16) 1447(10) 9401(9) 223(7) 
 
Table 3.   Bond lengths [Å] and angles [°] for m150mm. 
_____________________________________________________ 
C(1)-N(1)  1.470(8) 
C(1)-C(2)  1.557(11) 
C(2)-N(2)  1.426(9) 
C(3)-N(2)  1.478(9) 
C(3)-C(4)  1.514(11) 
C(4)-N(3)  1.465(10) 
C(5)-N(3)  1.487(10) 
C(5)-C(6)  1.517(11) 
C(6)-N(4)  1.487(9) 
C(7)-N(4)  1.461(9) 
C(7)-C(8)  1.517(9) 
C(8)-N(1)  1.462(8) 
C(9)-N(2)  1.457(10) 
C(9)-C(10)  1.498(12) 
C(10)-O(2)  1.184(10) 
C(10)-O(1)  1.331(9) 
C(11)-O(1)  1.514(8) 
C(11)-C(12)  1.515(10) 
C(13)-C(14)  1.476(14) 
C(13)-N(3)  1.482(11) 
C(14)-O(4)  1.215(5) 
C(14)-O(3)  1.301(14) 
C(14)-Na(1)  3.126(13) 
C(15)-C(16)  1.502(10) 
C(15)-O(3)  1.513(9) 
C(17)-N(4)  1.455(8) 
C(17)-C(18)  1.520(12) 
C(18)-O(6)  1.201(10) 
C(18)-O(5)  1.342(10) 
C(19)-C(20)  1.457(16) 
C(19)-O(5)  1.468(12) 
C(21)-N(1)  1.459(7) 
C(21)-C(22)  1.512(9) 
C(22)-O(7)  1.236(7) 
C(22)-N(5)  1.353(7) 
C(22)-Na(1)  3.121(8) 
C(23)-N(5)  1.468(5) 
C(23)-C(24)  1.4965 
C(23)-C(30)  1.539(8) 
C(24)-C(29)  1.3900 
C(24)-C(25)  1.3901 
C(25)-C(26)  1.3900 
C(26)-C(27)  1.3900 
C(27)-C(28)  1.3900 
C(28)-C(29)  1.3900 
C(30)-C(31)  1.367(10) 
C(30)-C(35)  1.371(11) 
C(31)-C(32)  1.392(12) 
C(32)-C(33)  1.349(17) 
C(33)-C(34)  1.355(17) 
C(34)-C(35)  1.423(14) 
C(36)-N(5)  1.479(5) 
C(36)-C(47)  1.531(9) 
C(36)-C(38)  1.5464 
C(37)-C(38)  1.3900 
C(37)-C(42)  1.3900 
C(38)-C(39)  1.3900 
C(39)-C(40)  1.3900 
C(40)-C(41)  1.3900 
C(41)-C(46)  1.3900 
C(41)-C(42)  1.3900 
C(42)-C(43)  1.3900 
C(43)-C(44)  1.3900 
C(44)-C(45)  1.3900 
C(45)-C(46)  1.3900 
C(47)-O(8)  1.203(8) 
C(47)-N(6)  1.364(9) 
C(48)-N(6)  1.489(7) 
C(48)-C(49)  1.5424 
C(49)-C(54)  1.3900 
C(49)-C(50)  1.3901 
C(50)-C(51)  1.3900 
C(51)-C(52)  1.3900 
C(52)-C(53)  1.3900 
C(53)-C(54)  1.3900 
N(1)-Na(1)  2.505(5) 
N(2)-Na(1)  2.617(6) 
N(3)-Na(1)  2.598(6) 
N(4)-Na(1)  2.540(6) 
O(2)-Na(1)  2.514(7) 
O(4)-Na(1)  2.521(9) 
O(6)-Na(1)  2.544(7) 
O(7)-Na(1)  2.394(5) 
O(9)-O(11)  0.965(19) 
O(9)-O(10)  0.98(2) 
O(11)-O(12)  1.06(2) 
O(13)-O(16)  1.19(2) 
O(13)-O(14)  1.40(2) 
O(14)-O(15)  1.68(2) 
 
N(1)-C(1)-C(2) 111.6(6) 
N(2)-C(2)-C(1) 112.7(6) 
N(2)-C(3)-C(4) 113.0(7) 
N(3)-C(4)-C(3) 112.5(7) 
N(3)-C(5)-C(6) 113.6(6) 
N(4)-C(6)-C(5) 111.7(6) 
N(4)-C(7)-C(8) 112.7(6) 
N(1)-C(8)-C(7) 114.8(6) 
N(2)-C(9)-C(10) 111.6(7) 
O(2)-C(10)-O(1) 123.9(9) 
O(2)-C(10)-C(9) 127.2(8) 
O(1)-C(10)-C(9) 108.9(9) 
O(1)-C(11)-C(12) 110.7(9) 
C(14)-C(13)-N(3) 111.9(8) 
O(4)-C(14)-O(3) 120.4(14) 
O(4)-C(14)-C(13) 124.7(12) 
O(3)-C(14)-C(13) 114.9(11) 
O(4)-C(14)-Na(1) 49.9(7) 
O(3)-C(14)-Na(1) 146.1(10) 
C(13)-C(14)-Na(1) 82.7(6) 
C(16)-C(15)-O(3) 113.2(9) 
N(4)-C(17)-C(18) 109.9(7) 
O(6)-C(18)-O(5) 124.6(10) 
O(6)-C(18)-C(17) 125.3(8) 
O(5)-C(18)-C(17) 110.0(10) 
C(20)-C(19)-O(5) 106.9(12) 
N(1)-C(21)-C(22) 111.6(5) 
O(7)-C(22)-N(5) 121.3(6) 
O(7)-C(22)-C(21) 120.2(6) 
N(5)-C(22)-C(21) 118.5(6) 
O(7)-C(22)-Na(1) 44.1(3) 
N(5)-C(22)-Na(1) 155.8(4) 
C(21)-C(22)-Na(1) 79.8(4) 
N(5)-C(23)-C(24) 114.5(2) 
N(5)-C(23)-C(30) 112.1(4) 
C(24)-C(23)-C(30) 114.7(4) 
C(29)-C(24)-C(25) 120.0 
C(29)-C(24)-C(23) 121.6 
C(25)-C(24)-C(23) 118.4 
C(26)-C(25)-C(24) 120.0 
C(25)-C(26)-C(27) 120.0 
C(28)-C(27)-C(26) 120.0 
C(27)-C(28)-C(29) 120.0 
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C(24)-C(29)-C(28) 120.0 
C(31)-C(30)-C(35) 118.3(8) 
C(31)-C(30)-C(23) 122.5(7) 
C(35)-C(30)-C(23) 119.2(8) 
C(30)-C(31)-C(32) 122.6(10) 
C(33)-C(32)-C(31) 118.9(12) 
C(32)-C(33)-C(34) 120.6(13) 
C(33)-C(34)-C(35) 120.6(13) 
C(30)-C(35)-C(34) 119.1(11) 
N(5)-C(36)-C(47) 109.5(4) 
N(5)-C(36)-C(38) 111.6(2) 
C(47)-C(36)-C(38) 114.2(3) 
C(38)-C(37)-C(42) 120.0 
C(37)-C(38)-C(39) 120.0 
C(37)-C(38)-C(36) 121.1 
C(39)-C(38)-C(36) 118.8 
C(40)-C(39)-C(38) 120.0 
C(41)-C(40)-C(39) 120.0 
C(40)-C(41)-C(46) 120.0 
C(40)-C(41)-C(42) 120.0 
C(46)-C(41)-C(42) 120.0 
C(43)-C(42)-C(41) 120.0 
C(43)-C(42)-C(37) 120.0 
C(41)-C(42)-C(37) 120.0 
C(42)-C(43)-C(44) 120.0 
C(45)-C(44)-C(43) 120.0 
C(44)-C(45)-C(46) 120.0 
C(41)-C(46)-C(45) 120.0 
O(8)-C(47)-N(6) 123.7(7) 
O(8)-C(47)-C(36) 123.5(6) 
N(6)-C(47)-C(36) 112.8(7) 
N(6)-C(48)-C(49) 109.8(3) 
C(54)-C(49)-C(50) 120.0 
C(54)-C(49)-C(48) 119.4 
C(50)-C(49)-C(48) 120.6 
C(51)-C(50)-C(49) 120.0 
C(50)-C(51)-C(52) 120.0 
C(53)-C(52)-C(51) 120.0 
C(52)-C(53)-C(54) 120.0 
C(49)-C(54)-C(53) 120.0 
C(21)-N(1)-C(8) 109.7(5) 
C(21)-N(1)-C(1) 111.8(5) 
C(8)-N(1)-C(1) 111.3(6) 
C(21)-N(1)-Na(1) 105.5(4) 
C(8)-N(1)-Na(1) 107.2(4) 
C(1)-N(1)-Na(1) 111.1(4) 
C(2)-N(2)-C(9) 109.4(7) 
C(2)-N(2)-C(3) 111.7(6) 
C(9)-N(2)-C(3) 111.4(6) 
C(2)-N(2)-Na(1) 108.6(4) 
C(9)-N(2)-Na(1) 105.6(4) 
C(3)-N(2)-Na(1) 109.9(5) 
C(4)-N(3)-C(13) 111.0(8) 
C(4)-N(3)-C(5) 111.2(7) 
C(13)-N(3)-C(5) 112.2(8) 
C(4)-N(3)-Na(1) 110.8(5) 
C(13)-N(3)-Na(1) 103.8(5) 
C(5)-N(3)-Na(1) 107.5(5) 
C(17)-N(4)-C(7) 111.4(6) 
C(17)-N(4)-C(6) 109.3(6) 
C(7)-N(4)-C(6) 111.1(6) 
C(17)-N(4)-Na(1) 105.3(4) 
C(7)-N(4)-Na(1) 108.9(4) 
C(6)-N(4)-Na(1) 110.7(4) 
C(22)-N(5)-C(23) 120.6(5) 
C(22)-N(5)-C(36) 121.4(5) 
C(23)-N(5)-C(36) 118.1(4) 
C(47)-N(6)-C(48) 120.2(7) 
C(10)-O(1)-C(11) 114.2(8) 
C(10)-O(2)-Na(1) 111.4(6) 
C(14)-O(3)-C(15) 123.2(17) 
C(14)-O(4)-Na(1) 108.4(9) 
C(18)-O(5)-C(19) 115.0(9) 
C(18)-O(6)-Na(1) 111.7(6) 
C(22)-O(7)-Na(1) 114.8(4) 
O(7)-Na(1)-N(1) 66.72(16) 
O(7)-Na(1)-O(2) 79.11(19) 
N(1)-Na(1)-O(2) 88.8(2) 
O(7)-Na(1)-O(4) 126.2(3) 
N(1)-Na(1)-O(4) 156.0(3) 
O(2)-Na(1)-O(4) 75.8(3) 
O(7)-Na(1)-N(4) 89.13(18) 
N(1)-Na(1)-N(4) 72.8(2) 
O(2)-Na(1)-N(4) 161.0(3) 
O(4)-Na(1)-N(4) 123.1(3) 
O(7)-Na(1)-O(6) 81.69(19) 
N(1)-Na(1)-O(6) 128.1(2) 
O(2)-Na(1)-O(6) 125.5(2) 
O(4)-Na(1)-O(6) 75.8(3) 
N(4)-Na(1)-O(6) 66.4(2) 
O(7)-Na(1)-N(3) 159.8(2) 
N(1)-Na(1)-N(3) 110.3(2) 
O(2)-Na(1)-N(3) 121.1(3) 
O(4)-Na(1)-N(3) 64.9(3) 
N(4)-Na(1)-N(3) 71.3(2) 
O(6)-Na(1)-N(3) 85.8(2) 
O(7)-Na(1)-N(2) 124.4(2) 
N(1)-Na(1)-N(2) 70.8(2) 
O(2)-Na(1)-N(2) 65.7(2) 
O(4)-Na(1)-N(2) 86.0(3) 
N(4)-Na(1)-N(2) 110.8(2) 
O(6)-Na(1)-N(2) 153.9(2) 
N(3)-Na(1)-N(2) 69.4(2) 
O(7)-Na(1)-C(22) 21.07(14) 
N(1)-Na(1)-C(22) 50.33(17) 
O(2)-Na(1)-C(22) 68.7(2) 
O(4)-Na(1)-C(22) 134.6(3) 
N(4)-Na(1)-C(22) 95.20(19) 
O(6)-Na(1)-C(22) 102.6(2) 
N(3)-Na(1)-C(22) 160.0(2) 
N(2)-Na(1)-C(22) 103.5(2) 
O(7)-Na(1)-C(14) 134.1(3) 
N(1)-Na(1)-C(14) 159.0(3) 
O(2)-Na(1)-C(14) 97.4(3) 
O(4)-Na(1)-C(14) 21.6(2) 
N(4)-Na(1)-C(14) 101.5(3) 
O(6)-Na(1)-C(14) 63.2(3) 
N(3)-Na(1)-C(14) 49.6(3) 
N(2)-Na(1)-C(14) 93.5(3) 
C(22)-Na(1)-C(14) 150.2(3) 
O(11)-O(9)-O(10) 155(2) 
O(9)-O(11)-O(12) 151(3) 
O(16)-O(13)-O(14) 137(2) 
O(13)-O(14)-O(15) 74.7(14) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms
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Table 4.   Anisotropic displacement parameters (Å2x 103)for m150mm.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 119(7)  122(6) 78(5)  -19(4) 18(4)  -41(5) 
C(2) 121(7)  131(6) 72(5)  -8(4) -26(5)  1(6) 
C(3) 111(6)  146(7) 92(5)  -11(5) -31(5)  -12(5) 
C(4) 132(7)  172(8) 100(6)  -8(6) -27(6)  -47(7) 
C(5) 145(7)  111(6) 106(6)  -22(5) -7(6)  -57(6) 
C(6) 164(8)  69(5) 110(6)  -17(4) 4(6)  -15(5) 
C(7) 100(6)  108(6) 112(6)  -28(5) 9(5)  12(5) 
C(8) 83(5)  118(6) 104(5)  -32(5) 13(4)  -6(5) 
C(9) 118(7)  138(7) 120(6)  -24(6) -43(5)  15(6) 
C(10) 118(7)  120(7) 149(8)  -12(6) -14(7)  44(6) 
C(11) 271(18)  228(15) 320(20)  -131(16) -137(17)  115(14) 
C(12) 730(70)  760(70) 300(30)  -30(40) 30(40)  -220(60) 
C(13) 144(8)  166(9) 137(8)  -13(7) 27(7)  -56(7) 
C(14) 124(10)  280(20) 133(9)  7(13) 50(7)  -36(12) 
C(15) 260(20)  840(60) 580(40)  -580(40) 70(30)  0(30) 
C(16) 460(40)  420(30) 580(40)  -340(30) -160(30)  190(30) 
C(17) 137(7)  99(6) 100(6)  -3(4) -2(6)  32(5) 
C(18) 157(9)  87(6) 91(6)  -5(5) -5(7)  -16(6) 
C(19) 315(17)  224(12) 74(6)  12(7) 27(8)  -49(11) 
C(20) 460(30)  204(12) 112(8)  33(8) -36(11)  -82(14) 
C(21) 88(5)  98(5) 78(4)  -8(4) 9(3)  -23(4) 
C(22) 65(4)  88(5) 76(4)  -5(4) -4(4)  5(4) 
C(23) 72(4)  83(5) 74(4)  -4(3) -10(3)  2(3) 
C(24) 90(5)  88(5) 62(4)  4(3) 7(4)  5(4) 
C(25) 138(7)  87(5) 87(5)  -12(4) 16(5)  7(5) 
C(26) 212(10)  94(6) 98(6)  -8(4) 48(7)  9(7) 
C(27) 147(8)  117(7) 119(7)  37(5) 56(6)  52(6) 
C(28) 127(7)  156(8) 115(6)  21(6) 42(6)  24(6) 
C(29) 96(6)  130(6) 89(5)  -2(4) 27(4)  9(5) 
C(30) 95(6)  80(5) 88(5)  -11(4) -26(4)  -6(4) 
C(31) 146(7)  96(6) 86(5)  1(5) -30(5)  -6(5) 
C(32) 224(13)  94(8) 116(7)  18(6) -48(8)  -8(7) 
C(33) 207(15)  107(9) 179(13)  21(9) -85(11)  20(9) 
C(34) 148(10)  125(10) 234(15)  5(9) -26(10)  45(7) 
C(35) 112(7)  125(7) 171(8)  11(6) -13(6)  47(6) 
C(36) 77(5)  93(5) 71(4)  -16(4) 12(3)  -8(3) 
C(37) 84(5)  88(5) 93(5)  -2(4) 4(4)  1(4) 
C(38) 88(5)  80(4) 61(4)  0(3) 16(3)  -13(4) 
C(39) 67(4)  112(5) 90(4)  -1(4) 10(4)  -3(4) 
C(40) 93(5)  100(5) 99(5)  3(4) 32(4)  8(4) 
C(41) 113(6)  65(4) 74(4)  -6(3) 26(4)  -11(4) 
C(42) 86(5)  78(4) 74(4)  -1(3) 10(4)  -1(4) 
C(43) 130(7)  88(5) 115(6)  -19(4) -19(5)  1(5) 
C(44) 180(9)  99(6) 127(7)  -2(5) -29(7)  -5(6) 
C(45) 205(11)  92(6) 101(6)  -23(5) 11(7)  -5(6) 
C(46) 134(7)  111(6) 106(6)  9(5) 34(5)  10(5) 
C(47) 96(6)  94(5) 89(5)  -29(4) 30(5)  -17(4) 
C(48) 131(8)  190(10) 190(9)  -86(8) 110(7)  -75(7) 
C(49) 92(6)  172(10) 160(9)  -69(8) 57(6)  -26(6) 
C(50) 178(11)  238(13) 148(9)  -57(9) 36(8)  -23(10) 
C(51) 167(11)  229(15) 254(16)  -152(14) 57(10)  -41(10) 
C(52) 111(8)  239(16) 284(18)  -136(15) 39(10)  -18(8) 
C(53) 118(8)  164(10) 243(14)  -13(9) 17(9)  46(7) 
C(54) 137(8)  163(10) 188(11)  -61(9) 41(8)  2(7) 
N(1) 78(4)  89(4) 71(3)  -16(3) 2(3)  -9(3) 
N(2) 92(4)  112(5) 88(4)  -13(4) -5(4)  -8(4) 
N(3) 115(5)  116(5) 104(5)  -22(4) 20(4)  -34(4) 
N(4) 113(5)  83(4) 82(4)  -12(3) -4(4)  5(3) 
N(5) 69(3)  72(3) 67(3)  -5(3) 3(3)  -9(3) 
N(6) 118(5)  103(5) 114(5)  -18(4) 23(4)  -30(4) 
O(1) 173(6)  149(5) 226(8)  -54(5) -83(6)  61(5) 
O(2) 141(5)  154(5) 131(5)  -34(4) -57(4)  52(4) 
O(3) 228(10)  333(14) 259(11)  12(10) 97(9)  -68(10) 
O(4) 131(6)  229(9) 177(7)  -23(7) 23(5)  2(6) 
O(5) 228(7)  117(4) 100(4)  10(4) -19(5)  -13(4) 
O(6) 136(5)  133(5) 104(4)  -5(4) 20(4)  -4(4) 
O(7) 86(3)  87(3) 73(3)  1(2) -2(2)  -13(2) 
O(8) 83(4)  166(5) 113(4)  -23(4) 6(3)  5(3) 
Na(1) 78(2)  87(2) 90(2)  -10(1) 3(1)  -3(1) 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for m150mm. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 8099 2570 8506 127 
H(1B) 8727 3191 8433 127 
H(2A) 9877 2392 8825 132 
H(2B) 9568 1977 8239 132 
H(3A) 11416 3071 8751 142 
H(3B) 10409 3461 8565 142 
H(4A) 11872 3979 8240 164 
H(4B) 12174 3397 7848 164 
H(5A) 10704 4763 7715 145 
H(5B) 9963 4282 8014 145 
H(6A) 9010 4899 7281 138 
H(6B) 9728 4684 6756 138 
H(7A) 7393 4238 7382 128 
H(7B) 8292 4042 7874 128 
H(8A) 7008 3276 7807 122 
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H(8B) 7124 3207 7088 122 
H(9A) 11377 1936 8327 153 
H(9B) 11953 2401 7901 153 
H(11A) 10755 925 6663 337 
H(11B) 11696 502 6905 337 
H(12A) 11996 905 5916 894 
H(12B) 12853 1152 6411 894 
H(12C) 11922 1585 6178 894 
H(13A) 11271 4360 6673 178 
H(13B) 12267 4253 7126 178 
H(15A) 13042 3408 5263 670 
H(15B) 13175 2868 5754 670 
H(16A) 11902 2540 5057 745 
H(16B) 11329 3186 5056 745 
H(16C) 11308 2746 5639 745 
H(17A) 7921 4506 6327 135 
H(17B) 7631 3794 6314 135 
H(19A) 10025 4280 4924 245 
H(19B) 9313 3709 4713 245 
H(20A) 9270 4453 3936 392 
H(20B) 8857 4945 4401 392 
H(20C) 8158 4374 4187 392 
H(21A) 7132 2160 7516 105 
H(21B) 8251 1862 7576 105 
H(23) 6446 1423 5635 92 
H(25) 6867 896 4772 124 
H(26) 8096 352 4240 160 
H(27) 9862 468 4525 151 
H(28) 10399 1127 5343 157 
H(29) 9171 1671 5875 125 
H(31) 7819 2362 4794 133 
H(32) 7377 3336 4399 177 
H(33) 6049 3878 4806 202 
H(34) 5168 3465 5596 205 
H(35) 5601 2468 5994 164 
H(36) 7186 1173 7173 96 
H(37) 5527 401 6071 106 
H(39) 8519 473 6754 107 
H(40) 8845 -469 6270 115 
H(43) 4923 -466 5431 135 
H(44) 5249 -1408 4947 164 
H(45) 6908 -1843 5047 159 
H(46) 8241 -1336 5631 139 
H(48A) 4192 1197 8000 199 
H(48B) 3871 1403 7310 199 
H(50) 4491 1991 8799 224 
H(51) 4567 3029 9101 258 
H(52) 4522 3810 8350 252 
H(53) 4400 3552 7296 210 
H(54) 4324 2513 6994 194 
H(6) 5902 1143 7742 133 
________________________________________________________________________________ 
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Appendix 1b: Benzyl Europium Ugi product M12M. Crystal structure 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
N
N
H
N
N
N
N
O
O
O
O
O
O
O
Eu
 
 
Appendix 1: Crystal structures 
 249
 
Table 1.  Crystal data and structure refinement for 2009 src0262. 
 
Identification code  2009src0262, B2Eu 
Empirical formula  C44 H49 D2 Eu N6 O9, 9.84(D2O) 
Formula weight  1158.97 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 2(1)/c 
Unit cell dimensions a = 11.2327(2) Å = 90°. 
 b = 43.0382(9) Å = 112.1750(10)°. 
 c = 11.6011(2) Å  = 90°. 
Volume 5193.56(17) Å3 
Z 4 
Density (calculated) 1.482 Mg/m3 
Absorption coefficient 1.285 mm-1 
F(000) 2361 
Crystal size 0.42 x 0.08 x 0.04 mm3 
Theta range for data collection 3.03 to 27.47°. 
Index ranges -14<=h<=14, -55<=k<=52, -15<=l<=14 
Reflections collected 43192 
Independent reflections 11813 [R(int) = 0.0652] 
Completeness to theta = 27.47° 99.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9504 and 0.6145 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 11813 / 27 / 685 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0519, wR2 = 0.1363 
R indices (all data) R1 = 0.0672, wR2 = 0.1459 
Largest diff. peak and hole 1.796 and -1.912 e.Å-3 
 
Notes: 
The occupancy of the water molecule oxygen atom O(001) was initially refined and then fixed at the final value,  
84 %. 
The deuterium atoms belonging to the water molecules O(901) and O(001) could not be successfully located in the 
electron density map. Thus, the hydrogen bonds involving these molecules could not be tabulated (see Table 6 for 
hydrogen bonds). 
The hydrogen atoms in the europium complex were fixed as riding models while the deuterium atoms (belonging 
to both bound and free water molecules) were located in the electron density map. The positions of these 
deuterium atoms were refined subject to restraints while the isotropic thermal parameters were fixed at a value of 
1.5Ueq of the parent oxygen atom. 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 2009src0262.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1972(5) 1057(1) -139(4) 30(1) 
C(2) 1878(5) 718(1) -350(5) 32(1) 
C(3) 1604(6) 203(1) 382(5) 33(1) 
C(4) 2941(5) 124(1) 1239(5) 35(1) 
C(5) 4658(5) 215(1) 3244(5) 34(1) 
C(6) 5226(5) 505(1) 2992(5) 35(1) 
C(7) 5041(5) 1078(1) 2733(5) 30(1) 
C(8) 4180(5) 1103(1) 1394(5) 31(1) 
C(9) -456(4) 894(1) 473(4) 17(1) 
C(10) -77(4) 604(1) -62(4) 24(1) 
C(11) 1235(5) 31(1) 2833(5) 24(1) 
C(12) 2647(5) -34(1) 3099(5) 31(1) 
C(13) 4611(4) 660(1) 5418(4) 22(1) 
C(14) 5303(4) 836(1) 4712(4) 23(1) 
C(15) 2549(4) 1457(1) 1527(4) 17(1) 
C(16) 2571(4) 1489(1) 2846(4) 15(1) 
C(17) 2189(4) 2056(1) 2468(4) 16(1) 
C(18) 1174(4) 2267(1) 2616(4) 17(1) 
C(19) -127(5) 2203(1) 1941(5) 27(1) 
C(20) -1070(5) 2389(1) 2091(6) 35(1) 
C(21) -742(5) 2639(1) 2903(6) 34(1) 
C(22) 559(5) 2706(1) 3591(5) 28(1) 
C(23) 1498(4) 2521(1) 3428(4) 20(1) 
C(24) 3462(4) 2224(1) 2675(4) 18(1) 
C(25) 3432(5) 2470(1) 1876(5) 24(1) 
C(26) 4543(5) 2638(1) 2031(5) 31(1) 
C(27) 5693(5) 2560(1) 2985(5) 33(1) 
C(28) 5740(5) 2315(1) 3759(5) 29(1) 
C(29) 4620(5) 2143(1) 3608(5) 26(1) 
C(30) 2299(4) 1792(1) 4495(4) 17(1) 
C(31) 951(4) 1727(1) 4476(4) 20(1) 
Appendix 1: Crystal structures 
 250
C(32) 78(4) 1531(1) 3615(4) 21(1) 
C(33) -1120(5) 1473(1) 3666(5) 28(1) 
C(34) -1460(5) 1606(1) 4576(5) 34(1) 
C(35) -591(5) 1804(2) 5450(5) 37(1) 
C(36) 597(5) 1867(1) 5389(5) 29(1) 
C(37) 3411(4) 1613(1) 5504(4) 18(1) 
C(38) 4116(5) 1306(1) 7402(4) 22(1) 
C(39) 4619(4) 1520(1) 8532(4) 19(1) 
C(40) 5897(5) 1495(1) 9348(4) 27(1) 
C(41) 6373(5) 1677(2) 10422(5) 39(1) 
C(42) 5583(6) 1889(1) 10684(5) 38(1) 
C(43) 4317(6) 1916(1) 9875(5) 34(1) 
C(44) 3841(5) 1734(1) 8807(4) 26(1) 
N(1) 2834(4) 1139(1) 1242(4) 26(1) 
N(2) 1329(4) 550(1) 413(4) 29(1) 
N(3) 3214(4) 199(1) 2529(4) 30(1) 
N(4) 4724(4) 787(1) 3352(4) 26(1) 
N(5) 2375(3) 1767(1) 3253(3) 15(1) 
N(6) 3117(4) 1447(1) 6322(3) 20(1) 
O(1) -1565(3) 1002(1) -98(3) 23(1) 
O(2) 338(3) 1006(1) 1467(3) 17(1) 
O(3) 560(4) -193(1) 2915(4) 40(1) 
O(4) 823(3) 306(1) 2555(3) 23(1) 
O(5) 5192(3) 618(1) 6565(3) 25(1) 
O(6) 3463(3) 572(1) 4811(3) 24(1) 
O(7) 2742(3) 1256(1) 3529(3) 16(1) 
O(8) 4534(3) 1651(1) 5568(3) 21(1) 
O(9) 976(3) 830(1) 4001(3) 23(1) 
D(9A) 1300(50) 877(14) 4850(20) 34 
D(9B) 80(20) 803(13) 3720(50) 34 
Eu 2213(1) 738(1) 2749(1) 15(1) 
O(101) 1120(4) -770(1) 3868(4) 28(1) 
D(1WA) 1080(60) -561(6) 3600(50) 42 
D(1WB) 1580(50) -879(11) 3460(50) 42 
O(201) 2618(3) 5977(1) 7603(3) 26(1) 
D(2WA) 2200(50) 5937(13) 6740(20) 40 
D(2WB) 3390(30) 5860(12) 7860(50) 40 
O(301) 1364(4) 970(1) 6473(3) 33(1) 
D(3WA) 490(20) 960(13) 6360(60) 50 
D(3WB) 1750(50) 774(8) 6740(60) 50 
O(401) -649(4) 1636(1) -396(4) 35(1) 
D(4WA) -1270(50) 1668(14) -1210(30) 53 
D(4WB) -950(60) 1457(10) -100(50) 53 
O(501) 1497(4) 5640(1) 1391(4) 39(1) 
D(5WA) 1260(70) 5426(6) 1250(60) 58 
D(5WB) 1600(70) 5712(13) 660(40) 58 
O(601) 7306(4) 1642(1) 7069(4) 35(1) 
D(6WA) 6420(20) 1694(13) 6770(60) 52 
D(6WB) 7310(60) 1426(5) 6920(60) 52 
O(701) 3145(5) 462(1) 7368(6) 63(2) 
D(7WA) 3600(60) 490(20) 6830(60) 94 
D(7WB) 3760(60) 380(20) 8150(40) 94 
O(801) 3154(5) 5741(2) 3917(6) 81(2) 
D(8WA) 3260(110) 5538(12) 4350(90) 121 
D(8WB) 2600(90) 5849(19) 4240(90) 121 
O(901) 4881(5) 327(1) -235(6) 69(2) 
O(001) 1200(7) 4994(1) 1209(7) 71(2) 
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Table 3.   Bond lengths [Å] and angles [°] for 2009src0262. 
_____________________________________________________ 
C(1)-C(2)  1.480(7) 
C(1)-N(1)  1.567(7) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(2)  1.449(7) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.493(8) 
C(3)-N(2)  1.528(7) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-N(3)  1.446(7) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(6)  1.479(8) 
C(5)-N(3)  1.519(7) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-N(4)  1.465(7) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-C(8)  1.492(7) 
C(7)-N(4)  1.548(7) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-N(1)  1.462(7) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-O(2)  1.257(5) 
C(9)-O(1)  1.259(5) 
C(9)-C(10)  1.524(6) 
C(9)-Eu  3.230(4) 
C(10)-N(2)  1.481(6) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-O(3)  1.253(6) 
C(11)-O(4)  1.267(5) 
C(11)-C(12)  1.523(7) 
C(11)-Eu  3.249(4) 
C(12)-N(3)  1.471(7) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-O(5)  1.255(6) 
C(13)-O(6)  1.272(5) 
C(13)-C(14)  1.526(7) 
C(13)-Eu  3.264(5) 
C(14)-N(4)  1.478(6) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-N(1)  1.473(5) 
C(15)-C(16)  1.528(6) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-O(7)  1.249(5) 
C(16)-N(5)  1.335(5) 
C(16)-Eu  3.255(4) 
C(17)-N(5)  1.505(5) 
C(17)-C(18)  1.519(6) 
C(17)-C(24)  1.540(6) 
C(17)-H(17)  1.0000 
C(18)-C(23)  1.397(6) 
C(18)-C(19)  1.401(6) 
C(19)-C(20)  1.388(7) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.387(8) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.405(7) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.390(7) 
C(22)-H(22)  0.9500 
C(23)-H(23)  0.9500 
C(24)-C(29)  1.387(6) 
C(24)-C(25)  1.399(6) 
C(25)-C(26)  1.394(7) 
C(25)-H(25)  0.9500 
C(26)-C(27)  1.388(8) 
C(26)-H(26)  0.9500 
C(27)-C(28)  1.374(7) 
C(27)-H(27)  0.9500 
C(28)-C(29)  1.412(7) 
C(28)-H(28)  0.9500 
C(29)-H(29)  0.9500 
C(30)-N(5)  1.479(5) 
C(30)-C(31)  1.532(6) 
C(30)-C(37)  1.556(6) 
C(30)-H(30)  1.0000 
C(31)-C(32)  1.390(6) 
C(31)-C(36)  1.401(7) 
C(32)-C(33)  1.392(6) 
C(32)-H(32)  0.9500 
C(33)-C(34)  1.376(7) 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.400(8) 
C(34)-H(34)  0.9500 
C(35)-C(36)  1.389(7) 
C(35)-H(35)  0.9500 
C(36)-H(36)  0.9500 
C(37)-O(8)  1.247(5) 
C(37)-N(6)  1.326(6) 
C(38)-N(6)  1.462(6) 
C(38)-C(39)  1.525(6) 
C(38)-H(38A)  0.9900 
C(38)-H(38B)  0.9900 
C(39)-C(44)  1.387(6) 
C(39)-C(40)  1.393(6) 
C(40)-C(41)  1.398(7) 
C(40)-H(40)  0.9500 
C(41)-C(42)  1.383(9) 
C(41)-H(41)  0.9500 
C(42)-C(43)  1.382(8) 
C(42)-H(42)  0.9500 
C(43)-C(44)  1.391(7) 
C(43)-H(43)  0.9500 
C(44)-H(44)  0.9500 
N(1)-Eu  2.728(4) 
N(2)-Eu  2.638(4) 
N(3)-Eu  2.633(4) 
N(4)-Eu  2.646(4) 
N(6)-H(6)  0.8800 
O(2)-Eu  2.369(3) 
O(4)-Eu  2.383(3) 
O(6)-Eu  2.380(3) 
O(7)-Eu  2.393(3) 
O(9)-Eu  2.391(3) 
O(9)-D(9A)  0.932(19) 
O(9)-D(9B)  0.941(19) 
O(101)-D(1WA)  0.949(19) 
O(101)-D(1WB)  0.946(19) 
O(201)-D(2WA)  0.952(19) 
O(201)-D(2WB)  0.948(19) 
O(301)-D(3WA)  0.942(19) 
O(301)-D(3WB)  0.942(19) 
O(401)-D(4WA)  0.950(19) 
O(401)-D(4WB)  0.955(19) 
O(501)-D(5WA)  0.957(19) 
O(501)-D(5WB)  0.95(2) 
O(601)-D(6WA)  0.950(19) 
O(601)-D(6WB)  0.946(19) 
O(701)-D(7WA)  0.95(2) 
O(701)-D(7WB)  0.97(2) 
O(801)-D(8WA)  0.99(2) 
O(801)-D(8WB)  0.96(2)C(2)-C(1)-N(1) 
C(2)-C(1)-H(1A) 109.3 
N(1)-C(1)-H(1A) 109.3 
C(2)-C(1)-H(1B) 109.3 
N(1)-C(1)-H(1B) 109.3 
H(1A)-C(1)-H(1B) 108.0 
N(2)-C(2)-C(1) 114.3(4) 
N(2)-C(2)-H(2A) 108.7 
C(1)-C(2)-H(2A) 108.7 
N(2)-C(2)-H(2B) 108.7 
C(1)-C(2)-H(2B) 108.7 
H(2A)-C(2)-H(2B) 107.6 
C(4)-C(3)-N(2) 111.6(4) 
C(4)-C(3)-H(3A) 109.3 
N(2)-C(3)-H(3A) 109.3 
C(4)-C(3)-H(3B) 109.3 
N(2)-C(3)-H(3B) 109.3 
H(3A)-C(3)-H(3B) 108.0 
N(3)-C(4)-C(3) 113.9(5) 
N(3)-C(4)-H(4A) 108.8 
C(3)-C(4)-H(4A) 108.8 
N(3)-C(4)-H(4B) 108.8 
C(3)-C(4)-H(4B) 108.8 
H(4A)-C(4)-H(4B) 107.7 
C(6)-C(5)-N(3) 112.5(4) 
C(6)-C(5)-H(5A) 109.1 
N(3)-C(5)-H(5A) 109.1 
C(6)-C(5)-H(5B) 109.1 
N(3)-C(5)-H(5B) 109.1 
H(5A)-C(5)-H(5B) 107.8 
N(4)-C(6)-C(5) 113.7(4) 
N(4)-C(6)-H(6A) 108.8 
C(5)-C(6)-H(6A) 108.8 
N(4)-C(6)-H(6B) 108.8 
C(5)-C(6)-H(6B) 108.8 
H(6A)-C(6)-H(6B) 107.7 
C(8)-C(7)-N(4) 111.6(4) 
C(8)-C(7)-H(7A) 109.3 
N(4)-C(7)-H(7A) 109.3 
C(8)-C(7)-H(7B) 109.3 
N(4)-C(7)-H(7B) 109.3 
H(7A)-C(7)-H(7B) 108.0 
N(1)-C(8)-C(7) 111.6(4) 
N(1)-C(8)-H(8A) 109.3 
C(7)-C(8)-H(8A) 109.3 
N(1)-C(8)-H(8B) 109.3 
C(7)-C(8)-H(8B) 109.3 
H(8A)-C(8)-H(8B) 108.0 
O(2)-C(9)-O(1) 124.0(4) 
O(2)-C(9)-C(10) 118.5(4) 
O(1)-C(9)-C(10) 117.4(4) 
O(2)-C(9)-Eu 38.0(2) 
O(1)-C(9)-Eu 159.4(3) 
C(10)-C(9)-Eu 81.2(2) 
N(2)-C(10)-C(9) 113.5(4) 
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N(2)-C(10)-H(10A) 108.9 
C(9)-C(10)-H(10A) 108.9 
N(2)-C(10)-H(10B) 108.9 
C(9)-C(10)-H(10B) 108.9 
H(10A)-C(10)-H(10B) 107.7 
O(3)-C(11)-O(4) 124.5(5) 
O(3)-C(11)-C(12) 117.2(4) 
O(4)-C(11)-C(12) 118.3(4) 
O(3)-C(11)-Eu 160.9(4) 
O(4)-C(11)-Eu 38.1(2) 
C(12)-C(11)-Eu 80.8(3) 
N(3)-C(12)-C(11) 112.3(4) 
N(3)-C(12)-H(12A) 109.2 
C(11)-C(12)-H(12A) 109.2 
N(3)-C(12)-H(12B) 109.2 
C(11)-C(12)-H(12B) 109.2 
H(12A)-C(12)-H(12B) 107.9 
O(5)-C(13)-O(6) 123.9(4) 
O(5)-C(13)-C(14) 118.2(4) 
O(6)-C(13)-C(14) 117.8(4) 
O(5)-C(13)-Eu 159.0(3) 
O(6)-C(13)-Eu 37.3(2) 
C(14)-C(13)-Eu 81.1(2) 
N(4)-C(14)-C(13) 113.2(4) 
N(4)-C(14)-H(14A) 108.9 
C(13)-C(14)-H(14A) 108.9 
N(4)-C(14)-H(14B) 108.9 
C(13)-C(14)-H(14B) 108.9 
H(14A)-C(14)-H(14B) 107.7 
N(1)-C(15)-C(16) 112.8(3) 
N(1)-C(15)-H(15A) 109.0 
C(16)-C(15)-H(15A) 109.0 
N(1)-C(15)-H(15B) 109.0 
C(16)-C(15)-H(15B) 109.0 
H(15A)-C(15)-H(15B) 107.8 
O(7)-C(16)-N(5) 120.3(4) 
O(7)-C(16)-C(15) 120.2(4) 
N(5)-C(16)-C(15) 119.5(4) 
O(7)-C(16)-Eu 37.81(19) 
N(5)-C(16)-Eu 150.3(3) 
C(15)-C(16)-Eu 85.4(2) 
N(5)-C(17)-C(18) 111.4(3) 
N(5)-C(17)-C(24) 112.6(3) 
C(18)-C(17)-C(24) 113.1(4) 
N(5)-C(17)-H(17) 106.4 
C(18)-C(17)-H(17) 106.4 
C(24)-C(17)-H(17) 106.4 
C(23)-C(18)-C(19) 118.8(4) 
C(23)-C(18)-C(17) 121.9(4) 
C(19)-C(18)-C(17) 119.3(4) 
C(20)-C(19)-C(18) 120.1(5) 
C(20)-C(19)-H(19) 120.0 
C(18)-C(19)-H(19) 120.0 
C(21)-C(20)-C(19) 120.8(5) 
C(21)-C(20)-H(20) 119.6 
C(19)-C(20)-H(20) 119.6 
C(20)-C(21)-C(22) 119.8(5) 
C(20)-C(21)-H(21) 120.1 
C(22)-C(21)-H(21) 120.1 
C(23)-C(22)-C(21) 119.1(5) 
C(23)-C(22)-H(22) 120.4 
C(21)-C(22)-H(22) 120.4 
C(22)-C(23)-C(18) 121.4(4) 
C(22)-C(23)-H(23) 119.3 
C(18)-C(23)-H(23) 119.3 
C(29)-C(24)-C(25) 119.3(4) 
C(29)-C(24)-C(17) 123.1(4) 
C(25)-C(24)-C(17) 117.7(4) 
C(26)-C(25)-C(24) 120.7(5) 
C(26)-C(25)-H(25) 119.7 
C(24)-C(25)-H(25) 119.7 
C(27)-C(26)-C(25) 119.7(5) 
C(27)-C(26)-H(26) 120.1 
C(25)-C(26)-H(26) 120.1 
C(28)-C(27)-C(26) 120.1(5) 
C(28)-C(27)-H(27) 120.0 
C(26)-C(27)-H(27) 120.0 
C(27)-C(28)-C(29) 120.6(5) 
C(27)-C(28)-H(28) 119.7 
C(29)-C(28)-H(28) 119.7 
C(24)-C(29)-C(28) 119.6(5) 
C(24)-C(29)-H(29) 120.2 
C(28)-C(29)-H(29) 120.2 
N(5)-C(30)-C(31) 113.2(3) 
N(5)-C(30)-C(37) 111.8(3) 
C(31)-C(30)-C(37) 115.4(4) 
N(5)-C(30)-H(30) 105.1 
C(31)-C(30)-H(30) 105.1 
C(37)-C(30)-H(30) 105.1 
C(32)-C(31)-C(36) 118.7(4) 
C(32)-C(31)-C(30) 123.2(4) 
C(36)-C(31)-C(30) 118.1(4) 
C(31)-C(32)-C(33) 120.7(4) 
C(31)-C(32)-H(32) 119.7 
C(33)-C(32)-H(32) 119.7 
C(34)-C(33)-C(32) 120.6(5) 
C(34)-C(33)-H(33) 119.7 
C(32)-C(33)-H(33) 119.7 
C(33)-C(34)-C(35) 119.4(5) 
C(33)-C(34)-H(34) 120.3 
C(35)-C(34)-H(34) 120.3 
C(36)-C(35)-C(34) 120.1(5) 
C(36)-C(35)-H(35) 119.9 
C(34)-C(35)-H(35) 119.9 
C(35)-C(36)-C(31) 120.4(5) 
C(35)-C(36)-H(36) 119.8 
C(31)-C(36)-H(36) 119.8 
O(8)-C(37)-N(6) 123.2(4) 
O(8)-C(37)-C(30) 119.1(4) 
N(6)-C(37)-C(30) 117.4(4) 
N(6)-C(38)-C(39) 113.7(4) 
N(6)-C(38)-H(38A) 108.8 
C(39)-C(38)-H(38A) 108.8 
N(6)-C(38)-H(38B) 108.8 
C(39)-C(38)-H(38B) 108.8 
H(38A)-C(38)-H(38B) 107.7 
C(44)-C(39)-C(40) 118.2(4) 
C(44)-C(39)-C(38) 122.5(4) 
C(40)-C(39)-C(38) 119.3(4) 
C(39)-C(40)-C(41) 120.8(5) 
C(39)-C(40)-H(40) 119.6 
C(41)-C(40)-H(40) 119.6 
C(42)-C(41)-C(40) 120.3(5) 
C(42)-C(41)-H(41) 119.8 
C(40)-C(41)-H(41) 119.8 
C(43)-C(42)-C(41) 119.1(5) 
C(43)-C(42)-H(42) 120.4 
C(41)-C(42)-H(42) 120.4 
C(42)-C(43)-C(44) 120.6(5) 
C(42)-C(43)-H(43) 119.7 
C(44)-C(43)-H(43) 119.7 
C(39)-C(44)-C(43) 121.0(5) 
C(39)-C(44)-H(44) 119.5 
C(43)-C(44)-H(44) 119.5 
C(8)-N(1)-C(15) 112.0(4) 
C(8)-N(1)-C(1) 108.1(4) 
C(15)-N(1)-C(1) 109.6(4) 
C(8)-N(1)-Eu 111.0(3) 
C(15)-N(1)-Eu 108.3(3) 
C(1)-N(1)-Eu 107.8(3) 
C(2)-N(2)-C(10) 109.5(4) 
C(2)-N(2)-C(3) 109.6(4) 
C(10)-N(2)-C(3) 110.0(4) 
C(2)-N(2)-Eu 113.1(3) 
C(10)-N(2)-Eu 105.6(3) 
C(3)-N(2)-Eu 108.9(3) 
C(4)-N(3)-C(12) 110.9(4) 
C(4)-N(3)-C(5) 109.9(4) 
C(12)-N(3)-C(5) 109.9(4) 
C(4)-N(3)-Eu 111.4(3) 
C(12)-N(3)-Eu 106.4(3) 
C(5)-N(3)-Eu 108.2(3) 
C(6)-N(4)-C(14) 111.2(4) 
C(6)-N(4)-C(7) 111.0(4) 
C(14)-N(4)-C(7) 107.2(4) 
C(6)-N(4)-Eu 110.2(3) 
C(14)-N(4)-Eu 106.8(3) 
C(7)-N(4)-Eu 110.5(3) 
C(16)-N(5)-C(30) 119.1(3) 
C(16)-N(5)-C(17) 121.9(3) 
C(30)-N(5)-C(17) 118.9(3) 
C(37)-N(6)-C(38) 121.3(4) 
C(37)-N(6)-H(6) 119.3 
C(38)-N(6)-H(6) 119.3 
C(9)-O(2)-Eu 122.9(3) 
C(11)-O(4)-Eu 122.8(3) 
C(13)-O(6)-Eu 123.8(3) 
C(16)-O(7)-Eu 123.5(3) 
Eu-O(9)-D(9A) 126(3) 
Eu-O(9)-D(9B) 124(3) 
D(9A)-O(9)-D(9B) 109(4) 
O(2)-Eu-O(6) 145.54(11) 
O(2)-Eu-O(4) 85.68(10) 
O(6)-Eu-O(4) 88.69(11) 
O(2)-Eu-O(9) 73.62(11) 
O(6)-Eu-O(9) 72.39(11) 
O(4)-Eu-O(9) 71.14(11) 
O(2)-Eu-O(7) 79.61(10) 
O(6)-Eu-O(7) 86.11(11) 
O(4)-Eu-O(7) 145.31(11) 
O(9)-Eu-O(7) 74.61(11) 
O(2)-Eu-N(3) 132.74(12) 
O(6)-Eu-N(3) 73.81(13) 
O(4)-Eu-N(3) 65.89(12) 
O(9)-Eu-N(3) 124.92(13) 
O(7)-Eu-N(3) 143.42(12) 
O(2)-Eu-N(2) 66.64(11) 
O(6)-Eu-N(2) 142.21(13) 
O(4)-Eu-N(2) 71.57(13) 
O(9)-Eu-N(2) 126.51(12) 
O(7)-Eu-N(2) 128.17(12) 
N(3)-Eu-N(2) 68.78(14) 
O(2)-Eu-N(4) 137.18(12) 
O(6)-Eu-N(4) 66.00(12) 
O(4)-Eu-N(4) 133.02(12) 
O(9)-Eu-N(4) 129.22(11) 
O(7)-Eu-N(4) 74.81(12) 
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N(3)-Eu-N(4) 69.17(13) 
N(2)-Eu-N(4) 104.26(13) 
O(2)-Eu-N(1) 70.84(12) 
O(6)-Eu-N(1) 129.62(12) 
O(4)-Eu-N(1) 138.55(12) 
O(9)-Eu-N(1) 129.23(12) 
O(7)-Eu-N(1) 64.34(11) 
N(3)-Eu-N(1) 105.83(13) 
N(2)-Eu-N(1) 67.90(13) 
N(4)-Eu-N(1) 67.27(13) 
O(2)-Eu-C(9) 19.06(10) 
O(6)-Eu-C(9) 153.77(11) 
O(4)-Eu-C(9) 73.25(11) 
O(9)-Eu-C(9) 83.64(11) 
O(7)-Eu-C(9) 97.90(10) 
N(3)-Eu-C(9) 113.69(13) 
N(2)-Eu-C(9) 49.48(12) 
N(4)-Eu-C(9) 140.10(12) 
N(1)-Eu-C(9) 74.20(12) 
O(2)-Eu-C(11) 104.11(11) 
O(6)-Eu-C(11) 76.48(12) 
O(4)-Eu-C(11) 19.14(11) 
O(9)-Eu-C(11) 81.76(12) 
O(7)-Eu-C(11) 154.03(11) 
N(3)-Eu-C(11) 48.62(13) 
N(2)-Eu-C(11) 75.06(13) 
N(4)-Eu-C(11) 113.94(13) 
N(1)-Eu-C(11) 141.47(12) 
C(9)-Eu-C(11) 89.92(11) 
O(2)-Eu-C(16) 66.88(10) 
O(6)-Eu-C(16) 104.22(11) 
O(4)-Eu-C(16) 147.80(10) 
O(9)-Eu-C(16) 84.65(11) 
O(7)-Eu-C(16) 18.65(10) 
N(3)-Eu-C(16) 145.82(12) 
N(2)-Eu-C(16) 109.55(12) 
N(4)-Eu-C(16) 78.82(12) 
N(1)-Eu-C(16) 48.41(11) 
C(9)-Eu-C(16) 83.49(10) 
C(11)-Eu-C(16) 165.48(12) 
D(1WA)-O(101)-D(1WB) 106(3) 
D(2WA)-O(201)-D(2WB) 105(3) 
D(3WA)-O(301)-D(3WB) 109(4) 
D(4WA)-O(401)-D(4WB) 104(4) 
D(5WA)-O(501)-D(5WB) 106(4) 
D(6WA)-O(601)-D(6WB) 104(4) 
D(7WA)-O(701)-D(7WB) 107(4) 
D(8WA)-O(801)-D(8WB) 101(4) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
 
 
Table 4.   Anisotropic displacement parameters (Å2x 103)for 2009src0262.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 32(3)  38(3) 23(2)  12(2) 15(2)  12(2) 
C(2) 32(3)  34(3) 26(3)  -3(2) 7(2)  0(2) 
C(3) 46(3)  25(3) 27(3)  -9(2) 13(2)  -10(2) 
C(4) 34(3)  24(3) 47(3)  4(2) 15(3)  4(2) 
C(5) 31(3)  36(3) 34(3)  2(2) 10(2)  15(2) 
C(6) 27(3)  43(3) 35(3)  -3(2) 10(2)  5(2) 
C(7) 24(2)  37(3) 30(3)  -4(2) 13(2)  -9(2) 
C(8) 31(3)  29(3) 38(3)  2(2) 19(2)  -1(2) 
C(9) 17(2)  15(2) 18(2)  1(2) 5(2)  -1(2) 
C(10) 19(2)  26(2) 21(2)  -4(2) -1(2)  6(2) 
C(11) 26(2)  13(2) 29(2)  2(2) 7(2)  -2(2) 
C(12) 23(2)  15(2) 48(3)  5(2) 4(2)  2(2) 
C(13) 21(2)  17(2) 25(2)  1(2) 8(2)  1(2) 
C(14) 18(2)  28(2) 19(2)  1(2) 3(2)  -2(2) 
C(15) 18(2)  14(2) 20(2)  2(2) 9(2)  1(2) 
C(16) 12(2)  13(2) 18(2)  -1(2) 3(2)  -3(2) 
C(17) 23(2)  9(2) 15(2)  3(2) 5(2)  2(2) 
C(18) 18(2)  13(2) 20(2)  3(2) 7(2)  0(2) 
C(19) 22(2)  17(2) 35(3)  2(2) 2(2)  1(2) 
C(20) 19(2)  26(3) 55(4)  4(2) 10(2)  1(2) 
C(21) 21(2)  29(3) 57(4)  8(3) 19(2)  8(2) 
C(22) 34(3)  23(2) 32(3)  -3(2) 16(2)  3(2) 
C(23) 19(2)  17(2) 23(2)  -1(2) 6(2)  -1(2) 
C(24) 20(2)  16(2) 21(2)  -2(2) 11(2)  2(2) 
C(25) 29(2)  16(2) 33(3)  2(2) 17(2)  6(2) 
C(26) 32(3)  22(2) 49(3)  10(2) 25(2)  5(2) 
C(27) 27(3)  28(3) 49(3)  3(2) 21(2)  -3(2) 
C(28) 20(2)  29(3) 34(3)  3(2) 6(2)  -4(2) 
C(29) 24(2)  23(2) 31(3)  5(2) 8(2)  0(2) 
C(30) 20(2)  14(2) 16(2)  1(2) 6(2)  0(2) 
C(31) 21(2)  20(2) 18(2)  1(2) 6(2)  1(2) 
C(32) 18(2)  24(2) 22(2)  -1(2) 9(2)  0(2) 
C(33) 21(2)  30(3) 32(3)  -2(2) 9(2)  -3(2) 
C(34) 26(3)  40(3) 43(3)  0(3) 20(2)  -1(2) 
C(35) 34(3)  49(4) 36(3)  -10(3) 23(2)  0(3) 
C(36) 32(3)  29(3) 28(3)  -7(2) 14(2)  -2(2) 
C(37) 20(2)  14(2) 16(2)  -6(2) 4(2)  0(2) 
C(38) 27(2)  20(2) 19(2)  3(2) 9(2)  6(2) 
C(39) 23(2)  17(2) 19(2)  4(2) 8(2)  1(2) 
C(40) 21(2)  39(3) 22(2)  0(2) 9(2)  6(2) 
C(41) 25(3)  60(4) 27(3)  2(3) 4(2)  -8(3) 
C(42) 52(3)  38(3) 23(3)  -6(2) 12(2)  -14(3) 
C(43) 51(3)  26(3) 26(3)  10(2) 16(2)  12(2) 
C(44) 27(2)  28(3) 22(2)  4(2) 6(2)  11(2) 
N(1) 41(2)  17(2) 29(2)  1(2) 23(2)  8(2) 
N(2) 20(2)  34(2) 28(2)  -8(2) 4(2)  7(2) 
N(3) 22(2)  21(2) 49(3)  1(2) 15(2)  2(2) 
N(4) 21(2)  38(2) 14(2)  0(2) 1(2)  -6(2) 
N(5) 16(2)  14(2) 12(2)  2(1) 1(1)  0(1) 
N(6) 21(2)  21(2) 17(2)  2(2) 6(2)  -1(2) 
O(1) 18(2)  25(2) 20(2)  -2(1) 0(1)  5(1) 
O(2) 15(1)  16(2) 16(1)  -2(1) 1(1)  2(1) 
O(3) 30(2)  20(2) 66(3)  9(2) 14(2)  -2(2) 
O(4) 20(2)  14(2) 29(2)  1(1) 5(1)  0(1) 
O(5) 27(2)  27(2) 16(2)  3(1) 2(1)  3(1) 
O(6) 15(2)  31(2) 21(2)  6(1) 2(1)  0(1) 
O(7) 18(1)  13(1) 15(1)  -1(1) 4(1)  -2(1) 
O(8) 16(2)  20(2) 23(2)  4(1) 4(1)  -1(1) 
O(9) 16(2)  30(2) 19(2)  1(1) 4(1)  -4(1) 
Eu 13(1)  12(1) 16(1)  1(1) 2(1)  0(1) 
O(101) 30(2)  20(2) 38(2)  5(2) 19(2)  2(1) 
O(201) 23(2)  33(2) 19(2)  2(1) 2(1)  0(2) 
O(301) 28(2)  43(2) 30(2)  1(2) 13(2)  -9(2) 
O(401) 30(2)  26(2) 42(2)  5(2) 5(2)  -6(2) 
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O(501) 25(2)  51(2) 40(2)  -1(2) 14(2)  2(2) 
O(601) 26(2)  37(2) 41(2)  1(2) 10(2)  -4(2) 
O(701) 80(4)  41(3) 102(4)  17(3) 73(4)  9(3) 
O(801) 42(3)  126(6) 77(4)  -49(4) 27(3)  -2(3) 
O(901) 67(3)  64(3) 101(4)  30(3) 60(3)  23(3) 
O(001) 93(5)  47(3) 100(5)  1(3) 68(5)  -4(3) 
 
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for 2009src0262. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 1100 1144 -340 36 
H(1B) 2340 1155 -704 36 
H(2A) 1348 678 -1237 38 
H(2B) 2750 635 -185 38 
H(3A) 985 83 627 40 
H(3B) 1484 142 -478 40 
H(4A) 3084 -101 1171 42 
H(4B) 3555 238 964 42 
H(5A) 4840 201 4146 41 
H(5B) 5069 35 3014 41 
H(6A) 6169 498 3448 42 
H(6B) 5058 515 2091 42 
H(7A) 4945 1266 3179 36 
H(7B) 5946 1066 2802 36 
H(8A) 4443 1283 1017 37 
H(8B) 4271 913 948 37 
H(10A) -497 421 139 29 
H(10B) -403 623 -980 29 
H(12A) 3131 -35 4011 38 
H(12B) 2729 -242 2777 38 
H(14A) 5290 1061 4888 27 
H(14B) 6213 769 5023 27 
H(15A) 1690 1519 924 20 
H(15B) 3189 1601 1424 20 
H(17) 1843 1985 1582 20 
H(19) -366 2033 1378 33 
H(20) -1951 2343 1632 42 
H(21) -1395 2765 2994 41 
H(22) 794 2875 4159 34 
H(23) 2379 2568 3878 24 
H(25) 2646 2523 1222 29 
H(26) 4513 2805 1486 38 
H(27) 6448 2677 3104 40 
H(28) 6533 2260 4401 35 
H(29) 4660 1973 4143 32 
H(30) 2463 2016 4728 20 
H(32) 301 1436 2985 25 
H(33) -1709 1339 3067 34 
H(34) -2276 1564 4610 41 
H(35) -814 1895 6087 44 
H(36) 1173 2006 5970 35 
H(38A) 4843 1244 7168 26 
H(38B) 3767 1115 7635 26 
H(40) 6451 1352 9171 33 
H(41) 7243 1656 10976 47 
H(42) 5907 2014 11411 45 
H(43) 3767 2060 10050 40 
H(44) 2970 1756 8257 32 
H(6) 2304 1421 6212 24 
 
 
Table 6.  Hydrogen bonds for 2009src0262 [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(6)-H(6)...O(301) 0.88 2.28 2.894(5) 126.5 
 O(9)-D(9A)...O(301) 0.932(19) 1.90(3) 2.798(5) 161(5) 
 O(9)-D(9B)...O(501)#1 0.941(19) 1.87(3) 2.764(5) 159(5) 
 O(101)-D(1WA)...O(3) 0.949(19) 1.77(2) 2.694(5) 164(6) 
 O(101)-D(1WB)...O(201)#2 0.946(19) 1.84(3) 2.764(5) 163(5) 
 O(201)-D(2WA)...O(1)#3 0.952(19) 1.78(3) 2.695(4) 160(5) 
 O(201)-D(2WB)...O(5)#4 0.948(19) 1.81(2) 2.751(5) 175(6) 
 O(301)-D(3WA)...O(101)#5 0.942(19) 1.91(3) 2.802(5) 157(5) 
 O(301)-D(3WB)...O(701) 0.942(19) 1.99(3) 2.879(7) 158(5) 
 O(401)-D(4WA)...O(601)#6 0.950(19) 2.03(2) 2.971(5) 168(5) 
 O(401)-D(4WB)...O(1) 0.955(19) 2.08(3) 2.983(5) 157(6) 
 O(501)-D(5WA)...O(001) 0.957(19) 1.86(3) 2.800(8) 167(6) 
 O(501)-D(5WB)...O(101)#2 0.95(2) 1.95(4) 2.850(6) 156(6) 
 O(601)-D(6WA)...O(8) 0.950(19) 2.06(3) 2.938(5) 154(5) 
 O(601)-D(6WB)...O(201)#7 0.946(19) 2.01(3) 2.885(5) 154(6) 
 O(701)-D(7WA)...O(5) 0.95(2) 2.01(5) 2.868(6) 150(7) 
 O(701)-D(7WA)...O(6) 0.95(2) 2.32(4) 3.155(6) 146(6) 
 O(701)-D(7WB)...O(901)#8 0.97(2) 1.84(3) 2.789(9) 166(8) 
 O(801)-D(8WA)...O(901)#9 0.99(2) 2.15(9) 2.799(9) 121(8) 
 O(801)-D(8WB)...O(1)#3 0.96(2) 1.91(3) 2.859(6) 169(8) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,y-1/2,-z+1/2    #2 x,-y+1/2,z-1/2    #3 -x,y+1/2,-z+1/2  
#4 -x+1,y+1/2,-z+3/2    #5 -x,-y,-z+1    #6 x-1,y,z-1  
#7 -x+1,y-1/2,-z+3/2    #8 x,y,z+1    #9 -x+1,y+1/2,-z+1/2  
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Appendix 1c: Benzyl Terbium Ugi complex M16M. Crystal structure 
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Table 1.  Crystal data and structure refinement for 2008JS2. 
 
Identification code  2008JS2, B2Tb 
Empirical formula  C44 H49 N6 O9 Tb, 10(D2O) 
Formula weight  1169.13 
Temperature  120(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P 2(1)/c 
Unit cell dimensions a = 11.20490(10) Å = 90°. 
 b = 42.9538(5) Å = 112.1950(10)°. 
 c = 11.5570(2) Å  = 90°. 
Volume 5150.16(12) Å3 
Z 4 
Density (calculated) 1.508 Mg/m3 
Absorption coefficient 7.418 mm-1 
F(000) 2376 
Crystal size 0.30 x 0.12 x 0.12 mm3 
Theta range for data collection 6.61 to 66.59°. 
Index ranges -13<=h<=13, -50<=k<=51, -12<=l<=13 
Reflections collected 52752 
Independent reflections 8969 [R(int) = 0.0267] 
Completeness to theta = 66.59° 98.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.4697 and 0.2144 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8969 / 31 / 704 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0263, wR2 = 0.0653 
R indices (all data) R1 = 0.0267, wR2 = 0.0656 
Largest diff. peak and hole 0.999 and -0.560 e.Å-3 
 
Notes: 
The water molecule O(001)/O(01’) is disordered over two sites at a ratio of 0.835 (8): 0.165 (8). Only one 
deuterium atom could be successfully located in the electron density map for the major site, O(001) while no 
deuterium atoms could be located for O(01’). 
The hydrogen atoms in the terbium complex were fixed as riding models while the deuterium atoms (belonging to 
both bound and free water molecules) were located in the electron density map. The positions of these deuterium 
atoms were refined subject to restraints while the isotropic thermal parameters were fixed at a value of 1.5Ueq of 
the parent oxygen atom. 
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for 2008js2.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1993(2) 1061(1) -141(2) 15(1) 
C(2) 1898(2) 713(1) -368(2) 17(1) 
C(3) 1606(2) 204(1) 382(2) 19(1) 
C(4) 2964(2) 123(1) 1248(2) 21(1) 
C(5) 4669(2) 219(1) 3255(2) 19(1) 
C(6) 5240(2) 517(1) 2984(2) 19(1) 
C(7) 5047(2) 1079(1) 2734(2) 17(1) 
C(8) 4185(2) 1104(1) 1373(2) 17(1) 
C(9) -437(2) 893(1) 470(2) 12(1) 
C(10) -70(2) 598(1) -42(2) 16(1) 
C(11) 1251(2) 41(1) 2860(2) 20(1) 
C(12) 2665(2) -23(1) 3152(2) 20(1) 
C(13) 4600(2) 665(1) 5405(2) 15(1) 
C(14) 5292(2) 846(1) 4709(2) 17(1) 
C(15) 2531(2) 1457(1) 1487(2) 12(1) 
C(16) 2570(2) 1488(1) 2810(2) 11(1) 
C(17) 2202(2) 2055(1) 2444(2) 13(1) 
C(18) 3468(2) 2224(1) 2655(2) 14(1) 
C(19) 4636(2) 2145(1) 3590(2) 21(1) 
C(20) 5746(2) 2316(1) 3753(3) 27(1) 
C(21) 5699(3) 2565(1) 2981(3) 27(1) 
C(22) 4544(3) 2640(1) 2024(3) 26(1) 
C(23) 3436(2) 2472(1) 1866(2) 20(1) 
C(24) 1176(2) 2266(1) 2597(2) 15(1) 
C(25) 1504(2) 2518(1) 3410(2) 19(1) 
C(26) 560(3) 2702(1) 3567(3) 25(1) 
C(27) -729(3) 2636(1) 2898(3) 32(1) 
C(28) -1068(3) 2388(1) 2074(3) 33(1) 
C(29) -118(2) 2203(1) 1918(2) 24(1) 
C(30) 2311(2) 1791(1) 4471(2) 13(1) 
C(31) 968(2) 1728(1) 4463(2) 15(1) 
C(32) 81(2) 1536(1) 3584(2) 18(1) 
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C(33) -1118(2) 1481(1) 3642(2) 24(1) 
C(34) -1443(3) 1615(1) 4570(3) 32(1) 
C(35) -568(3) 1808(1) 5441(3) 32(1) 
C(36) 623(2) 1866(1) 5379(2) 24(1) 
C(37) 3430(2) 1610(1) 5469(2) 14(1) 
C(38) 4135(2) 1307(1) 7385(2) 18(1) 
C(39) 4622(2) 1521(1) 8512(2) 15(1) 
C(40) 5902(2) 1504(1) 9319(2) 23(1) 
C(41) 6366(3) 1689(1) 10388(3) 33(1) 
C(42) 5552(3) 1892(1) 10651(2) 31(1) 
C(43) 4278(3) 1911(1) 9850(2) 26(1) 
C(44) 3809(2) 1728(1) 8783(2) 20(1) 
N(1) 2807(2) 1135(1) 1195(2) 13(1) 
N(2) 1335(2) 544(1) 425(2) 15(1) 
N(3) 3246(2) 208(1) 2569(2) 16(1) 
N(4) 4715(2) 803(1) 3340(2) 15(1) 
N(5) 2387(2) 1768(1) 3224(2) 11(1) 
N(6) 3134(2) 1445(1) 6301(2) 17(1) 
O(1) -1531(1) 1008(1) -112(2) 18(1) 
O(2) 362(1) 1003(1) 1472(1) 13(1) 
O(3) 564(2) -183(1) 2925(2) 38(1) 
O(4) 850(1) 315(1) 2584(2) 16(1) 
O(5) 5191(2) 619(1) 6544(1) 19(1) 
O(6) 3450(1) 583(1) 4792(1) 16(1) 
O(7) 2734(1) 1254(1) 3490(1) 11(1) 
O(8) 4543(2) 1646(1) 5537(2) 18(1) 
O(9) 996(2) 842(1) 3983(2) 17(1) 
D(9A) 1280(30) 902(7) 4785(17) 25 
D(9B) 179(19) 766(6) 3700(30) 25 
Tb 2222(1) 742(1) 2743(1) 10(1) 
O(101) 2605(2) 5972(1) 7611(2) 22(1) 
D(1WA) 3330(20) 5850(7) 7870(30) 33 
D(1WB) 2210(30) 5960(7) 6765(17) 33 
O(201) 1102(2) -763(1) 3872(2) 24(1) 
D(2WA) 1610(30) -860(6) 3510(30) 35 
D(2WB) 1020(30) -559(4) 3570(30) 35 
O(301) 8522(2) 647(1) 3605(2) 30(1) 
D(3WA) 8510(40) 719(7) 4360(20) 45 
D(3WB) 8640(30) 435(4) 3670(30) 45 
O(401) 1390(2) 965(1) 6478(2) 30(1) 
D(4WA) 1880(30) 793(6) 6830(30) 45 
D(4WB) 556(19) 936(8) 6430(30) 45 
O(501) -652(2) 1638(1) -424(2) 31(1) 
D(5WA) -950(30) 1466(6) -140(30) 47 
D(5WB) -1240(30) 1670(8) -1220(20) 47 
O(601) 2682(2) 6636(1) 7964(2) 31(1) 
D(6WA) 3542(19) 6685(7) 8360(30) 46 
D(6WB) 2670(30) 6423(4) 8000(30) 46 
O(701) 3182(3) 459(1) 7384(3) 55(1) 
D(7WA) 3830(30) 514(11) 7100(40) 82 
D(7WB) 2500(30) 398(11) 6620(30) 82 
O(801) 4889(3) 329(1) -205(3) 68(1) 
D(8WA) 5700(30) 398(12) -70(40) 102 
D(8WB) 4400(40) 244(12) -990(30) 102 
O(901) 6855(3) 753(1) 1081(3) 76(1) 
D(9WA) 7440(40) 748(13) 1940(20) 113 
D(9WB) 7330(40) 813(13) 590(40) 113 
O(001) 1201(4) 5002(1) 1181(4) 61(1) 
D(0WA) 920(60) 4958(14) 1820(40) 92 
O(01') 1926(11) 5085(3) 2262(14) 32(4) 
 
 
 
 
Table 3.   Bond lengths [Å] and angles [°] for 2008js2. 
_____________________________________________________ 
C(1)-N(1)  1.500(3) 
C(1)-C(2)  1.516(3) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(2)  1.483(3) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-N(2)  1.494(3) 
C(3)-C(4)  1.513(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-N(3)  1.482(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-N(3)  1.490(3) 
C(5)-C(6)  1.517(3) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-N(4)  1.483(3) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-N(4)  1.495(3) 
C(7)-C(8)  1.507(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-N(1)  1.485(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-O(1)  1.254(3) 
C(9)-O(2)  1.257(3) 
C(9)-C(10)  1.521(3) 
C(10)-N(2)  1.476(3) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-O(3)  1.250(3) 
C(11)-O(4)  1.261(3) 
C(11)-C(12)  1.515(3) 
C(12)-N(3)  1.482(3) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-O(5)  1.246(3) 
C(13)-O(6)  1.264(3) 
C(13)-C(14)  1.523(3) 
C(14)-N(4)  1.478(3) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-N(1)  1.484(3) 
C(15)-C(16)  1.519(3) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-O(7)  1.246(3) 
C(16)-N(5)  1.338(3) 
C(17)-N(5)  1.497(3) 
C(17)-C(24)  1.525(3) 
C(17)-C(18)  1.529(3) 
C(17)-H(17)  1.0000 
C(18)-C(19)  1.389(3) 
C(18)-C(23)  1.393(3) 
C(19)-C(20)  1.397(3) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.381(4) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.385(4) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.387(4) 
C(22)-H(22)  0.9500 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.390(3) 
C(24)-C(29)  1.390(3) 
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C(25)-C(26)  1.386(3) 
C(25)-H(25)  0.9500 
C(26)-C(27)  1.387(4) 
C(26)-H(26)  0.9500 
C(27)-C(28)  1.383(4) 
C(27)-H(27)  0.9500 
C(28)-C(29)  1.393(4) 
C(28)-H(28)  0.9500 
C(29)-H(29)  0.9500 
C(30)-N(5)  1.478(3) 
C(30)-C(31)  1.525(3) 
C(30)-C(37)  1.554(3) 
C(30)-H(30)  1.0000 
C(31)-C(36)  1.391(3) 
C(31)-C(32)  1.392(3) 
C(32)-C(33)  1.390(3) 
C(32)-H(32)  0.9500 
C(33)-C(34)  1.382(4) 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.384(4) 
C(34)-H(34)  0.9500 
C(35)-C(36)  1.386(4) 
C(35)-H(35)  0.9500 
C(36)-H(36)  0.9500 
C(37)-O(8)  1.230(3) 
C(37)-N(6)  1.331(3) 
C(38)-N(6)  1.456(3) 
C(38)-C(39)  1.518(3) 
C(38)-H(38A)  0.9900 
C(38)-H(38B)  0.9900 
C(39)-C(40)  1.386(3) 
C(39)-C(44)  1.392(3) 
C(40)-C(41)  1.394(4) 
C(40)-H(40)  0.9500 
C(41)-C(42)  1.376(4) 
C(41)-H(41)  0.9500 
C(42)-C(43)  1.380(4) 
C(42)-H(42)  0.9500 
C(43)-C(44)  1.388(4) 
C(43)-H(43)  0.9500 
C(44)-H(44)  0.9500 
N(1)-Tb  2.7150(18) 
N(2)-Tb  2.6216(18) 
N(3)-Tb  2.6037(18) 
N(4)-Tb  2.6250(18) 
N(6)-H(6)  0.8800 
O(2)-Tb  2.3329(14) 
O(4)-Tb  2.3527(14) 
O(6)-Tb  2.3467(15) 
O(7)-Tb  2.3545(14) 
O(9)-Tb  2.3698(15) 
O(9)-D(9A)  0.897(17) 
O(9)-D(9B)  0.909(17) 
O(101)-D(1WA)  0.917(17) 
O(101)-D(1WB)  0.910(17) 
O(201)-D(2WA)  0.920(17) 
O(201)-D(2WB)  0.937(17) 
O(301)-D(3WA)  0.933(18) 
O(301)-D(3WB)  0.922(18) 
O(401)-D(4WA)  0.921(18) 
O(401)-D(4WB)  0.923(18) 
O(501)-D(5WA)  0.924(18) 
O(501)-D(5WB)  0.915(18) 
O(601)-D(6WA)  0.921(18) 
O(601)-D(6WB)  0.917(18) 
O(701)-D(7WA)  0.941(19) 
O(701)-D(7WB)  0.959(19) 
O(801)-D(8WA)  0.915(19) 
O(801)-D(8WB)  0.935(19) 
O(901)-D(9WA)  0.960(19) 
O(901)-D(9WB)  0.946(19) 
O(001)-D(0WA)  0.93(2) 
O(01')-D(0WA)  1.18(6)N(1)-C(1)-C(2) 
N(1)-C(1)-H(1A) 109.4 
C(2)-C(1)-H(1A) 109.4 
N(1)-C(1)-H(1B) 109.4 
C(2)-C(1)-H(1B) 109.4 
H(1A)-C(1)-H(1B) 108.0 
N(2)-C(2)-C(1) 113.23(18) 
N(2)-C(2)-H(2A) 108.9 
C(1)-C(2)-H(2A) 108.9 
N(2)-C(2)-H(2B) 108.9 
C(1)-C(2)-H(2B) 108.9 
H(2A)-C(2)-H(2B) 107.7 
N(2)-C(3)-C(4) 111.71(18) 
N(2)-C(3)-H(3A) 109.3 
C(4)-C(3)-H(3A) 109.3 
N(2)-C(3)-H(3B) 109.3 
C(4)-C(3)-H(3B) 109.3 
H(3A)-C(3)-H(3B) 107.9 
N(3)-C(4)-C(3) 113.21(19) 
N(3)-C(4)-H(4A) 108.9 
C(3)-C(4)-H(4A) 108.9 
N(3)-C(4)-H(4B) 108.9 
C(3)-C(4)-H(4B) 108.9 
H(4A)-C(4)-H(4B) 107.7 
N(3)-C(5)-C(6) 111.44(18) 
N(3)-C(5)-H(5A) 109.3 
C(6)-C(5)-H(5A) 109.3 
N(3)-C(5)-H(5B) 109.3 
C(6)-C(5)-H(5B) 109.3 
H(5A)-C(5)-H(5B) 108.0 
N(4)-C(6)-C(5) 113.53(19) 
N(4)-C(6)-H(6A) 108.9 
C(5)-C(6)-H(6A) 108.9 
N(4)-C(6)-H(6B) 108.9 
C(5)-C(6)-H(6B) 108.9 
H(6A)-C(6)-H(6B) 107.7 
N(4)-C(7)-C(8) 111.69(18) 
N(4)-C(7)-H(7A) 109.3 
C(8)-C(7)-H(7A) 109.3 
N(4)-C(7)-H(7B) 109.3 
C(8)-C(7)-H(7B) 109.3 
H(7A)-C(7)-H(7B) 107.9 
N(1)-C(8)-C(7) 111.93(18) 
N(1)-C(8)-H(8A) 109.2 
C(7)-C(8)-H(8A) 109.2 
N(1)-C(8)-H(8B) 109.2 
C(7)-C(8)-H(8B) 109.2 
H(8A)-C(8)-H(8B) 107.9 
O(1)-C(9)-O(2) 124.0(2) 
O(1)-C(9)-C(10) 118.11(19) 
O(2)-C(9)-C(10) 117.83(18) 
N(2)-C(10)-C(9) 113.32(17) 
N(2)-C(10)-H(10A) 108.9 
C(9)-C(10)-H(10A) 108.9 
N(2)-C(10)-H(10B) 108.9 
C(9)-C(10)-H(10B) 108.9 
H(10A)-C(10)-H(10B) 107.7 
O(3)-C(11)-O(4) 124.4(2) 
O(3)-C(11)-C(12) 117.7(2) 
O(4)-C(11)-C(12) 117.88(19) 
N(3)-C(12)-C(11) 112.34(18) 
N(3)-C(12)-H(12A) 109.1 
C(11)-C(12)-H(12A) 109.1 
N(3)-C(12)-H(12B) 109.1 
C(11)-C(12)-H(12B) 109.1 
H(12A)-C(12)-H(12B) 107.9 
O(5)-C(13)-O(6) 124.8(2) 
O(5)-C(13)-C(14) 117.7(2) 
O(6)-C(13)-C(14) 117.45(19) 
N(4)-C(14)-C(13) 113.43(18) 
N(4)-C(14)-H(14A) 108.9 
C(13)-C(14)-H(14A) 108.9 
N(4)-C(14)-H(14B) 108.9 
C(13)-C(14)-H(14B) 108.9 
H(14A)-C(14)-H(14B) 107.7 
N(1)-C(15)-C(16) 112.41(17) 
N(1)-C(15)-H(15A) 109.1 
C(16)-C(15)-H(15A) 109.1 
N(1)-C(15)-H(15B) 109.1 
C(16)-C(15)-H(15B) 109.1 
H(15A)-C(15)-H(15B) 107.9 
O(7)-C(16)-N(5) 120.34(19) 
O(7)-C(16)-C(15) 120.34(18) 
N(5)-C(16)-C(15) 119.29(18) 
N(5)-C(17)-C(24) 111.04(18) 
N(5)-C(17)-C(18) 112.77(17) 
C(24)-C(17)-C(18) 113.19(18) 
N(5)-C(17)-H(17) 106.4 
C(24)-C(17)-H(17) 106.4 
C(18)-C(17)-H(17) 106.4 
C(19)-C(18)-C(23) 118.8(2) 
C(19)-C(18)-C(17) 123.4(2) 
C(23)-C(18)-C(17) 117.8(2) 
C(18)-C(19)-C(20) 120.2(2) 
C(18)-C(19)-H(19) 119.9 
C(20)-C(19)-H(19) 119.9 
C(21)-C(20)-C(19) 120.5(2) 
C(21)-C(20)-H(20) 119.8 
C(19)-C(20)-H(20) 119.8 
C(20)-C(21)-C(22) 119.5(2) 
C(20)-C(21)-H(21) 120.3 
C(22)-C(21)-H(21) 120.3 
C(21)-C(22)-C(23) 120.2(2) 
C(21)-C(22)-H(22) 119.9 
C(23)-C(22)-H(22) 119.9 
C(22)-C(23)-C(18) 120.7(2) 
C(22)-C(23)-H(23) 119.6 
C(18)-C(23)-H(23) 119.6 
C(25)-C(24)-C(29) 119.2(2) 
C(25)-C(24)-C(17) 121.5(2) 
C(29)-C(24)-C(17) 119.3(2) 
C(26)-C(25)-C(24) 120.9(2) 
C(26)-C(25)-H(25) 119.6 
C(24)-C(25)-H(25) 119.6 
C(25)-C(26)-C(27) 119.7(2) 
C(25)-C(26)-H(26) 120.2 
C(27)-C(26)-H(26) 120.2 
C(28)-C(27)-C(26) 120.0(2) 
C(28)-C(27)-H(27) 120.0 
C(26)-C(27)-H(27) 120.0 
C(27)-C(28)-C(29) 120.3(2) 
C(27)-C(28)-H(28) 119.9 
C(29)-C(28)-H(28) 119.9 
C(24)-C(29)-C(28) 120.0(2) 
C(24)-C(29)-H(29) 120.0 
C(28)-C(29)-H(29) 120.0 
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N(5)-C(30)-C(31) 113.72(17) 
N(5)-C(30)-C(37) 111.28(17) 
C(31)-C(30)-C(37) 115.69(18) 
N(5)-C(30)-H(30) 105.0 
C(31)-C(30)-H(30) 105.0 
C(37)-C(30)-H(30) 105.0 
C(36)-C(31)-C(32) 118.8(2) 
C(36)-C(31)-C(30) 118.5(2) 
C(32)-C(31)-C(30) 122.7(2) 
C(33)-C(32)-C(31) 120.1(2) 
C(33)-C(32)-H(32) 119.9 
C(31)-C(32)-H(32) 119.9 
C(34)-C(33)-C(32) 120.6(2) 
C(34)-C(33)-H(33) 119.7 
C(32)-C(33)-H(33) 119.7 
C(33)-C(34)-C(35) 119.5(2) 
C(33)-C(34)-H(34) 120.3 
C(35)-C(34)-H(34) 120.3 
C(34)-C(35)-C(36) 120.1(2) 
C(34)-C(35)-H(35) 119.9 
C(36)-C(35)-H(35) 119.9 
C(35)-C(36)-C(31) 120.8(2) 
C(35)-C(36)-H(36) 119.6 
C(31)-C(36)-H(36) 119.6 
O(8)-C(37)-N(6) 123.0(2) 
O(8)-C(37)-C(30) 119.84(19) 
N(6)-C(37)-C(30) 116.78(19) 
N(6)-C(38)-C(39) 113.66(19) 
N(6)-C(38)-H(38A) 108.8 
C(39)-C(38)-H(38A) 108.8 
N(6)-C(38)-H(38B) 108.8 
C(39)-C(38)-H(38B) 108.8 
H(38A)-C(38)-H(38B) 107.7 
C(40)-C(39)-C(44) 118.7(2) 
C(40)-C(39)-C(38) 119.5(2) 
C(44)-C(39)-C(38) 121.8(2) 
C(39)-C(40)-C(41) 120.8(2) 
C(39)-C(40)-H(40) 119.6 
C(41)-C(40)-H(40) 119.6 
C(42)-C(41)-C(40) 120.0(2) 
C(42)-C(41)-H(41) 120.0 
C(40)-C(41)-H(41) 120.0 
C(41)-C(42)-C(43) 119.6(2) 
C(41)-C(42)-H(42) 120.2 
C(43)-C(42)-H(42) 120.2 
C(42)-C(43)-C(44) 120.7(2) 
C(42)-C(43)-H(43) 119.7 
C(44)-C(43)-H(43) 119.7 
C(43)-C(44)-C(39) 120.2(2) 
C(43)-C(44)-H(44) 119.9 
C(39)-C(44)-H(44) 119.9 
C(15)-N(1)-C(8) 110.40(17) 
C(15)-N(1)-C(1) 109.47(16) 
C(8)-N(1)-C(1) 108.62(17) 
C(15)-N(1)-Tb 107.91(12) 
C(8)-N(1)-Tb 110.45(13) 
C(1)-N(1)-Tb 109.98(12) 
C(10)-N(2)-C(2) 109.92(17) 
C(10)-N(2)-C(3) 110.04(17) 
C(2)-N(2)-C(3) 108.54(17) 
C(10)-N(2)-Tb 105.26(13) 
C(2)-N(2)-Tb 112.77(13) 
C(3)-N(2)-Tb 110.28(13) 
C(12)-N(3)-C(4) 110.03(18) 
C(12)-N(3)-C(5) 110.11(17) 
C(4)-N(3)-C(5) 108.94(18) 
C(12)-N(3)-Tb 105.83(13) 
C(4)-N(3)-Tb 111.61(13) 
C(5)-N(3)-Tb 110.29(13) 
C(14)-N(4)-C(6) 109.98(18) 
C(14)-N(4)-C(7) 108.41(17) 
C(6)-N(4)-C(7) 109.38(18) 
C(14)-N(4)-Tb 106.60(13) 
C(6)-N(4)-Tb 109.82(13) 
C(7)-N(4)-Tb 112.60(13) 
C(16)-N(5)-C(30) 118.78(17) 
C(16)-N(5)-C(17) 122.04(18) 
C(30)-N(5)-C(17) 119.13(17) 
C(37)-N(6)-C(38) 121.20(19) 
C(37)-N(6)-H(6) 119.4 
C(38)-N(6)-H(6) 119.4 
C(9)-O(2)-Tb 123.82(13) 
C(11)-O(4)-Tb 123.31(14) 
C(13)-O(6)-Tb 124.70(14) 
C(16)-O(7)-Tb 124.45(13) 
Tb-O(9)-D(9A) 128.1(18) 
Tb-O(9)-D(9B) 117.0(18) 
D(9A)-O(9)-D(9B) 113(2) 
O(2)-Tb-O(6) 144.98(5) 
O(2)-Tb-O(4) 85.57(5) 
O(6)-Tb-O(4) 88.25(5) 
O(2)-Tb-O(7) 79.51(5) 
O(6)-Tb-O(7) 86.16(5) 
O(4)-Tb-O(7) 144.85(5) 
O(2)-Tb-O(9) 73.10(5) 
O(6)-Tb-O(9) 72.27(5) 
O(4)-Tb-O(9) 71.22(6) 
O(7)-Tb-O(9) 74.02(5) 
O(2)-Tb-N(3) 133.54(6) 
O(6)-Tb-N(3) 73.42(6) 
O(4)-Tb-N(3) 66.63(6) 
O(7)-Tb-N(3) 142.86(5) 
O(9)-Tb-N(3) 125.46(6) 
O(2)-Tb-N(2) 66.96(5) 
O(6)-Tb-N(2) 142.04(6) 
O(4)-Tb-N(2) 71.56(6) 
O(7)-Tb-N(2) 128.55(5) 
O(9)-Tb-N(2) 126.47(6) 
N(3)-Tb-N(2) 69.14(6) 
O(2)-Tb-N(4) 136.58(5) 
O(6)-Tb-N(4) 66.64(6) 
O(4)-Tb-N(4) 134.19(6) 
O(7)-Tb-N(4) 73.90(5) 
O(9)-Tb-N(4) 128.71(6) 
N(3)-Tb-N(4) 69.61(6) 
N(2)-Tb-N(4) 104.83(6) 
O(2)-Tb-N(1) 70.54(5) 
O(6)-Tb-N(1) 130.58(5) 
O(4)-Tb-N(1) 138.25(5) 
O(7)-Tb-N(1) 64.76(5) 
O(9)-Tb-N(1) 128.65(5) 
N(3)-Tb-N(1) 105.87(6) 
N(2)-Tb-N(1) 67.74(6) 
N(4)-Tb-N(1) 67.26(6) 
D(1WA)-O(101)-D(1WB) 109(2) 
D(2WA)-O(201)-D(2WB) 104(2) 
D(3WA)-O(301)-D(3WB) 107(3) 
D(4WA)-O(401)-D(4WB) 110(3) 
D(5WA)-O(501)-D(5WB) 105(3) 
D(6WA)-O(601)-D(6WB) 104(3) 
D(7WA)-O(701)-D(7WB) 101(3) 
D(8WA)-O(801)-D(8WB) 119(3) 
D(9WA)-O(901)-D(9WB) 107(3) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
 
 
 
 
 
Table 4.   Anisotropic displacement parameters (Å2x 103)for 2008js2.  The anisotropic 
displacement factor exponent takes the form: -22[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 18(1)  16(1) 12(1)  2(1) 6(1)  1(1) 
C(2) 20(1)  15(1) 16(1)  -3(1) 6(1)  0(1) 
C(3) 23(1)  11(1) 21(1)  -5(1) 6(1)  -1(1) 
C(4) 22(1)  13(1) 26(1)  -1(1) 8(1)  4(1) 
C(5) 13(1)  18(1) 23(1)  2(1) 4(1)  5(1) 
C(6) 12(1)  22(1) 22(1)  1(1) 6(1)  2(1) 
C(7) 13(1)  18(1) 21(1)  0(1) 7(1)  -3(1) 
C(8) 16(1)  17(1) 21(1)  2(1) 10(1)  0(1) 
C(9) 12(1)  13(1) 12(1)  2(1) 4(1)  -1(1) 
C(10) 12(1)  15(1) 15(1)  -2(1) 0(1)  0(1) 
C(11) 17(1)  14(1) 24(1)  4(1) 3(1)  -4(1) 
C(12) 18(1)  10(1) 29(1)  5(1) 6(1)  2(1) 
C(13) 16(1)  11(1) 17(1)  1(1) 6(1)  3(1) 
C(14) 10(1)  21(1) 14(1)  1(1) -1(1)  -2(1) 
C(15) 14(1)  9(1) 14(1)  0(1) 5(1)  0(1) 
C(16) 6(1)  11(1) 13(1)  -1(1) 1(1)  -2(1) 
C(17) 17(1)  9(1) 11(1)  1(1) 3(1)  0(1) 
C(18) 18(1)  10(1) 16(1)  -2(1) 9(1)  1(1) 
C(19) 21(1)  18(1) 24(1)  5(1) 7(1)  -1(1) 
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C(20) 19(1)  30(1) 30(1)  4(1) 6(1)  -3(1) 
C(21) 24(1)  22(1) 41(2)  0(1) 20(1)  -5(1) 
C(22) 31(1)  17(1) 38(2)  9(1) 22(1)  3(1) 
C(23) 21(1)  16(1) 26(1)  5(1) 12(1)  5(1) 
C(24) 17(1)  11(1) 18(1)  4(1) 7(1)  2(1) 
C(25) 19(1)  16(1) 20(1)  -1(1) 6(1)  0(1) 
C(26) 30(1)  17(1) 33(1)  -2(1) 16(1)  3(1) 
C(27) 23(1)  23(1) 55(2)  6(1) 22(1)  7(1) 
C(28) 16(1)  25(1) 52(2)  4(1) 9(1)  1(1) 
C(29) 19(1)  13(1) 32(1)  1(1) 3(1)  -1(1) 
C(30) 15(1)  11(1) 12(1)  -2(1) 3(1)  0(1) 
C(31) 16(1)  15(1) 13(1)  3(1) 4(1)  3(1) 
C(32) 18(1)  18(1) 18(1)  0(1) 7(1)  2(1) 
C(33) 16(1)  27(1) 28(1)  -2(1) 6(1)  -1(1) 
C(34) 21(1)  41(2) 39(2)  1(1) 17(1)  1(1) 
C(35) 33(2)  40(2) 32(2)  -5(1) 22(1)  5(1) 
C(36) 26(1)  25(1) 21(1)  -5(1) 10(1)  1(1) 
C(37) 18(1)  10(1) 11(1)  -4(1) 4(1)  -1(1) 
C(38) 21(1)  16(1) 16(1)  3(1) 6(1)  3(1) 
C(39) 18(1)  14(1) 13(1)  4(1) 7(1)  -2(1) 
C(40) 18(1)  31(1) 22(1)  1(1) 8(1)  2(1) 
C(41) 23(1)  47(2) 22(1)  -3(1) 2(1)  -10(1) 
C(42) 47(2)  25(1) 20(1)  -5(1) 12(1)  -12(1) 
C(43) 45(2)  16(1) 22(1)  3(1) 18(1)  7(1) 
C(44) 23(1)  19(1) 18(1)  5(1) 7(1)  7(1) 
N(1) 15(1)  11(1) 14(1)  -1(1) 7(1)  1(1) 
N(2) 14(1)  12(1) 17(1)  -3(1) 3(1)  1(1) 
N(3) 12(1)  12(1) 24(1)  2(1) 5(1)  2(1) 
N(4) 12(1)  18(1) 13(1)  1(1) 3(1)  -1(1) 
N(5) 13(1)  10(1) 11(1)  1(1) 3(1)  0(1) 
N(6) 17(1)  18(1) 14(1)  2(1) 4(1)  0(1) 
O(1) 11(1)  23(1) 16(1)  -1(1) 0(1)  4(1) 
O(2) 10(1)  13(1) 13(1)  0(1) 2(1)  2(1) 
O(3) 24(1)  19(1) 66(1)  15(1) 12(1)  -4(1) 
O(4) 14(1)  9(1) 23(1)  2(1) 5(1)  -3(1) 
O(5) 19(1)  21(1) 14(1)  3(1) 2(1)  0(1) 
O(6) 12(1)  19(1) 16(1)  5(1) 3(1)  0(1) 
O(7) 13(1)  9(1) 12(1)  -1(1) 4(1)  -2(1) 
O(8) 14(1)  18(1) 18(1)  2(1) 4(1)  -1(1) 
O(9) 12(1)  24(1) 15(1)  -2(1) 6(1)  -3(1) 
Tb 8(1)  8(1) 11(1)  1(1) 2(1)  -1(1) 
O(101) 18(1)  28(1) 16(1)  3(1) 2(1)  1(1) 
O(201) 26(1)  18(1) 32(1)  6(1) 17(1)  3(1) 
O(301) 20(1)  41(1) 31(1)  2(1) 12(1)  -2(1) 
O(401) 26(1)  41(1) 23(1)  1(1) 10(1)  -10(1) 
O(501) 26(1)  24(1) 36(1)  3(1) 2(1)  -5(1) 
O(601) 20(1)  33(1) 37(1)  -5(1) 7(1)  2(1) 
O(701) 71(2)  35(1) 90(2)  8(1) 67(2)  2(1) 
O(801) 66(2)  75(2) 88(2)  29(2) 58(2)  27(2) 
O(901) 37(1)  132(3) 62(2)  51(2) 25(1)  13(2) 
O(001) 88(3)  34(2) 89(3)  -5(2) 66(3)  -6(2) 
O(01') 23(7)  24(6) 58(10)  4(6) 26(6)  1(5) 
 
 
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for 2008js2. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 2373 1160 -695 18 
H(1B) 1118 1148 -349 18 
H(2A) 1361 673 -1257 21 
H(2B) 2770 629 -204 21 
H(3A) 1484 146 -483 22 
H(3B) 985 83 624 22 
H(4A) 3096 -104 1199 25 
H(4B) 3581 232 961 25 
H(5A) 5068 38 3006 22 
H(5B) 4870 203 4164 22 
H(6A) 6186 513 3443 23 
H(6B) 5072 526 2080 23 
H(7A) 5955 1063 2811 20 
H(7B) 4962 1270 3174 20 
H(8A) 4446 1286 1002 20 
H(8B) 4295 916 927 20 
H(10A) -485 418 188 19 
H(10B) -408 610 -966 19 
H(12A) 3139 -20 4069 24 
H(12B) 2759 -234 2848 24 
H(14A) 5278 1070 4900 20 
H(14B) 6204 778 5018 20 
H(15A) 1667 1520 889 15 
H(15B) 3172 1601 1377 15 
H(17) 1856 1985 1553 16 
H(19) 4679 1972 4121 25 
H(20) 6540 2261 4400 32 
H(21) 6452 2684 3105 32 
H(22) 4511 2807 1475 31 
H(23) 2647 2527 1213 24 
H(25) 2387 2565 3865 22 
H(26) 795 2873 4131 31 
H(27) -1380 2760 3006 38 
H(28) -1951 2343 1612 39 
H(29) -354 2033 1348 28 
H(30) 2483 2015 4711 16 
H(32) 295 1442 2943 21 
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H(33) -1719 1350 3038 29 
H(34) -2260 1575 4610 38 
H(35) -785 1901 6082 39 
H(36) 1211 2002 5970 28 
H(38A) 4869 1246 7155 22 
H(38B) 3791 1115 7618 22 
H(40) 6470 1365 9141 28 
H(41) 7245 1675 10935 39 
H(42) 5865 2018 11381 37 
H(43) 3716 2052 10030 32 
H(44) 2931 1744 8237 24 
H(6) 2320 1420 6193 20 
 
 
 
Table 6.  Hydrogen bonds for 2008js2 [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(6)-H(6)...O(401) 0.88 2.29 2.900(3) 126.0 
 O(9)-D(9A)...O(401) 0.897(17) 1.932(19) 2.797(2) 162(3) 
 O(9)-D(9B)...O(301)#1 0.909(17) 1.886(19) 2.767(2) 163(3) 
 O(101)-D(1WA)...O(5)#2 0.917(17) 1.827(18) 2.743(2) 177(3) 
 O(101)-D(1WB)...O(1)#3 0.910(17) 1.781(18) 2.681(2) 170(3) 
 O(201)-D(2WA)...O(101)#4 0.920(17) 1.856(19) 2.761(2) 167(3) 
 O(201)-D(2WB)...O(3) 0.937(17) 1.771(18) 2.698(2) 169(3) 
 O(301)-D(3WA)...O(201)#5 0.933(18) 1.93(2) 2.828(3) 161(3) 
 O(301)-D(3WB)...O(001)#6 0.922(18) 1.869(18) 2.790(4) 177(3) 
 O(301)-D(3WB)...O(01')#6 0.922(18) 1.82(3) 2.592(11) 140(3) 
 O(401)-D(4WA)...O(701) 0.921(18) 1.970(19) 2.874(3) 167(3) 
 O(401)-D(4WB)...O(201)#7 0.923(18) 1.91(2) 2.803(3) 164(3) 
 O(501)-D(5WA)...O(1) 0.924(18) 2.08(2) 2.950(2) 157(3) 
 O(501)-D(5WB)...O(601)#8 0.915(18) 2.06(2) 2.957(3) 167(3) 
 O(601)-D(6WA)...O(8)#2 0.921(18) 2.05(2) 2.933(2) 160(3) 
 O(601)-D(6WB)...O(101) 0.917(18) 1.98(2) 2.877(3) 165(3) 
 O(701)-D(7WA)...O(5) 0.941(19) 1.911(19) 2.851(3) 179(5) 
 O(701)-D(7WA)...O(6) 0.941(19) 2.55(4) 3.166(3) 123(3) 
 O(701)-D(7WB)...O(001)#9 0.959(19) 2.19(4) 2.908(5) 131(4) 
 O(801)-D(8WA)...O(901) 0.915(19) 2.11(4) 2.811(5) 132(4) 
 O(801)-D(8WB)...O(701)#10 0.935(19) 2.08(5) 2.776(4) 130(5) 
 O(901)-D(9WA)...O(301) 0.960(19) 1.90(2) 2.844(4) 168(5) 
 O(901)-D(9WB)...O(1)#11 0.946(19) 1.94(2) 2.874(3) 167(5) 
 O(001)-D(0WA)...O(3)#3 0.93(2) 1.89(4) 2.673(4) 140(5) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 -x+1,y+1/2,-z+3/2    #3 -x,y+1/2,-z+1/2  
#4 x,-y+1/2,z-1/2    #5 -x+1,-y,-z+1    #6 -x+1,y-1/2,-z+1/2  
#7 -x,-y,-z+1    #8 -x,y-1/2,-z+1/2    #9 x,-y+1/2,z+1/2  
#10 x,y,z-1    #11 x+1,y,z  
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Appendix 1d: Benzyl Ytterbium Ugi complex M20M. Crystal structure 
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Table 1.  Crystal data and structure refinement for B2Yb. 
Identification code  B2Yb, 2009src0812 
Empirical formula  C44 H49 D2 N6 O9 Yb, 10(D2 O) 
Formula weight  1183.25 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 2(1)/c 
Unit cell dimensions a = 11.1950(4) Å a= 90°. 
 b = 42.9194(14) Å b= 112.2910(10)°. 
 c = 11.5718(4) Å g = 90°. 
Volume 5144.5(3) Å
3 
Z 4 
Density (calculated) 1.528 Mg/m
3 
Absorption coefficient 1.896 mm
-1 
F(000) 2396 
Crystal size 0.68 x 0.20 x 0.06 mm
3 
Theta range for data collection 3.04 to 25.68°. 
Index ranges -13<=h<=13, -52<=k<=48, -14<=l<=14 
Reflections collected 27619 
Independent reflections 9207 [R(int) = 0.0566] 
Completeness to theta = 25.68° 94.2 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8947 and 0.3588 
Refinement method Full-matrix least-squares on F
2 
Data / restraints / parameters 9207 / 104 / 693 
Goodness-of-fit on F
2
 1.085 
Final R indices [I>2sigma(I)] R1 = 0.0629, wR2 = 0.1889 
R indices (all data) R1 = 0.0863, wR2 = 0.2337 
Largest diff. peak and hole 1.720 and -2.443 e.Å
-3 
 
Notes: 
The water molecule O(701)/O(71') is disordered over two sites at a ratio of 0.51 (7): 0.49 (7) and is refined 
isotropically while O(001)/O(01’) is disordered over two sites at a ratio of 0.73 (3): 0.27 (3) and O(01') is refined 
isotropically.  No deuterium atoms could be located in the electron density map for O(701)/O(71') or for O(01'). 
 
The hydrogen atoms in the ytterbium complex were fixed as riding models while the deuterium atoms (belonging 
to both bound and free water molecules) were located in the electron density map. The positions of these 
deuterium atoms were refined subject to restraints while the isotropic thermal parameters were fixed at a value of 
1.5Ueq of the parent oxygen atom. 
 
 
Table 2.  Atomic coordinates ( x 10
4
) and equivalent isotropic displacement parameters (Å
2
x 10
3
) 
for B2Yb.  U(eq) is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 1986(8) 1057(2) -161(8) 19(2) 
C(2) 1898(9) 709(2) -367(8) 16(2) 
C(3) 1624(9) 197(2) 399(9) 22(2) 
C(4) 2986(9) 129(2) 1279(9) 22(2) 
C(5) 4694(8) 235(2) 3286(8) 22(2) 
C(6) 5251(9) 534(2) 2993(9) 26(2) 
C(7) 5026(8) 1095(2) 2720(8) 19(2) 
C(8) 4168(8) 1109(2) 1338(9) 21(2) 
C(9) -425(8) 892(2) 473(8) 14(2) 
C(10) -59(8) 591(2) -39(8) 19(2) 
C(11) 1262(9) 54(2) 2871(8) 24(2) 
C(12) 2681(10) -4(3) 3173(11) 34(2) 
C(13) 4562(9) 681(2) 5377(9) 22(2) 
C(14) 5245(8) 866(2) 4690(8) 17(2) 
C(15) 2475(8) 1456(2) 1443(7) 16(2) 
C(16) 2513(7) 1483(2) 2773(7) 15(2) 
C(17) 2166(8) 2055(2) 2415(8) 18(2) 
C(18) 1136(8) 2267(2) 2572(8) 18(2) 
C(19) -168(9) 2202(2) 1873(10) 28(2) 
C(20) -1120(10) 2386(2) 2035(11) 32(2) 
C(21) -782(10) 2633(3) 2864(12) 38(3) 
C(22) 528(10) 2704(2) 3537(10) 31(2) 
C(23) 1474(9) 2517(2) 3380(9) 20(2) 
C(24) 3433(8) 2224(2) 2640(9) 20(2) 
C(25) 3394(9) 2473(2) 1826(9) 25(2) 
C(26) 4506(10) 2637(2) 2003(9) 27(2) 
C(27) 5654(10) 2566(3) 2943(10) 31(2) 
C(28) 5693(10) 2315(3) 3712(10) 34(3) 
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C(29) 4598(9) 2140(2) 3575(9) 25(2) 
C(30) 2255(8) 1786(2) 4425(8) 19(2) 
C(31) 923(8) 1723(2) 4420(8) 19(2) 
C(32) 28(9) 1536(2) 3548(9) 22(2) 
C(33) -1191(9) 1484(2) 3587(9) 27(2) 
C(34) -1489(10) 1618(3) 4528(11) 42(3) 
C(35) -623(10) 1808(3) 5398(11) 41(3) 
C(36) 581(10) 1870(3) 5335(10) 32(2) 
C(37) 3380(9) 1604(2) 5423(8) 19(2) 
C(38) 4092(10) 1304(2) 7369(8) 26(2) 
C(39) 4580(9) 1523(2) 8477(8) 20(2) 
C(40) 5861(9) 1503(2) 9283(9) 27(2) 
C(41) 6331(11) 1688(3) 10331(11) 41(3) 
C(42) 5515(12) 1895(3) 10605(10) 39(3) 
C(43) 4247(10) 1916(2) 9807(9) 27(2) 
C(44) 3778(9) 1728(2) 8753(9) 25(2) 
N(1) 2777(6) 1135(2) 1162(6) 16(2) 
N(2) 1360(6) 545(2) 446(6) 14(2) 
N(3) 3287(7) 223(2) 2608(7) 21(2) 
N(4) 4695(7) 816(2) 3315(7) 15(2) 
N(5) 2343(7) 1762(2) 3191(6) 15(2) 
N(6) 3087(8) 1443(2) 6263(7) 23(2) 
O(1) -1515(6) 1010(2) -106(6) 24(2) 
O(2) 392(5) 996(1) 1491(5) 16(1) 
O(3) 561(6) -169(2) 2911(7) 35(2) 
O(4) 884(5) 334(1) 2586(5) 17(1) 
O(5) 5138(6) 618(2) 6494(6) 25(2) 
O(6) 3391(5) 597(2) 4719(5) 18(1) 
O(7) 2683(6) 1249(1) 3439(5) 17(1) 
O(8) 4495(6) 1643(2) 5509(6) 22(1) 
O(9) 1011(6) 856(2) 3942(6) 23(1) 
Yb(1) 2222(1) 746(1) 2716(1) 13(1) 
D(9A) 210(30) 753(16) 3600(50) 20 
D(9B) 1490(40) 794(18) 4770(20) 20 
O(101) 1120(7) -751(1) 3874(7) 25(2) 
D(1WA) 1710(80) -820(20) 3510(90) 38 
D(1WB) 770(90) -559(13) 3490(90) 38 
O(201) 7381(6) 962(2) 7391(6) 24(1) 
D(2WA) 6650(70) 830(20) 7220(80) 35 
D(2WB) 7810(80) 970(20) 8280(20) 35 
O(301) 9307(7) 1635(2) 9548(7) 36(2) 
D(3WA) 8880(90) 1463(19) 9730(100) 54 
D(3WB) 8730(80) 1710(20) 8770(60) 54 
O(401) 8558(7) 647(2) 3615(7) 38(2) 
D(4WA) 8560(120) 690(30) 4420(40) 57 
D(4WB) 7890(90) 760(30) 3010(70) 57 
O(501) 7286(7) 1632(2) 6998(7) 37(2) 
D(5WA) 6420(40) 1700(20) 6670(110) 55 
D(5WB) 7290(100) 1412(5) 7020(120) 55 
O(601) 1386(7) 959(2) 6456(7) 42(2) 
D(6WA) 680(80) 1070(30) 6550(120) 63 
O(701) 6973(19) 837(8) 1300(20) 46(7) 
O(71') 6814(19) 715(8) 990(20) 38(7) 
O(801) 3194(12) 453(2) 7374(11) 71(3) 
D(8WA) 3870(80) 480(40) 7080(120) 106 
D(8WB) 2400(70) 500(50) 6680(90) 106 
O(901) 4928(12) 337(3) 9824(13) 90(4) 
D(9WA) 4520(150) 340(50) 8940(30) 135 
D(9WB) 5780(80) 420(50) 10070(150) 135 
O(001) 8787(16) -1(3) 3769(17) 73(7) 
D(0WA) 8700(200) 217(11) 3850(160) 91 
D(0WB) 9340(180) -80(40) 4560(90) 91 
O(01') 8080(40) 80(10) 2680(40) 61(14) 
 
Table 3.   Bond lengths [Å] and angles [°] for B2Yb. 
_____________________________________________________
C(1)-N(1)  1.486(11) 
C(1)-C(2)  1.510(11) 
C(1)-H(1A)  0.9900 
C(1)-H(1B)  0.9900 
C(2)-N(2)  1.474(11) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.507(12) 
C(3)-N(2)  1.524(11) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-N(3)  1.498(12) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-N(3)  1.471(11) 
C(5)-C(6)  1.520(13) 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-N(4)  1.472(12) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(7)-N(4)  1.495(11) 
C(7)-C(8)  1.522(12) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-N(1)  1.496(11) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-O(1)  1.256(10) 
C(9)-O(2)  1.267(10) 
C(9)-C(10)  1.538(12) 
C(9)-Yb(1)  3.173(8) 
C(10)-N(2)  1.484(10) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-O(3)  1.249(11) 
C(11)-O(4)  1.276(11) 
C(11)-C(12)  1.512(13) 
C(11)-Yb(1)  3.189(10) 
C(12)-N(3)  1.474(13) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-O(5)  1.235(11) 
C(13)-O(6)  1.292(11) 
C(13)-C(14)  1.521(13) 
C(13)-Yb(1)  3.210(9) 
C(14)-N(4)  1.488(11) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-N(1)  1.485(11) 
C(15)-C(16)  1.528(12) 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-O(7)  1.236(11) 
C(16)-N(5)  1.334(11) 
C(16)-Yb(1)  3.175(9) 
C(17)-N(5)  1.515(11) 
C(17)-C(24)  1.525(12) 
C(17)-C(18)  1.533(12) 
C(17)-H(17)  1.0000 
C(18)-C(23)  1.376(12) 
C(18)-C(19)  1.403(13) 
C(19)-C(20)  1.393(14) 
C(19)-H(19)  0.9500 
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C(20)-C(21)  1.385(16) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.407(15) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.395(12) 
C(22)-H(22)  0.9500 
C(23)-H(23)  0.9500 
C(24)-C(29)  1.390(13) 
C(24)-C(25)  1.414(13) 
C(25)-C(26)  1.377(13) 
C(25)-H(25)  0.9500 
C(26)-C(27)  1.367(14) 
C(26)-H(26)  0.9500 
C(27)-C(28)  1.387(15) 
C(27)-H(27)  0.9500 
C(28)-C(29)  1.396(14) 
C(28)-H(28)  0.9500 
C(29)-H(29)  0.9500 
C(30)-N(5)  1.471(11) 
C(30)-C(31)  1.514(12) 
C(30)-C(37)  1.558(12) 
C(30)-H(30)  1.0000 
C(31)-C(32)  1.377(13) 
C(31)-C(36)  1.406(13) 
C(32)-C(33)  1.400(13) 
C(32)-H(32)  0.9500 
C(33)-C(34)  1.381(15) 
C(33)-H(33)  0.9500 
C(34)-C(35)  1.370(17) 
C(34)-H(34)  0.9500 
C(35)-C(36)  1.403(14) 
C(35)-H(35)  0.9500 
C(36)-H(36)  0.9500 
C(37)-O(8)  1.225(11) 
C(37)-N(6)  1.332(12) 
C(38)-N(6)  1.472(12) 
C(38)-C(39)  1.514(13) 
C(38)-H(38A)  0.9900 
C(38)-H(38B)  0.9900 
C(39)-C(44)  1.379(13) 
C(39)-C(40)  1.386(13) 
C(40)-C(41)  1.377(15) 
C(40)-H(40)  0.9500 
C(41)-C(42)  1.394(17) 
C(41)-H(41)  0.9500 
C(42)-C(43)  1.372(16) 
C(42)-H(42)  0.9500 
C(43)-C(44)  1.389(14) 
C(43)-H(43)  0.9500 
C(44)-H(44)  0.9500 
N(1)-Yb(1)  2.692(7) 
N(2)-Yb(1)  2.581(7) 
N(3)-Yb(1)  2.570(8) 
N(4)-Yb(1)  2.605(7) 
N(6)-H(6)  0.8800 
O(2)-Yb(1)  2.270(6) 
O(4)-Yb(1)  2.286(6) 
O(6)-Yb(1)  2.278(6) 
O(7)-Yb(1)  2.299(6) 
O(9)-Yb(1)  2.351(6) 
O(9)-D(9A)  0.94(2) 
O(9)-D(9B)  0.94(2) 
O(101)-D(1WA)  0.95(2) 
O(101)-D(1WB)  0.95(2) 
O(201)-D(2WA)  0.95(2) 
O(201)-D(2WB)  0.95(2) 
O(301)-D(3WA)  0.95(2) 
O(301)-D(3WB)  0.95(2) 
O(401)-D(4WA)  0.95(2) 
O(401)-D(4WB)  0.94(2) 
O(501)-D(5WA)  0.95(2) 
O(501)-D(5WB)  0.95(2) 
O(601)-D(6WA)  0.96(2) 
O(801)-D(8WA)  0.95(2) 
O(801)-D(8WB)  0.96(2) 
O(901)-D(9WA)  0.95(2) 
O(901)-D(9WB)  0.95(2) 
O(001)-D(0WA)  0.95(2) 
O(001)-D(0WB)  0.95(2) 
 
N(1)-C(1)-C(2) 111.2(7) 
N(1)-C(1)-H(1A) 109.4 
C(2)-C(1)-H(1A) 109.4 
N(1)-C(1)-H(1B) 109.4 
C(2)-C(1)-H(1B) 109.4 
H(1A)-C(1)-H(1B) 108.0 
N(2)-C(2)-C(1) 112.9(7) 
N(2)-C(2)-H(2A) 109.0 
C(1)-C(2)-H(2A) 109.0 
N(2)-C(2)-H(2B) 109.0 
C(1)-C(2)-H(2B) 109.0 
H(2A)-C(2)-H(2B) 107.8 
C(4)-C(3)-N(2) 109.1(7) 
C(4)-C(3)-H(3A) 109.9 
N(2)-C(3)-H(3A) 109.9 
C(4)-C(3)-H(3B) 109.9 
N(2)-C(3)-H(3B) 109.9 
H(3A)-C(3)-H(3B) 108.3 
N(3)-C(4)-C(3) 114.7(7) 
N(3)-C(4)-H(4A) 108.6 
C(3)-C(4)-H(4A) 108.6 
N(3)-C(4)-H(4B) 108.6 
C(3)-C(4)-H(4B) 108.6 
H(4A)-C(4)-H(4B) 107.6 
N(3)-C(5)-C(6) 111.0(7) 
N(3)-C(5)-H(5A) 109.4 
C(6)-C(5)-H(5A) 109.4 
N(3)-C(5)-H(5B) 109.4 
C(6)-C(5)-H(5B) 109.4 
H(5A)-C(5)-H(5B) 108.0 
N(4)-C(6)-C(5) 113.0(7) 
N(4)-C(6)-H(6A) 109.0 
C(5)-C(6)-H(6A) 109.0 
N(4)-C(6)-H(6B) 109.0 
C(5)-C(6)-H(6B) 109.0 
H(6A)-C(6)-H(6B) 107.8 
N(4)-C(7)-C(8) 110.3(7) 
N(4)-C(7)-H(7A) 109.6 
C(8)-C(7)-H(7A) 109.6 
N(4)-C(7)-H(7B) 109.6 
C(8)-C(7)-H(7B) 109.6 
H(7A)-C(7)-H(7B) 108.1 
N(1)-C(8)-C(7) 110.8(7) 
N(1)-C(8)-H(8A) 109.5 
C(7)-C(8)-H(8A) 109.5 
N(1)-C(8)-H(8B) 109.5 
C(7)-C(8)-H(8B) 109.5 
H(8A)-C(8)-H(8B) 108.1 
O(1)-C(9)-O(2) 124.4(8) 
O(1)-C(9)-C(10) 118.8(7) 
O(2)-C(9)-C(10) 116.8(7) 
O(1)-C(9)-Yb(1) 158.9(6) 
C(10)-C(9)-Yb(1) 81.3(4) 
N(2)-C(10)-C(9) 111.8(6) 
N(2)-C(10)-H(10A) 109.3 
C(9)-C(10)-H(10A) 109.3 
N(2)-C(10)-H(10B) 109.3 
C(9)-C(10)-H(10B) 109.3 
H(10A)-C(10)-H(10B) 107.9 
O(3)-C(11)-O(4) 125.5(9) 
O(3)-C(11)-C(12) 119.0(9) 
O(4)-C(11)-C(12) 115.5(9) 
O(3)-C(11)-Yb(1) 161.0(7) 
C(12)-C(11)-Yb(1) 79.6(6) 
N(3)-C(12)-C(11) 114.1(9) 
N(3)-C(12)-H(12A) 108.7 
C(11)-C(12)-H(12A) 108.7 
N(3)-C(12)-H(12B) 108.7 
C(11)-C(12)-H(12B) 108.7 
H(12A)-C(12)-H(12B) 107.6 
O(5)-C(13)-O(6) 124.6(9) 
O(5)-C(13)-C(14) 119.6(8) 
O(6)-C(13)-C(14) 115.9(8) 
O(5)-C(13)-Yb(1) 159.2(7) 
C(14)-C(13)-Yb(1) 80.9(5) 
N(4)-C(14)-C(13) 113.4(7) 
N(4)-C(14)-H(14A) 108.9 
C(13)-C(14)-H(14A) 108.9 
N(4)-C(14)-H(14B) 108.9 
C(13)-C(14)-H(14B) 108.9 
H(14A)-C(14)-H(14B) 107.7 
N(1)-C(15)-C(16) 111.7(7) 
N(1)-C(15)-H(15A) 109.3 
C(16)-C(15)-H(15A) 109.3 
N(1)-C(15)-H(15B) 109.3 
C(16)-C(15)-H(15B) 109.3 
H(15A)-C(15)-H(15B) 107.9 
O(7)-C(16)-N(5) 120.9(7) 
O(7)-C(16)-C(15) 120.4(8) 
N(5)-C(16)-C(15) 118.7(8) 
N(5)-C(16)-Yb(1) 151.0(6) 
C(15)-C(16)-Yb(1) 86.6(5) 
N(5)-C(17)-C(24) 112.9(7) 
N(5)-C(17)-C(18) 111.0(7) 
C(24)-C(17)-C(18) 113.0(7) 
N(5)-C(17)-H(17) 106.5 
C(24)-C(17)-H(17) 106.5 
C(18)-C(17)-H(17) 106.5 
C(23)-C(18)-C(19) 120.3(9) 
C(23)-C(18)-C(17) 121.1(8) 
C(19)-C(18)-C(17) 118.6(8) 
C(20)-C(19)-C(18) 119.5(9) 
C(20)-C(19)-H(19) 120.3 
C(18)-C(19)-H(19) 120.3 
C(21)-C(20)-C(19) 120.3(10) 
C(21)-C(20)-H(20) 119.8 
C(19)-C(20)-H(20) 119.8 
C(20)-C(21)-C(22) 120.1(9) 
C(20)-C(21)-H(21) 120.0 
C(22)-C(21)-H(21) 120.0 
C(23)-C(22)-C(21) 119.2(10) 
C(23)-C(22)-H(22) 120.4 
C(21)-C(22)-H(22) 120.4 
C(18)-C(23)-C(22) 120.6(9) 
C(18)-C(23)-H(23) 119.7 
C(22)-C(23)-H(23) 119.7 
C(29)-C(24)-C(25) 119.8(8) 
C(29)-C(24)-C(17) 123.2(9) 
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C(25)-C(24)-C(17) 117.0(8) 
C(26)-C(25)-C(24) 119.4(9) 
C(26)-C(25)-H(25) 120.3 
C(24)-C(25)-H(25) 120.3 
C(27)-C(26)-C(25) 121.9(9) 
C(27)-C(26)-H(26) 119.1 
C(25)-C(26)-H(26) 119.1 
C(26)-C(27)-C(28) 118.4(9) 
C(26)-C(27)-H(27) 120.8 
C(28)-C(27)-H(27) 120.8 
C(27)-C(28)-C(29) 122.2(10) 
C(27)-C(28)-H(28) 118.9 
C(29)-C(28)-H(28) 118.9 
C(24)-C(29)-C(28) 118.3(9) 
C(24)-C(29)-H(29) 120.9 
C(28)-C(29)-H(29) 120.9 
N(5)-C(30)-C(31) 114.3(7) 
N(5)-C(30)-C(37) 110.6(7) 
C(31)-C(30)-C(37) 115.5(7) 
N(5)-C(30)-H(30) 105.1 
C(31)-C(30)-H(30) 105.1 
C(37)-C(30)-H(30) 105.1 
C(32)-C(31)-C(36) 118.9(9) 
C(32)-C(31)-C(30) 123.4(8) 
C(36)-C(31)-C(30) 117.7(8) 
C(31)-C(32)-C(33) 121.2(9) 
C(31)-C(32)-H(32) 119.4 
C(33)-C(32)-H(32) 119.4 
C(34)-C(33)-C(32) 119.2(9) 
C(34)-C(33)-H(33) 120.4 
C(32)-C(33)-H(33) 120.4 
C(35)-C(34)-C(33) 120.8(10) 
C(35)-C(34)-H(34) 119.6 
C(33)-C(34)-H(34) 119.6 
C(34)-C(35)-C(36) 120.0(10) 
C(34)-C(35)-H(35) 120.0 
C(36)-C(35)-H(35) 120.0 
C(35)-C(36)-C(31) 119.7(10) 
C(35)-C(36)-H(36) 120.1 
C(31)-C(36)-H(36) 120.1 
O(8)-C(37)-N(6) 122.4(8) 
O(8)-C(37)-C(30) 120.3(8) 
N(6)-C(37)-C(30) 116.6(8) 
N(6)-C(38)-C(39) 113.4(8) 
N(6)-C(38)-H(38A) 108.9 
C(39)-C(38)-H(38A) 108.9 
N(6)-C(38)-H(38B) 108.9 
C(39)-C(38)-H(38B) 108.9 
H(38A)-C(38)-H(38B) 107.7 
C(44)-C(39)-C(40) 118.8(9) 
C(44)-C(39)-C(38) 122.3(8) 
C(40)-C(39)-C(38) 118.7(8) 
C(41)-C(40)-C(39) 120.6(10) 
C(41)-C(40)-H(40) 119.7 
C(39)-C(40)-H(40) 119.7 
C(40)-C(41)-C(42) 120.2(10) 
C(40)-C(41)-H(41) 119.9 
C(42)-C(41)-H(41) 119.9 
C(43)-C(42)-C(41) 119.3(10) 
C(43)-C(42)-H(42) 120.3 
C(41)-C(42)-H(42) 120.3 
C(42)-C(43)-C(44) 120.2(10) 
C(42)-C(43)-H(43) 119.9 
C(44)-C(43)-H(43) 119.9 
C(39)-C(44)-C(43) 120.8(9) 
C(39)-C(44)-H(44) 119.6 
C(43)-C(44)-H(44) 119.6 
C(15)-N(1)-C(1) 109.7(6) 
C(15)-N(1)-C(8) 110.4(7) 
C(1)-N(1)-C(8) 107.9(6) 
C(15)-N(1)-Yb(1) 107.4(5) 
C(1)-N(1)-Yb(1) 110.5(5) 
C(8)-N(1)-Yb(1) 110.9(5) 
C(2)-N(2)-C(10) 109.4(7) 
C(2)-N(2)-C(3) 108.2(7) 
C(10)-N(2)-C(3) 108.3(6) 
C(2)-N(2)-Yb(1) 113.8(5) 
C(10)-N(2)-Yb(1) 105.8(5) 
C(3)-N(2)-Yb(1) 111.2(5) 
C(5)-N(3)-C(12) 111.5(8) 
C(5)-N(3)-C(4) 109.6(7) 
C(12)-N(3)-C(4) 108.4(8) 
C(5)-N(3)-Yb(1) 111.4(6) 
C(12)-N(3)-Yb(1) 104.8(6) 
C(4)-N(3)-Yb(1) 110.9(5) 
C(6)-N(4)-C(14) 110.2(7) 
C(6)-N(4)-C(7) 109.9(7) 
C(14)-N(4)-C(7) 107.6(7) 
C(6)-N(4)-Yb(1) 110.3(5) 
C(14)-N(4)-Yb(1) 105.5(5) 
C(7)-N(4)-Yb(1) 113.2(5) 
C(16)-N(5)-C(30) 119.1(7) 
C(16)-N(5)-C(17) 122.4(7) 
C(30)-N(5)-C(17) 118.4(7) 
C(37)-N(6)-C(38) 121.7(8) 
C(37)-N(6)-H(6) 119.1 
C(38)-N(6)-H(6) 119.1 
C(9)-O(2)-Yb(1) 125.2(5) 
C(11)-O(4)-Yb(1) 124.6(6) 
C(13)-O(6)-Yb(1) 125.7(6) 
C(16)-O(7)-Yb(1) 125.1(5) 
Yb(1)-O(9)-D(9A) 109(3) 
Yb(1)-O(9)-D(9B) 109(3) 
D(9A)-O(9)-D(9B) 112(4) 
O(2)-Yb(1)-O(6) 143.3(2) 
O(2)-Yb(1)-O(4) 84.9(2) 
O(6)-Yb(1)-O(4) 87.6(2) 
O(2)-Yb(1)-O(7) 79.0(2) 
O(6)-Yb(1)-O(7) 86.0(2) 
O(4)-Yb(1)-O(7) 143.2(2) 
O(2)-Yb(1)-O(9) 72.1(2) 
O(6)-Yb(1)-O(9) 71.5(2) 
O(4)-Yb(1)-O(9) 71.5(2) 
O(7)-Yb(1)-O(9) 72.2(2) 
O(2)-Yb(1)-N(3) 135.1(2) 
O(6)-Yb(1)-N(3) 72.9(2) 
O(4)-Yb(1)-N(3) 67.9(2) 
O(7)-Yb(1)-N(3) 142.5(2) 
O(9)-Yb(1)-N(3) 126.1(2) 
O(2)-Yb(1)-N(2) 67.8(2) 
O(6)-Yb(1)-N(2) 142.1(2) 
O(4)-Yb(1)-N(2) 72.0(2) 
O(7)-Yb(1)-N(2) 129.1(2) 
O(9)-Yb(1)-N(2) 127.1(2) 
N(3)-Yb(1)-N(2) 70.0(2) 
O(2)-Yb(1)-N(4) 136.8(2) 
O(6)-Yb(1)-N(4) 67.6(2) 
O(4)-Yb(1)-N(4) 135.3(2) 
O(7)-Yb(1)-N(4) 74.1(2) 
O(9)-Yb(1)-N(4) 127.9(2) 
N(3)-Yb(1)-N(4) 69.4(2) 
N(2)-Yb(1)-N(4) 105.0(2) 
O(2)-Yb(1)-N(1) 70.9(2) 
O(6)-Yb(1)-N(1) 131.6(2) 
O(4)-Yb(1)-N(1) 138.3(2) 
O(7)-Yb(1)-N(1) 65.5(2) 
O(9)-Yb(1)-N(1) 127.7(2) 
N(3)-Yb(1)-N(1) 106.2(2) 
N(2)-Yb(1)-N(1) 67.6(2) 
N(4)-Yb(1)-N(1) 67.3(2) 
O(2)-Yb(1)-C(9) 19.0(2) 
O(6)-Yb(1)-C(9) 152.3(2) 
O(4)-Yb(1)-C(9) 73.3(2) 
O(7)-Yb(1)-C(9) 97.1(2) 
O(9)-Yb(1)-C(9) 83.2(2) 
N(3)-Yb(1)-C(9) 116.0(2) 
N(2)-Yb(1)-C(9) 50.3(2) 
N(4)-Yb(1)-C(9) 139.8(2) 
N(1)-Yb(1)-C(9) 73.3(2) 
O(2)-Yb(1)-C(16) 66.7(2) 
O(6)-Yb(1)-C(16) 104.1(2) 
O(4)-Yb(1)-C(16) 146.3(2) 
O(7)-Yb(1)-C(16) 18.57(19) 
O(9)-Yb(1)-C(16) 82.3(2) 
N(3)-Yb(1)-C(16) 145.7(2) 
N(2)-Yb(1)-C(16) 110.5(2) 
N(4)-Yb(1)-C(16) 77.8(2) 
N(1)-Yb(1)-C(16) 49.5(2) 
C(9)-Yb(1)-C(16) 83.0(2) 
O(2)-Yb(1)-C(11) 103.4(2) 
O(6)-Yb(1)-C(11) 75.9(2) 
O(4)-Yb(1)-C(11) 19.2(2) 
O(7)-Yb(1)-C(11) 152.6(2) 
O(9)-Yb(1)-C(11) 82.5(2) 
N(3)-Yb(1)-C(11) 50.2(2) 
N(2)-Yb(1)-C(11) 75.0(2) 
N(4)-Yb(1)-C(11) 116.1(2) 
N(1)-Yb(1)-C(11) 141.5(2) 
C(9)-Yb(1)-C(11) 90.0(2) 
C(16)-Yb(1)-C(11) 163.9(2) 
D(1WA)-O(101)-D(1WB) 107(4) 
D(2WA)-O(201)-D(2WB) 107(4) 
D(3WA)-O(301)-D(3WB) 106(4) 
D(4WA)-O(401)-D(4WB) 110(5) 
D(5WA)-O(501)-D(5WB) 110(5) 
D(8WA)-O(801)-D(8WB) 106(5) 
D(9WA)-O(901)-D(9WB) 110(5) 
D(0WA)-O(001)-D(0WB) 109(5)
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_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 4.   Anisotropic displacement parameters (Å
2
x 10
3
)for B2Yb.  The anisotropic 
displacement factor exponent takes the form: -2p
2
[ h
2
a*
2
U
11
 + ... + 2 h k a* b* U
12
 ] 
______________________________________________________________________________ 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12 
______________________________________________________________________________ 
C(1) 23(4)  14(5) 21(5)  -4(4) 10(4)  -4(4) 
C(2) 22(5)  9(4) 17(5)  -7(3) 5(4)  -3(3) 
C(3) 24(5)  15(5) 25(5)  -4(4) 6(4)  1(4) 
C(4) 27(5)  14(5) 27(5)  4(4) 14(4)  7(4) 
C(5) 13(4)  29(5) 18(5)  10(4) 0(4)  5(4) 
C(6) 19(4)  34(6) 30(5)  -2(5) 15(4)  2(4) 
C(7) 10(4)  22(5) 23(5)  8(4) 5(4)  -3(4) 
C(8) 24(5)  15(5) 27(5)  7(4) 13(4)  2(4) 
C(9) 15(4)  13(4) 15(4)  -5(4) 6(4)  -8(3) 
C(10) 14(4)  21(5) 13(4)  -7(4) -5(3)  -6(4) 
C(11) 27(5)  23(5) 17(5)  -2(4) 2(4)  0(4) 
C(12) 30(5)  38(7) 41(6)  3(5) 22(5)  3(5) 
C(13) 15(4)  23(5) 23(5)  6(4) 2(4)  10(3) 
C(14) 15(4)  18(4) 15(4)  -5(3) 2(3)  -4(3) 
C(15) 13(3)  21(4) 11(3)  -1(3) 1(3)  -1(3) 
C(16) 6(3)  24(5) 13(4)  -4(3) 2(3)  -8(3) 
C(17) 26(4)  9(4) 19(4)  4(3) 8(3)  4(3) 
C(18) 23(4)  9(4) 23(4)  3(3) 9(4)  -1(3) 
C(19) 26(5)  18(5) 38(6)  1(4) 9(4)  1(4) 
C(20) 24(5)  15(5) 52(7)  0(5) 9(5)  5(4) 
C(21) 25(5)  28(6) 71(8)  11(6) 28(6)  11(5) 
C(22) 36(6)  22(5) 43(6)  8(5) 23(5)  18(4) 
C(23) 21(4)  11(4) 27(5)  -2(4) 8(4)  5(4) 
C(24) 21(4)  14(5) 29(5)  -15(4) 13(4)  -2(4) 
C(25) 27(5)  18(5) 31(5)  9(4) 13(4)  4(4) 
C(26) 38(6)  13(5) 32(5)  5(4) 15(5)  0(4) 
C(27) 26(5)  30(6) 41(6)  -1(5) 16(5)  -12(4) 
C(28) 28(5)  38(7) 36(6)  2(5) 13(5)  -6(5) 
C(29) 22(5)  29(6) 25(5)  11(4) 11(4)  -5(4) 
C(30) 22(4)  21(5) 11(4)  3(4) 4(4)  3(4) 
C(31) 20(4)  25(5) 13(4)  0(4) 6(4)  2(4) 
C(32) 24(5)  16(5) 28(5)  11(4) 13(4)  6(4) 
C(33) 23(5)  22(5) 34(6)  -11(4) 9(4)  -6(4) 
C(34) 28(5)  59(8) 48(7)  -1(6) 26(5)  2(6) 
C(35) 32(6)  56(8) 49(7)  2(6) 28(6)  2(6) 
C(36) 36(6)  33(6) 34(6)  -11(5) 24(5)  -3(5) 
C(37) 28(5)  15(5) 13(4)  -1(4) 5(4)  -4(4) 
C(38) 37(5)  24(5) 19(5)  4(4) 14(4)  5(4) 
C(39) 26(4)  14(4) 23(4)  10(3) 11(3)  2(3) 
C(40) 29(4)  30(5) 26(5)  -2(4) 14(4)  2(4) 
C(41) 30(6)  51(8) 35(6)  1(6) 4(5)  -9(5) 
C(42) 52(7)  36(7) 30(6)  -6(5) 15(5)  -15(6) 
C(43) 45(6)  7(5) 30(5)  1(4) 14(5)  5(4) 
C(44) 28(4)  27(5) 22(4)  5(4) 12(4)  7(4) 
N(1) 14(3)  20(4) 15(3)  -6(3) 7(3)  3(3) 
N(2) 13(3)  9(4) 15(4)  -2(3) -1(3)  0(3) 
N(3) 17(4)  25(4) 22(4)  -3(3) 9(3)  1(3) 
N(4) 13(3)  15(4) 15(4)  -2(3) 3(3)  -3(3) 
N(5) 18(4)  13(4) 11(3)  -1(3) 4(3)  -1(3) 
N(6) 27(4)  22(4) 23(4)  -5(3) 11(3)  -3(3) 
O(1) 17(3)  36(4) 17(3)  3(3) 4(3)  10(3) 
O(2) 16(3)  15(3) 16(3)  -2(3) 5(2)  -2(2) 
O(3) 26(3)  17(4) 58(5)  17(3) 12(3)  -5(3) 
O(4) 15(3)  13(3) 17(3)  3(3) 0(2)  2(2) 
O(5) 19(3)  31(4) 23(4)  4(3) 5(3)  2(3) 
O(6) 12(3)  23(4) 15(3)  8(3) 3(2)  4(3) 
O(7) 21(3)  17(3) 17(3)  11(3) 11(3)  6(3) 
O(8) 17(3)  20(3) 23(3)  -8(3) 2(3)  -4(3) 
O(9) 16(3)  35(4) 22(3)  11(3) 10(3)  9(3) 
Yb(1) 12(1)  13(1) 14(1)  0(1) 4(1)  -1(1) 
O(101) 28(4)  16(4) 35(4)  7(3) 16(3)  2(3) 
O(201) 23(3)  27(4) 15(3)  2(3) 0(3)  1(3) 
O(301) 33(4)  25(4) 46(5)  0(4) 10(4)  -9(3) 
O(401) 22(4)  60(5) 35(4)  3(4) 15(3)  -7(4) 
O(501) 30(4)  42(5) 37(4)  3(4) 10(3)  -5(4) 
O(601) 38(4)  62(6) 28(4)  -1(4) 14(3)  -8(4) 
O(801) 92(7)  49(6) 108(9)  9(6) 79(7)  -6(6) 
O(901) 93(8)  101(10) 113(10)  39(9) 81(8)  37(8) 
O(001) 98(13)  32(7) 124(16)  34(8) 82(12)  24(7) 
 
 
 
 
Table 5.   Hydrogen coordinates ( x 10
4
) and isotropic displacement parameters (Å
2
x 10
3
) 
for B2Yb. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1A) 2376 1154 -711 22 
H(1B) 1107 1143 -386 22 
H(2A) 1350 666 -1250 20 
H(2B) 2772 626 -210 20 
H(3A) 1008 76 645 27 
H(3B) 1511 137 -462 27 
H(4A) 3146 -97 1255 26 
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H(4B) 3589 239 976 26 
H(5A) 5098 54 3049 26 
H(5B) 4897 223 4196 26 
H(6A) 6197 535 3461 31 
H(6B) 5089 538 2091 31 
H(7A) 5942 1084 2818 22 
H(7B) 4907 1287 3141 22 
H(8A) 4413 1291 952 25 
H(8B) 4299 919 916 25 
H(10A) -467 411 198 22 
H(10B) -396 602 -963 22 
H(12A) 3144 0 4091 41 
H(12B) 2785 -216 2881 41 
H(14A) 5192 1091 4862 21 
H(14B) 6169 807 5020 21 
H(15A) 1606 1515 843 19 
H(15B) 3108 1602 1335 19 
H(17) 1821 1987 1522 22 
H(19) -401 2035 1294 34 
H(20) -2005 2340 1575 39 
H(21) -1435 2756 2977 46 
H(22) 764 2876 4092 37 
H(23) 2360 2562 3835 24 
H(25) 2608 2526 1164 30 
H(26) 4474 2805 1455 32 
H(27) 6407 2686 3067 38 
H(28) 6492 2261 4355 41 
H(29) 4648 1968 4106 30 
H(30) 2427 2010 4665 22 
H(32) 241 1441 2910 27 
H(33) -1806 1357 2972 32 
H(34) -2305 1578 4574 50 
H(35) -838 1897 6045 50 
H(36) 1163 2011 5908 38 
H(38A) 4828 1240 7147 31 
H(38B) 3741 1115 7612 31 
H(40) 6421 1360 9112 33 
H(41) 7215 1675 10869 49 
H(42) 5834 2020 11337 47 
H(43) 3689 2060 9976 33 
H(44) 2894 1741 8215 30 
H(6) 2270 1419 6154 28 
 
Table 6.  Hydrogen bonds for B2Yb [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(6)-H(6)...O(601) 0.88 2.29 2.883(11) 124.4 
 O(9)-D(9A)...O(401)#1 0.94(2) 1.92(3) 2.776(10) 151(4) 
 O(9)-D(9B)...O(601) 0.94(2) 2.12(4) 2.812(10) 129(5) 
 O(101)-D(1WA)...O(201)#2 0.95(2) 1.82(3) 2.765(10) 171(10) 
 O(101)-D(1WB)...O(3) 0.95(2) 1.78(4) 2.708(9) 164(9) 
 O(201)-D(2WA)...O(5) 0.95(2) 1.82(3) 2.752(9) 166(8) 
 O(201)-D(2WB)...O(1)#3 0.95(2) 1.74(2) 2.692(8) 175(11) 
 O(301)-D(3WA)...O(1)#3 0.95(2) 2.02(5) 2.911(10) 156(11) 
 O(301)-D(3WB)...O(501) 0.95(2) 2.10(6) 2.960(11) 149(9) 
 O(401)-D(4WA)...O(101)#2 0.95(2) 1.89(3) 2.824(11) 170(10) 
 O(401)-D(4WB)...O(701) 0.94(2) 1.88(6) 2.72(2) 147(9) 
 O(401)-D(4WB)...O(71') 0.94(2) 2.20(8) 2.94(3) 135(9) 
 O(501)-D(5WA)...O(8) 0.95(2) 2.08(6) 2.942(9) 150(9) 
 O(501)-D(5WB)...O(201) 0.95(2) 1.97(3) 2.908(11) 169(12) 
 O(601)-D(6WA)...O(101)#4 0.96(2) 2.32(13) 2.829(10) 113(10) 
 O(801)-D(8WA)...O(5) 0.95(2) 1.88(4) 2.821(11) 170(16) 
 O(801)-D(8WB)...O(601) 0.96(2) 2.26(17) 2.882(14) 122(15) 
 O(901)-D(9WA)...O(801) 0.95(2) 1.92(9) 2.807(19) 154(19) 
 O(901)-D(9WB)...O(71')#5 0.95(2) 1.77(13) 2.60(4) 142(19) 
 O(901)-D(9WB)...O(701)#5 0.95(2) 2.37(15) 3.13(4) 137(17) 
 O(001)-D(0WA)...O(401) 0.95(2) 1.86(6) 2.789(16) 165(18) 
 O(001)-D(0WB)...O(001)#6 0.95(2) 2.28(12) 3.10(4) 144(16) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x-1,y,z    #2 -x+1,-y,-z+1    #3 x+1,y,z+1    #4 -x,-y,-z+1  
#5 x,y,z+1    #6 -x+2,-y,-z 
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5.2 Appendix 2 
Variable temperature (VT) nmr 
 
Compound 04: Benzyl Ugi 
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Compound 05: Naphthyl Ugi 
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Compound 06: Pyrenyl Ugi 
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5.3 Appendix 3  
Lanthanide luminescence spectra 
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Combination: excitation of metal centre vs energy-transfer from chromophore 
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Excitation of chromophore 
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Combination: Excitation of metal centre vs energy-transfer from chromophore 
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Comparison: Excitation of metal centre vs excitation of chromophore 
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Comparison: Excitation of metal centre vs excitation of chromophore 
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Tb Benzyl H2O 
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Comparison: Excitation of metal centre vs excitation of chromophore 
Tb benzyl H2O comparison
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Excitation of chromophore  
Tb Naphthyl H2O Ex 290nm
-5000
45000
95000
145000
195000
245000
450 480 510 540 570 600 630 660 690 720 750 780
Wavelength (nm)
In
te
ns
it
y
 
 
Comparison: Excitation of metal centre vs excitation of chromophore 
Tb Naphthyl H2O comparison
-5000
45000
95000
145000
195000
245000
450 500 550 600 650 700 750 800
Wavelength (nm)
In
te
ns
it
y Ex 366nm
Ex 290nm
Ex 397nm
Ex 259nm
 
 
Tb Indole D2O 
Absorption  
Tb Indole D2O Abs
-100
0
100
200
300
400
500
600
700
800
22
0
23
6
25
2
26
8
28
4
30
0
31
6
33
2
34
8
36
4
38
0
39
6
41
2
42
8
44
4
46
0
47
6
49
2
Wavelength nm
In
te
ns
it
y
 
Appendix 3: Lanthanide luminescence spectra 
 284
Excitation of metal centre 
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Combination: excitation of metal centre vs energy-transfer from chromophore 
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Tb Indolyl H2O 
Excitation of metal centre 
Tb Indolyl H2O Ex 366nm
-500
4500
9500
14500
19500
24500
29500
45
0
47
0
49
0
51
0
53
0
55
0
57
0
59
0
61
0
63
0
65
0
67
0
69
0
71
0
73
0
75
0
77
0
79
0
Wavelength (nm)
In
te
ns
it
y
 
 
Excitation of chromophore 
Tb Indolyl H2O Ex 275nm
-2000
48000
98000
148000
198000
40
0
42
0
44
0
46
0
48
0
50
0
52
0
54
0
56
0
58
0
60
0
62
0
64
0
66
0
68
0
70
0
Wavelength (nm)
In
te
ns
it
y
 
Tb Indolyl H2O Ex 397nm
-500
4500
9500
14500
19500
45
0
47
0
49
0
51
0
53
0
55
0
57
0
59
0
61
0
63
0
65
0
67
0
69
0
71
0
73
0
75
0
77
0
79
0
Wavelength (nm)
In
te
ns
it
y
 
 
Appendix 3: Lanthanide luminescence spectra 
 286
Combination: excitation of metal centre vs energy-transfer from chromophore 
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Yb Pyrenyl MeOH 
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Yb Naphthyl d4-MeOH 
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Compound 69: Tb Benzyl peptide 
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Compound 34: Tb Indolyl caproic linker 
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5.4 Appendix 4 
Final product absorption & emission spectra 
 
Compound 61, cPep-NIR797  
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Emission spectrum 
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Emission at different excitation wavelengths 
 
cPepNIR797 Emission Spectra (0.1 mg/mL)
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Excitation Spectrum (with filter) 
cPepNIR797 Excitation Spectrum enlargement (Em 810 nm)
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
Excitation wavelength (nm)
E
m
is
si
on
 in
te
ns
it
y 
(a
rb
)
805 nm
710 nm
785 nm
800 nm
 
Appendix 4: Final product absorption & emission spectra 
 293
Excitation spectrum (without filter) 
 
cPepNIR797 excitation spectrum (0.1 mg/mL). Em 810nm
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Full excitation spectrum with 715nm filter 
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Compound 68, cPep-cap-Os 
 
 
UV absorption spectrum 
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Fluorescence emission spectrum 
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Excitation spectrum (scanning emission at specifically 770nm (maximum above) across a 
range of excitation wavelengths). 
cPep-Cap-Os excitation spectrum Em:770nm
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Excitation spectrum (as above) (with and without filter) 
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Compound 60, cPep-Fluorescein 
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Emission spectrum 
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Compound 88, Disaccharide-NIR797 
UV absorption spectrum 
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Excitation spectrum 
Excitation spectrum Em 815nm
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Compound 89, Disaccharide-Osmium 
Osmium complex absorption spectrum 
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Osmium complex emission spectrum 
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Compound 87, Disaccharide-Fluorescein 
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Emission spectra 
Disaccharide-Fluorescein (H2O) Ex 400nm
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Excitation spectrum. Emission set at 520nm. 
Disaccharide-Fluorescein (H2O) Em 520nm
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Fluorescein vs Osmium vs NIR797 emission spectra 
Fluorescence comparison (0.1 mg/mL)
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5.5 Appendix 5: HPLC & m/z data 
Ugi-lanthanide complexes 
Compound 12: Eu Benzyl 
HPLC        m/z 
         
 
Compound 13: Eu Naphthyl 
HPLC        m/z 
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Compound 14: Eu Pyrenyl 
HPLC       m/z 
        
 
Compound 15: Eu Indolyl 
HPLC       m/z 
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Compound 16: Tb Benzyl 
HPLC       m/z 
     
 
Compound 17: Tb Naphthyl 
HPLC       m/z 
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Compound 18: Tb Pyrenyl 
HPLC       m/z 
      
 
Compound 19: Tb Indolyl 
HPLC       m/z 
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Compound 20: Yb Benzyl 
HPLC       m/z 
      
 
Compound 21: Yb Naphthyl 
HPLC       m/z 
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Compound 22: Yb Pyrenyl 
HPLC       m/z 
      
 
Compound 23: Yb Indolyl 
HPLC       m/z 
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Peptides 
Compound 54 Linear Asp(tBu)-DPhe-Lys(Alloc)-Arg(pmc)-Gly 
m/z 
 
HPLC 
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Cyc Asp(tBu)-DPhe-Lys(Alloc)-Arg(pmc)-Gly 56 
m/z 
 
HPLC 
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Compound 58 Cyc Asp(tBu)-DPhe-Lys(NH2)-Arg(pmc)-Gly 
m/z 
 
HPLC 
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Compound 59 Cyc Asp-DPhe-Lys(NH2)-Arg-Gly 
m/z 
 
 
 
Compound 60: cPep-Fluorescein 
HPLC 
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m/z  
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Compound 61: cPep-NIR797 
m/z 
 
HPLC 
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Compound 68: cPep-cap-Os 
m/z 
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Compound 69: cPep-cap-benzyl Tb Ugi complex 
 
m/z 
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Compound 87 Disaccharide-Fluorescein 
m/z 
(acetylated) 
 
 
(deacetylated) 
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Cut-out of product peaks 
 
 
HPLC 
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Compound 88: Disaccharide-NIR797 
 
m/z 
 
 
HPLC (analytical) 
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Compound 89: Disaccharide – Osmium complex 
m/z 
 
   
 
HPLC 
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Compound 52: Osmium complex 
 
HPLC 
 
 
m/z 
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5.6 Appendix 6 
2D-nmr data 
Compound 71 
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Compound 72 
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Compound 78 
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Compound 79 
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Compound 81 
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Compound 80  
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Compound 83 
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Compound 85 
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Biotinylated compound 93 
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Biotinylated compound 94 (tBu cleavage product) 
 
Publication 
 338
 
 
